WO2014057435A1 - Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives - Google Patents

Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives Download PDF

Info

Publication number
WO2014057435A1
WO2014057435A1 PCT/IB2013/059233 IB2013059233W WO2014057435A1 WO 2014057435 A1 WO2014057435 A1 WO 2014057435A1 IB 2013059233 W IB2013059233 W IB 2013059233W WO 2014057435 A1 WO2014057435 A1 WO 2014057435A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methanone
methyl
pyrrolidin
triazol
Prior art date
Application number
PCT/IB2013/059233
Other languages
French (fr)
Inventor
Martin Bolli
Christoph Boss
Christine Brotschi
Markus Gude
Bibia Heidmann
Thierry Sifferlen
Jodi T. Williams
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2013328301A priority Critical patent/AU2013328301A1/en
Priority to BR112015007516A priority patent/BR112015007516A2/en
Priority to JP2015536264A priority patent/JP6244365B2/en
Priority to EA201500399A priority patent/EA201500399A1/en
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to SG11201502493XA priority patent/SG11201502493XA/en
Priority to KR1020157012089A priority patent/KR102151288B1/en
Priority to MA38075A priority patent/MA38075A1/en
Priority to CA2885180A priority patent/CA2885180C/en
Priority to US14/434,997 priority patent/US9493446B2/en
Priority to CN201380051391.3A priority patent/CN104703980B/en
Priority to MX2015004638A priority patent/MX2015004638A/en
Priority to EP13805561.1A priority patent/EP2906553B1/en
Publication of WO2014057435A1 publication Critical patent/WO2014057435A1/en
Priority to PH12015500627A priority patent/PH12015500627A1/en
Priority to IL238052A priority patent/IL238052A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • Orexin receptor antagonists which are ⁇ ortho bi-(hetero-)aryl1-r2-(f77ete bi-(hetero-)aryl)- pyrrolidin-1 -yll-methanone derivatives
  • the present invention relates to novel [ortho bi-(hetero-)aryl]-[2-(mefa bi-(hetero-)aryl)- pyrrolidin-1 -yl]-methanone derivatives and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), (II), (III), (IV), (V) or (VI) and especially their use as orexin receptor antagonists.
  • Orexins are neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G-protein-coupled receptors (OXi and OX 2 receptors).
  • the orexin-1 receptor (OX-i) is selective for OX-A
  • the orexin-2 receptor (OX 2 ) is capable to bind OX-A as well as OX-B.
  • Orexin receptor antagonists are a novel type of nervous system or psychotropic drugs. Their mode of action in animals and humans involves either blockade of both orexin-1 and orexin-2 receptor (dual antagonists), or individual and selective blockade of either the orexin-1 or the orexin-2 receptor (selective antagonists) in the brain. Orexins were initially found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585).
  • orexin neuropeptides and orexin receptors play an essential and central role in regulating circadian vigilance states.
  • orexin neurons collect sensory input about internal and external states and send short intrahypothalamic axonal projections as well as long projections to many other brain regions.
  • the particular distribution of orexin fibers and receptors in basal forebrain, limbic structures and brainstem regions - areas related to the regulation of waking, sleep and emotional reactivity- suggests that orexins exert essential functions as regulators of behavioral arousal; by activating wake-promoting cell firing, orexins contribute to orchestrate all brain arousal systems that regulate circadian activity, energy balance and emotional reactivity.
  • Human memory is comprised of multiple systems that have different operating principles and different underlying neuronal substrates. The major distinction is between the capacity for conscious, declarative memory and a set of unconscious, non-declarative memory abilities. Declarative memory is further subdivided into semantic and episodic memory. Non-declariative memory is further subdivided into priming and perceptual learning, procedural memory for skills and habits, associative and non-associative learning, and some others. While semantic memory refers to the general knowledge about the world, episodic memory is autobiographical memory of events. Procedural memories refer to the ability to perform skill-based operations, as e.g. motor skills.
  • Long-term memory is established during a multiple stage process through gradual changes involving diverse brain structures, beginning with learning, or memory acquisition, or formation. Subsequently, consolidation of what has been learned may stabilize memories. When long-term memories are retrieved, they may return to a labile state in which original content may be updated, modulated or disrupted. Subsequently, reconsolidation may again stabilize memories. At a late stage, long-term memory may be resistant to disruption. Long-term memory is conceptually and anatomically different from working memory, the latter of which is the capacity to maintain temporarily a limited amount of information in mind. Behavioural research has suggested that the human brain consolidates long-term memory at certain key time intervals.
  • the initial phase of memory consolidation may occur in the first few minutes after we are exposed to a new idea or learning experience.
  • the next, and possibly most important phase may occur over a longer period of time, such as during sleep; in fact, certain consolidation processes have been suggested to be sleep-dependent [R. Stickgold et al., Sleep-dependent memory consolidation; Nature 2005,437, 1272-1278].
  • Learning and memory processes are believed to be fundamentally affected in a variety of neurological and mental disorders, such as e.g. mental retardation, Alzheimer's disease or depression. Indeed, memory loss or impairment of memory acquisition is a significant feature of such diseases, and no effective therapy to prevent this detrimental process has emerged yet.
  • Orexin-1 receptor antagonism also attenuated the expression of amphetamine- and cocaine-induced CPP [Gozzi A et al., PLoS One 2011 , 6(1 ), e16406; Hutcheson DM et al., Behav Pharmacol 2011 , 22(2), 173-181 ], and reduced the expression or development of locomotor sensitization to amphetamine and cocaine [Borgland SL et al., Neuron 2006, 49(4), 589-601 ; Quarta D et al., "The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization.” Neurochem Int 2010, 56(1 ), 1 1-15].
  • hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal [Furlong T M et al., Eur J Neurosci 2009, 30(8), 1603-1614]. Stress response may lead to dramatic, usually time-limited physiological, psychological and behavioural changes that may affect appetite, metabolism and feeding behavior [Chrousos, GP et al., JAMA 1992, 267(9), 1244-1252].
  • the acute stress response may include behavioural, autonomic and endocrinological changes, such as promoting heightened vigilance, decreased libido, increased heart rate and blood pressure, or a redirection of blood flow to fuel the muscles, heart and the brain [Majzoub, JA et al., European Journal of Endocrinology 2006, 155 (suppl_1 ) S71-S76].
  • Orexins are also involved in mediating the acute behavioral and autonomous nervous system response to stress [Zhang Wet al., "Multiple components of the defense response depend on orexin: evidence from orexin knockout mice and orexin neuron-ablated mice.” Auton Neurosci 2006, 126-127, 139-145].
  • Mood disorders including all types of depression and bipolar disorder are characterized by disturbed "mood” and feelings, as well as by sleeping problems (insomnia as well as hypersomnia), changes in appetite or weight and reduced pleasure and loss of interest in daily or once enjoyed activities [Liu X et al., Sleep 2007, 30(1 ): 83-90].
  • disturbances in the orexin system may contribute to the symptoms of mood disorders.
  • the orexin system is also involved in stress-related appetitive/reward seeking behaviour (Berridge CW et al., Brain Res 2009, 1314, 91-102).
  • a modulatory effect on stress may be complementary to an effect on appetitive/reward seeking behaviour as such.
  • an OXi selective orexin receptor antagonist was able to prevent footshock stress induced reinstatement of cocaine seeking behaviour [Boutrel, B et al., Proc Natl Acad Sci 2005, 102(52), 19168-19173].
  • stress is also known to play an integral part in withdrawal which occurs during cessation of drug taking (Koob, GF et al., Curr Opin Investig Drugs 2010, 1 1 (1 ), 63-71 ).
  • Orexins have been found to increase food intake and appetite [Tsujino, N, Sakurai, T, Pharmacol Rev 2009, 61 (2) 162-176]. As an additional environmental factor, stress can contribute to binge eating behaviour, and lead to obesity [Adam, TC et al. Physiol ehav 2007, 91 (4) 449-458]. Animal models that are clinically relevant models of binge eating in humans are described for example in W. Foulds Mathes et al.; Appetite 2009, 52, 545-553.
  • orexins may play a role into several other important functions relating to arousal, especially when an organism must respond to unexpected stressors and challenges in the environment [Tsujino N and Sakurai T. Pharmacol Rev. 2009, 61 :162-176; Carter ME, Borg JS and deLecea L, Curr Op Pharmacol. 2009, 9: 39-45; C Boss, C Brisbare-Roch, F Jenck, Journal of Medicinal Chemistry 2009, 52: 891-903].
  • the orexin system interacts with neural networks that regulate emotion, reward and energy homeostasis to maintain proper vigilance states. Dysfunctions in its function may thus relate to many mental health disorders in which vigilance, arousal, wakefulness or attention is disturbed.
  • the compound further attenuated cardiovascular responses to conditioned fear and novelty exposure in rats [Furlong T M et al., Eur J Neurosci 2009, 30(8), 1603-1614]. It is also active in an animal model of conditioned fear: the rat fear-potentiated startle paradigm (WO2009/047723) which relates to emotional states of fear and anxiety diseases such as anxieties including phobias and post traumatic stress disorders (PTSDs).
  • WO2009/047723 relates to emotional states of fear and anxiety diseases such as anxieties including phobias and post traumatic stress disorders (PTSDs).
  • PTSDs post traumatic stress disorders
  • intact declarative and non-declarative learning and memory has been demonstrated in rats treated with this compound [WO2007/105177, H Dietrich, F Jenck, Psychopharmacology 2010, 212, 145-154].
  • Said compound furthermore decreased brain levels of amyloid-beta ( ⁇ ) as well as ⁇ plaque deposition after acute sleep restriction in amyloid precursor protein transgenic mice [JE Kang et al., "Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.”, Science 2009, 326(5955): 1005-1007].
  • ⁇ amyloid-beta
  • the accumulation of the ⁇ in the brain extracellular space is hypothesized to be a critical event in the pathogenesis of Alzheimer's disease.
  • the so-called and generally known "amyloid cascade hypothesis” links ⁇ to Alzheimer's disease and, thus, to the cognitive dysfunction, expressed as impairment of learning and memory.
  • the compound has also been shown to induce antidepressant-like activity in a mouse model of depression, when administered chronically [Nollet et al., NeuroPharm 2011 , 61 (1 -2):336-46]. Moreover, the compound has been shown to attenuate the natural activation induced by orexin A in fasted hungry rats exposed to food odors [MJ Prud'Neill et al., Neuroscience 2009, 162(4), 1287-1298]. The compound also displayed pharmacological activity in a rat model of nicotine self-administration [LeSage MG et al., Psychopharmacology 2010, 209(2), 203-212].
  • N-Biphenyl-2-yl-1 - ⁇ [(1 -methyl-1 H-benzimidazol- 2-yl)sulfanyl]acetyl ⁇ -L-prolinamide another dual orexin receptor antagonist, inhibited nicotine- reinstatement for a conditioned reinforcer and reduced behavioral (locomotor sensitization) and molecular (transcriptional responses) changes induced by repeated amphetamine administration in rodents [Winrow et al., Neuropharmacology 2009, 58(1 ), 185-94].
  • US 7, 105,538 discloses certain [1 ,3,4]oxadiazol-2,5-diyl compounds including two exemplified [3-phenyl-5-methyl-isoxazol-4-yl]-[2-(5-pyridyl-[1 ,3,4]oxadiazol-2-yl)-pyrrolidin-1 -yl]-methanone derivatives (CAS registry no. 1082288-15-0, 1082288-80-9) and their use as anti-depressants.
  • the compounds are claimed to inhibit serotonin re-uptake and, thus, to have a pronounced anti-depressive and analgesic effect. It has been found that tested [3-phenyl-5-methyl-isoxazol- 4-yl]-[pyrrolidin-1-yl]-methanone derivatives showed low or no activity within the limits of detection on the orexin receptors.
  • WO2006/123249, WO2005/044797, and WO2007/039781 disclose metabotropic glutamate (especially mGluR5) receptor modulators and, thus, to be useful for example for the treatment of anxiety disorders or depression.
  • Some compounds exemplified in WO2007/039781 comprise a 2-substituted pyrrolidine moiety, however, these compounds do not comprise an ortho bi- (hetero-)aryl group corresponding to the present group A-i attached to the carbonyl group of the pyrrolidine-amide.
  • Six example or analogue compounds of WO2007/039781 have been tested for their activity on the orexin receptors and showed low or no activity within the limits of detection.
  • Orexin receptor antagonists comprising a 2-substituted saturated cyclic amide derivatives (such as 2-substituted pyrrolidine-1-carboxamides) are known for example from WO2008/020405, WO2008/038251 , WO2008/081399, WO2008/08761 1 , WO2008/1 17241 , WO2008/139416, WO2009/004584, WO2009/016560, WO2009/016564, WO2009/040730, WO2009/104155, WO2010/004507, WO2010/038200, WO2001/096302, WO2002/044172, WO2002/089800, WO2002/090355, WO2003/002561 , WO2003/032991 , WO2003/04171 1 , WO2003/051368, WO2003/051873, WO2004/026866, WO2004/041791 , WO2004/041807, WO2004/04
  • WO2003/002559 discloses certain N-aroyl cyclic amine derivatives encompassing pyrrolidine, piperidine and morpholine derivatives as orexin receptor antagonists.
  • a linker group such as at least a methylene group (or longer groups such as -CH2-NH-CO-, -CH2-NH-, -CH2-O-, -CH2-S-, etc.) link the cyclic amide to the respective aromatic ring system substituent.
  • a particular 2-substituted pyrrolidine derived compound where the pyrrolidine is linked through a methylene group to an [1 ,3,4]oxadiazole ring 1-(5-(2- fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-[(S)-2-(5-phenyl-[1 ,3,4]oxadiazol-2-ylmethyl)-pyrrolidin-1 - yl)-methanone is exemplified in WO2003/002559 and further characterized in Langmead et. al, Brit. J. Pharmacol. 2004, 141 , 340-346 as being highly orexin-1 selective.
  • the present compounds that have an aromatic ring system directly attached to a pyrrolidine amide in position 2, are orexin receptor antagonists which may be active on both orexin receptors.
  • the present invention thus, provides novel [ortho bi-(hetero-)aryl]-[2-(mefa bi-(hetero-)aryl)- pyrrolidin-1 -yl]-methanone derivatives of formula (I), (II), (III), (IV), (V) and (VI), which are non- peptide antagonists of human orexin receptors potentially useful in the treatment of disorders relating to orexinergic dysfunctions, comprising especially sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders; and especially in the treatment of sleep disorders, anxiety disorders, and addiction disorders.
  • a first aspect of the invention relates to compounds of the formula (I),
  • R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (I), R represents especially hydrogen);
  • ring A 3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen; [wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent A 2 ; and that the ring A 3 does not carry any further substituent];
  • ring A 2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, hydroxy, (C 1-4 )alkoxy-(C 1-3 )alkyl, hydroxy-(C 1-3 )alkyl, -CO-(C 1-4 )alkyl, and (C 3-6 )cycloalkyl-oxy-; or ring A 2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl,
  • ring A represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted;
  • substituents are attached in orffro-position to the point of attachment of A to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy;
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A 3 represents a ring
  • said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X 2 , X 3 , and/or X 4 ; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen.
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), g A 3 represents a ring
  • said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X, Y and / or Z; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen.
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A 3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol-diyl, oxazol-diyl, thiazol-diyl, pyrazol-diyl, imidazol-diyl, isothiazol-diyl, and thiadiazol-diyl.
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A 3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol-diyl, oxazol-diyl, thiazol-diyl, and thiadiazol-diyl.
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A 3 is selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol-3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5- diyl, oxazol-2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, thiazol-2,5-diyl, isothiazol-3,5-diyl, [1 ,3,4]thiadiazol-2,5-diyl, and [1 ,3,4]oxadiazol-2,5-diyl (notably [1 ,2,4]oxadiazol-3,5-
  • a further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A 3 is [1 ,3,4]oxadiazol-2,5-diyl.
  • a further embodiment relates to compounds according to any one of embodiments 1 ) to 7), or pharmaceutically acceptable salts thereof, for use in the treatment of mental health disorders relating to orexinergic dysfunctions; wherein for the compounds of formula (I) such mental health disorders relating to orexinergic dysfunctions are especially selected from sleep disorders, anxiety disorders, and addiction disorders.
  • a second aspect of the invention relates to novel compounds of the formula (I) which are also compounds of the formula (II):
  • R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (II), R represents especially hydrogen);
  • ring A' 3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen; provided that said 5-membered heteroarylene ring is not [1 ,3,4]oxadiazol-2,5-diyl;
  • ring A' 2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci -3 )alkyl, hydroxy-(Ci -3 )alkyl, -CO-(Ci-4)alkyl, and (C 3-6 )cycloalkyl-oxy-; or ring A' 2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofurany
  • ring ⁇ represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted;
  • substituents are attached in orffro-position to the point of attachment of ⁇ to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy;
  • a further embodiment of the invention relates to compounds as defined in embodiment 9);
  • said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X 2 , X 3 , and/or X 4 ; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; provided that said ring is not [1 ,3,4]oxadiazol-2,5-diyl.
  • a further embodiment of the invention relates to compounds as defined in embodiment 9);
  • said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X, Y and / or Z; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; provided that said ring is not [1 ,3,4]oxadiazol-2,5-diyl.
  • a further embodiment relates to compounds of embodiment 9) wherein the ring A' 3 is [1 ,3,4]thiadiazol-2,5-diyl.
  • a further embodiment relates to compounds of embodiment 9), wherein the ring A' 3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol-3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5-diyl, oxazol-2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, and [1 ,3,4]thiadiazol-2,5-diyl (notably [1 ,2,4]oxadiazol-3,5-diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,
  • a further embodiment relates to compounds of embodiment 9), wherein the ring A' 3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol-3,5-diyl, and isoxazol-3,5-diyl (notably [1 ,2,4]oxadiazol- 3,5-diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,2,4]oxadiazol-3,5-diyl).
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A ; respectively ring ⁇ , represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri- substituted; wherein
  • substituents are attached in orffro-position to the point of attachment of A / A'i to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen;
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein • ring A ; respectively ring ⁇ , represents 5-membered heteroaryl, wherein the 5- membered heteroaryl is mono- or di-substituted; wherein
  • said ortho-su bstituent is phenyl, or 6-membered heteroaryl (especially pyridyl); wherein said phenyl or 6-membered heteroaryl is independently unsubstituted, or mono-, or di-substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy [wherein said orffro-substituent is especially phenyl which is especially unsubstituted, or mono-substituted with
  • ring A-i represents phenyl or 6-membered heteroaryl, wherein the phenyl or 6-membered heteroaryl independently is mono-, di-, or tri-substituted;
  • said orf/70-substituent is phenyl which is unsubstituted, mono-, or di- substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy
  • o or said orffro-substituent is 6-membered heteroaryl (especially pyridyl or pyrimidinyl) which is unsubstituted, mono-, or di-substituted (especially unsubstituted), wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl
  • ortho-su bstituent is 5-membered heteroaryl (notably pyrazol-1-yl or
  • [1 ,2,3]triazol-2-yl) which is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, and (Ci -3 )fluoroalkyl (especially (Ci -4 )alkyl, notably methyl); > and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy [especially (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen; notably (Ci -4 )alkyl and halogen].
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein
  • ring A-i represents represents 5-membered heteroaryl, wherein the 5-membered heteroaryl is mono- or di-substituted;
  • said orffro-substituent is phenyl, or 6-membered heteroaryl (especially pyridyl), wherein said phenyl or 6-membered heteroaryl is independently unsubstituted, mono-, or di-substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen,
  • ring A-i represents 6-membered heteroaryl, wherein the 6-membered heteroaryl is mono-, or di-substituted;
  • said orf/70-substituent is unsubstituted 5-membered heteroaryl (notably pyrazol-1-yl or [1 ,2,3]triazol-2-yl); or
  • said orffro-substituent is unsubstituted 6-membered heteroaryl (notably pyridin-2-yl); or
  • said orf/70-substituent is phenyl which is unsubstituted, or mono- or di- substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy
  • said orf/70-substituent is phenyl which is unsubstituted, mono-, or di- substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of
  • said orf/70-substituent is 6-membered heteroaryl (especially pyridyl or pyrimidinyl) which is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, and (C 1-3 )fluoroalkyl (especially (C 1 -4 )alkyl, (C 1-4 )alkoxy); or o said orf/70-substituent is 5-membered heteroaryl which is unsubstituted, or mono-substituted (especially unsubstituted), wherein
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein
  • ring A-i represents 5-membered heteroaryl, wherein the 5- membered heteroaryl is mono- or di-substituted;
  • said orffro-substituent is phenyl which is unsubstituted, or mono-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl and halogen;
  • ring A-i represents 6-membered heteroaryl, wherein the 6- membered heteroaryl is mono-, or di-substituted;
  • said orf/70-substituent is unsubstituted 5-membered heteroaryl (notably pyrazol-1-yl or [1 ,2,3]triazol-2-yl, especially in case Ar 1 represents pyridyl); or
  • said orf/70-substituent is unsubstituted 6-membered heteroaryl (notably pyridin-2-yl, especially in case Ar 1 represents pyridyl); or o said orf/70-substituent is phenyl which is unsubstituted, or mono- substituted (especially mono-substituted), wherein the substituents are independently selected from the group consisting of (C 1-4 )alkoxy and halogen;
  • said orf/70-substituent is unsubstituted phenyl
  • said orf/70-substituent is unsubstituted 6-membered heteroaryl (especially pyridyl or pyrimidinyl);
  • o or said orffro-substituent is 5-membered heteroaryl which is unsubstituted, or mono-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (notably methyl);
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7) and 15) to 18), or to compounds of formula (II) according to any one of embodiments 9) to 18), wherein the following characteristics are present:
  • ring A-i represents a 5-membered heteroaryl group, such group is an oxazolyl, imidazolyl, or thiazolyl group (especially a thiazolyl group); and/or
  • ring A-i represents a 6-membered heteroaryl group, such group is a pyridinyl, pyrazinyl, or pyrimidinyl group (especially a pyridinyl group);
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7) and 15) to 18), or to compounds of formula (II) according to any one of embodiments 9) to 19), wherein the following characteristics are present:
  • ring ⁇ represents a 5-membered heteroaryl group, such group is a triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1 -yl, or unsubstituted 2H-pyrazol-3-yl), an oxazolyl (especially unsubstituted oxazol-2-yl), or an oxadiazolyl (especially 3-methyl- [1 ,2,4]oxadiazol-5-yl); [notably such group is unsubstituted [1 ,2,3]triazol-2-yl or unsubstituted pyrazol-1 -yl]; and/or
  • ring A-i represents a 6-membered heteroaryl group
  • such group is a pyridinyl or a pyrimidinyl group (especially 6-methoxy- pyridin-3-yl, pyridin-2-yl, pyridin-3-yl, or pyrimidin-2-yl; notably unsubstituted pyridin-2-yl or unsubstituted pyrimidin-2-yl);
  • a further embodiment relates to compounds compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A-i, respectively ring ⁇ , represents a ring
  • X 5 , X 6 , X 7 , and X 8 represent ring carbon atoms; or one of X 5 and X 8 represents a ring nitrogen atom and the remaining of X 5 , X 6 , X 7 , and X 8 represent ring carbon atoms; or X 5 and X 8 represent ring nitrogen atoms and X 6 and X represent ring carbon atoms; or X 5 and X represent ring nitrogen atoms and X 6 and X 8 represent ring carbon atoms;
  • (R x ) m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; and
  • Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy.
  • a further embodiment relates to compounds compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A ; respectively ring ⁇ , represents a ring wherein one of X 5 and X 8 represents a ring nitrogen atom and the remaining of X 5 , X 6 , X 7 , and X 8 represent ring carbon atoms; or X 5 and X 8 represent ring nitrogen atoms and X 6 and X represent ring carbon atoms; or X 5 and X represent ring nitrogen atoms and X 6 and X 8 represent ring carbon atoms;
  • (R x ) m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; and
  • Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy.
  • Ar 4 is selected from the group consisting of unsubstituted or mono-substituted phenyl wherein the substituent is selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen (especially such group is phenyl, 3-methyl-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 3-chlorophenyl, or 3-methoxyphenyl; notably phenyl); triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl); pyrazolyl (especially unsubstituted pyrazol-1 -yl, or unsubstituted 2H-pyrazol-3-yl); pyridyl (especially unsubstituted pyridin-2-yl); and pyrimidinyl (especially unsubsti
  • (R x )m represents one or two optional substituents independently selected from (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, and (Ci -3 )fluoroalkyl.
  • a further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A ; respectively ring ⁇ , represents a ring
  • X 9 represents O, S, or NH
  • R y represents hydrogen or (Ci -4 )alkyl
  • Ar 5 represents phenyl or 6-membered heteroaryl; wherein said phenyl or 6-membered heteroaryl independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (C 1-3 )fluoroalkyl, and (C 1-3 )fluoroalkoxy.
  • Another embodiment relates to compounds according to embodiment 24), wherein
  • Ar 5 represents phenyl, wherein said phenyl is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen (especially such group is phenyl, 3-methyl-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3- chlorophenyl, or 3-methoxyphenyl); and
  • R y represents hydrogen or (Ci -4 )alkyl (especially hydrogen or methyl).
  • a third aspect of the invention relates to compounds of the formula (I) as defined in embodiment 1 ) which are also compounds of the formula (III):
  • R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (III), R represents especially hydrogen);
  • X-i represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X 2 , X3, and/or X 4 ; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen;
  • X 5 , X 6 , X 7 , and X 8 represent ring carbon atoms; or one of X 5 and X 8 represents a ring nitrogen atom and the remaining of X 5 , X 6 , X 7 , and X 8 represent ring carbon atoms; or X 5 and X 8 represent ring nitrogen atoms and X 6 and X represent ring carbon atoms; or X 5 and X represent ring nitrogen atoms and X 6 and X 8 represent ring carbon atoms;
  • Ar 2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of
  • Ar 2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro;
  • (R x )m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; and Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy;
  • a fourth aspect of the invention relates to novel compounds of the formula (I) as defined in embodiment 1 ), which are also compounds of the formula (IV):
  • R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (IV), R represents especially hydrogen);
  • Ar 2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, hydroxy, (C 1-4 )alkoxy-(C 1-3 )alkyl, hydroxy-(C 1-3 )alkyl, -CO-(C 1-4 )alkyl, and (C 3-6 )cycloalkyl-oxy-; or Ar 2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or
  • (R x )m represents one or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; and
  • Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy;
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol-diyl, oxazol-diyl, thiazol-diyl, and thiadiazol- diyl.
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • meta di-substituted 5-membered heteroarylene ring independently selected from one, or more (in any combination), or all of the following groups A) to J) [especially said meta di-substituted 5-membered heteroarylene ring is selected from B) or E); notably B)]:
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X 2 , X3, and/or X 4 ; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; provided that said 5-membered heteroarylene ring is not [1 ,3,4]oxadiazol-2,5-diyl.
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • meta di-substituted 5-membered heteroarylene ring independently selected from one, or more (in any combination), or all of the following groups A) to I) [especially said meta di- substituted 5-membered heteroarylene ring is selected from A) or D); notably A)]:
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • meta di-substituted 5-membered heteroarylene ring independently selected from one, or more (in any combination), or all of the following groups A) to C) [especially said meta di-substituted 5-membered heteroarylene ring is selected from A) or C); notably A)]:
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
  • a further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring represents
  • a further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A 2 , respectively ring A' 2 , respectively Ar 2 , represents
  • phenyl which is unsubstituted, or mono-, di-, or tri-substituted (especially unsubstituted, or mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, cyano,
  • heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkyl, and -CO-(C 1-4 )alkyl.
  • a further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A 2 , respectively ring A' 2 , respectively Ar 2 , represents
  • phenyl which is unsubstituted, or mono-, di-, or tri-substituted (notably unsubstituted, or mono- or di-substituted; especially mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, (C 3-6 )cycloalkyl, halogen, (Ci -3 )fluoroalkyl, (Ci -3 )fluoroalkoxy; hydroxy, (Ci- 4 )alkoxy-(Ci -3 )alkyl, and hydroxy-(Ci -3 )alkyl; or
  • heteroaryl is independently unsubstituted, or mono-, or di-substituted; wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, (C 1-3 )fluoroalkyl,
  • a further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A 2 , respectively ring A' 2 , respectively Ar 2 , represents
  • phenyl which is unsubstituted, or mono-, di-, or tri-substituted (notably unsubstituted, or mono- or di-substituted; especially mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci -4 )alkoxy, (C 3- 6)cycloalkyl, halogen, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; or
  • ring A 2 in a sub-embodiment, ring A 2 , respectively ring A' 2 , respectively Ar 2 , especially represents phenyl which is mono-, di-, or tri-substituted (notably mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy.
  • a further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A 2 , respectively ring A' 2 , respectively Ar 2 , represents
  • phenyl which is unsubstituted, or mono-, di-, or tri-substituted (notably unsubstituted, or mono- or di-substituted; especially mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, (Ci -3 )fluoroalkyl, (Ci -3 )fluoroalkoxy; hydroxy, (Ci- 4 )alkoxy-(Ci -3 )alkyl, and hydroxy-(Ci -3 )alkyl; or
  • ⁇ 8- to 10-membered heteroaryl selected from indolyl, pyrrolopyridyl, imidazothioazolyl, and indazolyl; wherein said heteroaryl is independently unsubstituted, or mono- substituted; wherein the substituent is independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and -CO-(Ci -4 )alkyl.
  • a further embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein one or more of the following characteristics are present:
  • Ar 4 represents a 5-membered heteroaryl group
  • such group is a triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1-yl, or unsubstituted 2H-pyrazol-3-yl), an oxazolyl (especially unsubstituted oxazol-2-yl), or an oxadiazolyl (especially 3-methyl-[1 ,2,4]oxadiazol-5-yl); [notably such group is unsubstituted [1 ,2,3]triazol-2-yl or unsubstituted pyrazol-1 -yl]; and/or
  • Ar 4 represents a 6-membered heteroaryl group, such group is a pyridinyl or a pyrimidinyl group (especially 6-methoxy-pyridin-3-yl, pyridin-2-yl, pyridin-3-yl, or pyrimidin-2-yl; notably unsubstituted pyridin-2-yl or unsubstituted pyrimidin-2-yl) and/or
  • Ar 4 represents a phenyl group
  • such phenyl group is an unsubstituted or mono- substituted phenyl group wherein the substituent is selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen (especially such group is phenyl, 3-methyl- phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 3- methoxyphenyl; notably phenyl);
  • Another embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
  • Ar 4 is selected from the group consisting of unsubstituted triazolyl (especially [1 ,2,3]triazol- 2-yl); unsubstituted pyrazolyl (especially pyrazol-1-yl, or 2H-pyrazol-3-yl); unsubstituted oxazolyl (especially oxazol-2-yl); oxadiazolyl mono-substituted with methyl (especially 3- methyl-[1 ,2,4]oxadiazol-5-yl); unsubstituted pyridyl (especially pyridin-2-yl); unsubstituted pyrimidinyl (especially pyrimidin-2-yl); and unsubstituted or mono-substituted phenyl wherein the substituent is selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen (especially such phenyl group is phenyl, 3-methyl
  • a further embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
  • Ar 4 represents a 5-membered heteroaryl group, selected from the group consisting of a triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1-yl, or unsubstituted 2H-pyrazol-3-yl), an oxazolyl (especially unsubstituted oxazol- 2-yl), and an oxadiazolyl group (especially 3-methyl-[1 ,2,4]oxadiazol-5-yl); [notably Ar 4 represents unsubstituted [1 ,2,3]triazol-2-yl or unsubstituted pyrazol-1 -yl]; wherein said groups independently are unsubstituted or substituted as defined in any one of the preceeding embodiments, or as explicitly defined herein; and
  • (R x ) m represents one or two optional substituents (especially (R x ) m represents one or two substituents) independently selected from (C 1-4 )alkyl, (C 1-4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy (in particular: methyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, and trifluoromethoxy).
  • Another embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
  • Ar 4 represents unsubstituted triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl); or unsubstituted pyrimidinyl (especially unsubstituted pyrimidin-2-yl); and
  • (R x ) m represents one or two substituents independently selected from (Ci_4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy (in particular: methyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, and trifluoromethoxy).
  • a further embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
  • Ar 4 represents unsubstituted [1 ,2,3]triazol-2-yl
  • R x ) m represents one or two substituents independently selected from (C 1-4 )alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy (in particular: methyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, and trifluoromethoxy).
  • a further embodiment relates to compounds of formulae (I), (II), (III), or (IV) according to any one of embodiments 1 ) to 41 ), wherein
  • the group is a group independently selected from one, or more (in any combination), or all of the following groups A) to C) [i.e. the group iii) being selected from groups A) or B); the group iv) being selected from groups A)]:
  • each of the groups A), B), C) and D) forms a particular sub-embodiment [and said group is especially selected from groups A) and B); notably from A1 )].
  • a further embodiment relates to compounds of formulae (I), (II), (III), or (IV) according to any one of embodiments 1 ) to 48), wherein
  • each of the groups A) to H) [notably the groups A) and B)] and their respective subgroups [notably the subgroups A1 ) and B1 )] forms a particular sub-embodiment.
  • a further embodiment relates to compounds of formulae (I), (II), (III), or (IV) according to any one of embodiments 1 ) to 48), wherein
  • each of the groups A) to E) and their respective subgroups forms a particular sub- embodiment [and said groups are especially selected from groups A), B), C), and D); notably from the groups A) and B); in particular from A1 ) and B1 )].
  • the invention thus, relates to compounds of the formula (I) as defined in embodiment 1), compounds of the formula (II) as defined in embodiment 9), compounds of the formula (III) as defined in embodiment 26), compounds of the formula (IV) as defined in embodiment 27); or to such compounds further limited by the characteristics of any one of embodiments 2) to 50), under consideration of their respective dependencies; to pharmaceutically acceptable salts thereof; and to the use of such compounds as medicaments especially in the treatment of mental health disorders relating to orexinergic dysfunctions, which disorders are as defined below and which are especially selected from sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders.
  • Especially the following embodiments relating to the compounds of formulae (I), (II), (III), and (IV) are thus possible and intended and herewith specifically disclosed in individualized form:
  • a further aspect of the invention relates to to compounds of the formula (I) according to embodiment 1 ), which are also compounds of the compounds of the formula (V); wherein the absolute configuration is as depicted in formula (V):
  • ring A 3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen; [wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent A 2 ; and that the ring A 3 does not carry any further substituent];
  • ring A 2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, cyano, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci -3 )alkyl, hydroxy-(Ci -3 )alkyl, -CO-(Ci-4)alkyl, and (C 3-6 )cycloalkyl-oxy-; or ring A 2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or
  • ring A represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted;
  • substituents are attached in orffro-position to the point of attachment of A to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy;
  • ring A is not isoxazol-4-yl, substituted in position 5 with (C 1-4 )alkyl, attached to the rest of the molecule at position 4, and carrying said further ortho- substitutent in position 3;
  • a further aspect of the invention relates to compounds of the formula (IV) according to embodiment 27), which are also compounds of the formula (VI); wherein the absolute configuration is as depicted in formula (VI):
  • Ar 2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C 1 -4 )alkyl, (Ci-4)alkoxy, (C 3 -6)cycloalkyl, halogen, cyano, (Ci -3 )fluoroalkyl, (Ci -3 )fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci -3 )alkyl, hydroxy-(Ci -3 )alkyl, -CO-(Ci-4)alkyl, and (C 3-6 )cycloalkyl-oxy-; or Ar 2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl,
  • (R x )m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; and
  • Ar 4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, cyano, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy;
  • Particular compounds according to embodiment 1 are selected from the group consisting of:
  • another particular compound according to embodiment 1 is (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- ⁇ (S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]W yl]-pyrrolidin-1-yl ⁇ -methanone.
  • a particular compound according to embodiment 1 is (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)- ⁇ (S)-2-methyl-2-[5-(2-trifluoromethoxy-ph
  • the compounds of formulae (I), (I I), (I I I), (IV), (V) and (VI) contain at least one stereogenic center which is situated in position 2 of the pyrrolidine moiety. It is understood that the absolute configuration of said chiral center is as depicted in formulae (I), (I I), (I II), (IV), (V) and (VI), i.e. it is in absolute (S) configuration.
  • the compounds of formula (I) and (I I) may contain one or more further stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
  • the compounds of formulae (I), (II), (I I I), (IV), (V) and (VI) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • the compounds of formulae (I), (I I), (I I I), (IV), (V) and (VI) may contain tautomeric forms.
  • Such tautomeric forms are encompassed in the scope of the present invention.
  • the present compounds contain heteroaromatic aromatic rings containing unsubstituted ring nitrogen atoms having a free valency such as imidazol-2,4-diyl, or [1 ,2,4]-triazol-3,5-diyl, such rings may be present in tautomeric forms.
  • the group imidazol-2,4-diyl represents the tautomeric forms 1 H-imidazol-2,4-diyl and 3H-imidazol-2,4-diyl; and the group [1 ,2,4]triazol-3,5-diyl represents the tautomeric forms 1 H-[1 ,2,4]triazol-3,5-diyl, 2H-[1 ,2,4]triazol-3,5-diyl and 4H-[1 ,2,4]triazol-3,5-diyl.
  • the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
  • isotopically labelled, especially 2 H (deuterium) labelled compounds of formulae (I), (II), (III), (IV), (V) and (VI) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g.
  • the compounds of formulae (I), (II), (III), (IV), (V) and (VI) are not isotopically labelled, or they are labelled only with one or more deuterium atoms.
  • the compounds of formulae (I), (II), (III), (IV), (V) and (VI) are not isotopically labelled at all. Isotopically labelled compounds of formulae (I), (II), (III), (IV), (V) and (VI) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
  • a dotted line shows the point of attachment of the radical drawn.
  • salts refers to non-toxic, inorg. or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201 -217.
  • halogen means fluorine, chlorine, or bromine, preferably fluorine or chlorine.
  • alkyl refers to a saturated straight or branched chain alkyl group containing one to six carbon atoms.
  • (C x-y )alkyl refers to an alkyl group as defined before, containing x to y carbon atoms.
  • a (Ci-4)alkyl group contains from one to four carbon atoms.
  • alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl.
  • cycloalkyl refers to a saturated cyclic alkyl group containing three to six carbon atoms.
  • (C x-y )cycloalkyl refers to a cycloalkyl group as defined before containing x to y carbon atoms.
  • a (C 3-6 )cycloalkyl group contains from three to six carbon atoms.
  • Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Preferred is cyclopropyl.
  • alkoxy refers to an alkyl-O- group wherein the alkyl group is as defined before.
  • (C x-y )alkoxy (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms.
  • a (Ci -4 )alkoxy group means a group of the formula (Ci -4 )alkyl-0- in which the term "(Ci -4 )alkyl” has the previously given significance.
  • alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy. Preferred are ethoxy and methoxy.
  • fluoroalkyl refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine.
  • (C x-y )fluoroalkyl (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms.
  • a (Ci -3 )fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine.
  • fluoroalkyl groups include trifluoromethyl, 2- fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred are (C-i)fluoroalkyl groups such as trifluoromethyl.
  • fluoroalkoxy refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine.
  • (C x-y )fluoroalkoxy (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms.
  • a (C 1-3 )fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine.
  • fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy.
  • aryl refers to a naphthyl or, preferably, to a phenyl group; wherein said group is unsubstituted or substituted as explicitly defined.
  • ring A-i respectively the ring ⁇ , representing a phenyl group wherein said phenyl is mono-, di-, or tri-substituted; wherein one of said substituents is attached in orffro-position to the point of attachment of ring A-i, respectively the ring ⁇ , to the rest of the molecule, are such that the other of said substituents, if present, is/are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen (especially methyl, methoxy and halogen).
  • halogen especially methyl, methoxy and halogen
  • X 5 to X 8 represent ring carbon atoms; respectively in the group
  • R x )m represents one or two optional substituents independently selected from (Ci -4 )alkyl, (Ci -4 )alkoxy, and halogen (especially methyl, methoxy and halogen).
  • Particular examples of the above mentioned phenyl groups are 1 ,2-phenylene, 4- methyl-1 ,2-phenylene, 5-methyl-1 ,2-phenylene, 4,5-dimethyl-1 ,2-phenylene, 3,5-dimethyl-1 ,2- phenylene, 3-methyl-1 ,2-phenylene, 6-methyl-1 ,2-phenylene, 5-fluoro-1 ,2-phenylene, 3-fluoro- 1 ,2-phenylene, 4-fluoro-1 ,2-phenylene, 4,5-difluoro-1 ,2-phenylene, 5-chloro-1 ,2-phenylene, 4- chloro-1 ,2-phenylene, 3-chloro-1 ,2-phenylene, 5-cyano-1 ,2-phenylene, 5-methoxy-1 ,2-
  • ring A 2 Particular examples of the ring A 2 , respectively the ring A' 2 , respectively Ar 2 ; representing an aryl group are especially phenyl groups which are unsubstituted, or mono-, di-, or tri- substituted; wherein the substituents are independently selected from the group consisting of (C -4 )alkyl, (C 1-4 )alkoxy, (C 3-6 )cycloalkyl, halogen, (C 1-3 )fluoroalkyl, (C 1-3 )fluoroalkoxy; hydroxy, (Ci- 4 )alkoxy-(Ci -3 )alkyl, and hydroxy-(Ci -3 )alkyl; [notably from (Ci -4 )alkyl, (Ci -4 )alkoxy, (C 3-6 )cycloalkyl, halogen, (Ci -3 )fluoroalkyl, and (Ci -3 )fluoroalkoxy; especially from methyl
  • Particular examples are phenyl, 2-methyl-phenyl, 2-ethyl-phenyl, 3-methyl-phenyl, 2,3-dimethyl-phenyl, 2,4-dimethyl- phenyl, 2,5-dimethyl-phenyl, 3,4-dimethyl-phenyl, 3,5-dimethyl-phenyl, 2-methoxy-phenyl, 3- methoxy-phenyl, 2-ethoxy-phenyl, 2-isopropoxy-phenyl, 2,3-dimethoxy-phenyl, 2- methoxymethyl-phenyl, 3-methoxy-2-methyl-phenyl, 3-methoxy-6-methyl-phenyl, 2-methoxy-5- methyl-phenyl, 3-methoxy-5-methyl-phenyl, 3-fluoro-2-methyl-phenyl, 2-fluoro-6-methyl-phenyl, 3-fluoro-2-methoxy-phenyl, 3-fluoro-2-ethoxy-phenyl, 2-chloro-pheny
  • Examples of the particular phenyl groups which are ortho substituents of ring A-i, respectively ring ⁇ , are unsubstituted or mono-substituted phenyl groups wherein the substituent is selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, and halogen (especially methyl, methoxy and halogen); such as especially phenyl, 3-methyl- phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, and 3-methoxyphenyl.
  • heteroaryl refers to a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1 to a maximum of 3 heteroatoms independently selected from oxygen, nitrogen and sulfur.
  • heteroaryl groups are 5- membered monocyclic heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, and triazolyl; 6- membered monocyclic heteroaryl such as pyridyl, pyrimidyl, pyridazinyl, and pyrazinyl; and 8- to 10-membered bicyclic heteroaryl such as indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl
  • Examples of the particular 5- or 6-membered heteroaryl groups which are further substituted in ortho position as used for the ring A ; respectively ring ⁇ , are the above mentioned 5- or 6- membered heteroaryl groups, notably oxazolyl (in particular oxazol-4,5-diyl, 2-methyl-oxazol- 4,5-diyl), thiazolyl (in particular thiazol-4,5-diyl, 2-methyl-thiazol-4,5-diyl), imidazolyl (in particular imidazol-4,5-diyl), pyridyl (in particular pyridin-2,3-diyl, 6-methyl-pyridin-2,3-diyl), pyrimidyl (in particular pyrimidin-4,5-diyl, 2-methyl-pyrimidin-4,5-diyl), and pyrazinyl (in particular pyrazin-2,3-diyl).
  • oxazolyl in particular ox
  • These groups are at least mono-substituted in ortho position, and preferably carry no further substituent or one further substitutent as explicitly defined.
  • optional further substituent is (Ci-4)alkyl, notably methyl.
  • the above groups are preferably attached to the rest of the molecule (i.e. the carbonyl group) in position 4 of oxazolyl, imidazolyl, or thiazolyl groups, in position 2 or 3 of pyridyl or pyrazinyl groups, or in position 5 of pyrimidinyl groups.
  • examples of such groups are thiazol-4,5-diyl, 2- methyl-thiazol-4,5-diyl, oxazol-4,5-diyl, 2-methyl-oxzol-4,5-diyl, imidazol-4,5-diyl, pyrimidin-4,5- diyl, 2-methyl-pyrimidin-4,5-diyl, pyridin-2,3-diyl and 6-methyl-pyridin-2,3-diyl.
  • particular examples of the group are thiazol-4,5-diyl, 2- methyl-thiazol-4,5-diyl, oxazol-4,5-diyl, 2-methyl-oxzol-4,5-diyl, imidazol-4,5-diyl, pyrimidin-4,5- diyl, 2-methyl-pyrimidin-4,5-diyl, pyridin-2,3-diyl and 6-methyl-pyridin-2,3-diyl.
  • X 5 to X 7 are pyrimidin-4,5-diyl, 2- methyl-pyrimidin-4,5-diyl, pyridin-2,3-diyl and 6-methyl-pyridin-2,3-diyl.
  • ring A 2 representing a 5- to 10-membered heteroaryl are especially 5- to 10-membered heteroaryl groups which are unsubstituted, or mono-substituted; wherein the substituent is selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, (C 3- 6)cycloalkyl, halogen, (Ci -3 )fluoroalkyl, (Ci -3 )fluoroalkoxy, -CO-(Ci -4 )alkyl, and (C 3 -6)cycloalkyl-oxy- [notably from (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkoxy, -CO-(Ci -4 )alkyl, and (C 3-6 )cycloalkyl-oxy-].
  • heteroaryl groups are 6-membered heteroaryl groups, such as pyrazinyl, pyrimidyl and notably pyridyl groups, which groups are unsubstituted, or mono-substituted; wherein the substituent is selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, (Ci -3 )fluoroalkoxy, and (C 3-6 )cycloalkyl-oxy- (especially methyl, methoxy, ethoxy, isopropoxy, halogen, difluoromethoxy, and cyclobutyloxy); such as especially 2-(cyclobutyl- oxy)-pyridin-3-yl, 2-difluoromethoxy-pyridin-3-yl, 2-isopropoxy-pyridin-3-yl, 2-ethoxy-pyridin-3-yl, 3-ethoxy-pyridin-4-yl, 6-ethoxy-
  • heteroaryl groups are 8- to 10-membered heteroaryl groups, such as imidazothiazolyl, indazolyl, pyrrolopyridyl (especially 1 H-pyrrolo[2,3-b]pyridinyl) and notably indolyl groups which are groups are unsubstituted, or mono-substituted; wherein the substituent is selected from the group consisting of (C 1-4 )alkyl, (C 1-4 )alkoxy, and -CO-(C 1-4 )alkyl (especially methyl, methoxy, and acetyl); such as especially indol-3-yl, 1-methyl-indol-3-yl, 4-methyl-indol- 3-yl, 1 -acetyl-indol-3-yl, indol-4-yl, 1 -methyl-indol-4-yl, indol-7-yl, 1-methyl-indol-7-yl,
  • Examples of the particular 5- or 6-membered heteroaryl groups which are ortho substituents of ring A-i , respectively ring ⁇ , are the above mentioned 5- or 6- membered heteroaryl groups, notably oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, and pyrazinyl.
  • the above mentioned groups are preferably unsubstituted or may be substituted as explicitly defined.
  • Preferred examples are triazolyl (notably unsubstituted [1 ,2,3]triazol-2-yl), pyrazolyl (notably unsubstituted pyrazol-1-yl, or unsubstituted 2H-pyrazol-3-yl), oxazolyl (notably unsubstituted oxazol-2-yl), oxadiazolyl (notably 3-methyl-[1 ,2,4]oxadiazol-5-yl); pyridinyl (notably unsubstituted pyridin-2-yl), and pyrimidinyl (notably unsubstituted pyrimidin-2-yl) [notably unsubstituted [1 ,2,3]triazol-2-yl, unsubstituted pyrazol-1-yl, and unsubstituted pyrimidin-2-yl].
  • An example of such group is 2,2-difluoro-benzo[1 ,3]dioxol-5-yl.
  • the compounds of compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject in need thereof a pharmaceutically active amount of a compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58).
  • the administered amount of such a compound of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) is comprised between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day.
  • the compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) are useful for the prevention or treatment of disorders relating to orexinergic dysfunctions.
  • disorders relating to orexinergic dysfunctions are diseases or disorders where an antagonist of a human orexin receptor is required, notably mental health disorders relating to orexinergic dysfunctions.
  • the above mentioned disorders may in particular be defined as comprising sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.
  • the above mentioned disorders comprise especially sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, and appetite disorders.
  • the above mentioned disorders comprise especially sleep disorders, anxiety disorders, and addiction disorders.
  • the above mentioned disorders comprise especially sleep disorders.
  • disorders relating to orexinergic dysfunctions are selected from treating, controlling, ameliorating or reducing the risk of epilepsy, including absence epilepsy; treating or controlling pain, including neuropathic pain; treating or controlling Parkinson's disease; treating or controlling psychosis including acute mania and bipolar disorder; treating or controlling stroke, particularly ischemic or haemorrhagic stroke; blocking an emetic response i.e. nausea and vomiting; and treating or controlling agitation, in isolation or co-morbid with another medical condition.
  • disorders relating to orexinergic dysfunctions are selected from schizoaffective disorders; dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; increased anaesthetic risk; anaesthetic responsiveness; hypothalamic-adrenal dysfunctions; all types of amnesia; severe mental retardation; dyskinesias and muscular diseases; muscle spasticity; tremors; movement disorders; spontaneous and medication- induced dyskinesias; neurodegenerative disorders including Huntington's, Creutzfeld-Jacob's, Alzheimer's diseases and Tourette syndrome; Amyotrophic lateral sclerosis; Parkinson's disease; Cushing's syndrome; traumatic lesions; spinal cord trauma; head trauma; perinatal hypoxia; hearing loss; tinnitus; demyelinating diseases; spinal and cranial nerve diseases; ocular damage; retinopathy; seizure disorders; complex partial and generalized seizures; Lennox-Gastau
  • a further disorder relating to orexinergic dysfunctions is sundowning (or sundown syndrome).
  • Anxiety disorders can be distinguished by the primary object or specificity of threat, ranging from rather diffuse as in generalized anxiety disorder, to circumscribed as encountered in phobic anxieties (PHOBs) or post-traumatic stress disorders (PTSDs).
  • Anxiety disorders may, thus, be defined as comprising generalized anxiety disorders (GAD), obsessive compulsive disorders (OCDs), acute stress disorders, posttraumatic stress disorders (PTSDs), panic anxiety disorders (PADs) including panic attacks, phobic anxieties (PHOBs), specific phobia, social phobia (social anxiety disorder), avoidance, somatoform disorders including hypochondriasis, separation anxiety disorder, anxiety disorders due to a general medical condition, and substance induced anxiety disorders.
  • circumscribed threat induced anxiety disorders are phobic anxieties or post-traumatic stress disorders.
  • Anxiety disorders especially include post-traumatic stress disorders, obsessive compulsive disorders, panic attacks, phobic anxieties, and avoidance.
  • Addiction disorders may be defined as addictions to one or more rewarding stimuli, notably to one rewarding stimulus. Such rewarding stimuli may be of either natural or synthetic origin.
  • Examples of such rewarding stimuli are substances / drugs ⁇ of either natural or synthetic origin; such as cocaine, amphetamines, opiates [of natural or (semi-)synthetic origin such as morphine or heroin], cannabis, ethanol, mescaline, nicotine, and the like ⁇ , which substances / drugs may be consumed alone or in combination; or other rewarding stimuli ⁇ of either natural origin (such as food, sweet, fat, or sex, and the like), or synthetic origin [such as gambling, or internet/IT (such as immoderate gaming, or inappropriate involvement in online social networking sites or blogging), and the like] ⁇ .
  • natural origin such as food, sweet, fat, or sex, and the like
  • synthetic origin such as gambling, or internet/IT (such as immoderate gaming, or inappropriate involvement in online social networking sites or blogging), and the like
  • addiction disorders relating to psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components.
  • Substance- related addiction disorders especially include substance use disorders such as substance dependence, substance craving and substance abuse; substance-induced disorders such as substance intoxication, substance withdrawal, and substance-induced delirium.
  • substance use disorders such as substance dependence, substance craving and substance abuse
  • substance-induced disorders such as substance intoxication, substance withdrawal, and substance-induced delirium.
  • prevention or treatment of addictions i.e.
  • preventive or curative treatment of patients who have been diagnosed as having an addiction, or as being at risk of developing addictions refers to diminishing addictions, notably diminishing the onset of addictions, to weakening their maintenance, to facilitating withdrawal, to facilitating abstinence, or to attenuating, decreasing or preventing the occurrence of reinstatement of addiction (especially to diminishing the onset of addictions, to facilitating withdrawal, or to attenuating, decreasing or preventing the occurrence of reinstatement of addiction).
  • Mood disorders include major depressive episode, manic episode, mixed episode and hypomanic episode; depressive disorders including major depressive disorder, dysthymic disorders; bipolar disorders including bipolar I disorder, bipolar II disorder (recurrent major depressive episodes with hypomanic episodes), cyclothymic disorder; mood disorders including mood disorder due to a general medical condition (including the subtypes with depressive features, with major depressive-like episode, with manic features, and with mixed features), substance-induced mood disorder (including the subtypes with depressive features, with manic features, and with mixed features).
  • mood disorders are especially major depressive episode, major depressive disorder, mood disorder due to a general medical condition; and substance-induced mood disorder.
  • Appetite disorders comprise eating disorders and drinking disorders.
  • Eating disorders may be defined as comprising eating disorders associated with excessive food intake and complications associated therewith; anorexias; compulsive eating disorders; obesity (due to any cause, whether genetic or environmental); obesity-related disorders including overeating and obesity observed in Type 2 (non-insulin-dependent) diabetes patients; bulimias including bulimia nervosa; cachexia; and binge eating disorder.
  • Particular eating disorders comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; bulimia or anorexia nervosa.
  • eating disorders may be defined as especially comprising anorexia nervosa, bulimia, cachexia, binge eating disorder, or compulsive obesities.
  • Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake.
  • Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance.
  • Cognitive dysfunctions include deficits in attention, learning and especially memory functions occurring transiently or chronically in psychiatric, neurologic, neurodegenerative, cardiovascular and immune disorders, and also occurring transiently or chronically in the normal, healthy, young, adult, or especially aging population. Cognitive dysfunctions especially relate to the enhancement or maintenance of memory in patients who have been diagnosed as having, or being at risk of developing, diseases or disorders in which diminished memory (notably declarative or procedural) is a symptom [in particular dementias such as frontotemporal dementia, or dementia with Lewy bodies, or (especially) Alzheimer's disease].
  • prevention or treatment of cognitive dysfunctions relates to the enhancement or maintenance of memory in patients who have a clinical manifestation of a cognitive dysfunction, especially expressed as a deficit of declarative memory, linked to dementias such as frontotemporal dementia, or dementia with Lewy bodies, or (especially) Alzheimer's disease. Furthermore, the term “prevention or treatment of cognitive dysfunctions” also relates to improving memory consolidation in any of the above mentioned patient populations.
  • Sleep disorders comprise dyssomnias, parasomnias, sleep disorders associated with a general medical condition and substance-induced sleep disorders.
  • dyssomnias include intrinsic sleep disorders (especially insomnias, breathing-related sleep disorders, periodic limb movement disorder, and restless leg syndrome), extrinsic sleep disorders, and circadian-rythm sleep disorders.
  • Dyssomnias notably include insomnia, primary insomnia, idiopathic insomnia, insomnias associated with depression, emotional/mood disorders, aging, Alzheimer's disease or cognitive impairment; REM sleep interruptions; breathing-related sleep disorders; sleep apnea; periodic limb movement disorder (nocturnal myoclonus), restless leg syndrome, circadian rhythm sleep disorder; shift work sleep disorder; and jet-lag syndrome.
  • Parasomnias include arousal disorders and sleep-wake transition disorders; notably parasomnias include nightmare disorder, sleep terror disorder, and sleepwalking disorder.
  • Sleep disorders associated with a general medical condition are in particular sleep disorders associated with diseases such as mental disorders, neurological disorders, neuropathic pain, and heart and lung diseases.
  • Substance-induced sleep disorders include especially the subtypes insomnia type, parasomnia type and mixed type, and notably include conditions due to drugs which cause reductions in REM sleep as a side effect. Sleep disorders especially include all types of insomnias, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift work sleep disorder, delayed or advanced sleep phase syndrome, or insomnias related to psychiatric disorders.
  • sleep disorders further include sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness.
  • the present compounds may be particularly useful for the treatment of such environmentally conditioned disorder or disease.
  • the present compounds can be prepared by well known literature methods, by the methods given below, by the methods given in the experimental part or by analogous methods.
  • Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
  • the final product may be further modified, for example, by manipulation of substituents to give a new final product. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art.
  • the order of carrying out the following reaction schemes, and/or reaction steps may be varied to facilitate the reaction or to avoid unwanted reaction products.
  • the generic groups R, A-i , A 2 , and A 3 are as defined for formula (I).
  • the generic groups A-i , A 2 , and A 3 may be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG).
  • protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place.
  • the compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se. Compounds are synthesized as their S- enantiomers from commercially available proline, 2-methyl-proline, or derivatives thereof.
  • a 3 is a [1 ,2,4]oxadiazol-3,5-diyl-
  • compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme A and B.
  • Compounds of structure A-1 can be coupled with commercially available L-proline methyl ester HCI using standard amide coupling conditions such as EDC/HOBt, HOAt/DCC, TBTU, HATU or PyBOP in the presence of a base such as DIPEA or Et 3 N at rt in a suitable solvent such as DCM, DMF, MeCN or mixtures thereof (Step a, Reaction Scheme A).
  • Carboxylic acids A-1 are well known in the art and can be especially prepared following the procedures reported in WO2008069997, WO2008008517, WO2010048012, WO2010063662, WO2010063663, WO201 1050198, WO201 1050200 and WO201 1050202. In addition, they may be prepared in analogy to the methods given in the experimental part.
  • nitrile-derivatives may be reacted with hydroxylamine under neutral or basic conditions such as NEt 3 , DIPEA, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide, potassium ferf-butoxide and the like in a suitable solvent (methanol, ethanol, etc) to obtain hydroxyamidine A-4.
  • the reaction typically proceeds by allowing the reaction temperature to go from rt to a range of 65-80°C, for about 30 min to several days (see WO 2006/12349, Lucca et al J. Med. Chem. 1998, 241 1 -2423).
  • Reaction Scheme C the synthesis starts with the coupling of commercially available (S)- pyrrolidine-2-carbonitrile and carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as mentioned in Step a, Reaction Scheme A.
  • the intermediates C-1 are converted to hydroxyamidines of structure C-2 in the presence of hydroxylamine, base such as NaHC0 3 in solvents such as MeOH.
  • the acyl-hydroxyamidine intermediates of structure C-4 can be synthesized by reacting compounds of structure C-2 with commercially available carboxylic acids C-3, in the presence of coupling reagents, base and solvents such as mentioned in Step c, Reaction Scheme A.
  • the cyclization of compounds of structure C-4 can be achieved thermally as mentioned in Step d, Reaction Scheme A, to yield compounds of formula (I).
  • the commercially available (S)-1 -Boc-pyrrolidine-2-carbonitrile can be converted to hydroxyamidine of structure D-1 , using methods described in Step b, Reaction Scheme C.
  • the acyl-hydroxyamidines of structure D-2 can be synthesized from coupling compounds of structure D-1 with compounds of structure C-3 as depicted in Step c, Reaction Scheme A.
  • the cyclization of compounds of structure D-2 can be achieved thermally as mentioned in Step d, Reaction Scheme A to yield compounds of structure D-3. Boc-deprotection using standard methods as mentioned in Step c, Scheme B lead to compounds D-4.
  • Reaction Scheme A furnishes compounds of formula (I).
  • a 3 is an isoxazol-3,5-diyl-
  • compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme E (Step a to d).
  • compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme E (Step e to h).
  • the commercially available Boc-L- prolinal was converted to the oxime E-5 using hydroxylamine HCI and NaOAc in solvents such as MeOH.
  • Isoxazoles E-7 can be synthesized by click chemistry of alkynes E-6 with oximes E-5 in the presence of chloramine T trihydrate in solvents such as MeOH at elevated temperature of about 70°C (Step f, Reaction Scheme E). Boc-deprotection using standard methods such as mentioned in Step c, Scheme B lead to compounds of structure E-8.
  • Reaction of amines E-8 with acid A-1 in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A furnishes compounds of formula (I).
  • a 3 is a [1 ,3,4]-oxadioxazol-2,5-diyl- compounds of formula (I) may in general be prepared as illustrated in Reaction Schemes F and G.
  • the commercially available Boc-L-proline can be coupled with hydrazides of structure F-1 , either commercially available or synthesized from commercially available carboxylic acid or esters according to procedures known by persons skilled in the art to yield derivatives F-2.
  • Cyclization to 1 ,3,4,dioxazoles can be achieved in presence of Burgess' reagent, in a solvent such as dioxane at elevated temperatures of 1 10-120°C under microwave irradiation for several minutes up to hours.
  • Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure F-4.
  • Amide coupling of amine F-4 with acids of A-1 in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
  • Methylesters of structure A-2 can be converted to hydrazides of structure G-3, using an excess of hydrazine in the presence or absence of coupling reagents such as TBTU or DMAP and base such as DIPEA in solvents such as DMF at rt.
  • coupling reagents such as TBTU or DMAP and base such as DIPEA in solvents such as DMF at rt.
  • Intermediates of structure G-4 can be synthesized by reacting compounds of structure G-3 with carboxylic acids C-3 in the presence of coupling reagents, base and solvents such as mentioned in Step c, Reaction Scheme A. Cyclization to a compound of formula (I) can be achieved in presence of Burgess' reagent, in solvents such as dioxane at elevated temperatures of about 120°C under microwave irradiation for several minutes up to hours.
  • Compounds of structure 1-1 are either commercially available or prepared by known literature methods from the corresponding methyl-ketone-analog.
  • Compounds of structure I-2 can be synthesized from A-3 and 1-1 in the presence of base such as K 2 C0 3 , in solvents such as DMF at ambient or elevated temperature. Cyclization can be achieved in the presence of acetamide and catalytic amounts of BF 3 - Et 2 0 in solvents or solvent mixtures such as diethylether and/or o-xylene at elevated temperature of about 120-140°C to yield compounds of formula (I).
  • Boc-L-proline can react with compounds of structure 1-1 to form compounds of structure I-3 under basic conditions such as K 2 C0 3 in solvents such as DMF at ambient or elevated temperature. Cyclization can be performed as outlined in Step b, Reaction Scheme I, or in presence of ammonium acetate in acetic acid at elevated temperature (see US 6,660,759, 2003), leading to compounds of structure I-4. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure I-5. Amide coupling of amines of structure I-5 with acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
  • Compounds of structure J-1 or a salt thereof are either commercially available or prepared by known literature methods. Coupling of compounds of structure A-3 with J-1 can be performed in the presence of coupling reagents, base and solvents such as mentioned in Step c, Reaction Scheme A.
  • Intermediate J-2 can be cyclized to compounds of formula (I) in the presence of polyphosphoric acid at elevated temperature of about 150°C adapted from the procedure described in WO2003/002559 or by using trifluoromethanesulfonic anhydride in the presence of pyridine in DCM at ambient temperature (see US 2006-19975).
  • the commercially available (S)-pyrrolidine-2-carbonitrile HCI can be coupled with carboxylic acids of structure A-1 to intermediate C-1 , in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A.
  • Reaction of nitriles of structure C- 1 with hydrazides of structure F-1 in the prescence of base such as K 2 C0 3 in solvent such as n- BuOH at elevated temperature of about 160°C in presence or absence of microwave irradiation furnishes compounds of formula (I).
  • Synthesis can be performed in accordance to published methods (WO2008/144380 for Step a and b).
  • the commercially available Boc-L-proline can be coupled with compounds of structure J-1 in the presence of coupling reagents, base and solvents as outlined in Step d,
  • Reaction Scheme B furnishes intermediates of structure L-1 , which may undergo cyclization to compounds of structure L-3, in the prescence of ammonium acetate in solvents such as acetic acid or mixture of acetic acid and xylene at elevated temperatures of about 1 10°C.
  • Boc- deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure L-4.
  • Amide coupling of amines of structure L-4 with carboxylic acids of structure A-1 in the presence of coupling reagents, base and solvents as outlined in Step d
  • Reaction Scheme B furnishes compounds of formula (I).
  • the commercially available (S)-1 -Boc-pyrrolidine-2-carbonitrile can be converted to the amidine L-2 in the presence of a base such as NaOMe and ammonium bromide in solvents such as MeOH at ambient temperature.
  • a base such as NaOMe and ammonium bromide
  • compounds of structure L-2 can react with compounds of structure 1-1 to compounds of structure L-3, in presence of a base such as K 2 C0 3 , in solvents such as DMF at ambient temperature.
  • Step e and f leads to compounds of formula (I).
  • a 3 is a [1 ,2,4]triazol-1 ,3-diyl-
  • compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme O. Synthesis can be performed in accordance to published methods (WO2005/121 131 ). Imidate of structure 0-1 can be synthesized from commercially available (S)-1-Boc-pyrrolidine-2- carbonitrile in the presence of NaOMe in solvents such as MeOH at ambient temperature.
  • Triazoles of structure 0-3 can be prepared in a two step reaction from compound of structure 0-1 and hydrazine of structure 0-2 in the presence of base such as trietyhlamine in solvent such as MeOH at rt for hours or several days and subsequent addition of triethyl orthoformate in pyridine and heating to 120° for several hours.
  • Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure 0-4.
  • Amide coupling of amines of structure 0-3 with carboxylic acids of structure A-1 in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
  • Compounds of formula (I), wherein R is methyl can be prepared from commercially available 2- methyl-proline or derivatives thereof in analogy to the methods given above.
  • a 3 is a [1 ,2,4]oxadiazol-3,5-diyl-
  • compounds of formula (I) may be prepared as outlined in Reaction Scheme Q.
  • the commercially available 2-methyl-L-proline HCI can be Boc-protected with Boc 2 0 in the presence of TEA, DIPEA or Na 2 C0 3 in solvents such as MeCN, DCM, THF and H 2 0 or mixtures thereof at rt within hours to days.
  • the obtained compound of structure Q-1 may be coupled with hydroxyamidines of structure A-4 to obtain acyl-hydroxyamidines of structure Q-2 (Step b, Reaction Scheme Q).
  • the coupling reaction may be promoted by coupling reagents outlined in Step c, Reaction Scheme A. Cyclization is performed as outlined in Step d, Reaction Scheme A, leading to compounds of structure Q-3 (Step c, Reaction Scheme Q). Boc-deprotection of compounds of structure Q-3 by using standard methods such as treatment with 4N HCI in dioxane or with TFA leads to compounds of structure Q-4 (Step d, Reaction Scheme Q).
  • Reaction of compounds of Q-4 with acids of structure A-1 in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A furnishes compounds of formula (I) (Step e, Reaction Scheme Q).
  • compounds of structure A-1 can be converted into the corresponding acid chloride (using standard reagents such as thionylchloride) which then react with the commercially available 2-methyl-L-proline HCI in presence of base such as TEA in solvents such as DCM, pyridine or mixtures thereof to compounds of structure Q-5.
  • Base such as TEA in solvents such as DCM, pyridine or mixtures thereof.
  • Compounds of structure Q-5 may be converted in a two step procedure to compounds of formula (I).
  • Compounds of formula (I), wherein R is methyl and A 3 is a [1 ,2,4]triazol-3,5-diyl- group can for example be prepared as outlined in Reaction Scheme R.
  • Compounds of structure R-1 can be synthesized from Q-1 by activation of ethyl chloroformate in the presence of base such as TEA or DIPEA in THF at around 0°C, followed by the addition of ammonia (Step a, Scheme R) at 0°C to rt.
  • Reduction of compound R-1 to nitrile of structure R-2 may be performed with trifluoroacetic anhydride in presence of base such as TEA in solvents such as DCM at temperature of about 0°C to rt (Step b, Scheme R).
  • Compounds of structure R-4 can be synthesized from nitrile R-2 and hydazides of structure F-1 in presence of a base such as K 2 C0 3 in a solvent such as n-butanol at elevated temperature of about 125°C for days or under microwave irradiation at a temperature of about 150°C (Step c, Scheme R). Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure R-4. Amide coupling of amines of structure R-4 with acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes the compounds of formula (I).
  • Method A Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Zorbax SB-aq (3.5 ⁇ , 4.6 x 50 mm). Conditions: MeCN [eluent A]; water + 0.04% TFA [eluent B]. Gradient: 95% B ⁇ 5% B over 1.5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
  • Method B Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (2.5 ⁇ , 4.6 x 30 mm). Conditions: MeCN [eluent A]; water + 0.04% TFA [eluent B]. Gradient: 95% B ⁇ 5% B over 1 .5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
  • Method C Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Zorbax Extend C18 (5 ⁇ , 4.6 x 50 mm). Conditions: MeCN [eluent A]; 13 mmol/L NH 3 in water [eluent B]. Gradient: 95% B ⁇ 5% B over 1 .5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
  • Method D Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole).
  • MS Finnigan single quadrupole
  • Column Waters XBridge C18 (5 ⁇ , 4.6 x 50 mm).
  • Conditions MeCN [eluent A]; 13 mmol/L NH 3 in water [eluent B].
  • Gradient 95% B ⁇ 5% B over 1 .5 min (flow: 4.5 mL/min).
  • Detection UV/Vis + MS.
  • Method E Column: Waters XBridge (10 ⁇ , 75 x 30 mm). Conditions: MeCN [eluent A]; water + 0.5% HCOOH [eluent B]; Gradient: 90% B ⁇ 5% B over 6.4 min (flow: 75 mL/min). Detection: UV/Vis + MS.
  • Method F Column: Waters Atlantis (10 ⁇ , 75 x 30 mm). Conditions: MeCN [eluent A]; water + 0.5% HCOOH [eluent B]; Gradient: 90% B ⁇ 5% B over 6.4 min (flow: 75 mL/min). Detection: UV/Vis + MS. Preparative HPLC with basic conditions
  • Method G Column: Waters XBridge (10 ⁇ , 75 x 30 mm). Conditions: MeCN [eluent A]; water + 0.5% NH 4 OH (25% aq.) [eluent B]; Gradient: 90% B ⁇ 5% B over 6.5 min (flow: 75 mL/min). Detection: UV/Vis + MS

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

Description

Orexin receptor antagonists which are \ortho bi-(hetero-)aryl1-r2-(f77ete bi-(hetero-)aryl)- pyrrolidin-1 -yll-methanone derivatives
The present invention relates to novel [ortho bi-(hetero-)aryl]-[2-(mefa bi-(hetero-)aryl)- pyrrolidin-1 -yl]-methanone derivatives and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), (II), (III), (IV), (V) or (VI) and especially their use as orexin receptor antagonists.
Orexins (orexin A or OX-A and orexin B or OX-B) are neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to the G-protein-coupled receptors (OXi and OX2 receptors). The orexin-1 receptor (OX-i) is selective for OX-A, and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B. Orexin receptor antagonists are a novel type of nervous system or psychotropic drugs. Their mode of action in animals and humans involves either blockade of both orexin-1 and orexin-2 receptor (dual antagonists), or individual and selective blockade of either the orexin-1 or the orexin-2 receptor (selective antagonists) in the brain. Orexins were initially found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et al., Cell, 1998, 92, 573-585).
On the other hand, orexin neuropeptides and orexin receptors play an essential and central role in regulating circadian vigilance states. In the brain, orexin neurons collect sensory input about internal and external states and send short intrahypothalamic axonal projections as well as long projections to many other brain regions. The particular distribution of orexin fibers and receptors in basal forebrain, limbic structures and brainstem regions - areas related to the regulation of waking, sleep and emotional reactivity- suggests that orexins exert essential functions as regulators of behavioral arousal; by activating wake-promoting cell firing, orexins contribute to orchestrate all brain arousal systems that regulate circadian activity, energy balance and emotional reactivity. This role opens large therapeutic opportunities for medically addressing numerous mental health disorders possibly relating to orexinergic dysfunctions [see for example: Tsujino N and Sakurai T, "Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward systems.", Pharmacol Rev. 2009, 61 :162-176; and Carter ME et al., "The brain hypocretins and their receptors: mediators of allostatic arousal.", Curr Op Pharmacol. 2009, 9: 39-45] that are described in the following sections. It was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to insomnia and other sleep disorders (Chemelli R.M. et al., Cell, 1999, 98, 437-451 ). Human memory is comprised of multiple systems that have different operating principles and different underlying neuronal substrates. The major distinction is between the capacity for conscious, declarative memory and a set of unconscious, non-declarative memory abilities. Declarative memory is further subdivided into semantic and episodic memory. Non-declariative memory is further subdivided into priming and perceptual learning, procedural memory for skills and habits, associative and non-associative learning, and some others. While semantic memory refers to the general knowledge about the world, episodic memory is autobiographical memory of events. Procedural memories refer to the ability to perform skill-based operations, as e.g. motor skills. Long-term memory is established during a multiple stage process through gradual changes involving diverse brain structures, beginning with learning, or memory acquisition, or formation. Subsequently, consolidation of what has been learned may stabilize memories. When long-term memories are retrieved, they may return to a labile state in which original content may be updated, modulated or disrupted. Subsequently, reconsolidation may again stabilize memories. At a late stage, long-term memory may be resistant to disruption. Long-term memory is conceptually and anatomically different from working memory, the latter of which is the capacity to maintain temporarily a limited amount of information in mind. Behavioural research has suggested that the human brain consolidates long-term memory at certain key time intervals. The initial phase of memory consolidation may occur in the first few minutes after we are exposed to a new idea or learning experience. The next, and possibly most important phase, may occur over a longer period of time, such as during sleep; in fact, certain consolidation processes have been suggested to be sleep-dependent [R. Stickgold et al., Sleep-dependent memory consolidation; Nature 2005,437, 1272-1278]. Learning and memory processes are believed to be fundamentally affected in a variety of neurological and mental disorders, such as e.g. mental retardation, Alzheimer's disease or depression. Indeed, memory loss or impairment of memory acquisition is a significant feature of such diseases, and no effective therapy to prevent this detrimental process has emerged yet.
In addition, both anatomical and functional evidence from in vitro and in vivo studies suggest an important positive interaction of the endogenous orexin system with reward pathways of the brain [Aston-Jones G et al., Brain Res 2010, 1314, 74-90; Sharf R et al., Brain Res 2010, 1314, 130-138]. Selective pharmacological OXR-1 blockade reduced cue- and stress-induced reinstatement of cocaine seeking [Boutrel B, et al., "Role for hypocretin in mediating stress- induced reinstatement of cocaine-seeking behavior." Proc Natl Acad Sci 2005, 102(52), 19168- 19173; Smith RJ et al., "Orexin/hypocretin signaling at the orexin 1 receptor regulates cue- elicited cocaine-seeking." Eur J Neurosci 2009, 30(3), 493-503; Smith RJ et al., "Orexin/hypocretin is necessary for context-driven cocaine-seeking." Neuropharmacology 2010, 58(1 ), 179-184], cue-induced reinstatement of alcohol seeking [Lawrence AJ et al., Br J Pharmacol 2006, 148(6), 752-759] and nicotine self-administration [Hollander JA et al., Proc Natl Acad Sci 2008, 105(49), 19480-19485; LeSage MG et al., Psychopharmacology 2010, 209(2), 203-212]. Orexin-1 receptor antagonism also attenuated the expression of amphetamine- and cocaine-induced CPP [Gozzi A et al., PLoS One 2011 , 6(1 ), e16406; Hutcheson DM et al., Behav Pharmacol 2011 , 22(2), 173-181 ], and reduced the expression or development of locomotor sensitization to amphetamine and cocaine [Borgland SL et al., Neuron 2006, 49(4), 589-601 ; Quarta D et al., "The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization." Neurochem Int 2010, 56(1 ), 1 1-15].
The effect of a drug to diminish addictions may be modelled in normal or particularly sensitive mammals used as animal models [see for example Spealman et al, Pharmacol. Biochem. Behav. 1999, 64, 327-336; or T.S. Shippenberg, G.F. Koob, "Recent advances in animal models of drug addiction" in Neuropsychopharmacology: The fifth generation of progress; K.L.Davis, D. Charney, J.T.Doyle, C. Nemeroff (eds.) 2002; chapter 97, pages 1381 -1397].
Several converging lines of evidence furthermore demonstrate a direct role of the orexin system as modulator of the acute stress response. For instance, stress (i.e. psychological stress or physical stress) is associated with increased arousal and vigilance which in turn is controlled by orexins [Sutcliffe, JG et al., Nat Rev Neurosci 2002, 3(5), 339-349]. Orexin neurons are likely to be involved in the coordinated regulation of behavioral and physiological responses in stressful environments [Y. Kayaba et al., Am. J. Physiol. Regul. Integr. Comp. Physiol. 2003, 285:R581 -593]. Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal [Furlong T M et al., Eur J Neurosci 2009, 30(8), 1603-1614]. Stress response may lead to dramatic, usually time-limited physiological, psychological and behavioural changes that may affect appetite, metabolism and feeding behavior [Chrousos, GP et al., JAMA 1992, 267(9), 1244-1252]. The acute stress response may include behavioural, autonomic and endocrinological changes, such as promoting heightened vigilance, decreased libido, increased heart rate and blood pressure, or a redirection of blood flow to fuel the muscles, heart and the brain [Majzoub, JA et al., European Journal of Endocrinology 2006, 155 (suppl_1 ) S71-S76].
As outlined above the orexin system regulates homeostatic functions such as sleep-wake cycle, energy balance, emotions and reward. Orexins are also involved in mediating the acute behavioral and autonomous nervous system response to stress [Zhang Wet al., "Multiple components of the defense response depend on orexin: evidence from orexin knockout mice and orexin neuron-ablated mice." Auton Neurosci 2006, 126-127, 139-145]. Mood disorders including all types of depression and bipolar disorder are characterized by disturbed "mood" and feelings, as well as by sleeping problems (insomnia as well as hypersomnia), changes in appetite or weight and reduced pleasure and loss of interest in daily or once enjoyed activities [Liu X et al., Sleep 2007, 30(1 ): 83-90]. Thus, there is a strong rationale that disturbances in the orexin system may contribute to the symptoms of mood disorders. Evidence in humans, for instance, exists that depressed patients show blunted diurnal variation in CSF orexin levels [Salomon RM et al., Biol Psychiatry 2003, 54(2), 96-104]. In rodent models of depression, orexins were also shown to be involved. Pharmacological induction of a depressive behavioral state in rats, for instance, revealed an association with increased hypothalamic orexin levels [Feng P et al., J Psychopharmacol 2008, 22(7): 784-791 ]. A chronic stress model of depression in mice also demonstrated an association of molecular orexin system disturbances with depressed behavioral states and a reversal of these molecular changes by antidepressant treatment [Nollet et al., NeuroPharm 2011 , 61 (1-2):336-46].
The orexin system is also involved in stress-related appetitive/reward seeking behaviour (Berridge CW et al., Brain Res 2009, 1314, 91-102). In certain instances, a modulatory effect on stress may be complementary to an effect on appetitive/reward seeking behaviour as such. For instance, an OXi selective orexin receptor antagonist was able to prevent footshock stress induced reinstatement of cocaine seeking behaviour [Boutrel, B et al., Proc Natl Acad Sci 2005, 102(52), 19168-19173]. In addition, stress is also known to play an integral part in withdrawal which occurs during cessation of drug taking (Koob, GF et al., Curr Opin Investig Drugs 2010, 1 1 (1 ), 63-71 ).
Orexins have been found to increase food intake and appetite [Tsujino, N, Sakurai, T, Pharmacol Rev 2009, 61 (2) 162-176]. As an additional environmental factor, stress can contribute to binge eating behaviour, and lead to obesity [Adam, TC et al. Physiol ehav 2007, 91 (4) 449-458]. Animal models that are clinically relevant models of binge eating in humans are described for example in W. Foulds Mathes et al.; Appetite 2009, 52, 545-553.
A number of recent studies report that orexins may play a role into several other important functions relating to arousal, especially when an organism must respond to unexpected stressors and challenges in the environment [Tsujino N and Sakurai T. Pharmacol Rev. 2009, 61 :162-176; Carter ME, Borg JS and deLecea L, Curr Op Pharmacol. 2009, 9: 39-45; C Boss, C Brisbare-Roch, F Jenck, Journal of Medicinal Chemistry 2009, 52: 891-903]. The orexin system interacts with neural networks that regulate emotion, reward and energy homeostasis to maintain proper vigilance states. Dysfunctions in its function may thus relate to many mental health disorders in which vigilance, arousal, wakefulness or attention is disturbed.
The compound (2R)-2-{(1 S)-6,7-dimethoxy-1-[2-(4-trifluoromethyl-phenyl)-ethyl]-3,4-dihydro- 1 H-isoquinolin-2-yl}-/V-methyl-2-phenyl-acetamide (WO2005/1 18548), a dual orexin receptor antagonist, showed clinical efficacy in humans when tested for the indication primary insomnia. In the rat, the compound has been shown to decrease alertness, characterized by decreases in both active wake and locomotion; and to dose-dependently increase the time spent in both REM and NREM sleep [Brisbare et al., Nature Medicine 2007, 13, 150-155]. The compound further attenuated cardiovascular responses to conditioned fear and novelty exposure in rats [Furlong T M et al., Eur J Neurosci 2009, 30(8), 1603-1614]. It is also active in an animal model of conditioned fear: the rat fear-potentiated startle paradigm (WO2009/047723) which relates to emotional states of fear and anxiety diseases such as anxieties including phobias and post traumatic stress disorders (PTSDs). In addition, intact declarative and non-declarative learning and memory has been demonstrated in rats treated with this compound [WO2007/105177, H Dietrich, F Jenck, Psychopharmacology 2010, 212, 145-154]. Said compound furthermore decreased brain levels of amyloid-beta (Αβ) as well as Αβ plaque deposition after acute sleep restriction in amyloid precursor protein transgenic mice [JE Kang et al., "Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.", Science 2009, 326(5955): 1005-1007]. The accumulation of the Αβ in the brain extracellular space is hypothesized to be a critical event in the pathogenesis of Alzheimer's disease. The so-called and generally known "amyloid cascade hypothesis" links Αβ to Alzheimer's disease and, thus, to the cognitive dysfunction, expressed as impairment of learning and memory. The compound has also been shown to induce antidepressant-like activity in a mouse model of depression, when administered chronically [Nollet et al., NeuroPharm 2011 , 61 (1 -2):336-46]. Moreover, the compound has been shown to attenuate the natural activation induced by orexin A in fasted hungry rats exposed to food odors [MJ Prud'homme et al., Neuroscience 2009, 162(4), 1287-1298]. The compound also displayed pharmacological activity in a rat model of nicotine self-administration [LeSage MG et al., Psychopharmacology 2010, 209(2), 203-212]. N-Biphenyl-2-yl-1 -{[(1 -methyl-1 H-benzimidazol- 2-yl)sulfanyl]acetyl}-L-prolinamide, another dual orexin receptor antagonist, inhibited nicotine- reinstatement for a conditioned reinforcer and reduced behavioral (locomotor sensitization) and molecular (transcriptional responses) changes induced by repeated amphetamine administration in rodents [Winrow et al., Neuropharmacology 2009, 58(1 ), 185-94].
US 7, 105,538 discloses certain [1 ,3,4]oxadiazol-2,5-diyl compounds including two exemplified [3-phenyl-5-methyl-isoxazol-4-yl]-[2-(5-pyridyl-[1 ,3,4]oxadiazol-2-yl)-pyrrolidin-1 -yl]-methanone derivatives (CAS registry no. 1082288-15-0, 1082288-80-9) and their use as anti-depressants. The compounds are claimed to inhibit serotonin re-uptake and, thus, to have a pronounced anti-depressive and analgesic effect. It has been found that tested [3-phenyl-5-methyl-isoxazol- 4-yl]-[pyrrolidin-1-yl]-methanone derivatives showed low or no activity within the limits of detection on the orexin receptors.
WO2006/123249, WO2005/044797, and WO2007/039781 disclose metabotropic glutamate (especially mGluR5) receptor modulators and, thus, to be useful for example for the treatment of anxiety disorders or depression. Some compounds exemplified in WO2007/039781 comprise a 2-substituted pyrrolidine moiety, however, these compounds do not comprise an ortho bi- (hetero-)aryl group corresponding to the present group A-i attached to the carbonyl group of the pyrrolidine-amide. Six example or analogue compounds of WO2007/039781 have been tested for their activity on the orexin receptors and showed low or no activity within the limits of detection.
Orexin receptor antagonists comprising a 2-substituted saturated cyclic amide derivatives (such as 2-substituted pyrrolidine-1-carboxamides) are known for example from WO2008/020405, WO2008/038251 , WO2008/081399, WO2008/08761 1 , WO2008/1 17241 , WO2008/139416, WO2009/004584, WO2009/016560, WO2009/016564, WO2009/040730, WO2009/104155, WO2010/004507, WO2010/038200, WO2001/096302, WO2002/044172, WO2002/089800, WO2002/090355, WO2003/002561 , WO2003/032991 , WO2003/04171 1 , WO2003/051368, WO2003/051873, WO2004/026866, WO2004/041791 , WO2004/041807, WO2004/041816, WO2009/003993, WO2009/003997, WO2009/124956, WO2010/060470, WO2010/060471 , WO2010/060472, WO2010/063662, WO2010/063663, WO2010/072722, WO2010/122151 , and WO2008/150364. WO2003/002559 discloses certain N-aroyl cyclic amine derivatives encompassing pyrrolidine, piperidine and morpholine derivatives as orexin receptor antagonists. Despite the great number of prior art compounds and their high structural variability, all compounds share a common structural feature, i.e. in position 2 of the saturated cyclic amide a linker group such as at least a methylene group (or longer groups such as -CH2-NH-CO-, -CH2-NH-, -CH2-O-, -CH2-S-, etc.) link the cyclic amide to the respective aromatic ring system substituent. A particular 2-substituted pyrrolidine derived compound where the pyrrolidine is linked through a methylene group to an [1 ,3,4]oxadiazole ring: 1-(5-(2- fluoro-phenyl)-2-methyl-thiazol-4-yl)-1-[(S)-2-(5-phenyl-[1 ,3,4]oxadiazol-2-ylmethyl)-pyrrolidin-1 - yl)-methanone is exemplified in WO2003/002559 and further characterized in Langmead et. al, Brit. J. Pharmacol. 2004, 141 , 340-346 as being highly orexin-1 selective. It has now surprisingly been found that, despite the substantial conformational and, thus, pharmacological changes that may be expected from the removal of a linker between two rigid structural elements, the present compounds, that have an aromatic ring system directly attached to a pyrrolidine amide in position 2, are orexin receptor antagonists which may be active on both orexin receptors.
The present invention, thus, provides novel [ortho bi-(hetero-)aryl]-[2-(mefa bi-(hetero-)aryl)- pyrrolidin-1 -yl]-methanone derivatives of formula (I), (II), (III), (IV), (V) and (VI), which are non- peptide antagonists of human orexin receptors potentially useful in the treatment of disorders relating to orexinergic dysfunctions, comprising especially sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders; and especially in the treatment of sleep disorders, anxiety disorders, and addiction disorders. 1 ) A first aspect of the invention relates to compounds of the formula (I),
Figure imgf000009_0001
Formula (I)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration; R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (I), R represents especially hydrogen);
ring A3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen; [wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent A2; and that the ring A3 does not carry any further substituent];
ring A2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy, hydroxy, (C1-4)alkoxy-(C1-3)alkyl, hydroxy-(C1-3)alkyl, -CO-(C1-4)alkyl, and (C3-6)cycloalkyl-oxy-; or ring A2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro; and
ring A represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; • provided that ring A is not isoxazol-4-yl, substituted in position 5 with (C1-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further ortho- substitutent in position 3;
with the exception of the compound (1 , 1 '-biphenyl)-2-yl-{(S)-2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5- yl]-1 -pyrrolidinyl}-methanone.
The compound (1 , 1 '-biphenyl)-2-yl-{2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5-yl]-1 -pyrrolidinyl}- methanone in racemic form (CAS Registry Number: 958700-10-2; PubChem CID 16672186) is known in the literature, however, no pharmaceutical activity of this compound has been reported.
2) A further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A3 represents a ring
Figure imgf000010_0001
wherein said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen.
3) A further embodiment of the invention relates to compounds according to embodiment 1 ), g A3 represents a ring
Figure imgf000010_0002
wherein said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X, Y and / or Z; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen.
4) A further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol-diyl, oxazol-diyl, thiazol-diyl, pyrazol-diyl, imidazol-diyl, isothiazol-diyl, and thiadiazol-diyl.
5) A further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol-diyl, oxazol-diyl, thiazol-diyl, and thiadiazol-diyl. 6) A further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A3 is selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol-3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5- diyl, oxazol-2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, thiazol-2,5-diyl, isothiazol-3,5-diyl, [1 ,3,4]thiadiazol-2,5-diyl, and [1 ,3,4]oxadiazol-2,5-diyl (notably [1 ,2,4]oxadiazol-3,5-diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,2,4]oxadiazol-3,5-diyl).
7) A further embodiment of the invention relates to compounds according to embodiment 1 ), wherein the ring A3 is [1 ,3,4]oxadiazol-2,5-diyl.
8) A further embodiment relates to compounds according to any one of embodiments 1 ) to 7), or pharmaceutically acceptable salts thereof, for use in the treatment of mental health disorders relating to orexinergic dysfunctions; wherein for the compounds of formula (I) such mental health disorders relating to orexinergic dysfunctions are especially selected from sleep disorders, anxiety disorders, and addiction disorders.
9) A second aspect of the invention relates to novel compounds of the formula (I) which are also compounds of the formula (II):
Figure imgf000011_0001
Formula (II)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration;
R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (II), R represents especially hydrogen);
ring A'3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen; provided that said 5-membered heteroarylene ring is not [1 ,3,4]oxadiazol-2,5-diyl;
[wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent A'2; and that the ring A'3 does not carry any further substituent];
ring A'2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, hydroxy-(Ci-3)alkyl, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-; or ring A'2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro; and
ring ΑΊ represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of ΑΊ to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of
Figure imgf000012_0001
(Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (C1-3)fluoroalkoxy;
• provided that ring ΑΊ is not isoxazol-4-yl, substituted in position 5 with (C1-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further ortho- substitutent in position 3;
with the exception of the compound (1 , 1 '-biphenyl)-2-yl-{(S)-2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5- yl]-1 -pyrrolidinyl}-methanone.
10) A further embodiment of the invention relates to compounds as defined in embodiment 9);
compounds the ring A'3 represents a ring
Figure imgf000012_0002
wherein said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; provided that said ring is not [1 ,3,4]oxadiazol-2,5-diyl.
1 1 ) A further embodiment of the invention relates to compounds as defined in embodiment 9);
compounds the ring A'3 represents a ring
Figure imgf000012_0003
wherein said ring is a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X, Y and / or Z; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; provided that said ring is not [1 ,3,4]oxadiazol-2,5-diyl.
12) A further embodiment relates to compounds of embodiment 9) wherein the ring A'3 is [1 ,3,4]thiadiazol-2,5-diyl.
13) A further embodiment relates to compounds of embodiment 9), wherein the ring A'3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol-3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5-diyl, oxazol-2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, and [1 ,3,4]thiadiazol-2,5-diyl (notably [1 ,2,4]oxadiazol-3,5-diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,2,4]oxadiazol-3,5-diyl).
14) A further embodiment relates to compounds of embodiment 9), wherein the ring A'3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol-3,5-diyl, and isoxazol-3,5-diyl (notably [1 ,2,4]oxadiazol- 3,5-diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,2,4]oxadiazol-3,5-diyl).
15) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A ; respectively ring ΑΊ, represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di-, or tri- substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A / A'i to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, or mono- or di-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and halogen;
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
• provided that ring A-i, respectively ring ΑΊ, is not isoxazol-4-yl, substituted in position 5 with (Ci-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further orf/?o-substitutent in position 3.
16) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein • ring A ; respectively ring ΑΊ, represents 5-membered heteroaryl, wherein the 5- membered heteroaryl is mono- or di-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A-i / A'i to the rest of the molecule; wherein said ortho-su bstituent is phenyl, or 6-membered heteroaryl (especially pyridyl); wherein said phenyl or 6-membered heteroaryl is independently unsubstituted, or mono-, or di-substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy [wherein said orffro-substituent is especially phenyl which is especially unsubstituted, or mono-substituted with
(Ci-4)alkyl, or halogen];
> and the other of said substituents, if present, is selected from (Ci-4)alkyl (especially methyl);
• provided that ring A ; respectively ring ΑΊ, is not isoxazol-4-yl, substituted in position 5 with (C1-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further orf/?o-substitutent in position 3;
• or ring A-i , respectively ring ΑΊ, represents phenyl or 6-membered heteroaryl, wherein the phenyl or 6-membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of
A-i / A'i to the rest of the molecule; wherein
o said orf/70-substituent is phenyl which is unsubstituted, mono-, or di- substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy
(especially (Ci-4)alkoxy, and halogen);
o or said orffro-substituent is 6-membered heteroaryl (especially pyridyl or pyrimidinyl) which is unsubstituted, mono-, or di-substituted (especially unsubstituted), wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, and (C1-3)fluoroalkyl
(especially (C1-4)alkyl);
o or said ortho-su bstituent is 5-membered heteroaryl (notably pyrazol-1-yl or
[1 ,2,3]triazol-2-yl) which is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, and (Ci-3)fluoroalkyl (especially (Ci-4)alkyl, notably methyl); > and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy [especially (Ci-4)alkyl, (Ci-4)alkoxy, and halogen; notably (Ci-4)alkyl and halogen].
17) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein
• ring A-i , respectively ring ΑΊ, represents represents 5-membered heteroaryl, wherein the 5-membered heteroaryl is mono- or di-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of
A-i / A'i to the rest of the molecule; wherein said orffro-substituent is phenyl, or 6-membered heteroaryl (especially pyridyl), wherein said phenyl or 6-membered heteroaryl is independently unsubstituted, mono-, or di-substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen,
(C1 -3)fluoroalkyl, and (C1 -3)fluoroalkoxy [wherein said orffro-substituent is especially phenyl which is especially unsubstituted, or mono-substituted with (Ci-4)alkyl, or halogen];
> and the other of said substituents, if present, is selected from (Ci-4)alkyl (especially methyl);
• provided that ring A-i , respectively ring ΑΊ, is not isoxazol-4-yl, substituted in position 5 with (Ci-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further orf/?o-substitutent in position 3;
• or ring A-i , respectively ring ΑΊ, represents represents 6-membered heteroaryl, wherein the 6-membered heteroaryl is mono-, or di-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A-i / A'i to the rest of the molecule; wherein
o said orf/70-substituent is unsubstituted 5-membered heteroaryl (notably pyrazol-1-yl or [1 ,2,3]triazol-2-yl); or
o said orffro-substituent is unsubstituted 6-membered heteroaryl (notably pyridin-2-yl); or
o said orf/70-substituent is phenyl which is unsubstituted, or mono- or di- substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy
(especially (Ci-4)alkyl, (Ci-4)alkoxy, and halogen); > and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, and (Ci-3)fluoroalkyl (especially (Ci-4)alkyl; notably methyl);
• or ring A-i, respectively ring ΑΊ, represents phenyl which is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A / A'i to the rest of the molecule; wherein
o said orf/70-substituent is phenyl which is unsubstituted, mono-, or di- substituted (especially unsubstituted, or mono-substituted), wherein the substituents are independently selected from the group consisting of
(Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; or o said orf/70-substituent is 6-membered heteroaryl (especially pyridyl or pyrimidinyl) which is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, and (C1-3)fluoroalkyl (especially (C1 -4)alkyl, (C1-4)alkoxy); or o said orf/70-substituent is 5-membered heteroaryl which is unsubstituted, or mono-substituted (especially unsubstituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, and (Ci-3)fluoroalkyl (especially (Ci-4)alkyl, notably methyl);
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy [especially (Ci-4)alkyl, (Ci-4)alkoxy, and halogen; notably (Ci-4)alkyl and halogen].
18) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein
• ring A-i , respectively ring ΑΊ, represents 5-membered heteroaryl, wherein the 5- membered heteroaryl is mono- or di-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of
A / ΑΊ to the rest of the molecule; wherein said orffro-substituent is phenyl which is unsubstituted, or mono-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl and halogen;
> and the other of said substituents, if present, is independently selected from the group consisting of (Ci-4)alkyl (especially methyl); • provided that ring A ; respectively ring ΑΊ, is not isoxazol-4-yl, substituted in position 5 with (Ci-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further orf/?o-substitutent in position 3;
• or ring A-i , respectively ring ΑΊ, represents 6-membered heteroaryl, wherein the 6- membered heteroaryl is mono-, or di-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A-i / A'i to the rest of the molecule; wherein
o said orf/70-substituent is unsubstituted 5-membered heteroaryl (notably pyrazol-1-yl or [1 ,2,3]triazol-2-yl, especially in case Ar1 represents pyridyl); or
o said orf/70-substituent is unsubstituted 6-membered heteroaryl (notably pyridin-2-yl, especially in case Ar1 represents pyridyl); or o said orf/70-substituent is phenyl which is unsubstituted, or mono- substituted (especially mono-substituted), wherein the substituents are independently selected from the group consisting of (C1-4)alkoxy and halogen;
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (notably methyl);
• or ring A-i, respectively ring ΑΊ, represents phenyl which is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A / A'i to the rest of the molecule; wherein
o said orf/70-substituent is unsubstituted phenyl; or
o said orf/70-substituent is unsubstituted 6-membered heteroaryl (especially pyridyl or pyrimidinyl);
o or said orffro-substituent is 5-membered heteroaryl which is unsubstituted, or mono-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (notably methyl);
> and the other of said substituents, if present, is/are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, (C1-3)fluoroalkyl, and
(C1-3)fluoroalkoxy [especially (C1-4)alkyl, (C1-4)alkoxy, and halogen; notably (C1-4)alkyl and halogen]. 19) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7) and 15) to 18), or to compounds of formula (II) according to any one of embodiments 9) to 18), wherein the following characteristics are present:
• in case ring A-i, respectively ring ΑΊ, represents a 5-membered heteroaryl group, such group is an oxazolyl, imidazolyl, or thiazolyl group (especially a thiazolyl group); and/or
• in case ring A-i, respectively ring ΑΊ, represents a 6-membered heteroaryl group, such group is a pyridinyl, pyrazinyl, or pyrimidinyl group (especially a pyridinyl group);
wherein said groups independently are substituted as defined in any one of the preceeding embodiments.
20) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7) and 15) to 18), or to compounds of formula (II) according to any one of embodiments 9) to 19), wherein the following characteristics are present:
• in case said ortho substituent of ring A ; respectively ring ΑΊ, represents a 5-membered heteroaryl group, such group is a triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1 -yl, or unsubstituted 2H-pyrazol-3-yl), an oxazolyl (especially unsubstituted oxazol-2-yl), or an oxadiazolyl (especially 3-methyl- [1 ,2,4]oxadiazol-5-yl); [notably such group is unsubstituted [1 ,2,3]triazol-2-yl or unsubstituted pyrazol-1 -yl]; and/or
• in case said ortho substituent of ring A-i, respectively ring ΑΊ, represents a 6-membered heteroaryl group, such group is a pyridinyl or a pyrimidinyl group (especially 6-methoxy- pyridin-3-yl, pyridin-2-yl, pyridin-3-yl, or pyrimidin-2-yl; notably unsubstituted pyridin-2-yl or unsubstituted pyrimidin-2-yl); and/or
• in case said ortho substituent of ring A-i, respectively ring ΑΊ, represents a phenyl group, such group is an unsubstituted or mono-substituted phenyl group wherein the substituent is selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen
(especially such group is phenyl, 3-methyl-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 3-chlorophenyl, 3-methoxyphenyl; notably phenyl);
wherein said groups independently are unsubstituted or substituted as defined in any one of the preceeding embodiments, or as explicitly defined herein. 21 ) A further embodiment relates to compounds compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A-i, respectively ring ΑΊ, represents a ring
Figure imgf000019_0001
wherein
X5, X6, X7, and X8 represent ring carbon atoms; or one of X5 and X8 represents a ring nitrogen atom and the remaining of X5, X6, X7, and X8 represent ring carbon atoms; or X5 and X8 represent ring nitrogen atoms and X6 and X represent ring carbon atoms; or X5 and X represent ring nitrogen atoms and X6 and X8 represent ring carbon atoms;
(Rx)m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; and
Ar4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, (C1-3)fluoroalkyl, and (C1-3)fluoroalkoxy.
22) A further embodiment relates to compounds compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A ; respectively ring ΑΊ, represents a ring
Figure imgf000019_0002
wherein one of X5 and X8 represents a ring nitrogen atom and the remaining of X5, X6, X7, and X8 represent ring carbon atoms; or X5 and X8 represent ring nitrogen atoms and X6 and X represent ring carbon atoms; or X5 and X represent ring nitrogen atoms and X6 and X8 represent ring carbon atoms;
(Rx)m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; and
Ar4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy.
23) Another embodiment relates to compounds according to embodiments 21 ) or 22), wherein Ar4 is selected from the group consisting of unsubstituted or mono-substituted phenyl wherein the substituent is selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and halogen (especially such group is phenyl, 3-methyl-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4- fluorophenyl, 3-chlorophenyl, or 3-methoxyphenyl; notably phenyl); triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl); pyrazolyl (especially unsubstituted pyrazol-1 -yl, or unsubstituted 2H-pyrazol-3-yl); pyridyl (especially unsubstituted pyridin-2-yl); and pyrimidinyl (especially unsubstituted pyrimidin-2-yl); and
(Rx)m represents one or two optional substituents independently selected from (Ci-4)alkyl, (Ci-4)alkoxy, halogen, and (Ci-3)fluoroalkyl.
24) A further embodiment relates to compounds of formula (I) according to any one of embodiments 1 ) to 7), or to compounds of formula (II) according to any one of embodiments 9) to 14), wherein ring A ; respectively ring ΑΊ, represents a ring
Figure imgf000020_0001
wherein X9 represents O, S, or NH; and
Ry represents hydrogen or (Ci-4)alkyl; and
Ar5 represents phenyl or 6-membered heteroaryl; wherein said phenyl or 6-membered heteroaryl independently is unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, (C1-3)fluoroalkyl, and (C1-3)fluoroalkoxy.
25) Another embodiment relates to compounds according to embodiment 24), wherein
Ar5 represents phenyl, wherein said phenyl is unsubstituted, mono-, or di-substituted (especially unsubstituted or mono-substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and halogen (especially such group is phenyl, 3-methyl-phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3- chlorophenyl, or 3-methoxyphenyl); and
Ry represents hydrogen or (Ci-4)alkyl (especially hydrogen or methyl).
26) A third aspect of the invention relates to compounds of the formula (I) as defined in embodiment 1 ) which are also compounds of the formula (III):
Figure imgf000021_0001
Formula (III)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration;
R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (III), R represents especially hydrogen);
wherein the ring
Figure imgf000021_0002
represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen;
X5, X6, X7, and X8 represent ring carbon atoms; or one of X5 and X8 represents a ring nitrogen atom and the remaining of X5, X6, X7, and X8 represent ring carbon atoms; or X5 and X8 represent ring nitrogen atoms and X6 and X represent ring carbon atoms; or X5 and X represent ring nitrogen atoms and X6 and X8 represent ring carbon atoms;
Ar2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of
Figure imgf000021_0003
(Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, hydroxy-(Ci-3)alkyl, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-; or
Ar2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro;
(Rx)m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; and Ar4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
with the exception of the compound (1 , 1 '-biphenyl)-2-yl-{(S)-2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5- yl]-1 -pyrrolidinyl}-methanone.
27) A fourth aspect of the invention relates to novel compounds of the formula (I) as defined in embodiment 1 ), which are also compounds of the formula (IV):
Figure imgf000022_0001
Formula (IV)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration; wherein
R represents hydrogen or methyl (in a sub-embodiment, for the compounds of formula (IV), R represents especially hydrogen);
the ring
Figure imgf000022_0002
represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen [wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent Ar2; and that the above-defined ring does not carry any further substituent];
Ar2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy, hydroxy, (C1-4)alkoxy-(C1-3)alkyl, hydroxy-(C1-3)alkyl, -CO-(C1-4)alkyl, and (C3-6)cycloalkyl-oxy-; or Ar2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro;
(Rx)m represents one or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; and
Ar4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
with the exception of the compound (1 , 1 '-biphenyl)-2-yl-{(S)-2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5- yl]-1 -pyrrolidinyl}-methanone.
28) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000023_0001
represents a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol-diyl, oxazol-diyl, thiazol-diyl, and thiadiazol- diyl.
29) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000023_0002
represents a group selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol- 3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5-diyl, oxazol- 2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, [1 ,3,4]thiadiazol-2,5-diyl, and [1 ,3,4]oxadiazol-2,5-diyl (notably [1 ,2,4]oxadiazol-3,5-diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,2,4]oxadiazol-3,5-diyl). 30) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000024_0001
represents a meta di-substituted 5-membered heteroarylene ring independently selected from one, or more (in any combination), or all of the following groups A) to J) [especially said meta di-substituted 5-membered heteroarylene ring is selected from B) or E); notably B)]:
Figure imgf000024_0002
wherein the asterisks indicate the bond that is linked to the pyrrolidine moiety of the molecule.
31 ) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000024_0003
represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen; provided that said 5-membered heteroarylene ring is not [1 ,3,4]oxadiazol-2,5-diyl.
32) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000025_0001
represents a group selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol- 3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5-diyl, oxazol-
2.4- diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, and [1 ,3,4]thiadiazol-2,5-diyl (notably [1 ,2,4]oxadiazol-
3.5- diyl or [1 ,2,4]triazol-3,5-diyl; especially [1 ,2,4]oxadiazol-3,5-diyl).
33) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000025_0002
represents a meta di-substituted 5-membered heteroarylene ring independently selected from one, or more (in any combination), or all of the following groups A) to I) [especially said meta di- substituted 5-membered heteroarylene ring is selected from A) or D); notably A)]:
Figure imgf000025_0003
Figure imgf000025_0004
Figure imgf000026_0001
wherein the asterisks indicate the bond that is linked to the pyrrolidine moiety of the molecule.
34) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000026_0002
represents a meta di-substituted 5-membered heteroarylene ring independently selected from one, or more (in any combination), or all of the following groups A) to C) [especially said meta di-substituted 5-membered heteroarylene ring is selected from A) or C); notably A)]:
Figure imgf000026_0003
wherein the asterisks indicate the bond that is linked to the pyrrolidine moiety of the molecule.
35) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000027_0001
represents a meta di-substituted 5-membered heteroarylene ring independently selected from one, or both of the following groups A) and B) [especially said meta di-substituted 5-membered heteroarylene ring is selected from A)]:
A B)
Figure imgf000027_0002
wherein the asterisks indicate the bond that is linked to the pyrrolidine moiety of the molecule.
36) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
"~<o 4i ^ represents -< Hx
wherein the asterisks indicate the bond that is linked to the pyrrolidine moiety of the molecule.
37) A further embodiment of the invention relates to compounds of formula (III) according to embodiment 26), or to compounds of formula (IV) according to embodiment 27), wherein the ring
Figure imgf000027_0003
represents
38) A further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A2, respectively ring A'2, respectively Ar2, represents
• phenyl which is unsubstituted, or mono-, di-, or tri-substituted (especially unsubstituted, or mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano,
(C1-3)fluoroalkyl, (C1-3)fluoroalkoxy; hydroxy, (C1-4)alkoxy-(C1-3)alkyl, hydroxy-(C1-3)alkyl, and (C3-6)cycloalkyl-oxy-; or
• a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group which is optionally di-substituted with fluoro; or • 5- or 6-membered heteroaryl; wherein said heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy-; (especially 6-membered heteroaryl containing one or two ring nitrogen atoms; notably pyridinyl; which is mono-or di-substituted, notably mono-substituted, with said substituents; wherein preferably at least one of said substituents is attached in ortho- or mefa-position with respect to the point of attachment of the rest of the molecule); or
• 8- to 10-membered heteroaryl; wherein said heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkyl, and -CO-(C1-4)alkyl.
39) A further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A2, respectively ring A'2, respectively Ar2, represents
• phenyl which is unsubstituted, or mono-, di-, or tri-substituted (notably unsubstituted, or mono- or di-substituted; especially mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy; hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, and hydroxy-(Ci-3)alkyl; or
• a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group which is optionally di-substituted with fluoro; or
• 6-membered heteroaryl; wherein said heteroaryl is independently unsubstituted, or mono-, or di-substituted; wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, (C1-3)fluoroalkyl,
(C1-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy-; (notably 6-membered heteroaryl containing one or two ring nitrogen atoms; especially pyridinyl; wherein such 6-membered heteroaryl is mono- or di-substituted, notably mono-substituted; wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy-; wherein preferably at least one of said substituents is attached in ortho- or mefa-position with respect to the point of attachment of the rest of the molecule); or
• 8- to 10-membered heteroaryl (notably 9-membered heteroaryl containing at least one ring nitrogen atom; especially indolyl, indazolyl, or pyrrolopyridinyl); wherein said heteroaryl is independently unsubstituted, or mono-substituted; wherein the substituent is independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and -CO-(Ci-4)alkyl.
40) A further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A2, respectively ring A'2, respectively Ar2, represents
• phenyl which is unsubstituted, or mono-, di-, or tri-substituted (notably unsubstituted, or mono- or di-substituted; especially mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; or
• a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group; or
• pyridinyl which is mono-, or di-substituted (especially mono-substituted); wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, (C1-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy- (especially (Ci-4)alkoxy and (C3-6)cycloalkyl-oxy-); wherein preferably at least one of said substituents is attached in ortho- or mefa-position with respect to the point of attachment of the rest of the molecule;
• indolyl or pyrrolopyridinyl which are independently unsubstituted, or mono-substituted; wherein the substituent is independently selected from (Ci-4)alkyl;
wherein in a sub-embodiment, ring A2, respectively ring A'2, respectively Ar2, especially represents phenyl which is mono-, di-, or tri-substituted (notably mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy.
41 ) A further embodiment relates to compounds of formulae (I), (II), (III), and (IV) according to any one of embodiments 1 ) to 37), wherein ring A2, respectively ring A'2, respectively Ar2, represents
• phenyl which is unsubstituted, or mono-, di-, or tri-substituted (notably unsubstituted, or mono- or di-substituted; especially mono- or di-substituted); wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy; hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, and hydroxy-(Ci-3)alkyl; or
• 2,3-dihydro-benzo[1 ,4]dioxin-5-yl, 2,3-dihydro-benzofuran-7-yl, benzo[1 ,3]dioxol-4-yl, benzo[1 ,3]dioxol-5-yl, or 2,2-difluoro-benzo[1 ,3]dioxol-5-yl; or
• 5- or 6-membered heteroaryl selected from pyridyl, pyrazolyl, and pyrazinyl; wherein said heteroaryl is independently mono-, or di-substituted (especially mono-substituted); wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, (C1-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy- (especially (Ci-4)alkyl, (Ci-4)alkoxy, and (C3-6)cycloalkyl-oxy-); wherein preferably at least one of said substituents is attached in ortho- or mefa-position with respect to the point of attachment of the rest of the molecule; or
· 8- to 10-membered heteroaryl selected from indolyl, pyrrolopyridyl, imidazothioazolyl, and indazolyl; wherein said heteroaryl is independently unsubstituted, or mono- substituted; wherein the substituent is independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and -CO-(Ci-4)alkyl.
42) A further embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein one or more of the following characteristics are present:
• in case Ar4 represents a 5-membered heteroaryl group, such group is a triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1-yl, or unsubstituted 2H-pyrazol-3-yl), an oxazolyl (especially unsubstituted oxazol-2-yl), or an oxadiazolyl (especially 3-methyl-[1 ,2,4]oxadiazol-5-yl); [notably such group is unsubstituted [1 ,2,3]triazol-2-yl or unsubstituted pyrazol-1 -yl]; and/or
• in case Ar4 represents a 6-membered heteroaryl group, such group is a pyridinyl or a pyrimidinyl group (especially 6-methoxy-pyridin-3-yl, pyridin-2-yl, pyridin-3-yl, or pyrimidin-2-yl; notably unsubstituted pyridin-2-yl or unsubstituted pyrimidin-2-yl) and/or
• in case Ar4 represents a phenyl group, such phenyl group is an unsubstituted or mono- substituted phenyl group wherein the substituent is selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and halogen (especially such group is phenyl, 3-methyl- phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 3- methoxyphenyl; notably phenyl);
wherein said groups independently are unsubstituted or substituted as defined in any one of the preceeding embodiments, or as explicitly defined herein.
43) Another embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
• Ar4 is selected from the group consisting of unsubstituted triazolyl (especially [1 ,2,3]triazol- 2-yl); unsubstituted pyrazolyl (especially pyrazol-1-yl, or 2H-pyrazol-3-yl); unsubstituted oxazolyl (especially oxazol-2-yl); oxadiazolyl mono-substituted with methyl (especially 3- methyl-[1 ,2,4]oxadiazol-5-yl); unsubstituted pyridyl (especially pyridin-2-yl); unsubstituted pyrimidinyl (especially pyrimidin-2-yl); and unsubstituted or mono-substituted phenyl wherein the substituent is selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and halogen (especially such phenyl group is phenyl, 3-methyl-phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, or 3-methoxyphenyl; notably phenyl); and • (Rx)m represents one or two optional substituents (especially (Rx)m represents one or two substituents) independently selected from (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy.
44) A further embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
• Ar4 represents a 5-membered heteroaryl group, selected from the group consisting of a triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl), a pyrazolyl (especially unsubstituted pyrazol-1-yl, or unsubstituted 2H-pyrazol-3-yl), an oxazolyl (especially unsubstituted oxazol- 2-yl), and an oxadiazolyl group (especially 3-methyl-[1 ,2,4]oxadiazol-5-yl); [notably Ar4 represents unsubstituted [1 ,2,3]triazol-2-yl or unsubstituted pyrazol-1 -yl]; wherein said groups independently are unsubstituted or substituted as defined in any one of the preceeding embodiments, or as explicitly defined herein; and
• (Rx)m represents one or two optional substituents (especially (Rx)m represents one or two substituents) independently selected from (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy (in particular: methyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, and trifluoromethoxy).
45) Another embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
• Ar4 represents unsubstituted triazolyl (especially unsubstituted [1 ,2,3]triazol-2-yl); or unsubstituted pyrimidinyl (especially unsubstituted pyrimidin-2-yl); and
• (Rx)m represents one or two substituents independently selected from (Ci_4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy (in particular: methyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, and trifluoromethoxy).
46) A further embodiment relates to compounds of formulae (III) and (IV) according to any one of embodiments 26) to 41 ), wherein
• Ar4 represents unsubstituted [1 ,2,3]triazol-2-yl; and
• (Rx)m represents one or two substituents independently selected from (C1-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy (in particular: methyl, methoxy, fluoro, chloro, cyano, trifluoromethyl, and trifluoromethoxy). 47) A further embodiment relates to compounds of formulae (I), (II), (III), or (IV) according to any one of embodiments 1 ) to 41 ), wherein
Figure imgf000032_0001
ii) : respectively, the ring ΑΊ,
iii): respectively, (mutatis mutandis) the group
Figure imgf000032_0002
iv):, respectively, (mutatis mutandis) the group
Figure imgf000032_0003
is a group independently selected from one, or more (in any combination), or all of the following groups A) to C) [i.e. the group iii) being selected from groups A) or B); the group iv) being selected from groups A)]:
A) substituted phenyl groups selected from the groups:
Figure imgf000032_0004
Figure imgf000033_0001
B) substituted 6-membered heteroaryl groups selected from the groups
Figure imgf000033_0002
C) substituted 5-membered heteroaryl groups selected from the groups:
Figure imgf000033_0003
wherein each of the groups A) to C) and their respective subgroups [especially group A1 )] forms a particular sub-embodiment. 48) A further embodiment relates to compounds of formula (IV) according to any one embodime in
the group
Figure imgf000034_0001
is a group independently selected from one, or more (in any combination), or all of the following groups A), B), C) and / or D):
Figure imgf000034_0002
wherein each of the groups A), B), C) and D) forms a particular sub-embodiment [and said group is especially selected from groups A) and B); notably from A1 )].
49) A further embodiment relates to compounds of formulae (I), (II), (III), or (IV) according to any one of embodiments 1 ) to 48), wherein
i): the group A3-A2,
ii) : respectively, the group A A^,
iii) : and, respectively, the group
Figure imgf000035_0001
represents a group independently selected from one, or more (in any combination), or all of the following groups A) to H) [especially from A) and/or B); and/or from F)]:
A): [1 ,2,4]oxadiazol-3,5-diyl groups selected from the groups:
Figure imgf000035_0002

Figure imgf000036_0001
B): [1 ,2,4]oxadiazol-3,5-diyl groups
Figure imgf000037_0001
Figure imgf000037_0002
C): oxazol-2,4-diyl groups selected from:
Figure imgf000037_0003
D): oxazol-2,5-diyl groups selected from:
Figure imgf000037_0004
Figure imgf000038_0001
wherein each of the groups A) to H) [notably the groups A) and B)] and their respective subgroups [notably the subgroups A1 ) and B1 )] forms a particular sub-embodiment.
50) A further embodiment relates to compounds of formulae (I), (II), (III), or (IV) according to any one of embodiments 1 ) to 48), wherein
i): the group A3-A2,
ii) : respectively, the group A'3-A'2,
iii) : and, respectively, the group
Figure imgf000039_0001
represents a group independently selected from one, or more (in any combination), or all of the following groups A) to E):
A): [1 ,2,4]oxadiazol-3,5-diyl groups selected from the groups:
Figure imgf000039_0002

Figure imgf000040_0001
D): [1 ,2,4]triazol-3,5-diyl groups selected from the groups:
Figure imgf000041_0001
wherein each of the groups A) to E) and their respective subgroups forms a particular sub- embodiment [and said groups are especially selected from groups A), B), C), and D); notably from the groups A) and B); in particular from A1 ) and B1 )].
51) The invention, thus, relates to compounds of the formula (I) as defined in embodiment 1), compounds of the formula (II) as defined in embodiment 9), compounds of the formula (III) as defined in embodiment 26), compounds of the formula (IV) as defined in embodiment 27); or to such compounds further limited by the characteristics of any one of embodiments 2) to 50), under consideration of their respective dependencies; to pharmaceutically acceptable salts thereof; and to the use of such compounds as medicaments especially in the treatment of mental health disorders relating to orexinergic dysfunctions, which disorders are as defined below and which are especially selected from sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders. Especially the following embodiments relating to the compounds of formulae (I), (II), (III), and (IV) are thus possible and intended and herewith specifically disclosed in individualized form:
1, 4+1, 6+1, 17+1, 17+4+1, 17+6+1, 18+1, 18+4+1, 18+6+1, 19+1, 19+4+1, 19+6+1, 19+17+1, 19+17+4+1 19+17+6+1, 19+18+1, 19+18+4+1, 19+18+6+1, 20+1, 20+4+1, 20+6+1, 20+17+1, 20+17+4+1, 20+17+6+1 20+18+1, 20+18+4+1, 20+18+6+1, 20+19+1, 20+19+4+1, 20+19+6+1, 20+19+17+1, 20+19+17+4+1 20+19+17+6+1, 20+19+18+1, 20+19+18+4+1, 20+19+18+6+1, 24+1, 24+4+1, 24+6+1, 25+24+1, 25+24+4+1 25+24+6+1, 40+1, 40+4+1, 40+6+1, 40+17+1, 40+17+4+1, 40+17+6+1, 40+18+1, 40+18+4+1, 40+18+6+1 40+19+1, 40+19+4+1, 40+19+6+1, 40+19+17+1, 40+19+17+4+1, 40+19+17+6+1, 40+19+18+1, 40+19+18+4+1 40+19+18+6+1, 40+20+1, 40+20+4+1, 40+20+6+1, 40+20+17+1, 40+20+17+4+1, 40+20+17+6+1, 40+20+18+1, 40+20+18+4+1, 40+20+18+6+1, 40+20+19+1, 40+20+19+4+1, 40+20+19+6+1, 40+20+19+17+1, 40+20+19+17+4+1, 40+20+19+17+6+1, 40+20+19+18+1, 40+20+19+18+4+1, 40+20+19+18+6+1, 41+1, 41+4+1, 41+6+1, 41+17+1, 41+17+4+1, 41+17+6+1, 41+18+1, 41+18+4+1, 41+18+6+1, 41+19+1, 41+19+4+1, 41+19+6+1, 41+19+17+1, 41+19+17+4+1, 41+19+17+6+1, 41+19+18+1, 41+19+18+4+1, 41+19+18+6+1, 41+20+1, 41+20+4+1, 41+20+6+1, 41+20+17+1, 41+20+17+4+1, 41+20+17+6+1, 41+20+18+1, 41+20+18+4+1, 41+20+18+6+1, 41+20+19+1, 41+20+19+4+1, 41+20+19+6+1, 41+20+19+17+1, 41+20+19+17+4+1, 41+20+19+17+6+1, 41+20+19+18+1, 41+20+19+18+4+1, 41+20+19+18+6+1; 47+1, 47+4+1, 47+6+1, 47+40+1, 47+41 +1 , 47+40+4+1 , 47+40+6+1 , 47+41+4+1 , 47+41+6+1 ;
9, 13+9, 14+9, 17+9, 17+13+9, 17+14+9, 17+40+9, 17+40+13+9, 17+40+14+9, 17+41+9, 17+41+13+9, 17+41+14+9, 17+49+9, 18+9, 18+13+9, 18+14+9, 18+40+9, 18+40+13+9, 18+40+14+9, 18+41+9, 18+41+13+9, 18+41+14+9, 18+49+9, 19+9, 19+13+9, 19+14+9, 19+17+9, 19+17+13+9, 19+17+14+9, 19+17+40+9, 19+17+40+13+9, 19+17+40+14+9, 19+17+41+9, 19+17+41+13+9, 19+17+41+14+9, 19+17+49+9, 19+18+9, 19+18+13+9, 19+18+14+9, 19+18+40+9, 19+18+40+13+9, 19+18+40+14+9, 19+18+41+9, 19+18+41+13+9, 19+18+41+14+9, 19+18+49+9, 19+40+9, 19+40+13+9, 19+40+14+9, 19+41+9, 19+41+13+9, 19+41+14+9, 19+49+9, 20+9, 20+13+9, 20+14+9, 20+17+9, 20+17+13+9, 20+17+14+9, 20+17+40+9, 20+17+40+13+9, 20+17+40+14+9, 20+17+41+9, 20+17+41+13+9, 20+17+41+14+9, 20+17+49+9, 20+18+9, 20+18+13+9, 20+18+14+9, 20+18+40+9, 20+18+40+13+9, 20+18+40+14+9, 20+18+41+9, 20+18+41+13+9, 20+18+41+14+9, 20+18+49+9, 20+19+9, 20+19+13+9, 20+19+14+9, 20+19+17+9, 20+19+17+13+9, 20+19+17+14+9, 20+19+17+40+9, 20+19+17+40+13+9, 20+19+17+40+14+9, 20+19+17+41+9, 20+19+17+41+13+9, 20+19+17+41+14+9, 20+19+17+49+9, 20+19+18+9, 20+19+18+13+9, 20+19+18+14+9, 20+19+18+40+9, 20+19+18+40+13+9, 20+19+18+40+14+9, 20+19+18+41+9, 20+19+18+41+13+9, 20+19+18+41+14+9, 20+19+18+49+9, 20+19+40+9, 20+19+40+13+9, 20+19+40+14+9, 20+19+41+9, 20+19+41+13+9, 20+19+41+14+9, 20+19+49+9, 20+40+9, 20+40+13+9, 20+40+14+9, 20+41+9, 20+41+13+9, 20+41+14+9, 20+49+9, 24+9, 24+13+9, 24+14+9, 24+40+9, 24+40+13+9, 24+40+14+9, 24+41+9, 24+41+13+9, 24+41+14+9, 24+49+9, 25+24+9, 25+24+13+9, 25+24+14+9, 25+24+40+9, 25+24+40+13+9, 25+24+40+14+9, 25+24+41+9, 25+24+41+13+9, 25+24+41+14+9, 25+24+49+9, 40+9, 40+13+9, 40+14+9, 41+9, 41+13+9, 41+14+9, 49+9, 49+17+9, 49+18+9, 49+17+19+9, 49+18+19+9, 49+17+20+9, 49+18+20+9, 49+17+19+20+9, 49+18+19+20+9, 49+24+9, 49+25+24+9, 49+47+9;
27, 28+27, 30+27, 32+27, 34+27, 35+27, 36+27, 40+27, 40+28+27, 40+30+27, 40+32+27, 40+34+27, 40+35+27, 40+36+27, 41+27, 41+28+27, 41+30+27, 41+32+27, 41+34+27, 41+35+27, 41+36+27, 42+27, 42+28+27, 42+30+27, 42+32+27, 42+34+27, 42+35+27, 42+36+27, 42+40+27, 42+40+28+27, 42+40+30+27, 42+40+32+27, 42+40+34+27, 42+40+35+27, 42+40+36+27, 42+41+27, 42+41+28+27, 42+41+30+27, 42+41+32+27, 42+41+34+27, 42+41+35+27, 42+41+36+27, 43+27, 43+28+27, 43+30+27, 43+32+27, 43+34+27, 43+35+27, 43+36+27, 43+40+27, 43+40+28+27, 43+40+30+27, 43+40+32+27, 43+40+34+27, 43+40+35+27, 43+40+36+27, 43+41+27, 43+41+28+27, 43+41+30+27, 43+41+32+27, 43+41+34+27, 43+41+35+27, 43+41+36+27, 46+27, 46+28+27, 46+30+27, 46+32+27, 46+34+27, 46+36+27, 46+37+27, 46+40+27, 46+40+28+27, 46+40+30+27, 46+40+32+27, 46+40+34+27, 46+40+35+27, 46+40+36+27, 46+41+27, 46+41+28+27, 46+41+30+27, 46+41+32+27, 46+41+34+27, 46+41+35+27, 46+41+36+27, 47+27, 47+28+27, 47+30+27, 47+32+27, 47+33+27, 47+34+27, 47+35+27, 47+35+27, 47+36+27, 47+40+27, 47+40+28+27, 47+40+30+27, 47+40+32+27, 47+40+34+27, 47+40+35+27, 47+40+36+27, 47+41+27, 47+41+28+27, 47+41+30+27, 47+41+32+27, 47+41+34+27, 47+41+35+27, 47+41+36+27, 48+27, 48+28+27, 48+30+27, 48+32+27, 48+33+27, 48+34+27, 48+35+27, 48+36+27, 48+40+27, 48+40+28+27, 48+40+30+27, 48+40+32+27, 48+40+34+27, 48+40+35+27, 48+40+36+27, 48+41+27, 48+41+28+27, 48+41+30+27, 48+41+32+27, 48+41+34+27, 48+41+35+27, 48+41+36+27, 49+27, 49+42+27, 49+43+27, 49+44+27, 49+45+27, 49+46+27, 49+47+27, 49+48+27, 50+27, 50+42+27, 50+43+27, 50+44+27, 50+45+27, 50+46+27, 50+47+27, 50+48+27.
In the list above, the numbers refer to the embodiments according to their numbering provided hereinabove whereas "+" indicates the dependency from another embodiment. The different individualized embodiments are separated by commas. In other words, "41 +28+27" for example refers to embodiment 41 ) depending on embodiment 28), depending on embodiment 27), i.e. embodiment "41 +28+27" corresponds to the compounds of embodiment 27) further limited by the features of the embodiments 28) and 41 ).
52) A further aspect of the invention relates to to compounds of the formula (I) according to embodiment 1 ), which are also compounds of the compounds of the formula (V); wherein the absolute configuration is as depicted in formula (V):
Figure imgf000043_0001
Formula (V)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration; ring A3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen; [wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent A2; and that the ring A3 does not carry any further substituent];
ring A2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, hydroxy-(Ci-3)alkyl, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-; or ring A2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro; and
ring A represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (C1-3)fluoroalkoxy;
> provided that ring A is not isoxazol-4-yl, substituted in position 5 with (C1-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further ortho- substitutent in position 3;
wherein the characteristics disclosed in embodiments 2) to 50) above are intended to apply mutatis mutandis also to the compounds formula (V) according to embodiment 52); wherein especially the following embodiments are thus possible and intended and herewith specifically disclosed in individualized form: 52, 4+52, 6+52, 17+52, 17+4+52, 17+6+52, 18+52, 18+4+52, 18+6+52, 19+52, 19+4+52, 19+6+52, 19+17+52, 19+17+4+52, 19+17+6+52, 19+18+52, 19+18+4+52, 19+18+6+52, 20+52, 20+4+52, 20+6+52, 20+17+52, 20+17+4+52, 20+17+6+52, 20+18+52, 20+18+4+52, 20+18+6+52, 20+19+52, 20+19+4+52, 20+19+6+52, 20+19+17+52, 20+19+17+4+52, 20+19+17+6+52, 20+19+18+52, 20+19+18+4+52, 20+19+18+6+52, 24+52, 24+4+52, 24+6+52, 25+24+52, 25+24+4+52, 25+24+6+52, 40+52, 40+4+52, 40+6+52, 40+17+52, 40+17+4+52, 40+17+6+52, 40+18+52, 40+18+4+52, 40+18+6+52, 40+19+52, 40+19+4+52, 40+19+6+52, 40+19+17+52, 40+19+17+4+52, 40+19+17+6+52, 40+19+18+52, 40+19+18+4+52, 40+19+18+6+52, 40+20+52, 40+20+4+52, 40+20+6+52, 40+20+17+52, 40+20+17+4+52, 40+20+17+6+52, 40+20+18+52, 40+20+18+4+52, 40+20+18+6+52, 40+20+19+52, 40+20+19+4+52, 40+20+19+6+52, 40+20+19+17+52, 40+20+19+17+4+52, 40+20+19+17+6+52, 40+20+19+18+52, 40+20+19+18+4+52, 40+20+19+18+6+52, 41+52, 41+4+52, 41+6+52, 41+17+52, 41+17+4+52, 41+17+6+52, 41+18+52, 41+18+4+52, 41+18+6+52, 41+19+52, 41+19+4+52, 41+19+6+52, 41+19+17+52, 41+19+17+4+52, 41+19+17+6+52, 41+19+18+52, 41+19+18+4+52, 41+19+18+6+52, 41+20+52, 41+20+4+52, 41+20+6+52, 41+20+17+52, 41+20+17+4+52, 41+20+17+6+52, 41+20+18+52, 41+20+18+4+52, 41+20+18+6+52, 41+20+19+52, 41+20+19+4+52, 41+20+19+6+52, 41+20+19+17+52, 41+20+19+17+4+52, 41+20+19+17+6+52, 41+20+19+18+52, 41+20+19+18+4+52, 41 +20+19+18+6+1 ; 47+52, 47+4+52, 47+6+52, 47+40+52, 47+41 +52, 47+40+4+52, 47+40+6+52, 47+41 +4+52, 47+41+6+52.
In the list above, the numbers refer to the embodiments according to their numbering provided hereinabove whereas "+" indicates the dependency from another embodiment. The different individualized embodiments are separated by commas. In other words, "41 +17+52" for example refers to embodiment 41 ) depending on embodiment 17), depending on embodiment 52), i.e. embodiment "41 +17+53" corresponds to the compounds of embodiment 52) further limited by the features of the embodiments 17) and 41 ).
53) A further aspect of the invention relates to compounds of the formula (IV) according to embodiment 27), which are also compounds of the formula (VI); wherein the absolute configuration is as depicted in formula (VI):
Figure imgf000045_0001
Formula (VI)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration; wherein the ring
Figure imgf000045_0002
represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen [wherein it is understood that the two mefa-arranged substituents are the pyrrolidine-2-yl group and the substituent Ar2; and that the above-defined ring does not carry any further substituent];
Ar2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C1 -4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, hydroxy-(Ci-3)alkyl, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-; or Ar2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro;
(Rx)m represents one, or two optional substituents [i.e. m represents the integer 0, 1 , or 2] independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; and
Ar4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
wherein the characteristics disclosed in embodiments 28) to 50) are intended to apply mutatis mutandis also to the compounds formula (VI) according to embodiment 53); wherein especially the following embodiments are thus possible and intended and herewith specifically disclosed in individualized form: 53, 28+53, 30+53, 32+53, 34+53, 36+53, 37+53, 40+53, 40+28+53, 40+30+53, 40+32+53, 40+34+53, 40+36+53, 40+37+53, 41+53, 41 +28+53, 41 +30+53, 41 +32+53, 41+34+53, 41+36+53, 41 +37+53, 42+53, 42+28+53, 42+30+53, 42+32+53, 42+34+53, 42+36+53, 42+37+53, 42+40+53, 42+40+28+53, 42+40+30+53, 42+40+32+53, 42+40+34+53, 42+40+36+53, 42+40+37+53, 42+41 +53, 42+41 +28+53, 42+41+30+53, 42+41 +32+53, 42+41 +34+53, 42+41+36+53, 42+41 +37+53, 43+53, 43+28+53, 43+30+53, 43+32+53, 43+34+53, 43+36+53, 43+37+53, 43+40+53, 43+40+28+53, 43+40+30+53, 43+40+32+53, 43+40+34+53, 43+40+36+53, 43+40+37+53, 43+41 +53, 43+41 +28+53, 43+41 +30+53, 43+41 +32+53, 43+41+34+53, 43+41 +36+53, 43+41 +37+53, 46+53, 46+28+53, 46+30+53, 46+32+53, 46+34+53, 46+36+53, 46+37+53, 46+40+53, 46+40+28+53, 46+40+30+53, 46+40+32+53, 46+40+34+53, 46+40+36+53, 46+40+37+53, 46+41+53, 46+41 +28+53, 46+41 +30+53, 46+41 +32+53, 46+41 +34+53, 46+41+36+53, 46+41 +37+53, 47+53, 47+28+53, 47+30+53, 47+32+53, 47+33+53, 47+34+53, 47+35+53, 47+36+53, 47+37+53, 47+40+53, 47+40+28+53, 47+40+30+53, 47+40+32+53, 47+40+34+53, 47+40+36+53, 47+40+37+53, 47+41 +53, 47+41+28+53, 47+41 +30+53, 47+41 +32+53, 47+41 +34+53, 47+41+36+53, 47+41 +37+53, 48+53, 48+28+53, 48+30+53, 48+32+53, 48+33+53, 48+34+53,48+35+53, 48+36+53, 48+37+53, 48+40+53, 48+40+28+53, 48+40+30+53, 48+40+32+53, 48+40+34+53, 48+40+36+53, 48+40+37+53, 48+41 +53, 48+41 +28+53, 48+41+30+53, 48+41 +32+53, 48+41 +34+53, 48+41+36+53, 48+41 +37+53, 49+53, 49+42+53, 49+43+53, 49+44+53, 49+45+53, 49+46+53, 49+47+53, 49+48+53, 50+53, 50+42+53, 50+43+53, 50+44+53, 50+45+53, 50+46+53, 50+47+53, 50+48+53.
In the list above, the numbers refer to the embodiments according to their numbering provided hereinabove whereas "+" indicates the dependency from another embodiment. The different individualized embodiments are separated by commas. In other words, "41 +28+53" for example refers to embodiment 41 ) depending on embodiment 28), depending on embodiment 53), i.e. embodiment "41 +28+53" corresponds to the compounds of embodiment 53) further limited by the features of the embodiments 28) and 41 ). 54) A further embodiment relates to compounds of formula (VI) according to embodiment 53), wherein the group
Figure imgf000047_0001
is a group selected from the following groups:
Figure imgf000047_0002
and the group
Figure imgf000047_0003
is as defined in embodiments 49) or 50); wherein, in a sub-embodiment, particular groups are independently selected from the following groups:
Figure imgf000047_0004
55) Particular compounds according to embodiment 1 ) are selected from the group consisting of:
{(S)-2-[3-(2-Cyclopropyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrTOlidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(1 H-lndol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-meth
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-meth
methanone;
{(S)-2-[3-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazo^
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrTOlidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl^henyl)- methanone;
{(S)-2-[3-(2,3-Dihydro-benzo[1 ,4]dioxin-5-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(2 thoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-meth
methanone; {(S)-2-[3-(1 H-lndol-7-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-meth
{(S)-2-[3-(1 -Methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
methanone;
{(S)-2-[3-(1 -Methyl-1 H-indol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-lsopropoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrol idin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
1-(3-{5-[(S)-1-(5-Methyl-2-[1,2,3]triazol-2-yl-benzoyl)-pyrrolidin-2-yl]-[1,2,4]oxadiazol-3-yl}-i
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-biphenyl-2-yl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,^^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methoxy-biphenyl-2-yl)-methanone; {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-oxazol-2-yl-p
methanone;
(4-Methyl-biphenyl-2-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; (5-Methyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
(5-Methyl-2-pyridin-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5^
methanone;
(2-Fluoro-3-methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2^]
1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]tnazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,^^
methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2^]oxadiazol^
methanone;
(5-Methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2^]oxad^
methanone;
(4-Methoxy-biphenyl-2-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-ph
pyrrolidin-1-yl}-methanone; (4,5-Dimethyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
[3-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol- methanone;
(5-Methyl-2-oxazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2- methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-me
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[3-(3-fluoro-2-methoxy-pheny
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-meth
phenyl)-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenylH(S)-2-[3-(2-ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)- methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phe^
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy -^
phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-oxazol-2-yl-phenyl)-methan
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-^^
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl-phenyl)-[1 ,2,4]oxad
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrroli
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH4-methy^
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-phenyl)-[1 ,2,4]oxadiazol-5^
methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy -methyl-2-[1 ,2
methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,2^]oxadi
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-p^
methanone; {(S)-2-[5-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-ph
pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy -meth
methanone;
{(S)-2-[5-(2-Ethoxy-py rid in-3-yl)-[1 ,2,4]oxad iazol-3-yl]-py rrol id i n- 1 -yl)-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH5
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH5-m
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dime
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-met
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ^
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-2- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadi
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadi
methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH5-meth
methanone;
(4, 5-Di methyl-2-[1 ,2, 3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-py ridin-3-yl)-[1 ,2,4]oxad iazol-3-yl]-py rrol id i n- 1 -yl)- methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrTOlidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrOlidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phen
methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3 luoro-2-methoxy-phen
methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
phenyl)-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3 luoro-2-methoxy-phenyl)-[1 ^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-methanon (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[4-(2-trifluoromethoxy-phenyl)-oxazol-2-yl]-pyrrolidin-1-yl}-methanone {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-(4,5-dimethy^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-y^
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-y^ pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-[1,2,4]o
yl}-methanone;
{(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]t
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxad^
methanone;
{(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl^
phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-chloro -me^
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-chloro-2-methyl-phenyl)-[1 ,2^
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1,2,4]o
yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-chloro -me^
phenyl)-methanone; (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-pheny^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3 luoro-2-methoxy-phenyl)-[1 ,^
methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tn
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-met^ methanone;
{(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl^ {(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol^ (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin {(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-[1 ,2,^ methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-pheny
{(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-met^ phenyl)-methanone;
{(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-[ methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-met^ phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-[1,2,4]oxad yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl^henyl)-[1 ,2,4]oxad methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-[1,2,4]oxad yl}-methanone;
{(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2^ methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-[1,2,4]oxadiazo yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-[1,2^]oxadi yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1,2,4]oxadi yl}-methanone; {(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl)-(5-m
phenyl)-methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yn
methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrol idin-1 -yl)-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[^
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-chloro-5-meth
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-meth
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-chloro-2-[1 ,2,3
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl^henyl)-[1 ,2,4]
pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,^
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-^^
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-tnfluoromethoxy-phenyl)-4H
methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phe
pyrrolidin-1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H
1-yl}-methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]W^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]tr^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H
pyrrolidin-1-yl}-methanone; (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]W^ methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy^h
pyrrolidin-1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3 luoro-2-methoxy-pheny^
methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-4H-[1
Figure imgf000054_0001
pyrrolidin-1-yl}-methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-y^
yl}-methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl) H-[1,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-me
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-4H-[1 ,2,4]tnazo methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-4H-[1 ,2,4]tnazol-3-yn methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-4H-[1,2,4] methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-chloro-5-meth phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl) H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4,5-di
phenyl)-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,^
1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazo 1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-[1 ,2,4]oxadi^^ methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,^
1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazo 1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1 ,2,4]oxad methanone;
{(S)-2-[5-(2-Methoxy-phenyl)-1H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-m {(S)-2-[5-(2-Ethoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-[
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl^
methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl^
methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(4-methyl-2-^
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-(5-rnethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-(5-meth
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-m
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-m and
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}- methanone.
In a sub-embodiment of embodiment 55), particular compounds according to embodiment 1 ) are
(5-Methoxy -methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phen
pyrrolidin-1-yl}-methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- pyrrolidin-1-yl}-methanone; and
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-di
methanone.
In a further sub-embodiment of embodiment 55), another particular compound according to embodiment 1 ) is (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]W yl]-pyrrolidin-1-yl}-methanone.
56) In addition to the above-listed compounds, further compounds according to embodiment 1 ) are selected from the group consisting of:
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-m-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidi
{(S)-2-[3-(3-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
{(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tn
{(S)-2-[3-(3,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,^
methanone;
{(S)-2-[3-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2^
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-o-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl^ {(S)-2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tr^
{(S)-2-[3-(2-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tm^
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2^]oxadiazol^
methanone;
{(S)-2-[3-(2-Chloro-3-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-m
methanone;
{(S)-2-[3-(2-Chloro-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tn
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2 rifluoromethyl^henyl)-[1,2,4]oxa^
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ^
methanone;
{(S)-2-[3-(3-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,^
methanone;
{(S)-2-[3-(2-Methoxymethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
[(S)-2-(3-Benzo[1 ,3]dioxol -yl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1 ,2,^
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methyl-3-trifluoromethyl-phenyl)-[1 ,2,4]o
yl}-methanone;
{(S)-2-[3-(3 thoxy-pyridin -yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[
methanone;
{(S)-2-[3-(2,3-Dimethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3^
methanone;
{(S)-2-[3-(1 -Methyl-1 H-indol-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Fluoro-6-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(1 -Methyl-1 H-indol-7-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 , 2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Methyl-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-rnethyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Dffluoromethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-y^
methanone; {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-fluoro-3-m
phenyl)-methanone;
Biphenyl-2-yl-{(S)-2-[3-(3-chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyrazol-1-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-m
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triazol-2
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-fluoro-2-[1 ,2,3]tn
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-pyrazol-1-yl- phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-pyrazol-1-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-pyrazol-1-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[5-fluoro-2-(2H-pyrazo
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyrazo
methanone;
{(S)-2-[3-(3-Chloro-2-methyl^henyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methoxy
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(3,5-dimethyl-2-[
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-oxazol-2-yl-phenyl)-methanone; {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-chloro-2-[1 ,2,3
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-fluoro-5-meth
phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl^henyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dime^
phenyl)-methanone;
Biphenyl-2-yl-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
(5-m-Tolyl-oxazol-4-yl)-{(S)-2-[3-(2-tnfluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; (2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-py
(5-Fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy^henyl)-[1,2
methanone;
(5-Methoxy-4-methyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-methanone;
[5-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin methanone;
(3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2 rifluoromethoxy-phe
methanone;
(2-Oxazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methan
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2^]oxadiaz^
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-phenyl)-[1 ,24]o
methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-ph
1-yl}-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-difluoromethoxy-phenyl)-[1 ,24]oxad
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-p^^
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)- methanone;
(3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)^^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiaz^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,24]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5 luoro-2-^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyr^^
methanone; {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-ph
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triazol-2-y^ phenyl)-methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-fluoro-5-meth
phenyl)-methanone;
(4,5-Dimethoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadi yl}-methanone;
(3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy^yridin-3-yl^
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]tto
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(6-methyl-3-[1 ,2,3]triazol-2 methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phen methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-[1 ,2^]oxad
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-fluoro-5-methoxy-2-[1 ,2,3]t phenyl)-methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyr^^ methanone;
{(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-[1 ,2,3]triazo
methanone;
{(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-[1 ,^
methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1,2,3]triazol-2-yl-phe
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl-phenyl)-[1 ,2^]oxadiazol-^^^ methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]tn methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl^ phenyl)-methanone; {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluorO-2-(2H-pyrazol-3-yl)-phenyl]- methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-iriethanone; {(S)-2-[3-(3,4-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2,4-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-pyrimidin-2-yl- phenyl)-methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-trifluoromethoxy-phenyl)-[
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyrirnidin-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,3-Dihydro-benzofuran -yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidi
methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy"4-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-5-meth
phenyl)-methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-5-methoxy-2-[1 ^
phenyl)-methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrol idin-1 -yl)-(4-fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triazol-2-yl-
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazd
methanone; {(S)-2-[3-(2,3-Dimethyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-inethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(3,5-Dimethyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(2-Methoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-iTiethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenylH
methanone;
[5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3^
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-chloro-2-methyl-ph
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1-yl}-methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-pyrimidin-2-yl- phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-pyrirnidin-2-yl-phenyl)- methanone;
(4-Fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1,2,4]ox
1-yl}-methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4 luoro-5-met
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2 rifluoromethoxy-phenyl)-[1 ,2,4^
pyrrolidin-1-yl}-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2^]oxadiazol- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1 ,2^]oxadiazol^^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl^henyl)-^^
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2^]W^
methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)- H-[1 ,2,4]triazol-3-yl]-pyrrol idin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone; {(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol^
methanone;
{(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-[1,2,4]o
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-[1,2,4]o
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-[1,2,4]ora^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-[1,2,4]ora^
methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl^
methanone;
{(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl^
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrol idin-1 -yl)- methanone; (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl>
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1 ,2
methanone;
{(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-m
phenyl)-methanone;
{(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methox^^
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl-phenyl)-[1 ,2,4^^
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]^ pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl-phenyl)-[1,2,4]ox
yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-chloro-2-[1 ,2,3
methanone;
{(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
phenyl)-methanone;
{(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,^
methanone;
(2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]tnaz^
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]tr^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrol^ methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-y^
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-met^
phenyl)-methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-methyl^
methanone; {(S)-2-[5-(3-Chloro-2-methoxy-phenyl) H-[1
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl) H-[1 ,2,4]triazol-3-yl]-pyrrolidi
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy^methyl-2-[1 ,2,3]triazol-2- yl-phenyl)-methanone;
{(S)-2-[5-(4-Chloro-6-methoxy-pyridin-2-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrro
phenyl)-methanone;
{(S)-2-[5-(3-Methoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-isoxazol-3-yl)-pyrrolidin-1-yl]-methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-isoxazol-3-yl)-pyrrolidin-1-yl]-methanone; and (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}- methanone. 57) In addition to the above-listed compounds, further compounds according to embodiment 1 ) are selected from the group consisting of:
{(S)-2-[3-(2-Cyclobutoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-m
methanone;
(2-Fluoro-3-methoxy-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-^
pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(2-Methoxy-phenyl) H-[1 ,2,4]W^
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyTO
methanone;
{(S)-2-[5-(2-Methoxy-phenyl) H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,^
and
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(1 -phenyl-1 H-[1 ,2,4]triazol-3-yl)-pyrrolidin-1-yl]-methanone.
58) In addition to the above-listed compounds, further compounds according to embodiment 1 ) are selected from the group consisting of:
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-^
1-yl}-methanone;
4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluorometho
1-yl}-methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ^
1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,^
pyrrolidin-1-yl}-methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-ph
pyrrolidin-1-yl}-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-ph
1-yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidi
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenylHH-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidi
phenyl)-methanone; and
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenylHH-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidi
phenyl)-methanone;
(5-Methyl-biphenyl-2-yl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-pheny
methanone; and
(4-Methyl-biphenyl-2-yl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl^
methanone.
In a sub-embodiment of embodiment 58), a particular compound according to embodiment 1 ) is (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-ph
1-yl}-methanone.
The compounds of formulae (I), (I I), (I I I), (IV), (V) and (VI) contain at least one stereogenic center which is situated in position 2 of the pyrrolidine moiety. It is understood that the absolute configuration of said chiral center is as depicted in formulae (I), (I I), (I II), (IV), (V) and (VI), i.e. it is in absolute (S) configuration. In addition, the compounds of formula (I) and (I I) may contain one or more further stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. The compounds of formulae (I), (II), (I I I), (IV), (V) and (VI) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
In some instances, the compounds of formulae (I), (I I), (I I I), (IV), (V) and (VI) may contain tautomeric forms. Such tautomeric forms are encompassed in the scope of the present invention. For example, in case the present compounds contain heteroaromatic aromatic rings containing unsubstituted ring nitrogen atoms having a free valency such as imidazol-2,4-diyl, or [1 ,2,4]-triazol-3,5-diyl, such rings may be present in tautomeric forms. For example, the group imidazol-2,4-diyl represents the tautomeric forms 1 H-imidazol-2,4-diyl and 3H-imidazol-2,4-diyl; and the group [1 ,2,4]triazol-3,5-diyl represents the tautomeric forms 1 H-[1 ,2,4]triazol-3,5-diyl, 2H-[1 ,2,4]triazol-3,5-diyl and 4H-[1 ,2,4]triazol-3,5-diyl.
The present invention also includes isotopically labelled, especially 2H (deuterium) labelled compounds of formula (I), which compounds are identical to the compounds of formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature. Isotopically labelled, especially 2H (deuterium) labelled compounds of formulae (I), (II), (III), (IV), (V) and (VI) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in-vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile. In one embodiment of the invention, the compounds of formulae (I), (II), (III), (IV), (V) and (VI) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of formulae (I), (II), (III), (IV), (V) and (VI) are not isotopically labelled at all. Isotopically labelled compounds of formulae (I), (II), (III), (IV), (V) and (VI) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
In this patent application, a dotted line shows the point of attachment of the radical drawn. For example, the radical drawn below
Figure imgf000066_0001
2-(2-triazolyl)-phenyl group.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like.
Any reference to compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
The term "pharmaceutically acceptable salts" refers to non-toxic, inorg. or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201 -217.
Definitions provided herein are intended to apply uniformly to the compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 53), and, mutatis mutandis, throughout the description and the claims unless an otherwise expressly set out definition provides a broader or narrower definition. It is well understood that a definition or preferred definition of a term defines and may replace the respective term independently of (and in combination with) any definition or preferred definition of any or all other terms as defined herein.
The term "halogen" means fluorine, chlorine, or bromine, preferably fluorine or chlorine.
The term "alkyl", used alone or in combination, refers to a saturated straight or branched chain alkyl group containing one to six carbon atoms. The term "(Cx-y)alkyl" (x and y each being an integer), refers to an alkyl group as defined before, containing x to y carbon atoms. For example a (Ci-4)alkyl group contains from one to four carbon atoms. Examples of alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl.
The term "cycloalkyl", used alone or in combination, refers to a saturated cyclic alkyl group containing three to six carbon atoms. The term "(Cx-y)cycloalkyl" (x and y each being an integer), refers to a cycloalkyl group as defined before containing x to y carbon atoms. For example a (C3-6)cycloalkyl group contains from three to six carbon atoms. Examples of cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Preferred is cyclopropyl.
The term "alkoxy", used alone or in combination, refers to an alkyl-O- group wherein the alkyl group is as defined before. The term "(Cx-y)alkoxy" (x and y each being an integer) refers to an alkoxy group as defined before containing x to y carbon atoms. For example a (Ci-4)alkoxy group means a group of the formula (Ci-4)alkyl-0- in which the term "(Ci-4)alkyl" has the previously given significance. Examples of alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.-butoxy. Preferred are ethoxy and methoxy.
The term "fluoroalkyl" refers to an alkyl group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term "(Cx-y)fluoroalkyl" (x and y each being an integer) refers to a fluoroalkyl group as defined before containing x to y carbon atoms. For example a (Ci-3)fluoroalkyl group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkyl groups include trifluoromethyl, 2- fluoroethyl, 2,2-difluoroethyl and 2,2,2-trifluoroethyl. Preferred are (C-i)fluoroalkyl groups such as trifluoromethyl.
The term "fluoroalkoxy" refers to an alkoxy group as defined before containing one to three carbon atoms in which one or more (and possibly all) hydrogen atoms have been replaced with fluorine. The term "(Cx-y)fluoroalkoxy" (x and y each being an integer) refers to a fluoroalkoxy group as defined before containing x to y carbon atoms. For example a (C1-3)fluoroalkoxy group contains from one to three carbon atoms in which one to seven hydrogen atoms have been replaced with fluorine. Representative examples of fluoroalkoxy groups include trifluoromethoxy, difluoromethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy and 2,2,2-trifluoroethoxy. Preferred are (C-i)fluoroalkoxy groups such as trifluoromethoxy and difluoromethoxy.
The term "aryl" refers to a naphthyl or, preferably, to a phenyl group; wherein said group is unsubstituted or substituted as explicitly defined.
Particular examples of the ring A-i, respectively the ring ΑΊ, representing a phenyl group wherein said phenyl is mono-, di-, or tri-substituted; wherein one of said substituents is attached in orffro-position to the point of attachment of ring A-i, respectively the ring ΑΊ, to the rest of the molecule, are such that the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and halogen (especially methyl, methoxy and halogen). Likewise, in the group
X5 to X8 represent ring carbon atoms; respectively in the group
Figure imgf000068_0001
group (Rx)m represents one or two optional substituents independently selected from (Ci-4)alkyl, (Ci-4)alkoxy, and halogen (especially methyl, methoxy and halogen). Particular examples of the above mentioned phenyl groups are 1 ,2-phenylene, 4- methyl-1 ,2-phenylene, 5-methyl-1 ,2-phenylene, 4,5-dimethyl-1 ,2-phenylene, 3,5-dimethyl-1 ,2- phenylene, 3-methyl-1 ,2-phenylene, 6-methyl-1 ,2-phenylene, 5-fluoro-1 ,2-phenylene, 3-fluoro- 1 ,2-phenylene, 4-fluoro-1 ,2-phenylene, 4,5-difluoro-1 ,2-phenylene, 5-chloro-1 ,2-phenylene, 4- chloro-1 ,2-phenylene, 3-chloro-1 ,2-phenylene, 5-cyano-1 ,2-phenylene, 5-methoxy-1 ,2- phenylene, 4-methoxy-1 ,2-phenylene, 4,5-dimethoxy-1 ,2-phenylene, 4-methyl-5-methoxy-1 ,2- phenylene, 4-chloro-5-methoxy-1 ,2-phenylene, 5-chloro-4-methyl-1 ,2-phenylene, 5- trifluoromethyl-1 ,2-phenylene, 4-trifluoromethoxy-1 ,2-phenylene, 5-trifluoromethoxy-1 ,2- phenylene, 6-fluoro-5-methyl-1 ,2-phenylene, 5-fluoro-3-methyl-1 ,2-phenylene, 4-fluoro-5- methoxy-1 ,2-phenylene, and 6-fluoro-5-methoxy-1 ,2-phenylene; wherein in the above groups the carbonyl group is attached in position 1.
Particular examples of the ring A2, respectively the ring A'2, respectively Ar2; representing an aryl group are especially phenyl groups which are unsubstituted, or mono-, di-, or tri- substituted; wherein the substituents are independently selected from the group consisting of (C -4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy; hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, and hydroxy-(Ci-3)alkyl; [notably from (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; especially from methyl, methoxy, cyclopropyl, halogen, trifluoromethyl, and trifluoromethoxy]. Particular examples are phenyl, 2-methyl-phenyl, 2-ethyl-phenyl, 3-methyl-phenyl, 2,3-dimethyl-phenyl, 2,4-dimethyl- phenyl, 2,5-dimethyl-phenyl, 3,4-dimethyl-phenyl, 3,5-dimethyl-phenyl, 2-methoxy-phenyl, 3- methoxy-phenyl, 2-ethoxy-phenyl, 2-isopropoxy-phenyl, 2,3-dimethoxy-phenyl, 2- methoxymethyl-phenyl, 3-methoxy-2-methyl-phenyl, 3-methoxy-6-methyl-phenyl, 2-methoxy-5- methyl-phenyl, 3-methoxy-5-methyl-phenyl, 3-fluoro-2-methyl-phenyl, 2-fluoro-6-methyl-phenyl, 3-fluoro-2-methoxy-phenyl, 3-fluoro-2-ethoxy-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 3- chloro-2-methyl-phenyl, 2-chloro-3-methyl-phenyl, 2-trifluoromethyl-phenyl, 2-methyl-3- trifluoromethyl-phenyl, 2-trifluoromethoxy-phenyl, 3-trifluoromethoxy-phenyl, 2-difluoromethoxy- phenyl, 3-difluoromethoxy-phenyl, and 2-cyclopropyl-phenyl.
Examples of the particular phenyl groups which are ortho substituents of ring A-i, respectively ring ΑΊ, (in particular: groups Ar4 and Ar5) are unsubstituted or mono-substituted phenyl groups wherein the substituent is selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and halogen (especially methyl, methoxy and halogen); such as especially phenyl, 3-methyl- phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, and 3-methoxyphenyl.
The term "heteroaryl", if not explicitly stated otherwise, refers to a 5- to 10-membered monocyclic or bicyclic aromatic ring containing 1 to a maximum of 3 heteroatoms independently selected from oxygen, nitrogen and sulfur. Examples of such heteroaryl groups are 5- membered monocyclic heteroaryl groups such as furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, and triazolyl; 6- membered monocyclic heteroaryl such as pyridyl, pyrimidyl, pyridazinyl, and pyrazinyl; and 8- to 10-membered bicyclic heteroaryl such as indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl (or benzooxazolyl), benzisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1 ,5- a]pyridyl, pyrazolo[1 ,5-a]pyrimidyl, imidazo[1 ,2-a]pyridyl, 1 H-pyrrolo[3,2-b]pyridyl, 1 H- pyrrolo[2,3-b]pyridyl, pyrrolo[3,2-d]pyrimidinyl, pyrrolo[2,3-d]pyrimidinyl, 4H-furo[3,2-b]pyrrolyl, pyrrolo[2, 1 -b]thiazolyl, and imidazo[2, 1-b]thiazolyl.
Examples of the particular 5- or 6-membered heteroaryl groups which are further substituted in ortho position as used for the ring A ; respectively ring ΑΊ, are the above mentioned 5- or 6- membered heteroaryl groups, notably oxazolyl (in particular oxazol-4,5-diyl, 2-methyl-oxazol- 4,5-diyl), thiazolyl (in particular thiazol-4,5-diyl, 2-methyl-thiazol-4,5-diyl), imidazolyl (in particular imidazol-4,5-diyl), pyridyl (in particular pyridin-2,3-diyl, 6-methyl-pyridin-2,3-diyl), pyrimidyl (in particular pyrimidin-4,5-diyl, 2-methyl-pyrimidin-4,5-diyl), and pyrazinyl (in particular pyrazin-2,3-diyl). These groups are at least mono-substituted in ortho position, and preferably carry no further substituent or one further substitutent as explicitly defined. In particular such optional further substituent is (Ci-4)alkyl, notably methyl. The above groups are preferably attached to the rest of the molecule (i.e. the carbonyl group) in position 4 of oxazolyl, imidazolyl, or thiazolyl groups, in position 2 or 3 of pyridyl or pyrazinyl groups, or in position 5 of pyrimidinyl groups. In a sub-embodiment, examples of such groups are thiazol-4,5-diyl, 2- methyl-thiazol-4,5-diyl, oxazol-4,5-diyl, 2-methyl-oxzol-4,5-diyl, imidazol-4,5-diyl, pyrimidin-4,5- diyl, 2-methyl-pyrimidin-4,5-diyl, pyridin-2,3-diyl and 6-methyl-pyridin-2,3-diyl. Likewise, particular examples of the group
Figure imgf000070_0001
wherein at least one of X5 to X7 is nitrogen are pyrimidin-4,5-diyl, 2- methyl-pyrimidin-4,5-diyl, pyridin-2,3-diyl and 6-methyl-pyridin-2,3-diyl.
Particular examples of the ring A2, respectively the ring A'2, respectively Ar2; representing a 5- to 10-membered heteroaryl are especially 5- to 10-membered heteroaryl groups which are unsubstituted, or mono-substituted; wherein the substituent is selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy- [notably from (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkoxy, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-]. Particular examples of such heteroaryl groups are 6-membered heteroaryl groups, such as pyrazinyl, pyrimidyl and notably pyridyl groups, which groups are unsubstituted, or mono-substituted; wherein the substituent is selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy- (especially methyl, methoxy, ethoxy, isopropoxy, halogen, difluoromethoxy, and cyclobutyloxy); such as especially 2-(cyclobutyl- oxy)-pyridin-3-yl, 2-difluoromethoxy-pyridin-3-yl, 2-isopropoxy-pyridin-3-yl, 2-ethoxy-pyridin-3-yl, 3-ethoxy-pyridin-4-yl, 6-ethoxy-pyridin-3-yl, 2-methoxy-pyridin-3-yl, 6-methoxy-pyridin-3-yl, 6- isopropoxy-pyridin-3-yl, 2-methyl-pyridin-3-yl, and 2-chloro-pyridin-3-yl. Further particular examples of such heteroaryl groups are 8- to 10-membered heteroaryl groups, such as imidazothiazolyl, indazolyl, pyrrolopyridyl (especially 1 H-pyrrolo[2,3-b]pyridinyl) and notably indolyl groups which are groups are unsubstituted, or mono-substituted; wherein the substituent is selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and -CO-(C1-4)alkyl (especially methyl, methoxy, and acetyl); such as especially indol-3-yl, 1-methyl-indol-3-yl, 4-methyl-indol- 3-yl, 1 -acetyl-indol-3-yl, indol-4-yl, 1 -methyl-indol-4-yl, indol-7-yl, 1-methyl-indol-7-yl, 5- methoxy-indol-3-yl, 1 H-pyrrolo[2,3-b]pyridin-3-yl, 1-methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl, and 1 H-pyrrolo[2,3-b]pyridin-4-yl.
Examples of the particular 5- or 6-membered heteroaryl groups which are ortho substituents of ring A-i , respectively ring ΑΊ, (in particular: groups Ar4) are the above mentioned 5- or 6- membered heteroaryl groups, notably oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, and pyrazinyl. The above mentioned groups are preferably unsubstituted or may be substituted as explicitly defined. Preferred examples are triazolyl (notably unsubstituted [1 ,2,3]triazol-2-yl), pyrazolyl (notably unsubstituted pyrazol-1-yl, or unsubstituted 2H-pyrazol-3-yl), oxazolyl (notably unsubstituted oxazol-2-yl), oxadiazolyl (notably 3-methyl-[1 ,2,4]oxadiazol-5-yl); pyridinyl (notably unsubstituted pyridin-2-yl), and pyrimidinyl (notably unsubstituted pyrimidin-2-yl) [notably unsubstituted [1 ,2,3]triazol-2-yl, unsubstituted pyrazol-1-yl, and unsubstituted pyrimidin-2-yl].
In benzo[1 ,3]dioxolyl groups which are optionally di-substituted with fluoro, such fluoro substituents are preferably attached to the methylene group of the dioxole ring. An example of such group is 2,2-difluoro-benzo[1 ,3]dioxol-5-yl.
The compounds of compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral (such especially oral) or parenteral administration (including topical application or inhalation).
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject in need thereof a pharmaceutically active amount of a compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58).
In a preferred embodiment of the invention, the administered amount of such a compound of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) is comprised between 1 mg and 1000 mg per day, particularly between 5 mg and 500 mg per day, more particularly between 25 mg and 400 mg per day, especially between 50 mg and 200 mg per day.
For avoidance of any doubt, if compounds are described as being useful for the prevention or treatment of certain diseases, such compounds are likewise suitable for use in the preparation of a medicament for the prevention or treatment of said diseases.
The compounds of formulae (I), (II), (III), (IV), (V) and (VI) as defined in any one of embodiments 1 ) to 58) are useful for the prevention or treatment of disorders relating to orexinergic dysfunctions.
Such disorders relating to orexinergic dysfunctions are diseases or disorders where an antagonist of a human orexin receptor is required, notably mental health disorders relating to orexinergic dysfunctions. The above mentioned disorders may in particular be defined as comprising sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders. In one sub-embodiment, the above mentioned disorders comprise especially sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, and appetite disorders. In another sub-embodiment, the above mentioned disorders comprise especially sleep disorders, anxiety disorders, and addiction disorders. In yet another sub-embodiment, the above mentioned disorders comprise especially sleep disorders.
In addition, further disorders relating to orexinergic dysfunctions are selected from treating, controlling, ameliorating or reducing the risk of epilepsy, including absence epilepsy; treating or controlling pain, including neuropathic pain; treating or controlling Parkinson's disease; treating or controlling psychosis including acute mania and bipolar disorder; treating or controlling stroke, particularly ischemic or haemorrhagic stroke; blocking an emetic response i.e. nausea and vomiting; and treating or controlling agitation, in isolation or co-morbid with another medical condition.
In another embodiment, further disorders relating to orexinergic dysfunctions are selected from schizoaffective disorders; dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; increased anaesthetic risk; anaesthetic responsiveness; hypothalamic-adrenal dysfunctions; all types of amnesia; severe mental retardation; dyskinesias and muscular diseases; muscle spasticity; tremors; movement disorders; spontaneous and medication- induced dyskinesias; neurodegenerative disorders including Huntington's, Creutzfeld-Jacob's, Alzheimer's diseases and Tourette syndrome; Amyotrophic lateral sclerosis; Parkinson's disease; Cushing's syndrome; traumatic lesions; spinal cord trauma; head trauma; perinatal hypoxia; hearing loss; tinnitus; demyelinating diseases; spinal and cranial nerve diseases; ocular damage; retinopathy; seizure disorders; complex partial and generalized seizures; Lennox-Gastaut syndrome; migraine and headache; anaesthesia and analgesia; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; dental pain; pain related to infection e.g. by HIV; post-chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; osteoarthritis; conditions associated with visceral pain such as irritable bowel syndrome; eating disorders; diabetes; toxic and dysmetabolic disorders including cerebral anoxia, diabetic neuropathies and alcoholism; somatoform disorders including hypochondriasis; vomiting/nausea; emesis; gastric dyskinesia; gastric ulcers; Kallman's syndrome (anosmia); impaired glucose tolerance; intestinal motility dyskinesias; hypothalamic diseases; hypophysis diseases; hyperthermia syndromes, pyrexia, febrile seizures, idiopathic growth deficiency; dwarfism; gigantism; acromegaly; basophil adenoma; prolactinoma; hyperprolactinemia; brain tumors, adenomas; benign prostatic hypertrophy, prostate cancer; endometrial, breast, colon cancer; all types of testicular dysfunctions, fertility control; reproductive hormone abnormalities; hot flashes; hypothalamic hypogonadism, functional or psychogenic amenorrhea; urinary bladder incontinence asthma; allergies; all types of dermatitis, acne and cysts, sebaceous gland dysfunctions; cardiovascular disorders; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; dyslipidemias, hyperlipidemias, insulin resistance; urinary retention; osteoporosis; angina pectoris; myocardial infarction; arrhythmias, coronary diseases, left ventricular hypertrophy; all types of cerebrovascular disorders including subarachnoid haemorrhage, and vascular dementia; chronic renal failure and other renal diseases; gout; kidney cancer; and urinary incontinence.
In another embodiment, a further disorder relating to orexinergic dysfunctions is sundowning (or sundown syndrome).
Anxiety disorders can be distinguished by the primary object or specificity of threat, ranging from rather diffuse as in generalized anxiety disorder, to circumscribed as encountered in phobic anxieties (PHOBs) or post-traumatic stress disorders (PTSDs). Anxiety disorders may, thus, be defined as comprising generalized anxiety disorders (GAD), obsessive compulsive disorders (OCDs), acute stress disorders, posttraumatic stress disorders (PTSDs), panic anxiety disorders (PADs) including panic attacks, phobic anxieties (PHOBs), specific phobia, social phobia (social anxiety disorder), avoidance, somatoform disorders including hypochondriasis, separation anxiety disorder, anxiety disorders due to a general medical condition, and substance induced anxiety disorders. In a sub-embodiment, particular examples of circumscribed threat induced anxiety disorders are phobic anxieties or post-traumatic stress disorders. Anxiety disorders especially include post-traumatic stress disorders, obsessive compulsive disorders, panic attacks, phobic anxieties, and avoidance. Addiction disorders may be defined as addictions to one or more rewarding stimuli, notably to one rewarding stimulus. Such rewarding stimuli may be of either natural or synthetic origin. Examples of such rewarding stimuli are substances / drugs {of either natural or synthetic origin; such as cocaine, amphetamines, opiates [of natural or (semi-)synthetic origin such as morphine or heroin], cannabis, ethanol, mescaline, nicotine, and the like}, which substances / drugs may be consumed alone or in combination; or other rewarding stimuli {of either natural origin (such as food, sweet, fat, or sex, and the like), or synthetic origin [such as gambling, or internet/IT (such as immoderate gaming, or inappropriate involvement in online social networking sites or blogging), and the like]}. In a sub-embodiment, addiction disorders relating to psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components. Substance- related addiction disorders especially include substance use disorders such as substance dependence, substance craving and substance abuse; substance-induced disorders such as substance intoxication, substance withdrawal, and substance-induced delirium. The expression "prevention or treatment of addictions" (i.e. preventive or curative treatment of patients who have been diagnosed as having an addiction, or as being at risk of developing addictions) refers to diminishing addictions, notably diminishing the onset of addictions, to weakening their maintenance, to facilitating withdrawal, to facilitating abstinence, or to attenuating, decreasing or preventing the occurrence of reinstatement of addiction (especially to diminishing the onset of addictions, to facilitating withdrawal, or to attenuating, decreasing or preventing the occurrence of reinstatement of addiction).
Mood disorders include major depressive episode, manic episode, mixed episode and hypomanic episode; depressive disorders including major depressive disorder, dysthymic disorders; bipolar disorders including bipolar I disorder, bipolar II disorder (recurrent major depressive episodes with hypomanic episodes), cyclothymic disorder; mood disorders including mood disorder due to a general medical condition (including the subtypes with depressive features, with major depressive-like episode, with manic features, and with mixed features), substance-induced mood disorder (including the subtypes with depressive features, with manic features, and with mixed features). Such mood disorders are especially major depressive episode, major depressive disorder, mood disorder due to a general medical condition; and substance-induced mood disorder.
Appetite disorders comprise eating disorders and drinking disorders. Eating disorders may be defined as comprising eating disorders associated with excessive food intake and complications associated therewith; anorexias; compulsive eating disorders; obesity (due to any cause, whether genetic or environmental); obesity-related disorders including overeating and obesity observed in Type 2 (non-insulin-dependent) diabetes patients; bulimias including bulimia nervosa; cachexia; and binge eating disorder. Particular eating disorders comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; bulimia or anorexia nervosa. In a sub-embodiment, eating disorders may be defined as especially comprising anorexia nervosa, bulimia, cachexia, binge eating disorder, or compulsive obesities. Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake. Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance.
Cognitive dysfunctions include deficits in attention, learning and especially memory functions occurring transiently or chronically in psychiatric, neurologic, neurodegenerative, cardiovascular and immune disorders, and also occurring transiently or chronically in the normal, healthy, young, adult, or especially aging population. Cognitive dysfunctions especially relate to the enhancement or maintenance of memory in patients who have been diagnosed as having, or being at risk of developing, diseases or disorders in which diminished memory (notably declarative or procedural) is a symptom [in particular dementias such as frontotemporal dementia, or dementia with Lewy bodies, or (especially) Alzheimer's disease]. Especially, the term "prevention or treatment of cognitive dysfunctions" relates to the enhancement or maintenance of memory in patients who have a clinical manifestation of a cognitive dysfunction, especially expressed as a deficit of declarative memory, linked to dementias such as frontotemporal dementia, or dementia with Lewy bodies, or (especially) Alzheimer's disease. Furthermore, the term "prevention or treatment of cognitive dysfunctions" also relates to improving memory consolidation in any of the above mentioned patient populations.
Sleep disorders comprise dyssomnias, parasomnias, sleep disorders associated with a general medical condition and substance-induced sleep disorders. In particular, dyssomnias include intrinsic sleep disorders (especially insomnias, breathing-related sleep disorders, periodic limb movement disorder, and restless leg syndrome), extrinsic sleep disorders, and circadian-rythm sleep disorders. Dyssomnias notably include insomnia, primary insomnia, idiopathic insomnia, insomnias associated with depression, emotional/mood disorders, aging, Alzheimer's disease or cognitive impairment; REM sleep interruptions; breathing-related sleep disorders; sleep apnea; periodic limb movement disorder (nocturnal myoclonus), restless leg syndrome, circadian rhythm sleep disorder; shift work sleep disorder; and jet-lag syndrome. Parasomnias include arousal disorders and sleep-wake transition disorders; notably parasomnias include nightmare disorder, sleep terror disorder, and sleepwalking disorder. Sleep disorders associated with a general medical condition are in particular sleep disorders associated with diseases such as mental disorders, neurological disorders, neuropathic pain, and heart and lung diseases. Substance-induced sleep disorders include especially the subtypes insomnia type, parasomnia type and mixed type, and notably include conditions due to drugs which cause reductions in REM sleep as a side effect. Sleep disorders especially include all types of insomnias, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift work sleep disorder, delayed or advanced sleep phase syndrome, or insomnias related to psychiatric disorders. In addition, sleep disorders further include sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness.
In the context of the present invention, it is to be understood that, in case certain environmental conditions such as stress or fear (wherein stress may be of social origin (e.g. social stress) or of physical origin (e.g. physical stress), including stress caused by fear) facilitate or precipitate any of the disorders or diseases as defined before, the present compounds may be particularly useful for the treatment of such environmentally conditioned disorder or disease.
Preparation of compounds of formulae (I), (II), (III) (IV), (V) and (VI):
The present compounds can be prepared by well known literature methods, by the methods given below, by the methods given in the experimental part or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures. In some cases the final product may be further modified, for example, by manipulation of substituents to give a new final product. These manipulations may include, but are not limited to, reduction, oxidation, alkylation, acylation, and hydrolysis reactions which are commonly known to those skilled in the art. In some cases the order of carrying out the following reaction schemes, and/or reaction steps, may be varied to facilitate the reaction or to avoid unwanted reaction products. In the general sequence of reactions outlined below, the generic groups R, A-i , A2, and A3 are as defined for formula (I). In some instances the generic groups A-i , A2, and A3 may be incompatible with the assembly illustrated in the schemes below and so will require the use of protecting groups (PG). The use of protecting groups is well known in the art (see for example "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-lnterscience, 1999). For the purposes of this discussion, it will be assumed that such protecting groups as necessary are in place. The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se. Compounds are synthesized as their S- enantiomers from commercially available proline, 2-methyl-proline, or derivatives thereof.
Figure imgf000077_0001
Reaction Scheme A
In case A3 is a [1 ,2,4]oxadiazol-3,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme A and B. Compounds of structure A-1 can be coupled with commercially available L-proline methyl ester HCI using standard amide coupling conditions such as EDC/HOBt, HOAt/DCC, TBTU, HATU or PyBOP in the presence of a base such as DIPEA or Et3N at rt in a suitable solvent such as DCM, DMF, MeCN or mixtures thereof (Step a, Reaction Scheme A). Saponification of the ester function of compounds of structure A-2 using methods known in the art such as treatment with base such as NaOH in a solvent or a solvent mixture such as EtOH/water or THF may afford the desired carboxylic acids of structure A-3 (Step b, Reaction Scheme A). Compounds of structure A-3 may be converted in a two step procedure to compounds of formula (I). First, coupling of a compound of structure A-3 with hydroxyamidine A-4 in the presence of coupling reagents such as EDC/HOBT, PyBOP, HATU, TBTU in the presence of a base such as DIPEA or Et3N at rt in a suitable solvent such as DCM, DMF or mixture thereof to give intermediate acyl hydroxyamidines of structure A-5 (Step c, Reaction Scheme A). Second, the cyclization of compounds of structure A-5 in solvents such as dioxane or xylene may be achieved thermally in a temperature range from 60-100°C for hours to days to obtain compounds of formula (I) (Step d, Reaction Scheme A).
Carboxylic acids A-1 are well known in the art and can be especially prepared following the procedures reported in WO2008069997, WO2008008517, WO2010048012, WO2010063662, WO2010063663, WO201 1050198, WO201 1050200 and WO201 1050202. In addition, they may be prepared in analogy to the methods given in the experimental part.
Commercially available nitrile-derivatives may be reacted with hydroxylamine under neutral or basic conditions such as NEt3, DIPEA, sodium carbonate, sodium hydrogencarbonate, sodium hydroxide, potassium ferf-butoxide and the like in a suitable solvent (methanol, ethanol, etc) to obtain hydroxyamidine A-4. The reaction typically proceeds by allowing the reaction temperature to go from rt to a range of 65-80°C, for about 30 min to several days (see WO 2006/12349, Lucca et al J. Med. Chem. 1998, 241 1 -2423).
Figure imgf000078_0001
Reaction Scheme B
Compounds of formula (I), wherein A3 is a [1 ,2,4]oxadiazol-3,5-diyl-, can alternatively be prepared as outlined in Reaction Scheme B. The commercially available Boc-L-proline may be coupled with hydroxyamidines of structure A-4 to obtain acyl-hydroxyamidines of structure B-1 (Step a, Reaction Scheme B). The coupling reaction may be promoted by coupling reagents outlined in Step c, Reaction Scheme A. Cyclization is performed as outlined in Step d, Reaction Scheme A, leading to compounds of structure B-2 (Step b, Reaction Scheme B). Boc- deprotection of compounds of structure B-2 by using standard methods such as treatment with 4N HCI in dioxane or with TFA leads to compounds of structure B-3 (Step c, Reaction Scheme B). Reaction of compounds of B-3 with acids of structure A-1 in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A furnishes compounds of formula (I) (Step d, Reaction Scheme B).
Figure imgf000078_0002
Reaction Scheme C In case A3 is a [1 ,2,4]oxadiazol-3,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Schemes C and D.
In Reaction Scheme C, the synthesis starts with the coupling of commercially available (S)- pyrrolidine-2-carbonitrile and carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as mentioned in Step a, Reaction Scheme A. The intermediates C-1 are converted to hydroxyamidines of structure C-2 in the presence of hydroxylamine, base such as NaHC03 in solvents such as MeOH. The acyl-hydroxyamidine intermediates of structure C-4 can be synthesized by reacting compounds of structure C-2 with commercially available carboxylic acids C-3, in the presence of coupling reagents, base and solvents such as mentioned in Step c, Reaction Scheme A. The cyclization of compounds of structure C-4 can be achieved thermally as mentioned in Step d, Reaction Scheme A, to yield compounds of formula (I).
Figure imgf000079_0001
Reaction Scheme
Compounds of formula (I), wherein A3 is a [1 ,2,4]oxadiazol-3,5-diyl-, can alternatively be prepared as outlined in Reaction Scheme D.
The commercially available (S)-1 -Boc-pyrrolidine-2-carbonitrile can be converted to hydroxyamidine of structure D-1 , using methods described in Step b, Reaction Scheme C. The acyl-hydroxyamidines of structure D-2 can be synthesized from coupling compounds of structure D-1 with compounds of structure C-3 as depicted in Step c, Reaction Scheme A. The cyclization of compounds of structure D-2 can be achieved thermally as mentioned in Step d, Reaction Scheme A to yield compounds of structure D-3. Boc-deprotection using standard methods as mentioned in Step c, Scheme B lead to compounds D-4. Reaction of amines D-4 with carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A furnishes compounds of formula (I). In case A3 is an isoxazol-3,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme E (Step a to d).
The commercially available Boc-L-prolinal was converted to the alkyne-derivative E-1 using methods described in patent WO2010/1 14978. Isoxazoles E-3 can be synthesized by click chemistry of alkynes E-1 with oximes E-2 in the presence of chloramine T trihydrate in solvents such as MeOH at elevated temperature of about 70°C (Step b, Reaction Scheme E). Oximes of structure E-2 can be synthesized from the corresponding aldehyde in the presence of hydroxylamine HCI and NaOAc in solvents such as MeOH. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B lead to compounds of structure E-4. Reaction of amines E-4 with acid A-1 , in the presence of coupling reagents, base and solvents as outlined in, Step a, Reaction Scheme A furnishes compounds of formula (I).
Figure imgf000080_0001
Reaction Scheme E
Alternatively, in case A3 is an isoxazol-3,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme E (Step e to h). The commercially available Boc-L- prolinal was converted to the oxime E-5 using hydroxylamine HCI and NaOAc in solvents such as MeOH. Isoxazoles E-7 can be synthesized by click chemistry of alkynes E-6 with oximes E-5 in the presence of chloramine T trihydrate in solvents such as MeOH at elevated temperature of about 70°C (Step f, Reaction Scheme E). Boc-deprotection using standard methods such as mentioned in Step c, Scheme B lead to compounds of structure E-8. Reaction of amines E-8 with acid A-1 , in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A furnishes compounds of formula (I).
In case A3 is a [1 ,3,4]-oxadioxazol-2,5-diyl- compounds of formula (I) may in general be prepared as illustrated in Reaction Schemes F and G.
The commercially available Boc-L-proline can be coupled with hydrazides of structure F-1 , either commercially available or synthesized from commercially available carboxylic acid or esters according to procedures known by persons skilled in the art to yield derivatives F-2. Cyclization to 1 ,3,4,dioxazoles can be achieved in presence of Burgess' reagent, in a solvent such as dioxane at elevated temperatures of 1 10-120°C under microwave irradiation for several minutes up to hours. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure F-4. Amide coupling of amine F-4 with acids of A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Figure imgf000081_0001
Reaction Scheme F
Figure imgf000082_0001
Reaction Scheme G
Compounds of formula (I), wherein A3 is a [1 ,3,4]-oxadioxazol-2,5-diyl-, can alternatively be prepared as outlined in Reaction Scheme G.
Methylesters of structure A-2 (see Scheme A) can be converted to hydrazides of structure G-3, using an excess of hydrazine in the presence or absence of coupling reagents such as TBTU or DMAP and base such as DIPEA in solvents such as DMF at rt.
Intermediates of structure G-4 can be synthesized by reacting compounds of structure G-3 with carboxylic acids C-3 in the presence of coupling reagents, base and solvents such as mentioned in Step c, Reaction Scheme A. Cyclization to a compound of formula (I) can be achieved in presence of Burgess' reagent, in solvents such as dioxane at elevated temperatures of about 120°C under microwave irradiation for several minutes up to hours.
Figure imgf000082_0002
Reaction Scheme H
In case A3 is a [1 ,3,4]-thiadiazol-2,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme H.
Intermediates of structure F-2 can be converted to thiadiazoles of structure H-1 in the presence of Lawesson's reagent in solvents such as dioxane at elevated temperature of about 120°C. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds H-2. Reaction of amines of structure H-2 with carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Figure imgf000083_0001
Reaction Scheme I
In case A3 is an oxazol-2,4-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme I, in analogy to WO 2003/002559.
Compounds of structure 1-1 are either commercially available or prepared by known literature methods from the corresponding methyl-ketone-analog. Compounds of structure I-2 can be synthesized from A-3 and 1-1 in the presence of base such as K2C03, in solvents such as DMF at ambient or elevated temperature. Cyclization can be achieved in the presence of acetamide and catalytic amounts of BF3 - Et20 in solvents or solvent mixtures such as diethylether and/or o-xylene at elevated temperature of about 120-140°C to yield compounds of formula (I).
Alternatively, Boc-L-proline can react with compounds of structure 1-1 to form compounds of structure I-3 under basic conditions such as K2C03 in solvents such as DMF at ambient or elevated temperature. Cyclization can be performed as outlined in Step b, Reaction Scheme I, or in presence of ammonium acetate in acetic acid at elevated temperature (see US 6,660,759, 2003), leading to compounds of structure I-4. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure I-5. Amide coupling of amines of structure I-5 with acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Figure imgf000084_0001
Reaction Scheme J
In case A3 is an oxazol-2,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme J.
Compounds of structure J-1 or a salt thereof (such as HCI or HBr) are either commercially available or prepared by known literature methods. Coupling of compounds of structure A-3 with J-1 can be performed in the presence of coupling reagents, base and solvents such as mentioned in Step c, Reaction Scheme A. Intermediate J-2 can be cyclized to compounds of formula (I) in the presence of polyphosphoric acid at elevated temperature of about 150°C adapted from the procedure described in WO2003/002559 or by using trifluoromethanesulfonic anhydride in the presence of pyridine in DCM at ambient temperature (see US 2006-19975).
Figure imgf000084_0002
Reaction Scheme K
In case A3 is a [1 ,2,4]triazol-3,5-diyl -, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme K.
Compounds of structure K-1 can be synthesized from (S)-1 -Boc-pyrrolidine-2-carbonitrile and hydrazides of structure F-1 in presence of a base such as K2C03 in a solvent such as n-butanol at elevated temperature of about 125°C or under microwave irradiation at a temperature of about 150°C. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure K-2. Amide coupling of amines of structure K-2 with acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Alternatively, the commercially available (S)-pyrrolidine-2-carbonitrile HCI can be coupled with carboxylic acids of structure A-1 to intermediate C-1 , in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A. Reaction of nitriles of structure C- 1 with hydrazides of structure F-1 in the prescence of base such as K2C03 in solvent such as n- BuOH at elevated temperature of about 160°C in presence or absence of microwave irradiation furnishes compounds of formula (I).
Figure imgf000085_0001
Reaction Scheme L
In case A3 is a 1 H-imidazol-2,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme L.
Synthesis can be performed in accordance to published methods (WO2008/144380 for Step a and b). The commercially available Boc-L-proline can be coupled with compounds of structure J-1 in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes intermediates of structure L-1 , which may undergo cyclization to compounds of structure L-3, in the prescence of ammonium acetate in solvents such as acetic acid or mixture of acetic acid and xylene at elevated temperatures of about 1 10°C. Boc- deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure L-4. Amide coupling of amines of structure L-4 with carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Alternatively, the commercially available (S)-1 -Boc-pyrrolidine-2-carbonitrile can be converted to the amidine L-2 in the presence of a base such as NaOMe and ammonium bromide in solvents such as MeOH at ambient temperature. In a two step reaction compounds of structure L-2 can react with compounds of structure 1-1 to compounds of structure L-3, in presence of a base such as K2C03, in solvents such as DMF at ambient temperature. Following Step e and f, as mentioned above, leads to compounds of formula (I).
Figure imgf000086_0001
Reaction Scheme M
In case A3 is a 1 H-imidazol-2,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme M.
Compounds of structure M-1 are prepared by known literature methods (US 2008-300279, WO2012/39717) from the corresponding commercially available Boc-L-proline. In a two step reaction, compounds of structure M-1 can react with amidine of structure M-2 to compounds of structure M-3, in presence of a base such as K2C03, in solvents such as DMF at ambient temperature. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure M-4. Amide coupling of amines of structure M-4 with carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Figure imgf000087_0001
Reaction Scheme
In case A3 is a 1 /-/-pyrazol-3,5-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme N.
Synthesis can be performed in accordance to published methods (WO2008/144380). Commercially available N-Boc-L-proline N'-methoxy-N'-methylamide can be converted to alkyne N-1 in the presence of alkyne E-6 and ethylmagnesium bromide in THF at 0°C to rt. Pyrazoles of structure N-2 can be synthesized from compounds of structure N-1 in the presence of hydrazine, in solvents such as EtOH at elevated temperature of about 80°C. Boc- deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure N-3. Amide coupling of amines of structure N-3 with carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Figure imgf000087_0002
Reaction Scheme O
In case A3 is a [1 ,2,4]triazol-1 ,3-diyl-, compounds of formula (I) may in general be prepared as illustrated in Reaction Scheme O. Synthesis can be performed in accordance to published methods (WO2005/121 131 ). Imidate of structure 0-1 can be synthesized from commercially available (S)-1-Boc-pyrrolidine-2- carbonitrile in the presence of NaOMe in solvents such as MeOH at ambient temperature. Triazoles of structure 0-3 can be prepared in a two step reaction from compound of structure 0-1 and hydrazine of structure 0-2 in the presence of base such as trietyhlamine in solvent such as MeOH at rt for hours or several days and subsequent addition of triethyl orthoformate in pyridine and heating to 120° for several hours. Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure 0-4. Amide coupling of amines of structure 0-3 with carboxylic acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes compounds of formula (I).
Figure imgf000088_0001
Reaction Scheme P
In case A3 is a [1 ,2,3]-triazol-1 ,4-diyl-, compounds of formula (I) may in general be prepared in accordance to published methods (WO2005/121 131 ), as illustrated in Reaction Scheme P; see experimental part for details.
Figure imgf000089_0001
Reaction Scheme Q
Compounds of formula (I), wherein R is methyl can be prepared from commercially available 2- methyl-proline or derivatives thereof in analogy to the methods given above. For example when A3 is a [1 ,2,4]oxadiazol-3,5-diyl-, compounds of formula (I) may be prepared as outlined in Reaction Scheme Q. The commercially available 2-methyl-L-proline HCI can be Boc-protected with Boc20 in the presence of TEA, DIPEA or Na2C03 in solvents such as MeCN, DCM, THF and H20 or mixtures thereof at rt within hours to days. The obtained compound of structure Q-1 may be coupled with hydroxyamidines of structure A-4 to obtain acyl-hydroxyamidines of structure Q-2 (Step b, Reaction Scheme Q). The coupling reaction may be promoted by coupling reagents outlined in Step c, Reaction Scheme A. Cyclization is performed as outlined in Step d, Reaction Scheme A, leading to compounds of structure Q-3 (Step c, Reaction Scheme Q). Boc-deprotection of compounds of structure Q-3 by using standard methods such as treatment with 4N HCI in dioxane or with TFA leads to compounds of structure Q-4 (Step d, Reaction Scheme Q). Reaction of compounds of Q-4 with acids of structure A-1 in the presence of coupling reagents, base and solvents as outlined in Step a, Reaction Scheme A furnishes compounds of formula (I) (Step e, Reaction Scheme Q).
Alternatively, compounds of structure A-1 can be converted into the corresponding acid chloride (using standard reagents such as thionylchloride) which then react with the commercially available 2-methyl-L-proline HCI in presence of base such as TEA in solvents such as DCM, pyridine or mixtures thereof to compounds of structure Q-5. Compounds of structure Q-5 may be converted in a two step procedure to compounds of formula (I). First, coupling of a compound of structure Q-5 with hydroxyamidine A-4 in the presence of coupling reagents such as EDC/HOBT, PyBOP, HATU, TBTU in the presence of a base such as DIPEA or TEA at rt in a suitable solvent such as DCM, DMF or mixture thereof to give intermediate acyl hydroxyamidines of structure Q-6 (Step g, Reaction SchemeQ). Second, the cydization of compounds of structure Q-6 in solvents such as dioxane, xylene and pyridine or mixtures thereof may be achieved thermally in a temperature range from 60-100°C for hours to days to obtain compounds of formula (I) (Step h, Reaction Scheme Q).
Figure imgf000090_0001
Reaction Scheme R
Compounds of formula (I), wherein R is methyl and A3 is a [1 ,2,4]triazol-3,5-diyl- group, can for example be prepared as outlined in Reaction Scheme R. Compounds of structure R-1 can be synthesized from Q-1 by activation of ethyl chloroformate in the presence of base such as TEA or DIPEA in THF at around 0°C, followed by the addition of ammonia (Step a, Scheme R) at 0°C to rt. Reduction of compound R-1 to nitrile of structure R-2 may be performed with trifluoroacetic anhydride in presence of base such as TEA in solvents such as DCM at temperature of about 0°C to rt (Step b, Scheme R). Compounds of structure R-4 can be synthesized from nitrile R-2 and hydazides of structure F-1 in presence of a base such as K2C03 in a solvent such as n-butanol at elevated temperature of about 125°C for days or under microwave irradiation at a temperature of about 150°C (Step c, Scheme R). Boc-deprotection using standard methods such as mentioned in Step c, Scheme B leads to compounds of structure R-4. Amide coupling of amines of structure R-4 with acids of structure A-1 , in the presence of coupling reagents, base and solvents as outlined in Step d, Reaction Scheme B furnishes the compounds of formula (I).
Experimental Part
I. Chemistry All temperatures are stated in °C. Commercially available starting materials were used as received without further purification. Unless otherwise specified, all reactions were carried out under an atmosphere of nitrogen or argon. Compounds were purified by flash column chromatography on silica gel or by preparative HPLC. Compounds described in the invention are characterized by LC-MS data (retention time tR is given in min; molecular weight obtained from the mass spectrum is given in g/mol) using the conditions listed below. In cases where compounds of the present invention appear as a mixture of conformational isomers, particularly visible in their LC-MS spectra, the retention time of the most abundant conformer is given.
LC-MS with acidic conditions
Method A: Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Zorbax SB-aq (3.5 μηη, 4.6 x 50 mm). Conditions: MeCN [eluent A]; water + 0.04% TFA [eluent B]. Gradient: 95% B → 5% B over 1.5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
Method B: Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (2.5 μηη, 4.6 x 30 mm). Conditions: MeCN [eluent A]; water + 0.04% TFA [eluent B]. Gradient: 95% B→ 5% B over 1 .5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
LC-MS with basic conditions
Method C: Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Zorbax Extend C18 (5 μιη, 4.6 x 50 mm). Conditions: MeCN [eluent A]; 13 mmol/L NH3 in water [eluent B]. Gradient: 95% B→ 5% B over 1 .5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
Method D: Agilent 1 100 series with mass spectrometry detection (MS: Finnigan single quadrupole). Column: Waters XBridge C18 (5 μηη, 4.6 x 50 mm). Conditions: MeCN [eluent A]; 13 mmol/L NH3 in water [eluent B]. Gradient: 95% B→ 5% B over 1 .5 min (flow: 4.5 mL/min). Detection: UV/Vis + MS.
Preparative HPLC with acidic conditions
Method E: Column: Waters XBridge (10 μηη, 75 x 30 mm). Conditions: MeCN [eluent A]; water + 0.5% HCOOH [eluent B]; Gradient: 90% B→ 5% B over 6.4 min (flow: 75 mL/min). Detection: UV/Vis + MS.
Method F: Column: Waters Atlantis (10 μηη, 75 x 30 mm). Conditions: MeCN [eluent A]; water + 0.5% HCOOH [eluent B]; Gradient: 90% B→ 5% B over 6.4 min (flow: 75 mL/min). Detection: UV/Vis + MS. Preparative HPLC with basic conditions
Method G: Column: Waters XBridge (10 μηη, 75 x 30 mm). Conditions: MeCN [eluent A]; water + 0.5% NH4OH (25% aq.) [eluent B]; Gradient: 90% B→ 5% B over 6.5 min (flow: 75 mL/min). Detection: UV/Vis + MS
Abbreviations (as used hereinbefore or hereinafter):
aq. aqueous
atm atmosphere
BSA bovine serum albumin
Boc butyloxycarbonyl
Boc20 di-ferf-butyl dicarbonate
Burgess reagent methyl A/-(triethylammoniumsulfonyl)carbamate
CDI carbonyl diimidazole
Chloramine T trihydrate /V-chloro-p-toluenesulfonamide sodium salt
d days
dba dibenzylidene acetone
DCC dicyclohexyl carbodiimide
DCM dichloromethane
DIPEA diisopropyl-ethylamine, Hunig's base, ethyl-diisopropyl
DMAP 4-dimethylaminopyridne
DMCDA trans-/V,/\/'-dimethylcyclohexane-1 ,2-diamine
DME 1 ,2-dimethoxyethane
DMF dimethylformamide
DMSO dimethylsulfoxide
EDC A/-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide
eq. equivalent(s)
Et ethyl
EtOAc ethyl acetate
Ex. example(s)
FC flash chromatography
GM general method
h hour(s)
hex hexane
hept heptane
HOBt 1 -hydroxybenzotriazole
HPLC high performance liquid chromatography
KOfBu potassium ferf-butoxide Lawesson's reagent 2,4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane-2,4- dithione
LC-MS liquid chromatography - mass spectrometry
Me methyl
MeCN acetonitrile
MeOH methanol
min minute(s)
NaOAc sodium acetate
OAc acetate
org. organic
Pd(dppf)CI2- DCM [1 ,1 '-bis(diphenylphosphino)-ferrocene]dichloropalladium (II)
complex with dichloromethane
Pd(PPh3)4 tetrakis(triphenylphosphine)palladium
Pd(PPh3)2CI2 bis(triphenylphosphine)palladiumchloride
Ph phenyl
PPh3 triphenyl phosphine
prep. preparative
PyBOP benzotriazol-1 -yl-oxy-tris-pyrrolidino-phosphonium- hexafluoro-phosphate
rt room temperature
rxn reaction
s second(s)
sat. saturated
SM starting material
TBTU 2-(1 H-benzotriazole-1-yl)-1 ,2,3,3-tetramethyluronium
tetrafluoroborate
TEA triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
TLC thin layer chromatography
tR retention time
Synthesis of Intermediate A-1
Compounds of structure A-1 were prepared in analogy to the procedure described in WO2008/069997. The addition of DMCDA is optional, but may alter the yield. 2-Fluoro-3-methyl-6-(2H-1 ,2,3-triazol-2-yl)benzoic acid (A-1 -1)
Cs2C03 (6.98 g, 21.4 mmol) was added portionwise to a rt solution of 2-fluoro-6-iodo-3-methyl- benzoic acid (3.0 g, 10.7 mmol) in DMF (15 ml.) followed by 1 H-1 ,2,3-triazole (1 .24 ml_, 21.4 mmol) and Cu(l)l (103 mg, 0.54 mmol) and the resulting blue suspension was stirred at 80°C overnight. The rxn mixture was quenched with 2M aq. HCI and filtered through a celite plug before being extracted with DCM (3x). The combined org. layers were dried (Na2S04), filtered and evaporated in vacuo to give the crude product that was purified by prep. HPLC (method E) to give the title compound A-1 -1 as a pale yellow solid. LC-MS B: tR = 0.55 min; [M+H]+ = 222.01.
Listed in Table 1 below are o-triazolocarboxylic or o-pyrazolocarboxylic acids of structure A-1 , unless otherwise stated, prepared from the corresponding commercially available iodo- carboxylic acid according to the above procedure (see A-1 -1 ), using 1 H-1 ,2,3-triazole or 1 H- pyrazole accordingly.
Table 1
A-1 Name fR [min]; MS-data
LC-MS m/z Method [M+H]+
A-1 -2 5-Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.53; B 204.13
A-1 -3 4-Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.53; B 204.23
A-1 -4 2-(2H-1 ,2,3-Triazol-2-yl)benzoic acid 0.55; A 190.08
A-1 -5 5-Chloro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.66; A (35CI)
224.3
A-1 -6 4,5-Dimethyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.59; B 218.09
A-1 -7 5-Fluoro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.49; B 208.32
A-1 -8* 4-Fluoro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.51 ; B 208.16
A-1 -9 2-Fluoro-3-methoxy-6-(2H-1 ,2,3-triazol-2-yl)benzoic 0.48; B 238.01
acid
A-1-10 5-Methoxy-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.49; B 220.19
A-1-1 1*1 5-Methoxy-4-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic 0.68; A 234.05
acid
A-1-12 4,5-Dimethoxy-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.46; B 250.03
A-1 -13* 5-Methoxy-4-methyl-2-(1 H-pyrazol-1-yl)benzoic acid 0.58; B 233.17
A-1 -14 6-Methyl-3-(2H-1 ,2,3-triazol-2-yl)picolinic acid 0.30; B 205.35
A-1 -15* 3-Fluoro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.56; A 208.08 A-1 -16 4-Chloro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.66; A (35CI)
224.10
A-1-17*1 3,5-Dimethyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.66; A 218.10
A-1 -18 2-Methyl-6-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.51 ; B 204.22
A-1 -19 5-Cyano-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.46; B No ionization
A-1 -20* 4-Methoxy-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.60; A 220.05
A-1 -21 2-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic 0.64; B No acid ionization
A-1 -22* 2-(2H-1 ,2,3-triazol-2-yl)-4-(trifluoromethyl)benzoic 0.72; A No acid ionization
A-1 -23 2-(2H-1 ,2,3-triazol-2-yl)-5-(trifluoromethoxy)benzoic 0.66; B 273.71 acid
A-1 -24* 4,5-Difluoro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.56; B No ionization
A-1 -25 4,5-Dimethyl-2-(1 H-pyrazol-1 -yl)benzoic acid 0.59; B 217.18
A-1-26*1 4-Fluoro-5-methoxy-2-(2H-1 ,2,3-triazol-2-yl)benzoic 0.64; A 238.1 acid
A-1 -27 3,4-Dimethyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.65; A 218.23
A-1 -28 5-Methyl-2-(1 H-pyrazol-1 -yl)benzoic acid 0.52; B 203.22
A-1 -29* 5-Methoxy-2-(1 H-pyrazol-1 -yl)benzoic acid 0.49; B 219.18
A-1 -30* 3-Fluoro-2-(1 H-pyrazol-1 -yl)benzoic acid 0.47; A 207.19
A-1 -31 6-Methyl-3-(1 H-pyrazol-1 -yl)picolinic acid 0.26; B No ionization
A-1 -32* 4-Fluoro-2-(1 H-pyrazol-1 -yl)benzoic acid 0.50; B 207.20
A-1-33*1 5-Fluoro-3-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic 0.62; A 222.15 acid
A-1 -59*1 4-Chloro-5-methoxy-2-(2H-1 ,2,3-triazol-2-yl)benzoic 0.70; A (35CI) acid 254.01
A-1 -61* 3-Chloro-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid 0.61 ; A No ionization
* Preparec from the corresponding o-bromo-carboxylic acid 1 Corresponding o-bromo-carboxylic acid was synthesized according to below mentioned procedures.
Synthesis of 2-bromo-substituted benzoic acids were performed in analogy to described methods (Tetrahedron Letters, 2009, 1267-1269, J. Org. Chem, 2007, 9786-9).
2-Bromo-5-methoxy-4-methyl-benzoic acid
Br2 (0.74 ml_, 14.4 mmol) was added to a rt suspension of 3-methoxy-4-methylbenzoic acid (2.00 g, 12 mmol) in acetic acid (15 ml.) and water (15 ml_), then the mixture was heated to 60°C for 2h. The mixture was allowed to reach rt and the solids were filtered off and rinsed with cold water (40 ml.) to yield 2-bromo-5-methoxy-4-methylbenzoic acid as a white solid which was used further without purification. LC-MS A: tR = 0.76 min, [M+H]+ = no ionization. 1H NMR (DMSO) δΗ: 7.49 (s, 1 H), 7.29 (s, 1 H), 3.82 (s, 3 H), 2.17 (s, 3 H).
2-Bromo-4-fluoro-5-methoxy-benzoic acid
The title compound was prepared from 4-fluoro-3-methoxybenzoic acid in analogy to the above described method. LC-MS A: tR = 0.72 min, [M+H]+ = no ionization. 1H NMR (DMSO) δΗ: 13.52 (bs, 1 H), 7.77 (dd, 1 H), 7.44 (dd, 1 H), 4.01 (s, 3 H).
2-Bromo-3,5-dimethyl-benzoic acid
The title compound was prepared from 3,5-dimethyl-benzoic acid in analogy to the above described method. LC-MS A: tR = 0.75 min, [M+H]+ = no ionization. 1 H NMR (DMSO) δΗ: 7.56 (s, 1 H), 7.28 (m, 2 H), 2.36 (s, 3 H), 2.27 (s, 3 H).
2-Bromo-4-chloro-5-methoxybenzoic acid
The title compound was prepared from 4-chloro-3-methoxybenzoic acid in analogy to the above described method. LC-MS A: tR = 0.77 min, [M+H]+ = no ionization. 1H NMR (DMSO) δΗ: 13.60 (bs, 1 H), 7.82 (s, 1 H), 7.47 (s, 1 H), 3.91 (s, 3 H).
2-Bromo-5-fluoro-3-methylbenzoic acid
Synthesis was performed in analogy to methods described in WO201 1/9091 1 : A solution of 2,3-dibromo-5-fluorotoluene (1 .0 g, 3.73 mmol) in THF (32 mL) was cooled to -30°C (dry-ice/ acetone) and isopropylmagnesium chloride solution (2.0M in THF, 2.5 mL) was added. During the addition the rxn mixture was allowed to reach -12°C, but was cooled down after the addition to -40°C and stirred at this temperature for 45 min before the rxn mixture warmed to -15°C. After 4h at this temperature, a pellet of dry ice was added (gas evolution) and the rxn mixture was allowed to reach rt overnight. The rxn mixture was basified with 1 M aq. NaOH to pH 14 and washed with EtOAc (2x). These combined org. layers did not contain any product and were discarded. The aq. layer was acidified with 2N aq. HCI to pH 1 and extracted with EtOAc (2x). The combined org. layers were dried (MgS04), filtered and concentrated under reduced pressure to yield the title compound as a white solid which was used in the next step without further purification. 3- Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid (A-1 -34)
Step A: K2C03 (8.18 g, 59.2 mmol) was added to a rt solution of 2-fluoro-3-methylbenzonitrile (4.0 g, 29.6 mmol) and 1 H-1 ,2,3-triazole (1 .72 ml_, 29.6 mmol) in DMF (80 ml.) and the resulting suspension was heated to 120°C for 4h. The mixture was allowed to reach rt, water was added and the rxn mixture was extracted with EtOAc (3x). The combined org. extracts were washed with brine, dried (Na2S04), filtered, evaporated in vacuo and purified by FC (hex/EtOAc 2:1 to 1 :1 ) to give 3-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzonitrile as a white solid. LC-MS B: tR = 0.62 min; [M+H]+ = 185.16.
Step B: 4N aq. NaOH (10 ml_, 40.2 mmol) was added to a rt solution of 3-methyl-2-(2H-1 ,2,3- triazol-2-yl)benzonitrile (1 .48 g, 8.04 mmol) in MeOH (15 ml.) and the resulting mixture was heated to 90°C for 50h. After the rxn mixture reached rt, water was added and the org. solvent was removed in vacuo. The residue was extracted with EtOAc (2x) and the combined org. layers were washed with 1 M aq. HCI and brine, dried (Na2S04), filtered and evaporated in vacuo. To remove the residual side product, the crude product was re-dissolved in 2N aq. NaOH and washed with EtOAc (2x). The aq. layer was acidified with 2N aq. HCI and extracted with EtOAc (3x). The combined acidic org. extracts were washed with brine, dried (Na2S04), filtered and evaporated in vacuo to give the title compound A-1 -34 that was used further without purification. LC-MS B: tR = 0.50 min; [M+H]+ = 186.17.
4- Methyl-[1 ,1'-biphenyl]-2-carboxylic acid (A-1 -35)
Step A: H2S04 95-98% (2.54 ml_, 0.048 mol) was added to a solution of 2-iodo-5- methylbenzoic acid (25.0 g, 0.095 mol) in MeOH (220 ml.) and refluxed for 20h. The rxn mixture was cooled with an ice bath, and 1 N aq. NaOH was added dropwise until pH 8 was reached. The org. solvent was removed in vacuo and the aq. layer was extracted with DCM (2x). The combined org. extracts were washed with sat. aq. NaHC03 (1 x) and H20 (1x), dried (Na2S04), filtered and concentrated in vacuo to give methyl 2-iodo-5-methylbenzoate as a pale yellow liquid which was used in the next step without further purification. LC-MS A: tR = 0.87 min; [M+H]+ = 259.22.
Step B: Pd(PPh3)4 (523 mg, 0.45 mmol) was added to a rt solution of methyl 2-iodo-5- methylbenzoate in toluene (23 mL). After the solution was stirred for 10 min, a solution of phenylboronic acid (1 .24 g, 9.96 mmol) in EtOH (10 mL) was added, followed by 2M aq. Na2C03 (21 mL). The mixture was vigorously stirred and heated to reflux for 24h. The rxn mixture was allowed to reach rt, then Et20 was added and the org. layer was separated and concentrated in vacuo. Purification by FC (Biotage SP1 : EtOAc/hept eluting with a gradient of 0-10% EtOAc) was performed to give methyl 4-methyl-[1 , 1 '-biphenyl]-2-carboxylate as a colorless oil. LC-MS A: tR = 0.94 min; [M+H]+ = 227.16. Step C: 32% aq. NaOH (74 mL) was added to a rt solution of methyl 4-methyl-[1 , 1 '-biphenyl]-2- carboxylate (15.5 g, 0.068 mol) in MeOH (124 mL). The rxn mixture was stirred at 65°C for 2h, then the org. solvent was evaporated, water added, and the aq. layer acidified with cone. HCI. The mixture was stirred at rt for 30 min, and the precipitate was filtered off to give the title compound A-1 -35 as a white solid. LC-MS D: tR = 0.55 min; [M+H]+ = 21 1 .27.
2-(Oxazol-2-yl)benzoic acid (A-1 -36)
Step A: Pd(PPh3)2CI2 (34 mg, 0.05 mmol) was added to a degassed rt solution of methyl 2- iodobenzoate (250 mg, 0.95 mmol) and 2-(tri-n-butylstannyl)oxazole (0.25 mL, 1.14 mmol) in DMF (3 mL). The rxn mixture was irradiated in the microwave at 130°C for 25 min (with cooling function). The rxn mixture was diluted with DCM and sat. aq. NaHC03. The org. layer was separated and the aq. layer was extracted with DCM (3x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo. Purification by FC (hex/EtOAc 2:3) yielded methyl 2-(oxazol-2-yl)benzoate as a beige solid. LC-MS A: tR = 0.70 min; [M+H]+ = 204.12.
Step B: Methyl 2-(oxazol-2-yl)benzoate (314 mg, 0.39 mmol) was suspended in MeOH (1 mL) and THF (1 mL), then treated with 1 N aq. NaOH (0.9 mL). The solution was stirred at rt for 6h, then the rxn mixture was concentrated, diluted with DCM and acidified with 1 N HCI to pH 1. The org. layer was separated and the aq. layer was extracted with DCM (2x). The combined org. layers were washed with brine (1 x), dried (MgS04), filtered and concentrated to yield the title compound A-1 -36 as a white solid that was used in the next step without purification. LC- MS A: tR = 0.57 min; [M+H]+ = 190.14.
5-Methyl-2-(oxazol-2-yl)benzoic acid (A-1 -37)
Step A: Pd(PPh3)2Cl2 (34 mg, 0.05 mmol) was added to a rt solution of 2-iodo-5-methylbenzoic acid methyl ester (263 mg, 0.95 mmol) and 2-(tri-n-butylstannyl)oxazole (0.25 mL, 1.14 mmol) in degassed DMF (3 mL). The rxn mixture was irradiated in the microwave at 125°C for 25 min (with cooling function). The rxn mixture was diluted with DCM and sat. aq. NaHC03. The org. layer was separated and the aq. layer was extracted with DCM (3x). The combined org. layer were dried (MgS04), filtered, concentrated in vacuo and purified by FC (hex/EtOAc 2:3) to yield methyl 5-methyl-2-(oxazol-2-yl)benzoate as a beige solid. LC-MS A: tR = 0.76 min; [M+H]+ = 218.17.
Step B: 2N aq. NaOH (0.9 mL) was added to a rt solution of methyl 5-methyl-2-(oxazol-2- yl)benzoate (157 mg, 0.72 mmol) in MeOH (2.5 mL). The rxn mixture was stirred at rt for 2h, then another 0.5 mL of 2N aq. NaOH was added and stirred at rt for 18h. The rxn mixture was concentrated, then diluted with DCM and acidified with 1 N HCI to pH 1 . The org. layer was separated and the aq. layer was extracted with DCM (2x). The combined org. layers were washed with brine (1x), dried (MgS04), filtered and concentrated to yield the title compound A- 1 -37 as white crystals. LC-MS A: tR = 0.64 min; [M+H]+ = 204.20. 5-Methyl-2-(pyridin-2-yl)benzoic acid (A-1 -38)
Step A: Pd(PPh3)4 (1.59 g, 1.38 mmol) was added to a rt solution of 2-iodo-5-methylbenzoic acid methyl ester (3.80 g, 13.77 mmol), Cul (0.52 g, 2.75 mmol), CsF (4.22 g, 27.53 mmol), 2- tributylstannylpyridine (5.96 g, 20.65 mmol) in DMF (60 mL). The resulting suspension was stirred at 90°C overnight. The obtained rxn mixture was diluted with EtOAc and filtered through a short pad of celite, then a solution of sat. aq. NaHC03 was added to the filtrate and the aq. layer extracted with EtOAc (3x). The combined org. layers were washed with H20 and brine, dried (Na2S04), filtered and concentrated under reduced pressure. Purification by FC (EtOAc/hept 1 :4 to 3:7) yielded methyl 5-methyl-2-(pyridin-2-yl)benzoate as a brown oil. LC-MS B: tR = 0.67 min, [M+H]+ = 228.07.
Step B: 1 M aq. NaOH (23.2 mL) was added to a solution of methyl 5-methyl-2-(pyridin-2- yl)benzoate (1 1.62 mmol) in MeOH (15 mL) and THF (17 mL), and the resulting mixture was stirred at rt overnight. The volatiles were evaporated under reduced pressure and the remaining aq. layer was acidified with 2M HCI to pH 1 and extracted with DCM (3x). The combined org. layers were dried (Na2S04), filtered and concentrated under reduced pressure to give the title compound A-1 -38 as a pale brown foam. LC-MS B: tR = 0.39 min, [M+H]+ = 214.25.
4- Methoxy-[1 ,1'-biphenyl]-2-carboxylic acid (A-1 -39)
Step A: Pd(PPh3)4 (1.06 g, 0.92 mmol) was added to a rt solution of methyl-2-bromo-5- methoxybenzoate (2.26 g, 9.2 mmol), phenylboronic acid (1.68 g, 13.8 mmol), K2C03 (2.54 g, 18.4 mmol), toluene (12 mL) and MeOH (10 mL), and the yellow suspension was heated to 80°C overnight. After the rxn mixture reached rt, water was added until all solids were dissolved. The org. layer was separated and the aq. layer was extracted with EtOAc (3x). The combined org. layers were dried (Na2S04), filtered and concentrated under reduced pressure. Purification by FC (Biotage SP1 : EtOAc/hex 1 :9 to 3:7) yielded methyl 4-methoxy-[1 , 1 '- biphenyl]-2-carboxylate as a colorless oil. LC-MS B: tR = 0.85 min, [M+H]+ = 241.58.
Step B: To a solution of methyl 4-methoxy-[1 , 1 '-biphenyl]-2-carboxylate (2.22 g, 9.18 mmol) in THF (20 mL) 1 N aq. NaOH (20 mL) was added and the resulting rxn mixture was stirred at 65°C overnight. The org. solvent was evaporated and the residue was diluted with DCM and acidified with 2N aq. HCI to pH 1. The org. layer was separated and the aq. layer was extracted with DCM (3x). The combined org. layers were washed with brine, dried (MgS04), filtered and concentrated under reduced pressure to give title compound A-1 -39 as an off-white solid. LC- MS B: tR = 0.70 min, [M+H]+ = 229.04.
5- Fluoro-2-(1 H-pyrazol-5-yl)benzoic acid (A-1 -40)
Step A: A flask was charged with methyl 2-bromo-5-fluorobenzoate (1.0 g, 4.3 mmol), 1 H- pyrazole-5-boronic acid (554 mg, 4.7 mmol), DME (15.3 mL) and a solution of NaHC03 (721 mg, 8.6 mmol) in H20 (3 mL). The flask was evacuated and backfilled with N2 several times, then Pd(PPh3)4 (236 mg, 0.204 mmol) was added and refluxed overnight. The rxn mixture was allowed to cool to rt, and the solid was filtered off and rinsed with EtOAc. The filtrate was washed with water (1x), dried (MgS04), filtered and concentrated under reduced pressure. Purification by FC (Biotage SP1 : EtOAc/hex eluting with a gradient of 0-30% EtOAc) yielded 5- fluoro-2-(1 /-/-pyrazol-5-yl)benzoate as a colorless oil. LC-MS B: tR = 0. 59 min, [M+H]+ = 221 .07.
Step B: 2M aq. NaOH (1.33 mL) was added to a rt solution of 5-fluoro-2-(1 H-pyrazol-5- yl)benzoate (237 mg, 1 .08 mmol) in MeOH (4 mL) and the mixture was stirred at rt for 2h. The rxn mixture was concentrated, diluted with DCM and acidified with 1 N aq. HCI to pH 1. Part of the product precipitated and was filtered off. The remaining filtrate was extracted with DCM (2x), the combined org. layers were dried (MgS04), filtered and concentrated together with the solids to obtain the title compound A-1 -40 as a white solid. LC-MS B: tR = 0. 48 min, [M+H]+ = 207.09.
3-Fluoro-2-(1 H-pyrazol-5-yl)benzoic acid (A-1 -41)
Step A: A solution of NaHC03 (2.0 g, 23.9 mmol) in H20 (8.5 mL) was added to a rt solution of 2-bromo-3-fluorobenzonitrile (2.84 g, 14.2 mmol), 1 H-pyrazole-5-boronic acid (2.25 g, 19.1 mmol) in DME (40 mL) The flask was evacuated and backfilled with N2 several times, then Pd(PPh3)4 (1 .3 g, 1 .14 mmol) was added and refluxed overnight. The rxn mixture was allowed to cool to rt, and the solid was filtered off and rinsed with EtOAc. The layers were separated and the aq. layer was extracted with EtOAc (1 x), dried (MgS04), filtered and concentrated under reduced pressure. Purification by FC (Biotage SP1 : EtOAc/hex eluting with a gradient of 0-30% EtOAc) yielded 3-fluoro-2-(1 H-pyrrol-2-yl)benzonitrile as a white solid. LC-MS B: tR = 0.54 min, [M+H]+ =188.17.
Step B: 4M aq. NaOH (5.6 mL) was added to a rt solution of 3-fluoro-2-(1 /-/-pyrrol-2- yl)benzonitrile (995 mg, 5.32 mmol) in MeOH (10 mL) and the resulting suspension was refluxed for 2 days. The rxn mixture was allowed to reach rt and acidified with 4N aq. HCI to pH 1 and extracted with EtOAc (2x). The combined org. layers were dried (MgS04), filtered and concentrated under reduced pressure to yield the title compound A-1 -41 as a crude white solid which was used as such. LC-MS B: tR = 0.47 min, [M+H]+ =207.10.
5-Methoxy-4-methyl-2-(pyrimidin-2-yl)benzoic acid (A-1 -56)
Step A was performed in analogy to a described method (J. Org. Chem, 2007, 9786-9).
Step A: Br2 (1.1 1 mL, 21 .7 mmol) was added to a rt suspension of 3-methoxy-4-methylbenzoic acid (3.00 g, 18.1 mmol) in a mixture of acetic acid (23 mL) and water (23 mL) and the mixture was heated to 60°C for 2h. The mixture was allowed to reach rt and the solids were filtered and rinsed with water to yield 2-bromo-5-methoxy-4-methylbenzoic acid as a white solid which was used as such in the next step. LC-MS A: tR = 0.76 min, no ionization.
Step B: H2S04 (0.5 mL, 9.3 mmol) was added to a suspension of 2-bromo-5-methoxy-4- methylbenzoic acid (4.07 g, 16.6 mmol) in MeOH (40 mL) and the resulting rxn mixture was heated to 70°C overnight. The rxn mixture was cooled to 0°C and basified with 1 M aq. NaOH (10 mL) to pH 1 1 . The rxn mixture was extracted with DCM and the combined org. layers were dried (MgS04), filtered and concentrated in vacuo to yield methyl 2-bromo-5-methoxy-4- methylbenzoate as a yellow solid that was used as such in the next step without purification. LC-MS A: tR = 0.90 min, [M+H]+ = 258.91 .
Step C: Pd(PPh3)4 (416 mg, 0.36 mmol) was added to a rt solution of 2- tributylstannylpyrimidine (1.40 g, 3.6 mmol) and methyl 2-bromo-5-methoxy-4-methylbenzoate (1 .03 g, 3.96 mmol) in degassed DME (7 mL) and the resulting mixture was irradiated in the microwave at 160°C for 1 h. To the rxn mixture was added Pd(PPh3)4 (315 mg, 0.27 mmol) and irradiation was continued at 160°C for another 2h. The rxn mixture was diluted with EtOAc and H20, filtered over celite, the org. layer was separated and the aq. layer was re-extracted with EtOAc. The combined org. extracts were dried (MgS04), filtered, concentrated in vacuo and purified by FC (Biotage SP1 : EtOAc/hex 1 :9 to 3:7) to yield methyl 5-methoxy-4-methyl-2- (pyrimidin-2-yl)benzoate as a brown solid which was used without further purification. LC-MS A: tR = 0.75 min, [M+H]+ = 258.99.
Step D: 1 M aq. NaOH (4 mL) was added to a rt suspension of methyl 5-methoxy-4-methyl-2- (pyrimidin-2-yl)benzoate (503 mg, 1 .95 mmol) in MeOH (5 mL) and THF (5 mL) and stirred at rt for 2 days. The residue was acidified with 25% aq. HCI, washed with DCM and concentrated in vacuo to yield the title compound A-1 -56 as a off-white solid as its HCI-salt. LC-MS A: tR = 0.63 min, [M+H]+ = 245.06.
5-Chloro-4-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid (A-1 -58)
Cs2C03 (742 mg, 2.28 mmol) was added portionwise to a rt solution of 2-bromo-5-chloro-4- methyl-benzoic acid methyl ester (300 mg, 1 .14 mmol) in DMF (3 mL) followed by 1 H-1 ,2,3- triazole (0.1 mL, 1.71 mmol), Cu(l)l (13 mg, 0.068 mmol) and DMCDA (40 uL, 0.23 mmol). The resulting suspension was stirred at 120°C for 4h. The rxn mixture was quenched with 2M aq. HCI and extracted with EtOAc (3x). The combined org. layers were dried (Na2S04), filtered and evaporated in vacuo to obtain the crude product that was purified by prep. HPLC (method E) to give the title compound A-1 -58 as a pale yellow solid. LC-MS A: tR = 0.72 min; [M+H]+ = 238.01.
5-Methyl-[1 ,1'-biphenyl]-2-carboxylic acid (A-1 -66) Pd(PPh3)4 (0.40 g, 0.34 mmol) was added to a rt solution of 2-iodo-4-methylbenzoic acid (3.00 g, 1 1.4 mmol) and phenylboronic acid (1 .41 g, 1 1.6 mmol) in 2M aq. NaHC03 (30 mL), toluene (30 mL) and isopropanol (30 mL). The rxn mixture was heated to 80°C overnight. The rxn mixture was diluted with EtOAc, acidified with 1 N aq. HCI to pH 1 and extracted with EtOAc (2x). The combined org. layers were dried (MgS04), filtered and concentrated. The crude was purified by prep. HPLC (Method G) to yield the title compound as a beige solid. LC-MS A: tR = 0.81 min; [M+H+MeCN]+ = 254.12.
Carboxylic acids from Table 2 are either commercially available or fully described literature.
Table 2
A-1 Name of Carboxylic Acid Literature Procedure or Commercial Availability
A-1 -42 5-(m-Tolyl)oxazole-4-carboxylic acid WO200977990
WO20101431 16
A-1 -43 5-(3-Chlorophenyl)thiazole-4-carboxylic acid WO200916560
A-1 -44 5-(3-Fluorophenyl)-2-methylthiazole-4-carboxylic acid WO200838251
A-1 -45 5-(4-Fluorophenyl)-2-methylthiazole-4-carboxylic acid WO200838251
A-1 -46 5-(2-Fluorophenyl)-2-methylthiazole-4-carboxylic acid WO200838251
A-1 -47 4-(Phenyl)-1 H-imidazole-5-carboxylic acid US2005-14765
or commercially
available
A-1 -48 3-(3-Methoxyphenyl)pyrazine-2-carboxylic acid WO201044054
WO201038200
A-1 -49 2-Methyl-4-(3-Chloro-phenyl)-pyrimidine-5-carboxylic WO201044054
acid page140
A-1 -50 2-(3-Methyl-1 ,2,4-oxadiazol-5-yl)benzoic acid commercially available
A-1 -51 [2,2'-Bipyridine]-3-carboxylic acid J. Org. Chem., 1999,
1015-1021 or commercially available
A-1 -52 [1 , 1 '-Biphenyl]-2-carboxylic acid commercially available
A-1 -53 2-Methyl-5-(m-tolyl)oxazole-4-carboxylic acid WO20104507
WO200977990
A-1 -54 2-Methyl-5-(m-tolyl)thiazole-4-carboxylic acid WO200881399
WO200865626 A-1 -55 5-Methyl-2-(pyrimidin-2-yl)benzoic acid commercially available
A-1 -57 5-(3-Chlorophenyl)-2-methylthiazole-4-carboxylic acid WO200838251
A-1 -60 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid commercially available
A-1 -62 2-Methyl-5-phenyl-thiazole-4-carboxylic acid commercially available
A-1 -63 5-Phenyl-1 ,3-thiazole-4-carboxylic acid commercially available
A-1 -64 5-Phenyl-1 ,3-oxazole-4-carboxylic acid commercially available
A-1 -65 5-(m-Tolyl)thiazole-4-carboxylic acid WO 2010044054
Synthesis of Intermediate A-2
(S)-Methyl 1 -(5-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylate (A-2-1 )
TBTU (7.1 g, 22.1 mmol) was added to a rt solution of 5-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoic acid A-1 -3 (3.0 g, 14.8 mmol) and DIPEA (10.1 mL, 59.1 mmol) in DCM (30 mL), and after stirring for 10 min, amine L-proline methylester HCI (3.19 g, 15.4 mmol) was added and stirred at rt for 18h. The rxn mixture was diluted with DCM and water, the org. layer was separated and the aq. layer was extracted with DCM (2x). The combined org. extracts were washed with brine, dried (MgS04), filtered and the solvent removed under reduced pressure to give the crude product that was purified by FC (EtOAc/hept 7:3) to give the title compound A-2-1 as a white solid. LC-MS A: tR=0.75 min; [M+H]+ = 315.29.
(S)-Methyl 1 -(4-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylate (A-2-2)
TBTU (4.17 g, 13.0 mmol) was added to a rt solution of 4-methyl-2-(2H-1 ,2,3-triazol-2- yl)benzoic acid A-1 -4 (2.20 g, 10.8 mmol) and DIPEA (7.41 mL, 43.3 mmol) in DCM (50 mL), and after stirring for 5 min, amine L-proline methyl ester HCI (1 .83 g, 10.8 mmol) was added and stirred at rt for 48h. The rxn mixture was diluted with DCM and washed with sat. aq. NaHC03. The aq. layer was re-extracted with DCM (1 x) and the combined org. extracts were dried (MgS04), filtered and the solvent was removed under reduced pressure to give the title compound A-2-2 as an orange oil which was used further without purification. LC-MS A: tR = 0.66 min; [M+H]+ = 315.07.
Synthesis of Intermediate A-3
(S)-1 -(5-Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylic acid (A-3-1 )
2N aq. NaOH (6.3 mL) was added to a rt solution of (S)-methyl 1-(5-methyl-2-(2H-1 ,2,3-triazol- 2-yl)benzoyl)pyrrolidine-2-carboxylate A-2-1 (2.2 g, 7.0 mmol) in MeOH (9 mL) and THF (9 mL). The mixture was stirred at rt for 2h, then the org. solvents were removed in vacuo and the residue was acidified with 1 N aq. HCI. The aq. layer was extracted with DCM (3x), the combined org. layers washed with brine, dried (MgS04), filtered and concentrated in vacuo to give the title compound A-3-1 as a white solid that was used further without purification. LC-MS A: tR = 0.66 min; [M+H]+ = 301.28. (S)-1 -(4-Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylic acid (A-3-2)
1 M aq. NaOH (50 ml.) was added to a rt solution of (S)-methyl 1 -(4-methyl-2-(2H-1 ,2,3-triazol- 2-yl)benzoyl)pyrrolidine-2-carboxylate A-2-2 (5.79 g, 18.4 mmol) in MeOH (30 mL) and THF (30 ml_). The rxn mixture was stirred at rt for 2h, then the org. solvents were removed in vacuo and the residue was acidified with 1 M aq. HCI. The aq. layer was extracted with DCM (2x), the combined org. layers washed with brine, dried (MgS04), filtered and concentrated in vacuo to give the title compound A-3-2 as a white foam that was used further without purification. LC-MS A: tR = 0.58 min; [M+H]+ = 301.05.
Synthesis of Intermediate A-4
General Method A for the synthesis of hydroxyamidines (A-4)
To a solution of nitrile-derivative (1 .0 eq.) in MeOH (0.5 M), hydroxylamine HCI (1 .1 to 3.0 eq.) and NaHC03 (1 .1 to 3.0 eq.) was added at rt. The resulting suspension was stirred at a given temperature and time (see Table 3). The mixture was concentrated in vacuo, then EtOAc was added to the remaining residue and the org. layer was washed with brine (1x), dried (MgS04), filtered and concentrated to yield hydroxyamidine A-4.
General Method B for the synthesis of hydroxyamidines (A-4)
Hydroxylamine HCI (1 .0 eq.) was added to a rt solution of nitrile-derivative (1 eq.) and 1 M aq. NaOH (1 eq.) in EtOH (1 M). The resulting suspension was stirred at a given temperature and time (see Table 3). The org. solvent was concentrated in vacuo and the remaining residue was extracted with DCM (3x). The combined org. layers were dried (MgS04), filtered and concentrated to yield hydroxyamidine A-4.
General Method C for the synthesis of hydroxyamidines (A-4)
To a solution of hydroxylamine HCI (1 .1 to 3 eq.) and NaHC03 (1 .1 to 3 eq.) in water (2M), nitrile-derivative and EtOH (2M) was added at rt and stirred at a given temperature and time (see Table 3). The org. solvent was concentrated in vacuo and the remaining residue was extracted with DCM (3x). The combined org. layers were dried (MgS04), filtered and concentrated to yield hydroxyamidine A-4.
General Method D for the synthesis of hydroxyamidines (A-4)
To a solution of nitrile-derivative (1 eq.) in MeOH (0.5 M), hydroxylamine HCI (1 .1 to 3.0 eq.) and NEt3 (1.1 to 3.0 eq.) was added at rt. The resulting mixture was stirred at a given temperature and time (see Table 3). The mixture was concentrated in vacuo, then to the remaining residue EtOAc was added and the org. layer was washed with brine (1 x), dried (MgS04), filtered and concentrated to yield hydroxyamidine A-4. General Method E for the synthesis of hydroxyamidines (A-4)
To a solution of KOfBu (1 .1 - 3.0 eq.) in MeOH (1 M), hydroxylamine HCI (1.1 to 3.0 eq.) was added. After stirring for 30 min at rt, nitrile-derivative was added and the mixture was stirred at a given temperature and time (see Table 3). The org. solvent was concentrated in vacuo and the remaining residue was extracted with DCM (3x). The combined org. layers were dried (MgS04), filtered and concentrated to yield hydroxyamidine A-4.
Listed in Table 3 below are hydroxylamidines of type A-4, prepared from either commercially available nitrile-derivates or synthesized according to described methods.
Table 3
Figure imgf000105_0001
A-4-9 3,5-Difluoro-A -hydroxy- A 60 0.26 172.95 benzamidine 18 B
F
A-4-10 2,3-Difluoro-A -hydroxy- A 60 0.22 172.96 benzamidine 18 B
A-4-1 1 A/-Hydroxy-2,4-dimethyl- A 70 0.35 165.23 benzamidine 96 B
A-4-12 N-Hyd roxy-3, 5-d imethyl- A 80 0.38 165.02 benzamidine 5 B
A-4-13 A/-Hydroxy-4,6-dimethyl- A 80 0.38 166.14 pyridine-2-carboxamidine 3 A
A-4-14 N-Hydroxy-2,3-dimethyl- A 85 0.41 165.18 benzamidine 72 A
A-4-15 /\/-Hydroxy-4-methyl- A 80 0.32 152.2 pyridine-2-carboxamidine 0.25 A
A-4-16 3-Fluoro-A/-hydroxy- A 80 0.3 155.17 benzamidine 1 .5 A
Figure imgf000106_0001
A-4-17 N-Hydroxy-1 H-indole-3- A 60 0.42 176.19 carboxamidine 72 A
A-4-18 /\/-Hydroxy-3-methyl- A 80 0.18 152.22 pyridine-2-carboxamidine 18 A
A-4-19 /\/-Hydroxy-2-methyl- A 85 0.3 151 .23 benzamidine 48 A
A-4-20 N-Hyd roxy-2, 5-d imethyl- A 85 0.43 165.07 benzamidine 96 A
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
A-4-56 N-Hydroxy- A 80 0.37 181 .15 benzo[1 ,3]dioxole-4- 5 A
carboxamidine
A-4-57 2-Ethyl-N-hydroxy- A 70 0.1 165.99 nicotinamidine 72 B
A-4-58 N-Hydroxy-2- A 70 0.41 219.07 trifluoromethyl-benzamidine 3 B
A-4-59 3-Ethoxy-/\/-hydroxy- A 80 0.27 182.18 isonicotinamidine 18 A
A-4-60 2-Ethoxy-3-fluoro-N- A 70 0.36 199.16 hydroxy-benzamidine 18 B
F a)
A-4-61 N-Hydroxy-l-methyl-I H- A 80 0.47 190.29 indole-3-carboxamidine 18 A
\ a)
A-4-62 /\/-Hydroxy-4-methyl- A 80 0.17 152.18 nicotinamidine 25 A
A-4-63 N-Hyd roxy-2, 3-d i methoxy- A 60 0.29 197.17 benzamidine P 18 B
A-4-64 N-Hydroxy-l-methyl-I H- C rt 0.44 142.02 pyrazole-4-carboxamidine 18 A
\
A-4-65 5-Ethyl-A -hydroxy-4- D 75 0.54 180.01 methyl-pyridine-2- 6 A
carboxamidine
A-4-66 N-Hyd roxy-4, 5-d imethyl- D 75 0.48 166.05 pyridine-2-carboxamidine 18 A A-4-67 A/-Hydroxy-5,6-dimethyl- D 75 0.49 166.03 pyridine-2-carboxamidine 48 A
A-4-68 4,N-Dihydroxy-2-methoxy- E 65 0.41 183.05 benzamidine 18 A
A-4-69 A/-Hydroxy-2,6-dimethyl- E 60 0.12 166.04 isonicotinamidine 15 B
A-4-70 /\/-Hydroxy-2-methoxy-6- E 65 0.43 181 .96 methyl-isonicotinamidine 18 A
A-4-71 N-Hydroxy-6-isobutyl-4- E 60 0.63 208.29 methyl-pyridine-2- 18 A
carboxamidine
A-4-72 /\/-Hydroxy-2-methyl- A 60 0.1 1 152.06 isonicotinamidine 18 B
A-4-73 2-6-Difluoro-A -hydroxy-5- A 60 0.24 203.1 1 methoxy-benzamidine 18 B
A-4-74 2-Chloro-A/-hydroxy-3- A 60 0.27 (35CI) methoxy-benzamidine 18 B 201 .10
A-4-75 2-lsopropoxy-/\/-hydroxy- A 65 0.35 196.17 nicotinamidine 18 B
A-4-76 2-Fluoro-A/-hydroxy-6- A 65 0.22 185.16 methoxy-benzamidine 18 B
A-4-77 2-Chloro-A/-hydroxy- A 65 0.21 (35CI) isonicotinamidine 18 B 171 .88 A-4-78 W-Hydroxy-1-methyl-1H- A 65 0.32 190.19 indole-4-carboxamidine 18 B
A-4-79 N-Hydroxy-1 H-pyrrolo[2,3- A 65 0.13 177.21 b]pyridine-4-carboxamidine 18 B
A-4-80 2-Fluoro-A/-hydroxy-6- A 70 0.21 168.96 methyl-benzamidine 18 B
A-4-81 W-Hydroxy-1-methyl-1H- \ A 70 0.34 190.18 indole-7-carboxamidine 18 B
A-4-82 /\/-Hydroxy-2-methyl- A 60 0.10 152.2 nicotinamidine 18 B
A-4-83 N,2-Dihydroxy A 60 0.10 154.03 nicotinamidine 4 B
Figure imgf000112_0001
A-4-84 N-Hydroxy-3- A 70 0.49 221 .16 trifluoromethoxy- 2 A
benzamidine
CF3
A-4-85 N-Hyd roxy-3,4-d i methoxy- A 60 0.39 197.27 benzamidine 2 A a) Nitriles, which are not commercially available, are synthesized according to procedures described below.
Synthesis of Nitriles:
5-Methoxy-1 H-indole-3-carbonitrile
NaOAc (3.51 g, 42.8 mmol) was added to a rt solution of 5-methoxyindole-3-carboxaldehyde (3.0 g, 17.1 mmol), hydroxylamine HCI (2.98 g, 42.8 mmol) in AcOH (20 mL) and the resulting mixture was stirred for 1.5h, then acetic anhydride (16.2 mL, 171 mmol) was added and the rxn mixture was heated to 1 15°C for 30 min. After the rxn mixture reached rt, it was poured into ice- water and extracted with EtOAc (4x). The combined org. layers were washed with brine, dried (MgS04), decolorized with charcoal, filtered and the solvent was removed under reduced pressure. The crude was purified by FC (EtOAc/hex 3:1 ) to yield 5-methoxy-1 /-/-indole-3- carbonitrile as a yellow solid. LC-MS B: tR = 0.71 min; [M+H]+ = no ionization. 1 H NMR (CDCI3) δΗ: 8.67 (m, 1 H), 7.70 (d, J = 2.9 Hz, 1 H), 7.37 (d, J = 8.9 Hz, 1 H), 7.21 (s, 1 H), 7.00 (m, 1 H), 3.91 (s, 3 H).
2-Cyclobutoxynicotinonitrile
NaH 60% dispersion in mineral oil (100 mg, 2.5 mmol) was added to a rt solution of cyclobutanol (0.125 ml_, 1 .6 mmol) in DMF (1 .5 ml_). After stirring for 1 h, 3-cyano-2- fluoropyridine (150 mg, 1.23 mmol) was added and the brown suspension was stirred at rt for 1 h. The rxn mixture was quenched with water and extracted with DCM (2x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo to yield 2- cyclobutoxynicotinonitrile as an orange oil. LC-MS B: tR = 0.76 min; [M+H]+ = 175.21 . 1H NMR (DMSO) δΗ: 8.43 (m, 1 H), 8.26 (dd, Ji = 7.6 Hz, J2 = 1.9 Hz, 1 H), 7.17 (dd, Ji = 7.6 Hz, J2 = 5.0 Hz, 1 H), 5.25 (m, 1 H), 2.43 (m, 2 H), 2.13 (m, 2 H), 1.82 (m, 1 H), 1.66 (m, 1 H).
2-(Cyclopentyloxy)nicotinonitrile
The title compound was prepared from 3-cyano-2-fluoropyridine and cyclopentanol in analogy to the procedure described for 2-cyclobutoxynicotinonitrile. LC-MS B: tR = 0.81 min; [M+H]+ = no ionization. 1H NMR (DMSO) δ: 8.46 (dd, 4 = 5.0 Hz, J2 = 1 .9 Hz, 1 H), 8.24 (dd, 4 = 7.6 Hz, J2 = 1.9 Hz, 1 H), 7.15 (dd, 4 = 7.6 Hz, J2 = 5.0 Hz, 1 H), 5.50 (m, 1 H), 1 .97 (m, 2 H), 1.68 (m, 6 H).
ferf-Butyl 3-cyano-1H-pyrrolo[2,3-b]pyridine-1 -carboxylate
Step A: Hydroxylamine HCI (264 mg, 3.8 mmol) was added to a rt solution of 7-azaindole-3- carboxaldehyde (500 mg, 3.42 mmol) in pyridine (1 mL) and the resulting yellow solution was stirred for 1 h before acetic anhydride (0.63 mL, 6.56 mmol) was added and heated to 1 10°C for 30 min. The rxn mixture was cooled to rt, EtOAc was added and the org. layer was washed with sat. aq. NaHC03. The aq. layer was re-extracted with EtOAc, and the combined org. layers were dried (MgS04), filtered and concentrated in vacuo to yield 1 H-pyrrolo[2,3-b]pyridine-3- carbonitrile as an off-white solid which was used in the next step without further purification.
Step B: NaH 60% dispersion in mineral oil (1 15 mg, 2.88 mmol) was added to a rt solution of 1 H-pyrrolo[2,3-b]pyridine-3-carbonitrile (275 mg, 1 .92 mmol) in DMF (10 mL) and after stirring for 5 min at rt, di-tert-butyldicarbonate (629 mg, 2.88 mmol) was added at rt and stirring was continued for 1 h. The rxn mixture was quenched with water and extracted with EtOAc (2x). The combined org. layers were concentrated in vacuo to yield the title compound as a yellow solid. LC-MS B: tR = 0.73 min; [M+H]+ = 244.05.
1 -Methyl-1 H-pyrrolo[2,3-b]pyridine-3-carbonitrile
NaH 60% dispersion in mineral oil (1 15 mg, 2.88 mmol) was added to a rt solution of 1 H- pyrrolo[2,3-b]pyridine-3-carbonitrile (275 mg, 1.92 mmol) in DMF (10 mL) and the resulting mixture was stirred for 5 min before Mel (0.18 mL, 2.88 mmol) was added and stirring was continued for 1 h. The rxn mixture was quenched with water, extracted with EtOAc (2x) and the combined org. layers were dried (MgS04) and concentrated in vacuo to yield the title compound as a yellow solid. LC-MS B: tR = 0.51 min; [M+H]+ = 158.05.
3-Ethoxyisonicotinonitrile
Sodium ethoxide (53 mg, 0.743 mmol) was added to a 0°C solution of 3-chloro-4-cyanopyridine (100 mg, 0.72 mmol) in DMF (1 mL). The mixture was stirred at 0°C for 30 min and at rt for 2h, then the mixture was concentrated in vacuo. To the residue Et20 was added and the salts were filtered off. The filtrate was concentrated in vacuo to yield the title compound as a white solid. LC-MS A: tR = 0.67 min; [M(35CI)+H]+ = 149.06.
2- Ethoxy-3-fluorobenzonitrile
NaH 60% dispersion in mineral oil (575 mg, 14.4 mmol) was added to a rt solution of EtOH (1 .0 mL, 17.1 mmol) in DMF (6.0 mL). After stirring for 40 min at rt, the solution was cooled to 0°C, 2,3-difluorobenzonitrile (1 .59 mL, 14.4 mmol) was added dropwise and stirring was continued for 1 h at rt. The rxn mixture was quenched with water and extracted with DCM (2x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo to yield 2-ethoxy-
3- fluorobenzonitrile as an orange oil. LC-MS B: tR = 0.74 min; [M+H]+ = no ionization. 1H NMR (CDCI3) δΗ: 7.66 (m, 2 H), 7.27 (m, 1 H), 4.32 (q, 2 H), 1 .35 (t, 3 H).
1 -Methyl-1 H-indole-3-carbonitrile
The title compound was prepared from 1-methylindole-3-carboxaldehyde in analogy to the procedure described for 5-methoxy-1 /-/-indole-3-carbonitrile. LC-MS A: tR = 0.78 min; [M+H]+ = 157.16.
Synthesis of Intermediate B-2
(S)-2-[3-(3-Chloro-2-methylphenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester (B-2-1)
Step A: PyBOP (9.89 g, 19.0 mmol) was added to a 0°C solution of Boc-L-proline (3.40 g, 15.8 mmol), hydroxyamidine A-4-27 (2.92 g, 15.8 mmol) and DIPEA (8.12 mL, 47.4 mmol) in DCM (50 mL). The resulting mixture was stirred at rt for 3h, then concentrated in vacuo to yield (S)- ferf-butyl 2-((((amino(3-chloro-2-methylphenyl)methylene)amino)oxy)carbonyl)pyrrolidine-1 - carboxylate B-1 -1 that was used further without purification.
Step B: The crude B-1 -1 was taken up in dioxane (50 mL) and refluxed (75°C) for 2 days. The rxn mixture was concentrated and purified by FC (Biotage SP1 : EtOAc/hex 3:7) to give the title compound B-2-1 as a yellow oil. LC-MS B: tR = 1.02 min; [M(35CI)+H]+ = 363.98. Listed in Table 4 below are compounds of structure B-2, prepared from the commercially available Boc-L-proline and the corresponding hydroxyamidine according to the above procedure (see B-2-1 ).
Table 4
Figure imgf000115_0001
(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester (B-2-7)
Step A: TBTU (6.49 g, 20.2 mmol) was added to a rt solution of (S)-1-(fert- butoxycarbonyl)pyrrolidine-2-carboxylic acid (2.90 g, 13.5 mmol) and DIPEA (7 mL, 40.9 mmol) in DCM (32 mL) and stirred for 15 min before hydroxyamidine A-4-6 (2.46 g, 14.8 mmol) was added. After stirring for 1 h, the mixture was diluted with DCM and water. The layers were separated and the aq. layer was extracted with DCM (2x). The combined org. layers were washed with brine, dried (MgS04), filtered and concentrated in vacuo to obtain (S -ferf-butyl 2- ((((amino(2-methoxyphenyl)methylene)amino)oxy)carbonyl)pyrrolid -carboxylate (B-1 -7) as an oil which was used further without purification.
Step B: The crude B-1 -7 was taken up in dioxane (85 mL) and refluxed (90°C) for 2 days. The rxn mixture was concentrated and purified by FC (EtOAc/hept 2:3) to give the title compound B- 2-7 as a yellow oil. LC-MS A: tR = 0.88 min; [M+H]+ = 346.05.
Listed in Table 5 below are compounds of structure B-2, prepared from the commercially available (S)-1-(fert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and the corresponding hydroxyamidine according to the above procedure (see B-2-7).
Table 5
Figure imgf000116_0001
Synthesis of Intermediate B-3
3-(3-Chloro-2-methyl-phenyl)-5-(S)-pyrrolidin-2-yl-[1 ,2,4]oxadiazole (B-3-1 )
TFA (4.88 mL, 63.8 mmol) was added to a 0°C solution of B-2-1 (1.85 g, 5.08 mmol) in DCM (70 mL). The resulting rxn mixture was warmed to rt and stirred overnight. The volatiles were removed under reduced pressure, the residue diluted with DCM and basified with 1 N aq. NaOH. The org. layer was separated and the aq. layer extracted with DCM (2x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo to give title compound B-3-1 as a brown oil which was used further without purification. LC-MS B: tR = 0.54 min; [M(35CI)+H]+ = 264.1 1 .
Listed in Table 6 below are compounds of structure B-3, prepared according to the above procedure (see B-3-1 ).
Table 6
B-3 B-2 Name tR [min] MS-data
LC/MS- m/z
Method [M+H]+ B-3-2 B-2-2 5-(S)-Pyrrolidin-2-yl-3-(2-trifluoromethoxy- 0.52 300.08 phenyl)-[1 ,2,4]oxadiazole B
B-3-3 B-2-3 5-(S)-Pyrrolidin-2-yl-3-(2-trifluoromethyl- 0.50 284.02 phenyl)-[1 ,2,4]oxadiazole B
B-3-4 B-2-4 3-(2-Difluoromethoxy-phenyl)-5-(S)-pyrrolidin- 0.48 282.02
2-yl-[1 ,2,4]oxadiazole B
B-3-5 B-2-5 3-(3-Fluoro-2-methoxy-phenyl)-5-(S)-pyrrolidin- 0.45 264.04
2-yl-[1 ,2,4]oxadiazole B
B-3-6 B-2-6 2-Ethoxy-3-((S)-5-pyrrolidin-2-yl- 0.43 261.60
[1 ,2,4]oxadiazol-3-yl)-pyridine B
B-3-1 1 B-2-1 1 3-(2-Ethoxy-3-fluoro-phenyl)-5-(S)-pyrrolidin-2- 0.61 278.10 yl-[1 ,2,4]oxadiazole A
B-3-12 B-2-12 5-(S)-Pyrrolidin-2-yl-3-(3-trifluoromethoxy- 0.64 300.13 phenyl)-[1 ,2,4]oxadiazole A
3-(2-Methoxy-phenyl)-5-(S)-pyrrolidin-2-yl-[1 ,2,4]oxadiazole (B-3-7)
4N HCI in dioxane (22 ml_, 88 mmol) was added to a 0°C solution of (S)-fert-butyl 2-(3-(2- methoxyphenyl)-1 ,2,4-oxadiazol-5-yl)pyrrolidine-1-carboxylate (3.76 g, 10.9 mmol) in DCM (40 ml_). The resulting mixture was allowed to warm to rt and stirred at rt for 2h, then poured into an ice-cooled solution of 4M aq. NaOH (20 ml.) and extracted with DCM (2x). The combined org. extracts were washed with brine, dried (MgS04), filtered and concentrated in vacuo to obtain the title compound B-3-7 as a yellow oil that was used further without purification. LC-MS A: tR = 0.53 min; [M+H]+ = 246.05.
Listed in Table 7 below are compounds of structure B-3, prepared according to the above procedure (see B-3-7).
Table 7
B-3 SM Name tR [min] MS-data
(B-2) LC/MS- m/z
Method [M+H]+
B-3-8 B-2-8 3-(2-Chloro-phenyl)-5-(S)-pyrrolidin-2-yl- 0.56 (3bCI)
[1 ,2,4]oxadiazole A 250.01
B-3-9 B-2-9 3-(3-Fluoro-2-methyl-phenyl)-5-(S)-pyrrolidin-2- 0.61 248.05 yl-[1 ,2,4]oxadiazole A
B-3-10 B-2-10 3-(2-Ethoxy-phenyl)-5-(S)-pyrrolidin-2-yl- 0.58 260.08
[1 ,2,4]oxadiazole A Synthesis of Intermediate C-1
(S)-1 -(5-Methyl-2-[1 ,2,3]triazol-2-yl-benzoyl)-pyrrolidine-2-carbonitrile (C-1 -1 )
TBTU (2.03 g, 6.34 mmol) was added to a rt solution of carboxylic acid A-1 -2 (1 .07 g, 5.28 mmol) and DIPEA (2.71 ml_, 15.8 mmol) in DCM (40 ml.) and stirred for 5 min, before (S)- pyrrolidine-2-carbonitrile (700 mg, 5.28 mmol) was added. The resulting mixture was stirred at rt for 18h, then the mixture was diluted with DCM and the org. layer was washed with water. The aq. layer was re-extracted with DCM (2x) and the combined org. layers were dried (MgS04), filtered and concentrated in vacuo to give the crude product that was purified by FC (Biotage SP1 : EtOAc/hex 3:7 to 1 :1 ) to give the title compound C-1 -1 as a white solid. LC-MS A: tR = 0.74 min; [M+H]+ = 282.12.
Listed in Table 8 below are compounds of structure C-1 , prepared according to the above procedure (see C-1 -1 ).
Table 8
Figure imgf000118_0001
Synthesis of Intermediate C-2
(S)-W-Hydroxy-I -(5-methyl-2-[1 ,2,3]triazol-2-yl-benzoyl)-pyrrolidine-2-carboxamidine (C-2- 1)
Hydroxylamine HCI (25 mg, 0.36 mmol) was added to a rt solution of C-1 -1 (50 mg, 0.18 mmol) and NaHC03 (30 mg, 0.36 mmol) in MeOH (1.2 ml.) and the mixture was stirred at rt for 1 h. After the solvent was removed in vacuo, the residue was taken up in EtOAc and brine. The layers were separated and the org. layer was dried (MgS04), filtered and concentrated in vacuo to afford the title compound C-2-1 as a yellow paste. LC-MS A: tR = 0.56 min; [M+H]+ = 315.15. Listed in Table 9 below are compounds of structure C-2, prepared according to the above procedure (see C-2-1 ).
Table 9
C-2 SM Name tR [min] MS-data
(C-1) LC/MS- m/z
Method [M+H]+ C-2-2 C-1-2 (S)-/V-Hydroxy-1 -(5-methoxy-4-methyl-2- 0.60 345.03
[1 ,2,3]triazol-2-yl-benzoyl)-pyrrolidine-2- carboxamidine A
C-2-3 C-1-3 (S)-1-(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-benzoyl)- 0.60 329.1
A/-hydroxy-pyrrolidine-2-carboxamidine A
Synthesis of Intermediate D-1
(S)-2-(A -Hydroxycarbamimidoyl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (D-1)
Hydroxylamine HCI (429 mg, 6.1 1 mmol) was added to a rt solution of (S)-1-Boc-pyrrolidine-2- carbonitrile (800 mg, 4.08 mmol), and NaHC03 (514 mg, 6.1 1 mmol) in MeOH (10 ml_). The resulting suspension was stirred at 60°C for 1 .5h, then filtered (washed with MeOH) and concentrated in vacuo to yield the title compound D-1 as a white solid that was used further without purification. LC-MS B: tR = 0.36 min; [M+H]+ = 230.1 1.
Synthesis of Intermediate D-3
(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester (D-3-1)
Step A: PyBOP (10.16 g, 19.5 mmol) was added to a 0°C solution of D-1 (4.10 g, 17.9 mmol), 3-chloro-2-methylbenzoic acid (2.77 g, 16.2 mmol) and DIPEA (8.34 ml_, 48.7 mmol) in DCM (50 ml_). The cooling bath was removed and the mixture was stirred at rt for 2h, then the mixture was concentrated in vacuo to give (S)-ferf-butyl 2-(/\/'-hydroxycarbamimidoyl) pyrrolidine-1-carboxylate D-2-1 that was used further without purification. LC-MS B: tR = 0.88 min; [M(35CI)+H]+ = 382.14.
Step B: The crude D-2-1 was dissolved in dioxane (30 ml.) and the resulting solution was stirred at 90°C overnight. The mixture was concentrated in vacuo, diluted with EtOAc and washed with sat. aq. NaHC03 (2x). The org. layer was dried (MgS04), filtered and concentrated in vacuo to give crude product that was purified by FC (Biotage SP1 : EtOAc/hex 1 :9 to 1 :4) to give the title compound D-3-1 as a yellow oil. LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 364.14.
Listed in Table 10 below are compounds of structure D-3, prepared according to the above procedure (see D-3-1 ).
Table 10
D-3 SM Name tR [min] MS-data
LC/MS- m/z
Method [M+H]+
Figure imgf000120_0001
D-3-13 0 (S)-2-[5-(3-Chloro-2-methoxy-phenyl)- 0.97 380.04
HO^^CI [1 ,2,4]oxadiazol-3-yl]-pyrrolidine-1- carboxylic acid ferf-butyl ester A
D-3-14 (S)-2-[5-(2-Methyl-3-methoxy-phenyl)- 0.98 360.12
[1 ,2,4]oxadiazol-3-yl]-pyrrolidine-1- carboxylic acid ferf-butyl ester A
Synthesis of Intermediate D-4
5-(3-Chloro-2-methyl-phenyl)-3-(S)-pyrrolidin-2-yl-[1 ,2,4]oxadiazole (D-4-1 )
TFA (10 mL, 131 mmol) was added to a rt solution of D-3-1 (3.68 g, 10.1 mmol) in DCM (50 mL) and the resulting mixture was stirred for 1 h. The volatiles were removed in vacuo and the residue was dissolved in EtOAc and basified with 1 M aq. NaOH. The org. layer was separated and the aq. layer extracted with EtOAc (1 x). The combined org. extracts were concentrated in vacuo to give the title compound D-4-1 as a red oil that was used further without purification. LC-MS A: tR = 0.61 min; [M(35CI)+H]+ = 264.22.
Listed in Table 1 1 below are compounds of structure D-4, prepared according to the above procedure (see D-4-1 ).
Table 11
D-4 SM Name tR [min] MS-data
(D-3) LC/MS- m/z
Method [M+H]+
D-4-2 D-3-2 3-(S)-Pyrrolidin-2-yl-5-(2-trifluoromethoxy- 0.63 300.1 1 phenyl)-[1 ,2,4]oxadiazole A
D-4-3 D-3-3 5-(2-Ethoxy-3-fluoro-phenyl)-3-(S)-pyrrolidin- 0.59 278.24
2-yl-[1 ,2,4]oxadiazole A
D-4-4 D-3-4 2-Ethoxy-3-((S)-3-pyrrolidin-2-yl- 0.53 261.23
[1 ,2,4]oxadiazol-5-yl)-pyridine A
D-4-5 D-3-5 5-(3-Fluoro-2-methyl-phenyl)-3-(S)-pyrrolidin- 0.59 248.09
2-yl-[1 ,2,4]oxadiazole A
D-4-6 D-3-6 5-(3-Fluoro-2-methoxy-phenyl)-3-(S)- 0.56 264.08 pyrrolidin-2-yl-[1 ,2,4]oxadiazole A
D-4-7 D-3-7 5-(2,3-Dimethyl-phenyl)-3-(S)-pyrrolidin-2-yl- 0.61 244.10
[1 ,2,4]oxadiazole A
D-4-8 D-3-8 5-(2-Ethyl-phenyl)-3-(S)-pyrrolidin-2-yl- 0.60 244.1 1
[1 ,2,4]oxadiazole A D-4-9 D-3-9 5-(2,5-Dimethyl-phenyl)-3-(S)-pyrrolidin-2-yl- 0.60 244.1 1
[1 ,2,4]oxadiazole A
D-4-10 D-3-10 5-(3-Methoxy-5-methyl-phenyl)-3-(S)- 0.60 260.1 1 pyrrolidin-2-yl-[1 ,2,4]oxadiazole A
D-4-1 1 D-3-1 1 5-(5-Methoxy-2-methyl-phenyl)-3-(S)- 0.60 260.10 pyrrolidin-2-yl-[1 ,2,4]oxadiazole A
D-4-12 D-3-12 5-(2-Methoxy-5-methyl-phenyl)-3-(S)- 0.58 260.10 pyrrolidin-2-yl-[1 ,2,4]oxadiazole A
D-4-13 D-3-13 5-(3-Chloro-2-methoxy-phenyl)-3-(S)- 0.59 280.05 pyrrolidin-2-yl-[1 ,2,4]oxadiazole A
D-4-14 D-3-14 5-(3-Methoxy-2-methyl-phenyl)-3-(S)- 0.60 260.10 pyrrolidin-2-yl-[1 ,2,4]oxadiazole
Synthesis of Intermediate E-1
(S)-2-Ethynyl-pyrrolidine-1 -carboxylic acid ferf-butyl ester (E-1)
Dimethyl(1-diazo-2-oxopropyl)phosphonate (2.30 g, 12 mmol) was added to a rt solution of Boc-L-prolinal (1 .88 mL, 10 mmol) and K2C03 (2.77 g, 20.1 mmol) in MeOH (100 mL) and the resulting suspension was stirred at rt for 18h. The rxn mixture was concentrated in vacuo, dissolved in DCM and washed with sat. aq. NaHC03 and brine. The org. layer was dried (MgS04), filtered and evaporated to give the title compound (E-1 ) a yellow oil that was used further without purification. LC-MS B: tR = 0.75 min; [M+H]+ = 196.28.
Synthesis of Intermediate E-2
2,3-Dimethyl-benzaldehyde oxime (E-2-1 )
Hydroxylamine HCI (1.056 g, 15.2 mmol) was added to a rt solution of 2,3- dimethylbenzaldehyde (2.00 g, 14.9 mmol) and NaOAc (1.26 g, 15.3 mmol) in MeOH (8.5 mL) and the resulting suspension was stirred at rt for 2h. The rxn mixture was concentrated in vacuo, then DCM and water were added. The layers were separated and the aq. layer was extracted with DCM. The combined org. layers were dried (MgS04), filtered and concentrated in vacuo to give the title compound (E-2-1 ) as a white solid that was used further without purification. LC-MS B: tR = 0.66 min; [M+H]+ = 150.15.
Listed in Table 12 below are compounds of structure E-2, prepared according to the above procedure (see E-2-1 ). All aldehydes were commercially available. Table 12
Figure imgf000123_0001
Synthesis of Intermediate E-3
(S)-2-(3-Phenyl-isoxazol-5-yl)-pyrrolidine-1 -carboxylic acid ieri-butyl ester (E-3-1 )
Chloramine T trihydrate (741 mg, 3.26 mmol) was added to a rt solution of commercially available benzaldehyde oxime (394 mg, 3.26 mmol) in MeOH (15 mL) and the rxn mixture was stirred for 5 min, before a solution of E-1 (636 mg, 3.26 mmol) in MeOH (15.0 mL) was added. The rxn mixture was stirred at rt for 1 h, then heated to 60° C for 1 h and at 50°C for 18h. The rxn mixture was concentrated, dissolved in DCM, washed with sat. aq. NaHC03 and the org. layer concentrated in vacuo. Purification by FC (Biotage SP1 : EtOAc/hex 1 :9 to 3:7) gave the title compound E-3-1 as a yellow oil. LC-MS B: tR = 0.89 min; [M+H]+ = 315.22.
Listed in Table 13 below are compounds of structure E-3, prepared according to the above procedure (see E-3-1 ).
Table 13
Figure imgf000124_0001
Synthesis of Intermediate E-4
3-Phenyl-5-(S)-pyrrolidin-2-yl-isoxazole (E-4-1 )
TFA (1 .2 mL, 15.7 mmol) was added to a 0°C solution of E-3-1 (393 mg, 1 .25 mmol) in DCM (10 mL) and the resulting rxn mixture was stirred at rt for 3h. The rxn mixture was concentrated in vacuo, the residue dissolved in DCM and basified with 1 M aq. NaOH. The layers were separated and the aq. layer was extracted with DCM (2x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo to give the title compound E-4-1 as an orange solid that was used further without purification. LC-MS B: tR = 0.44 min; [M+H]+ = 215.23.
Listed in Table 14 below are compounds of structure E-4, prepared according to the above procedure (see E-4-1 ). Table 14
Figure imgf000125_0001
Synthesis of Intermediate E-5
(S)-ferf-butyl 2-((hydroxyimino)methyl)pyrrolidine-1 -carboxylate (E-5)
Hydroxylamine HCI (355 mg, 5.1 1 mmol) was added to a rt solution of Boc-L-prolinal (1.00 g, 5.02 mmol) and sodium acetate (423 mg, 5.15 mmol) in MeOH (4.5 ml.) and stirred at rt overnight. The rxn mixture was concentrated and taken up in DCM and water. The layers were separated and the inorg. layer was extracted with DCM (1 x). The combined org. layers were washed with brine (1 x), dried (MgS04), filtered and concentrated to yield the title compound E-5 as a colorless oil which was used in the next step without further purification. LC-MS A: tR = 0.66 min; [M+H]+ = 215.21 .
Synthesis of Intermediate E-6
1 -Chloro-3-ethynyl-2-methyl benzene (E-6-2)
Dimethyl(1-diazo-2-oxopropyl)phosphonate (482 mg, 2.51 mmol) was added to a rt solution of 3-chloro-2-methylbenzaldehyde (388 mg, 2.51 mmol) and K2C03 (694 mg, 5.02 mmol) in MeOH (25 ml.) and the resulting solution was stirred overnight at rt. The rxn mixture was concentrated, DCM and sat. NaHC03 (2x) was added, the layers separated and the inorg. layer extracted with DCM (2x). The combined org. extracts were washed with brine (1x), dried (MgS04), filtered and concentrated to give the title compound E-6-2 as a brown liquid which was used further without purification. LC-MS A: tR = 0.91 min; [M+H]+ = no ionization. 1H NMR (CDCIs) δΗ: 7.39 (dd, Ji = 15.3 Hz, J2 = 7.7 Hz, 2 H), 7.10 (t, J = 7.8 Hz, 1 H), 3.33 (s, 1 H), 2.55 (s, 3 H).
1 -Ethynyl-2-(trifluoromethoxy)benzene (E-6-3)
Dimethyl(1 -diazo-2-oxopropyl)phosphonate (1.1 1 mL, 7.36 mmol) was added to a rt solution of 2-(trifluoromethoxy)benzaldehyde (1 .40 g, 7.36 mmol) and K2C03 (2.04 g, 14.7 mmol) in MeOH (70 mL) and the resulting mixture was stirred at rt for 3h. The rxn mixture was concentrated, DCM and sat. NaHC03 were added, the layers separated and the inorg. layer extracted with DCM (2x). The combined org. extracts were dried (MgS04), filtered and concentrated to give the title compound E-6-3 as a yellow oil which was used as such without further purification. LC-MS A: tR = 0.90 min; [M+H]+ = no ionization. 1H NMR (DMSO) δΗ: 7.56 (m, 5 H), 4.56 (s, 1 H).
Synthesis of Intermediate E-7
(S)-2-(5-Phenyl-isoxazol-3-yl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (E-7-1 )
Chloroamine T trihydrate (319 mg, 1 .4 mmol) was added to a rt solution of E-5 (300 mg, 1 .4 mmol) in MeOH (6.5 mL) and the resulting mixture was stirred at rt for 5 min before a solution of phenylacetylene (154 uL, 1.4 mmol) in MeOH (6.5 mL) was added. The resulting mixture was strirred at rt for 1 h, then heated to 60°C for 3 h. The rxn mixture was concentrated, dissolved in DCM and washed with sat. aq. NaHC03 and brine. The org. layer was dried (MgS04), filtered and concentrated in vacuo. The crude was purified by FC (EtOAc/hex 2:3) to give the title compound E-7-1 as a colorless oil. LC-MS A: tR = 0.93 min; [M+H]+ = 315.04.
Listed in Table 15 below are compounds of structure E-7, prepared according to the above procedure (see E-7-1 ).
Table 15
E-7 SM Name tR [min] MS-data
E-6 LC/MS- m/z
Method [M+H]+
E-7-2 E-6-2 (S)-2-[5-(3-Chloro-2-methyl-phenyl)-isoxazol-3- 1.01 (35CI) yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester A 362.94
E-7-3 E-6-3 (S)-2-[5-(2-Trifluoromethoxy-phenyl)-isoxazol-3- 1.01 399.06 yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester A Synthesis of Intermediate E-8
5-Phenyl-3-(S)-pyrrolidin-2-yl-isoxazole HCI (E-8-1)
4 N HCI in dioxane (1 .0 mL) was added to an ice-cooled solution of E-7-1 (150 mg, 0.48 mmol) in DCM (1 mL). The rxn mixture was stirred at rt for 2.5 h, then the solvent was removed in vacuo to yield the title compound as yellow oil which was used as such in the next step. LC-MS A: tR = 0.57 min; [M+H]+ = 215.17.
Listed in Table 16 below are compounds of structure E-8, prepared according to the above procedure (see E-8-1 ).
Table 16
Figure imgf000127_0001
Synthesis of Intermediate F-1
3-Methyl-benzoic acid hydrazide (F-1 -2)
Hydrazine monohydrate (2.07 mL, 66.6 mmol) was added to a rt solution of methyl 3- methylbenzoate (0.94 mL, 6.66 mmol) in EtOH (10 mL). The resulting solution was refluxed (80°C) overnight. After the rxn mixture was concentrated in vacuo, ice water (30 mL) was added and stirred at rt for 15 min. The formed precipitate was filtered off and rinsed with toluene to give the title compound as a white solid. The mother liquid was extracted with DCM (3x). The combined org. layers and the solids were combined and concentrated in vacuo to yield the title compound F-1 -2 as a white solid. LC-MS B: tR = 0.36 min; [M+H]+ = 151.21 .
3-Chloro-2-methyl-benzoic acid hydrazide (F-1 -3)
TBTU (678 mg, 2.1 1 mmol) was added to a rt solution of 3-chloro-2-methylbenzoic acid (300 mg, 1.76 mmol) and DIPEA (0.9 mL, 5.28 mmol) in DMF (5.0 mL) and the resulting solution was stirred at rt for 15 min. The mixture was cooled to 0°C and 1 M hydrazine in THF (10.6 mL, 10.6 mmol) was added and the yellow solution was stirred at rt overnight. The rxn mixture was diluted with DCM and washed with sat. aq. NaHC03. The aq. layer was re-extracted with DCM (1 x) and the combined org. layers were concentrated in vacuo to give the title compound F-1 -3 as a light orange solid that was used further without purification. LC-MS A: tR = 0.50 min; [M(35CI)+H]+ = 185.24. Listed in Table 17 below are compounds of structure F-1 , prepared according to the above procedure (see F-1 -2 for ester or F-1 -3 for carboxylic acid as SM).
Table 17
Figure imgf000128_0001
F-1-14 4-Methoxybenzohydrazide 0.41 167.05
A
I
F-1-15 2-Propoxybenzohydrazide 0.57 195.24
A
F-1-16 0 3-Chloro-2-methoxybenzohydrazide 0.50 (35CI)
HO^^CI A 201.09
Synthesis of Intermediate F-3
(S)-2-[5-(Phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester (F-3- 1)
Step A: PyBOP (945 mg, 1.81 mmol) was added to a 0°C solution of Boc-L-proline (300 mg, 1.39 mmol), commercially available benzohydrazide (190 mg, 1 .39 mmol) and DIPEA (0.716 mL, 4.18 mmol) in DCM (5.0 mL) and the resulting mixture was stirred at rt for 3h. The rxn mixture was washed with water and the aq. layer was re-extracted with DCM (2x). The combined org. layers were concentrated in vacuo and purified by FC (Biotage SP1 : EtOAc/hex 3:7 to 1 :1 ) to give (S)-ferf-butyl 2-(2-benzoylhydrazinecarbonyl)pyrrolidine-1 -carboxylate F-2-1 as a white solid.
Step B: 1-Methoxy-/V-triethylammoniosulfonyl-methanimidate (456 mg, 1 .91 mmol) was added to a solution of F-2-1 (319 mg, 0.96 mmol) in dioxane (10 mL) and the resulting solution was irradiated in the microwave at 1 10°C for 20 min. The mixture was diluted with a sat. aq. NaHC03, extracted with EtOAc (2x) and the combined org. layers were concentrated in vacuo to give the title compound F-3-1 that was used without further purification. LC-MS B: tR = 0.79 min; [M+H]+ = 316.30.
Listed in Table 18 below are compounds of structure F-3, prepared according to the above procedure (see F-3-1 ).
Table 18
F-3 SM Name tR [min] MS-data (F-1) LC/MS- m/z
Method [M+H]+
F-3-2 F-1 -2 (S)-2-(5-m-Tolyl-[1 ,3,4]oxadiazol-2-yl)-pyrrolidine- 0.85 330.26
1-carboxylic acid ferf-butyl ester B F-3-3 F-1 -3 (S)-2-[5-(3-Chloro-2-methyl-phenyl)- 0.94 (35CI)
[1 ,3,4]oxadiazol-2-yl]-pyrrolidine-1-carboxylic acid A 364.10 ferf-butyl ester
F-3-4 F-1 -4 (S)-2-(5-o-Tolyl-[1 ,3,4]oxadiazol-2-yl)-pyrrolidine- 0.89 330.20
1-carboxylic acid ferf-butyl ester A
F-3-5 F-1 -5 (S)-2-[5-(2-Trifluoromethoxy-phenyl)- 0.93 400.08
[1 ,3,4]oxadiazol-2-yl]-pyrrolidine-1-carboxylic acid A ferf-butyl ester
Synthesis of Intermediate F-4
2-Phenyl-5-(S)-pyrrolidin-2-yl-[1 ,3,4]oxadiazole (F-4-1)
TFA (1 .5 mL, 19.5 mmol) was added to a 0°C solution of F-3-1 (500 mg, 1.57 mmol) in DCM (15.0 mL) and the resulting rxn mixture was stirred at rt for 4h. The rxn mixture was concentrated in vacuo to remove TFA, the residue was dissolved in DCM and basified with 1 M aq. NaOH to pH 12. The layers were separated and the aq. layer was extracted with DCM (1 x). The combined org. layers were concentrated in vacuo to give the title compound F-4-1 as a yellow oil that was used without further purification. LC-MS B: tR = 0.38 min; [M+H]+ = 216.30. Listed in Table 19 below are compounds of structure F-4, prepared according to the above procedure (see F-4-1 ).
Table 19
Figure imgf000130_0001
Synthesis of G-3
(S)-1 -(5-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carbohydrazide (G-3-1)
Hydrazine monohydrate (813 mg, 15.9 mmol) was added to a rt solution of (S)-methyl 1 -(5- methyl-2-(2/-/-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboxylate A-2-1 (500 mg, 1.59 mmol) in EtOH (2.3 mL) and the resulting suspension was heated to 80°C for 1 h. The rxn mixture was concentrated in vacuo and diluted with water and DCM. The org. layer was separated and the aq. layer was extracted with DCM (1 x). The combined org. layers were dried (MgS04), filtered and concentrated to give the title compound as a white foam. LC-MS A: tR = 0.57 min; [M+H]+ = 315.18.
Synthesis of H-2
2-(S)-Pyrrolidin-2-yl-5-(2-trifluoromethoxy-phenyl)-[1 ,3,4]thiadiazole (H-2-1 )
Step A: TBTU (3.42 g, 10.7 mmol) was added to a rt solution of Boc-S-proline (1.53 g, 7.1 1 mmol) and DIPEA (3.65 mL, 21.3 mmol) in DCM (15 mL) and the rxn mixture was stirred for 10 min at rt, before hydrazide F-1 -5 (3.13 g, 7.81 mmol) in DCM (5 mL) was added and stirring continued for 30 min. The rxn mixture was diluted with DCM and water, the org. layer separated and the aq. layer extracted with DCM (1x). The combined org. extracts were washed with brine, dried (MgS04), filtered and concentrated in vacuo. The crude oil was purified by FC (EtOAc/hept 7:3) to obtain (S)-2-[/\/'-(2-Trifluoromethoxy-benzoyl)-hydrazinocarbonyl]- pyrrolidine-1-carboxylic acid ferf-butyl ester (F-2-5) as a white solid. LC-MS A: tR = 0.78 min; [M+H]+ = 417.87
Step B: Lawesson's reagent (194 mg, 0.479 mmol) was added to a rt solution of F-2-5 (200 mg, 0.48 mmol) in dioxane (2 mL) and the rxn mixture was heated in a sealed tube to 1 15°C for 1.5h. The mixture was allowed to reach rt, then the rxn mixture was quenched with water and extracted with EtOAc (2x). The combined org. extracts were dried (MgS04), filtered and concentrated. The crude oil was purified by FC (EtOAc/hept 2:3) to give (S)-2-[5-(2- trifluoromethoxy-phenyl)-[1 ,3,4]thiadiazol-2-yl]-pyrrolidine-1-carboxylic acid ferf-butyl ester (H-1 - 1). LC-MS A: tR = 0.98 min; [M+H]+ = 416.05
Step C: 4 M HCI in dioxane (0.44 mL, 1.76 mmol) was added dropwise to a 0°C solution of H- 1 -1 (91 mg, 0.22 mmol) in DCM (1.2 mL) and stirred at rt for 7h. The mixture was quenched with ice-cooled 2N aq. NaOH (2 mL) until pH 14, then extracted with DCM (2x) The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to obtain the title compound H-2-1 as a yellow oil: LC-MS A: tR = 0.61 min; [M+H]+ = 316.1 1
Synthesis of Intermediate 1-1
2-Bromo-1 -(2-(trifluoromethoxy)phenyl)ethanone (1-1 -2)
Phenyltrimethylammonium tribromide (1 .20 g, 3.18 mmol) was added to a rt solution of 2'- (trifluoromethoxy)acetophenone (650 mg, 3.18 mmol) in THF (8.5 mL) and the resulting suspension was stirred at rt for 1 h. The rxn mixture was diluted with EtOAc and water. The org. layer was separated and the aq. layer was extracted with EtOAc (1x). The combined org. layers were dried (MgS04), filtered and the solvent was removed in vacuo to yield the title compound (1-1 -2) as a colorless oil which was used further without purification. LC-MS A: tR = 0.89 min; [M+H]+ = no ionization. 1H NMR (DMSO) δΗ: 7.97 (dd, 4 = 7.7 Hz, J2 = 1.7 Hz, 1 H), 7.76 (m, 1 H), 7.59 (m, 2 H), 4.86 (s, 2 H).
2-Bromo-1 -(3-chloro-2-methylphenyl)ethanone (1-1 -3)
The title compound was prepared from 1 -(3-chloro-2-methylphenyl)ethanone in analogy to the procedure described for 1-1 -2. LC-MS A: tR = 0.89 min; [M+H]+ = no ionization. 1H NMR (DMSO) δΗ: δ: 7.71 (m, 2 H), 7.39 (m, 1 H), 4.90 (s, 2 H), 2.29 (m, 3 H).
Synthesis of Intermediate I-2
(S)-2-Oxo-2-phenylethyl 1 -(5-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2- carboxylate (1-2-1 )
K2C03 (107 mg, 0.78 mmol) was added to a rt solution of A-3-1 (200 mg, 0.67 mmol), 2- bromoacetophenone (135 mg, 0.67 mmol) in DMF (6.0 mL) and the suspension was stirred for 18h. The rxn mixture was diluted with EtOAc and washed with water (1x). The aq. layer was re- extracted with EtOAc (2x) and the combined org. layers were concentrated in vacuo to yield the title compound as a yellow oil which was used further without purification. LC-MS A: tR = 0.88 min; [M+H]+ = 419.04.
(S)-2-Oxo-2-(2-(trifluoromethoxy)phenyl)ethyl 1 -(5-methyl-2-(2H-1 ,2,3-triazol-2- yl)benzoyl)pyrrolidine-2-carboxylate (I-2-2)
The title compound was prepared from 1-1 -2 in analogy to the procedure described for 1-2-1. LC-MS A: tR = 0.95 min; [M+H]+ = 503.07.
Synthesis of Intermediate J-1
2-Amino-1 -(2-methoxyphenyl)ethanone HBr (J-1 -2)
Step A: 2-Bromo-1-(2-methoxyphenyl)ethanone (5.0 g, 21 .4 mmol) in CHCI3 (10 mL) was added to a rt solution of hexamethylenetetramine (3.03 g, 21.4 mmol) in CHCI3 (50 mL) and the rxn mixture was stirred at rt for 16h. The suspension was filtered, the solid washed with CHCI3 and concentrated in vacuo to yield (3r,5r,7r)-1 -(2-(2-methoxyphenyl)-2-oxoethyl)-1 , 3,5,7- tetraazaadamantan-1-ium bromide which was used us such in the next step. LC-MS B: tR = 0.39 min; [M+H]+ = 289.2.
Step B: HBr (48% in H20, 28 mL) in MeOH (50 mL) was added dropwise to a solution of (3r,5r,7r)-1 -(2-(2-methoxyphenyl)-2-oxoethyl)-1 ,3,5,7-tetraazaadamantan-1 -ium bromide (9.0 g) in MeOH (100 mL) and the rxn mixture was stirred at rt overnight. The rxn mixture was concentrated in vacuo and the residue was triturated with CHCI3, followed by crystallization in MeOH to yield the title compound as a beige solid. LC-MS B: tR = 0.33 min; [M+H]+ = 166.26. 2-Amino-1 -(3-chloro-phenyl)ethanone HBr (J-1 -3)
The title compound was prepared from commercially available 2-bromo-1 -(3- chlorophenyl)ethanone in analogy to the procedure described for J-1 -2. LC-MS A: tR = 0.38 min; [M+H]+ = 21 1.21. 2-Amino-1 -(3-methoxyphenyl)ethanone HBr (J-1 -4)
The title compound was prepared from commercially available 2 2-bromo-1-(3- methoxyphenyl)ethanone in analogy to the procedure described for J-1 -2. LC-MS A: tR = 0.33 min; [M+H]+ = 166.26.
Synthesis of Intermediate J-2
(S)-1 -(5-Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)-A -(2-oxo-2-phenylethyl)pyrrolidine-2- carboxamide (J-2-1 )
TBTU (192 mg, 0.60 mmol) was added to a rt solution of A-3-1 (150 mg, 0.50 mmol), DIPEA (0.43 ml_, 2.5 mmol) in DCM (2 ml.) and the resulting rxn mixture was stirred at rt for 10 min before commercially available 2-amino-1-phenylethanone HCI (89 mg, 0.49 mmol) was added and stirring continued at rt overnight. The rxn mixture was washed with sat. NaHC03 solution and the organic layer was dried (MgS04), filtered and concentrated in vacuo to yield the title compound as a brownish oil which was used as such without further purification. LC-MS A: tR = 0.81 min; [M+H]+ = 417.90.
(S)-1 -(5-Methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)-W-(2-oxo-2-(o-tolyl)ethyl)pyrrolidine-2- carboxamide (J-2-2)
The title compound was prepared from A-3-1 and 2-amino-1 -(o-tolyl)ethanone in analogy to the procedure described for J-2-1. LC-MS A: tR = 0.85 min; [M+H]+ = 432.1 1 .
Synthesis of Intermediate K-1
(S)-2-[5-(2-Trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester (K-1 -1)
K2C03 (51 mg, 0.39 mmol) was added to a rt solution of (S)-1 -Boc-pyrrolidine-2-carbonitrile (433 mg, 2.21 mmol) and F-1 -5 (200 mg, 0.74 mmol) in n-BuOH (2.9 mL) and the mixture was refluxed (oil bath at 125°C) overnight. The mixture was concentrated in vacuo, then DCM and 1 N HCI until pH 6 was added. The org. layer was separated and the aq. layer was extracted with DCM (2x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo. The crude was purified by FC (EtOAc/hept 1 :1 ) to give title compound K-1 -1. LC-MS A: tR = 0.84 min; [M+H]+ = 399.04.
Listed in Table 20 below are compounds of structure K-1 prepared according to the above procedure (see K-1 -1 ).
Table 20
K-1 SM Name tR [min] MS-data
(F-1) LC/MS- m/z
Method [M+H]+ K-1 -2 Benzo (S)-2-(5-Phenyl-4H-[1 ,2,4]triazol-3-yl)- 0.75 315.17 hydrazide pyrrolidine-1 -carboxylic acid ferf-butyl ester A
K-1 -3 F-1-3 (S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H- 0.84 (35CI)
[1 ,2,4]triazol-3-yl]-pyrrolidine-1 -carboxylic A 363.10 acid ferf-butyl ester
Κ-1 -4 F-1-6 (S)-2-[5-(3-Fluoro-2-methyl-phenyl)-4H- 0.81 347.13
[1 ,2,4]triazol-3-yl]-pyrrolidine-1 -carboxylic A
acid ferf-butyl ester
Κ-1 -5 F-1-7 (S)-2-[5-(2-Ethoxy-phenyl)-4H-[1 ,2,4]triazol-3- 0.80 359.13 yl]-pyrrolidine-1 -carboxylic acid ferf-butyl A
ester
Κ-1 -6 F-1-9 (S)-2-[5-(2-Ethoxy-pyridin-3-yl)-4H- 0.78 360.12
[1 ,2,4]triazol-3-yl]-pyrrolidine-1 -carboxylic A
acid ferf-butyl ester
Κ-1 -7 F-1-8 (S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H- 0.80 363.10
[1 ,2,4]triazol-3-yl]-pyrrolidine-1 -carboxylic A
acid ferf-butyl ester
Κ-1 -8 F-1-10 (S)-2-[5-(2-Methoxy-phenyl)-4H-[1 ,2,4]triazol- 0.76 345.13
3-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl A
ester
Κ-1 -9 F-1-16 (S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H- 0.82 379.10
[1 ,2,4]triazol-3-yl]-pyrrolidine-1 -carboxylic A
acid ferf-butyl ester
Synthesis of Intermediate K-2
(S)-3-(2-Trifluoromethoxy-phenyl)-5-pyrrolidin-2-yl-4H-[1 ,2,4]triazole (K-2-1)
4 N HCI in dioxane (0.8 mL, 3.2 mmol) was added dropwise to a 0°C solution of K-1 -1 (156 mg, 0.39 mmol) in DCM (2.5 mL). The resulting mixture was allowed to warm to rt and stirred at rt for 45 min. The rxn mixture was quenched with 2 N NaOH at 0°C until pH 6, then extracted with DCM (2x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to obtain the title compound K-2-1 as an oil that was used as such without further purification. LC-MS A: tR = 0.55 min; [M+H]+ = 299.13.
Listed in Table 21 below are compounds of structure K-2, prepared according to the above procedure (see K-2-1 ). Table 21
Figure imgf000135_0001
Synthesis of Intermediate L-2
0.5 M NaOMe solution in MeOH (1.29 ml_, 0.645 mmol) was added to a rt solution of Boc-S- pyrrolidine-2-carbonitrile (1.50 g, 6.45 mmol) in MeOH (4.3 ml.) and the resulting mixture was stirred at rt overnight. Next morning, ammonium bromide (631 mg, 6.45 mmol) was added and stirring at rt was continued for 2h, then the rxn mixture was concentrated in vacuo. The residue was triturated with Et20 to yield the title compound L-2 as a white solid which was used further without purification. LC-MS A: tR = 0.45 min; [M+H]+ = 214.17. Synthesis of Intermediate L-3
(S)-2-(5-Phenyl-1 H-imidazol-2-yl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (L-3-1 )
K2C03 (953 mg, 6.89 mmol) was added to a rt solution of L-2 (1 .01 g, 3.45 mmol) in DMF (6 ml.) and stirred at rt for 5 min, before 2-bromoacetophenone (350 mg, 1.72 mmol) was added and the mixture stirred at rt for 3 days. The rxn mixture was extracted with EtOAc (2x) and the combined org. layers were washed with water (1 x), concentrated in vacuo and purified by prep. HPLC (method G) to give the title compound L-3-1 as a yellow solid. LC-MS A: tR = 0.63 min; [M+H]+ = 314.14.
(S)-2-[4-(2-Methoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidine-1 -carboxylic acid ferf-butyl ester (L-3-6)
Step A: HATU (4.94 g, 13.0 mmol) was added to a rt solution of Boc-S-proline (2.66 g, 12.4 mmol), J-1 -2 (4.35 g, 12.4 mmol) and DIPEA (10.6 mL, 61 .8 mmol) in DCM (100 mL) and the rxn mixture was stirred at rt for 1 h. The rxn mixture was concentrated in vacuo, to the residue was added EtOAc (200 mL) and the org. layer was washed with H20 (100 mL) and brine (100 mL). The org. layer was dried (MgS04), filtered and concentrated in vacuo. The crude was purified by FC (Biotage SP1 : EtOAc/hept 1 :1 to 3:2) to give (S)-tert-butyl 2-((2-(2- methoxyphenyl)-2-oxoethyl)carbamoyl)pyrrolidine-1-carboxylate L-1 -1. LC-MS B: tR = 0.58 min; [M+H]+ = 344.22.
Step B: Acetic acid (13 mL) was added to a rt solution of L-1 -1 (3.09 g, 8.52 mmol) and ammonium acetate (19.70 g, 256 mmol) in xylene (25 mL) and the rxn mixture was heated to 130°C for 1.5h. The rxn mixture was allowed to reacht rt and was poured on ice, then 25% ammonium hydroxide solution was added until basic, and extracted with EtOAc (2x). The combined org. layers were dried (MgS04), filtered and concentrated in vacuo to yield the title compound L-3-6 which was used further without purification. LC-MS B: tR = 0.58 min; [M+H]+ = 344.22.
Listed in Table 22 below are compounds of structure L-3, prepared according to the above procedures (L-3-1 or L-3-6).
Table 22
L-3 SM Name tR [min] MS-data
1-1 LC/MS- m/z or J-1 Method [M+H]+
L-3-2 1-1 -3 (S)-2-[5-(3-Chloro-2-methyl-phenyl)-1 H- 0.71 362.10
imidazol-2-yl]-pyrrolidine-1 -carboxylic acid ferf- A butyl ester
L-3-3 1-1 -4* (S)-2-[5-(2-Ethoxy-phenyl)-1 H-imidazol-2-yl]- 0.71 358.12
pyrrolidine-1 -carboxylic acid ferf-butyl ester A
L-3-4 1-1 -5* (S)-2-[5-(2-Trifluoromethyl-phenyl)-1 H- 0.69 382.05
imidazol-2-yl]-pyrrolidine-1 -carboxylic acid ferf- A butyl ester L-3-5 1-1 -2 (S)-2-[5-(2-Trifluoromethoxy-phenyl)-1 H- 0.71 398.08
imidazol-2-yl]-pyrrolidine-1 -carboxylic acid tert- A butyl ester
L-3-7 J-1 -3 (S)-2-[4-(3-Chloro-phenyl)-1 H-imidazol-2-yl]- 0.60 348.17
pyrrolidine-1 -carboxylic acid ferf-butyl ester B
L-3-8 J-1 -4 (S)-2-[4-(3-Methoxy-phenyl)-1 H-imidazol-2-yl]- 0.57 344.01
pyrrolidine-1 -carboxylic acid ferf-butyl ester B
*Commercially available: 1-1 -4 = 2-bromo-1 -(2-ethoxyphenyl)ethanone; 1-1 -5 = 2-bromo-1 -(2- (trifluoromethyl)phenyl)ethanone
Synthesis of Intermediate L-4
5-Phenyl-2-(S)-pyrrolidin-2-yl-1 H-imidazole (L-4-1)
4N HCI in dioxane (1.5 mL, 6.04 mmol) was added to a 0°C solution of L-3-1 (235 mg, 0.75 mmol) in DCM (12 mL) and the resulting mixture was stirred at rt for 4h. The rxn mixture was concentrated in vacuo to yield the title compound as a yellow oil which was used further without purification. LC-MS A: tR = 0.44 min; [M+H]+ = 214.21.
Listed in Table 23 below are compounds of structure L-4, prepared according to the above procedure (L-4-1 ).
Table 23
L-4 SM Name tR [min] MS-data
L-3 LC/MS- m/z
Method [M+H]+
L-4-2 L-3-2 5-(3-Chloro-2-methyl-phenyl)-2-(S)-pyrrolidin- 0.55 262.13
2-yl-1 /-/-imidazole A
L-4-3 L-3-3 5-(2-Ethoxy-phenyl)-2-(S)-pyrrolidin-2-yl-1 H- 0.51 258.16
imidazole A
L-4-4 L-3-4 2-(S)-Pyrrolidin-2-yl-5-(2-trifluoromethyl- 0.55 282.1 1
phenyl)-1 /-/-imidazole A
L-4-5 L-3-5 2-(S)-Pyrrolidin-2-yl-5-(2-trifluoromethoxy- 0.61 298.09
phenyl)-1 /-/-imidazole A
L-4-6 L-3-6 4-(2-Methoxy-phenyl)-2-(S)-pyrrolidin-2-yl-1 H- 0.38 244.17
imidazole B
L-4-7 L-3-7 4-(3-Chloro-phenyl)-2-(S)-pyrrolidin-2-yl-1 H- 0.49 248.12
imidazole B L-4-8 L-3-8 4-(3-Methoxy-phenyl)-2-(S)-pyrrolidin-2-yl-1 H- 0.40 244.16
imidazole B
Synthesis of Intermediate M-1
(S)-ferf-Butyl 2-(2-bromoacetyl)pyrrolidine-1 -carboxylate (M-1 )
Step A: Isobutyl chloroformate (1.82 mL, 13.9 mmol) was added to a 0°C solution of Boc-L- proline (2.00 g, 9.29 mmol) and DIPEA (2.75 ml, 16.1 mmol) in THF (20 mL) and the solution was stirred at 0°C for 4h before MeCN (10 mL) was added. A solution of trimethylsilyldiazomethane solution (2.0 M in hexane; 9.3 mL, 18.6 mmol) in a THF/MeOH- mixture (6.4 mL/ 6.4 mL) was added dropwise over 10 min to the rxn mixture. After stirring at 0°C for 3.5h, the rxn mixture was allowed to reach rt overnight. The mixture was concentrated in vacuo and the crude was purified by FC (EtOAc/hept 3:7) to obtain (S)-ferf-butyl 2-(2- diazoacetyl)pyrrolidine-1-carboxylate as a yellow oil. LC-MS A: tR = 0.70 min; [M+H]+ = no ionization.
Step B: HBr (48% in water (100 uL) was added to a 0°C solution of (S)-tert-butyl 2-(2- diazoacetyl)pyrrolidine-1-carboxylate (462 mg, 0.869 mmol) in Et20 (2.2 mL) and the rxn mixture was stirred at 0°C for 5 min. The mixture was diluted with EtOAc, washed with sat. aq. NaHC03 and brine. The org. layer was dried (MgS04), filtered and concentrated, then purified by FC (EtOAc/hept 3:7) to yield title compound M-1 as a colorless oil. LC-MS A: tR = 0.81 min; [M+H]+ = 235.96.
Synthesis of Intermediate M-2
3-Chloro-2-methylbenzimidamide (M-2-1)
Trimethylaluminium in hepatane (2M, 9.9 mL, 19.8 mmol) was added dropwise to a 0°C suspension of ammonium chloride (1.07 g, 19.8 mmol) in toluene (6.4 mL) and stirred for 15 min at rt before 3-chloro-2-methylbenzonitrile (1.02 g, 6.6 mmol) in toluene (6.4 mL) was added. The resulting mixture was heated at 80°C for 40h, then added to a freshly prepared mixture of trimethylaluminium in heptanes (2Mm, 4.95 mL), ammonium chloride (535 mg) in toluene (3mL). The resulting mixture was heated at 80°C for 15h. The rxn mixture was allowed to reach rt, DCM (90 mL) and silica gel (27 g) were added and stirred vigorously for 10 min. The silica gel was filtered off, washed with DCM/MeOH and the filtrate was concentrated in vacuo to give a white solid. The solid was dissolved with 10% aq. HCI (100 mL) and Et20 (100 mL). The org. layer was separated, dried (MgS04), filtered and concentrated in vacuo to recover remaining starting material. The inorg. layer was basified with 12.5 N aq. NaOH, extracted with DCM (2x) and the combined DCM-extracts were dried (MgS04), filtered and concentrated in vacuo to yield the title compound M-2-1 as a beige solid. LC-MS A: tR = 0.40 min; [M(35CI)+H]+ = 169.01 . Synthesis of Intermediate M-3
(S)-2-(2-Phenyl-3H-imidazol-4-yl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (M-3-1)
Compound M-1 (231 mg, 0.672 mmol) dissolved in DMF (1.3 ml.) was added to a rt suspension of commercially available benzamidine (170 mg, 1.34 mmol) and K2C03 (372 mg, 2.69 mmol) in DMF (1 ml.) and the resulting mixture was stirred at rt for 1 h, then heated at 65°C for 8 h. To the rxn mixture were added EtOAc and water and the phases were separated. The inorg. layer was extracted with EtOAc (2x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo. The crude was purified by FC (EtOAc/hept 3:2) to give the title compound M-3-1 as a colorless oil. LC-MS A: tR = 0.63 min; [M+H]+ = 314.21 .
(S)-2-[2-(3-Chloro-2-methyl-phenyl)-3H-imidazol-4-yl]-pyrrolidine-1 -carboxylic acid ferf- butyl ester (M-3-2)
The title compound was prepared from M-1 and M-2-1 in analogy to the procedure described for M-3-1. LC-MS A: tR = 0.69 min; [M(35CI)+H]+ = 362.14.
Synthesis of Intermediate M-4
2-Phenyl-5-(S)-pyrrolidin-2-yl-1 H-imidazole HCI (M-4-1 )
4N HCI in dioxane (1 .3 ml_, 5.2 mmol) was added to a 0°C solution of M-3-1 (188 mg, 0.52 mmol) in DCM (2 ml.) and the rxn mixture was stirred at rt for 3h. The rxn mixture was concentrated in vacuo to give the title compound M-4-1 as a white solid. LC-MS A: tR = 0.35 min; [M+H]+ = 214.13.
2-(3-Chloro-2-methyl-phenyl)-5-(S)-pyrrolidin-2-yl-1 H-imidazole HCI (M-4-2)
The title compound was prepared from M-3-2 in analogy to the procedure described for M-4-1. LC-MS A: tR = 0.45 min; [M(35CI)+H]+ = 262.10.
Synthesis of Intermediate N-1
(S)-2-(3-Phenyl-propynoyl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (N-1 -1 )
Ethylmagnesium bromide (1.0 M in THF (3.9 mL, 3.89 mmol) was added dropwise to a 0°C solution of commercially available phenylacetylene (374 mg, 3.66 mmol) in THF (10 mL) and the resulting rxn mixture was stirred at 0°C for 10 min and at rt for 1 h. /V-Boc-L-proline N'- methoxy-N'-methylamide (700 mg, 2.71 mmol) dissolved in THF (9.0 mL) was added at 0°C and the resulting mixture was allowed to reach rt overnight. The rxn mixture was quenched with sat. aq. NH4CI and extracted with EtOAc (2x). The combined org. layers were washed with water and brine, dried (MgS04), filtered and concentrated in vacuo to give the title compound N-1 -1 as a yellow oil which was used further without purification. LC-MS A: tR = 0.94 min; [M+H]+ = no ionization. (S)-2-(3-(3-Chloro-2-methylphenyl)propioloyl)pyrrolidine-1 -carboxyic acid ieri-butyl ester (N-1 -2)
The title compound was prepared from E-6-2 in analogy to the procedure described for N-1 -1. LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 348.12.
(S)-2-(3-(2-Trifluoromethoxyphenyl)propioloyl)pyrrolidine-1 -carboxyic acid ieri-butyl ester (N -1 -3)
The title compound was prepared from E-6-3 in analogy to the procedure described for N-1 - 1.LC-MS A: tR = 1.01 min; [M+H]+ = 384.08.
Synthesis of Intermediate N-2
(S)-2-(5-Phenyl-2H-pyrazol-3-yl)-pyrrolidine-1 -carboxylic acid ieri-butyl ester (N-2-1)
Hydrazine hydrate (80%, 0.145 mL) was added to rt solution of N-1 -1 (659 mg, 1.98 mmol) in EtOH (18 mL) and the resulting mixture was heated to 85°C for 80 min. The rxn mixture was concentrated and the residue was taken up in DCM and H20. The org. layer was collected and the inorg. layer was extracted with DCM. The combined org. extracts were dried (MgS04), filtered and concentrated. The crude was purified by FC (Biotage SP1 : EtOAc/hex 3:7 to 1 :1 ) to give the title compound N-2-1 as an off-white foam. LC-MS A: tR = 0.84 min; [M+H]+ = 314.19. (S)-2-[5-(3-Chloro-2-methyl-phenyl)-2H-pyrazol-3-yl]-pyrrolidine-1 -carboxylic acid ieri- butyl ester (N-2-2)
The title compound was prepared from N-1 -2 in analogy to the procedure described for N-2-1. LC-MS A: tR = 0.92 min; [M(35CI)+H]+ = 362.13.
(S)-2-[5-(2-Trifluoromethoxy-phenyl)-2H-pyrazol-3-yl]-pyrrolidine-1 -carboxylic acid ieri- butyl ester (N-2-3)
The title compound was prepared from N-1 -3 in analogy to the procedure described for N-2-1. LC-MS A: tR = 0.93 min; [M+H]+ = 398.06.
Synthesis of Intermediate N-3
3-Phenyl-5-(S)-pyrrolidin-2-yl-1 H-pyrazole HCI (N-3-1)
4N HCI in dioxane (5.0 mL, 20.1 mmol) was added to a 0°C solution of N-2-1 (758 mg, 2.42 mmol) in DCM (10 mL) and the resulting mixture was stirred at rt overnight. The rxn mixture was concentrated in vacuo and triturated with Et20 to give the title compound N-3-1 as an off- white solid which was used further without purification. LC-MS A: tR = 0.53 min; [M+H]+ = 214.13.
3-(3-Chloro-2-methyl-phenyl)-5-(S)-pyrrolidin-2-yl-1 H-pyrazole HCI (N-3-2)
The title compound was prepared from N-2-3 in analogy to the procedure described for N-3-1. LC-MS A: tR = 0.61 min; [M(35CI)+H]+ = 262.08. 5-(S)-Pyrrolidin-2-yl-3-(2-trifluoromethoxy-phenyl)-1H-pyrazole HCI (N-3-3)
The title compound was prepared from N-2-3 in analogy to the procedure described for N-3-1. LC-MS A: tR = 0.62 min; [M+H]+ = 298.10.
Synthesis of Intermediate 0-1
(S)-2-Methoxycarbonimidoyl-pyrrolidine-1 -carboxylic acid ferf-butyl ester (0-1 )
A solution of Boc-(S)-pyrrolidine-2-carbonitrile (100 mg, 0.51 mmol, 1 eq) in MeOH (1.8 mL) was added to a rt solution of NaOMe in MeOH (5.4 M, 100 uL) in MeOH (2 mL) and the resulting mixture was stirred at rt overnight. The reaction was quenched with sat. aq. KH2P04 until pH 6. The rxn mixture was concentrated in vacuo and the residue was taken up in DCM and H20. The org. layer was separated and the inorg. layer was extracted with DCM (1 x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give the title compound 0-1 as an oil which was used further without purification. LC-MS A: tR = 0.51 min; [M+H]+ = 229.1 1.
Synthesis of Intermediate 0-3
(S)-2-(1 -Phenyl-1 H-[1 ,2,4]triazol-3-yl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (0-3-1 )
Phenylhydrazine (42 uL, 0.412 mmol) was added to a rt solution of 0-1 (94 mg, 0.41 mmol) and TEA (172 uL, 1.24 mmol) in MeOH (1.5 mL) and the resulting mixture was stirred at rt for 4 d. The mixture was concentrated in vacuo, then the residue was dissolved in pyridine (1 .53 mL, 18.9 mmol) and triethyl orthoformate (1.54 mL, 9.06 mmol) was added. The mixture was heated to 120°C for 1 h30, then the rxn mixture was concentrated in vacuo, dissolved in DCM, washed with sat. aq. citric acid, sat. aq. NaHC03 and brine. The org. layer was dried (MgS04), filtered and concentrated in vacuo. The crude was purified by FC (EtOAc/hept 2:3) to give the title compound 0-3-1 as an oil. LC-MS A: tR = 0.82 min; [M+H]+ = 315.17.
Synthesis of Intermediate 0-4
1 -Phenyl-3-(S)-pyrrolidin-2-yl-1 H-[1 ,2,4]triazole (0-4-1 )
TFA (180 uL, 2.39 mmol) was added to a rt solution of 0-3-1 (75 mg, 0.24 mmol) in DCM (1 mL) and the resulting mixture was stirred at rt overnight. The rxn mixture was cooled to 0°C, then diluted with DCM and basified with 4N aq. NaOH. The layers were separated and the inorg. layer was extracted with DCM (1 x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give the title compound 0-4-1 which was used further without purification. LC-MS A: tR = 0.48 min; [M+H]+ = 215.13.
Synthesis of Intermediate P-1
Phenylazide (P-1 -1 )
ferf-Butyl nitrite (0.4 mL, 3 mmol), followed by trimethylsilylazide (0.33 mL, 2.4 mmol) was added to a 0°C solution of phenylamine (0.18 mL, 2 mmol) in MeCN (4.0 mL) and the resulting mixture was stirred at rt for 2h. The rxn mixture was carefully concentrated in vacuo to give the title compound P-1 -1 which was used immediately in the next step. LC-MS A: tR = 0.8 min; [M+H]+ = no ionization.
Synthesis of Intermediate P-2
(S)-2-(1 -Phenyl-1 H-1 ,2,3-triazol-4-yl)pyrrolidine-1 -carboxylic acid ferf-butyl ester (P-2-1) P-1 -1 (73 mg, 0.62 mmol) was added to a rt solution of E-1 (100 mg, 0.51 mmol) in DMF (1.0 mL) and the resulting mixture was heated at 150°C (pre-heated oilbath) for 15 min, then P-1 -1 (73 mg, 0.62 mmol) was added to the 150°C hot rxn mixture and strirred for another 10 min. This addition was repeated for a third time. The rxn mixture was allowed to reach rt, then directly purified by prep. HPLC (method G) (elimination of wrong isomer) to give the title compound P-2-1 as a brown oil. LC-MS A: tR = 0.85 min; [M+H]+ = 315.18.
Synthesis of Intermediate P-3
(S)-1 -Phenyl-4-(pyrrolidin-2-yl)-1 H-1 ,2,3-triazole (P-3-1 )
4N HCI in dioxane (0.62 mL, 2.47 mmol) was added to a 0°C solution of P-2-1 (72 mg, 0.23 mmol) in DCM (3 mL) and the resulting mixture was stirred at rt for 3h. The rxn mixture was concentrated in vacuo to give the title compound P-3-1 as a brown oil which was used further without purification. LC-MS A: tR = 0.49 min; [M+H]+ = 215.12.
Synthesis of Intermediate Q-1
(S)-2-Methyl-pyrrolidine-1 ,2-dicarboxylic acid 1 -ferf-butyl ester HCI
A solution of Boc20 (145 g, 0.66 mol) in MeCN (200 mL) was added dropwise to a 10-15°C solution of commercially available 2-methyl-L-proline HCI and TEA (254 mL, 1.81 mol) in a 1/1 mixture of MeCN/H20 (800 mL). The reaction mixture was allowed to reach rt and stirred at rt for 2h to 2 days, then the MeCN was evaoporated in vacuo, the residue quenched with 2N aq. NaOH (250 mL) and washed with diethylether (2x). The inorg. layer was cooled to 0°C, then the product was precipitated by adding 25% aq. HCI until pH 2. The product was filtered off, washed with cold water and dried in vacuo to yield the title compound Q-1 as a beige solid. LC- MS A: tR = 0.68 min; [M+H]+ = 230.13
Synthesis of Intermediate Q-3
(S)-2-Methyl-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidine-1 -carboxylic acid ferf-butyl ester (Q-3-1 )
Step A: PyBOP (1 .36 g, 2.62 mmol) was added to a 0°C solution of Q-1 (500 mg, 2.18 mmol), benzamidoxime (324 mg, 2.38 mmol) and DIPEA (1 .12 mL) in DCM (22 mL). The resulting mixture was stirred at rt for 16h, then concentrated in vacuo to yield Q-2-1 that was used further without purification. LC-MS B: tR = 0.74 min; [M+H]+ = 348.15.
Step B: The crude Q-2-1 was taken up in dioxane (35 mL) and refluxed (90 to 105°C) for 2 days. The rxn mixture was concentrated in vacuo and purified by FC (Biotage SP1 : EtOAc/hex 3:7) to give the title compound Q-3-1 as a yellow oil. LC-MS B: tR = 0.94 min; [M+H]+ = 330.18. Synthesis of Intermediate Q-4
5-((S)-2-Methyl-pyrrolidin-2-yl)-3-phenyl-[1 ,2,4]oxadiazole (Q-4-1 )
TFA (1.37 mL, 17.9 mmol) was added to a 0°C solution of Q-3-1 (470 mg, 1 .43 mmol) in DCM (5.0 mL) and the resulting mixture was stirred at rt for 1 h. The rxn mixture was cooled to 0°C, then diluted with DCM and basified with 1 N aq. NaOH. The org. layer was separated and the inorg. layer was extracted with DCM (1 x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give the title compound Q-4-1 as a brown oil which was used further without purification. LC-MS B: tR = 0.47 min; [M+H]+ = 230.19.
Synthesis of Intermediate Q-5
(S)-2-Methyl-1 -(5-methyl-2-[1 ,2,3]triazol-2-yl-benzoyl)-pyrrolidine-2-carboxylic acid
Step A: Thionylchloride (33 mL, 450 mmol) was added to A-1 -2 (6.10 g, 30.0 mmol) and the solution was stirred at 60°C, then the reaction mixture was concentrated in vacuo by coevaporation with toluene to yield 5-methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl chloride which was used as such in the next step.
Step B: A solution of 5-methyl-2-(2/-/-1 ,2,3-triazol-2-yl)benzoyl chloride in DCM (180 mL) was added dropwise to a -20°C solution of 2-methyl-L-proline HCI (4.97 g, 30 mmol) and TEA (16.6 mL, 120 mmol) in pyridine (121 mL) and DCM (120 mL). The reaction mixture was allowed to reach rt and stirring was continued at rt for 16h. After the reaction mixture was quenched with methylamine in THF (18.8 mL), the mixture was concentrated in vacuo, dissolved in DCM and washed with sat. KH2P04 solution (2x). The org. layer was dried (MgS04), filtered, concentrated and purified by FC (Biotage SP1 : EtOAc/ hept.) to yield the title compound Q-5 as a white solid. LC-MS A: tR = 0.71 min; [M+H]+ = 315.23.
Synthesis of Intermediate R-1
(S)-2-Carbamoyl-2-methyl-pyrrolidine-1 -carboxylic acid tert-butyl ester
Ethyl chloroformate (0.5 mL, 5.12 mmol) was added to a 0°C solution of Q-1 (988 mg, 4.33 mmol) and TEA (1.22 mL, 8.76 mmol) in THF (10 mL) and the rxn mixture was stirred at 0°C for 30 min. A solution of 25% aq. NH4OH (7.5 mL) was added at 0°C and the resulting mixture was allowed to reach rt and stirring was continued at rt for 45 min. The mixture was concentrated in vacuo, then DCM and water was added. The org. layer was separated and the inorg. layer was extracted with DCM (2x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give the title compound R-1 as a yellow solid that was used as such in the next step without further purification. LC-MS A: tR = 0.58 min; [M+H]+ = 229.07. Synthesis of Intermediate R-2
(S)-2-Cyano-2-methyl-pyrrolidine-1 -carboxylic acid tert-butyl ester
Trifluoroacetic anhydride (0.85 ml_, 5.95 mmol) was added to a 0°C solution of R-1 (752 mg, 3.29 mmol) and TEA (1 .38 ml_, 9.88 mmol) in DCM (9 ml.) and the resulting mixture was strirred for 15 min at 0°C and at rt overnight. The mixture was diluted with DCM, washed with water (1x), dried (MgS04), filtered and concentrated in vacuo. The crude was purified by FC (Biotage SP1 : EtOAc/hex 1 :1 ) to give the title compound R-2 as a yellow oil. LC-MS A: tR = 0.8 min; [M+H]+ = 21 1 .21 .
Synthesis of Intermediate R-3
(S)-2-Methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidine-1 - carboxylic acid tert-butyl ester (R-3-1)
K2C03 (1 .22 g, 8.86 mmol) was added to a rt solution of R-2 (3.73 g, 17.7 mmol), F-1 -5 (3.90 g, 17.7 mmol) in n-butanol (35 ml.) and the rxn mixture was stirred at 120°C for 3 days. The rxn mixture was cooled to rt, then concentrated in vacuo. To the residue was added DCM and water and the mixture was acidified with 1 N aq. HCI. The org. layer was separated and the inorg. layer was extracted with DCM (1 x). The combined org. extracts were dried (MgS04), filtered, concentrated in vacuo and the crude purified by FC (Biotage SP1 : EtOAc/hept. 1 :9 to 3:7) followed by prep. HPLC (method E) to give the title compound R-3-1 as a white foam. LC- MS A: tR = 0.87 min; [M+H]+ = 413.17.
(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidine-1 - carboxylic acid tert-butyl ester (R-3-2)
The title compound R-3-2 was prepared from R-2 and F-1 -3 in analogy to the above described method (see R-3-1 ). LC-MS A: tR = 0.85 min; [M(35CI)+H]+ = 377.21 .
Synthesis of Intermediate R-4
3-((S)-2-Methyl-pyrrolidin-2-yl)-5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazole (R-4-1)
4N HCI in dioxane (1 .3 mL, 5.2 mmol) was added to a 0°C solution of R-3-1 (128 mg, 0.31 mmol) in DCM (3 mL) and the resulting mixture was stirred at rt for 2h. The rxn mixture was concentrated in vacuo to give the title compound R-4-1 as a white foam which was used further without purification. LC-MS A: tR = 0.58 min; [M+H]+ = 313.18.
3-(3-Chloro-2-methyl-phenyl)-5-((S)-2-methyl-pyrrolidin-2-yl)-4H-[1 ,2,4]triazole (R-4-2)
The title compound R-4-2 was prepared from R-3-2 in analogy to the above described method (see R-4-1 ). LC-MS A: tR = 0.58 min; [M(35CI)+H]+ = 277.13. Example compounds
Example 1 : (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)- pyrrolidin-1 -yl]-methanone
Step A: PyBOP (260 mg, 0.50 mmol) was added to a rt solution of A-3-3 (100 mg, 0.33 mmol) and DI PEA (0.171 mL, 1 .0 mmol) in DCM (3 mL) and after stirring for 10 min, commercially available hydroxyl-benzamidine (59 mg, 0.40 mmol) was added and the resulting mixture was stirred at rt for 1 -18h. The mixture was quenched with water and extracted with DCM (2x). The combined org. extracts were washed with brine, dried (MgS04), filtered and the solvent was evaporated in vacuo to give the crude product A-5-1 that was used further without purification. Step B: The crude A-5-1 was dissolved in dioxane (4.0 mL) and heated to reflux (90°C) for 18h to 4 days. The solvent was removed in vacuo and the residue was purified by prep. HPLC (method F) to give the title compound as a beige solid. LC-MS A: tR = 0.93 min; [M+H]+ = 401 .14.
Listed in Table 24 below are example compounds, prepared according to the above mentioned method, from the corresponding hydroxyamidine A-4 and carboxylic acid A-3-3, prepared as described above (see Example 1 ).
Table 24
Ex A-4 Compound of Formula (I)
No.
2 A-4-01 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-m-tDlyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]- methanone; LC-MS B: tR = 0.96 min; [M+H]+ = 415.33
3 A-4-02 {(S)-2-[3-(3-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrFolidin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol- 2-yl-phenyl)-methanone; LC-MS A: tR = 0.94 min; [M+H]+ = 431.38
4 A-4-03 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-pyridin-3-yl-[1 ,2,4]oxadiazol-5-yl)-pynOlidin-1- yl]-methanone; LC-MS A: tR = 0.79 min; [M+H]+ = 402.29
5 A-4-04 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-p-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]- methanone; LC-MS A: tR = 0.96 min; [M+H]+ = 415.24
6 A-4-05 {(S)-2-[3-(2-Cyclopropyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.94 min; [M+H]+ = 441.94
7 A-4-06 {(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrFolidin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol- 2-yl-phenyl)-methanone; LC-MS B: tR = 0.81 min; [M+H]+ = 430.99
8 A-4-07 {(S)-2-[3-(2-Methoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.76 min; [M+H]+ = 431.99
9 A-4-09 {(S)-2-[3-(3,5-Difluoro-phenyl)-[1 ,2,4]oxad^
2-yl-phenyl)-methanone; LC-MS B: tR = 0.92 min; [M+H]+ = 437.01 A-4-10 {(S)-2-[3-(2,3-Difluoro-phenyl)-[1 ,2^]oxad
2-yl-phenyl)-methanone; LC-MS B: tR = 0.88 min; [M+H]+ = 436.92
A-4-12 {(S)-2-[3-(3,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 429.38
A-4-13 {(S)-2-[3-(4,6-Dimethyl-pyridin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.83 min; [M+H]+ = 430.28
A-4-14 {(S)-2-[3-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 429.25
A-4-16 {(S)-2-[3-(3-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2- yl-phenyl)-methanone; LC-MS A: tR = 0.95 min; [M+H]+ = 419.23
A-4-17 {(S)-2-[3-(1 H-lndol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone; LC-MS A: tR = 0.89 min; [M+H]+ = 440.00
A-4-19 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-o-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]- methanone; LC-MS A: tR = 0.96 min; [M+H]+ = 415.25
A-4-21 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-tnfluoromethoxy-phenyl)-[1 ,2,4]oxadi
5-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 485.05
A-4-22 {(S)-2-[3-(3-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2- yl-phenyl)-methanone; LC-MS B: tR = 0.94 min; [M(35CI)+H]+ = 434.97
A-4-23 {(S)-2-[3-(2,2-Difluoro-benzo[1 ,3]dioxol-5-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl- 2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.96 min; [M+H]+ =481.00
A-4-24 {(S)-2-[3-(3,4-Difluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazo
2-yl-phenyl)-methanone; LC-MS B: tR = 0.97 min; [M+H]+ = 436.98
A-4-25 {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2- yl-phenyl)-methanone; LC-MS B: tR = 0.89 min; [M(35CI)+H]+ = 435.08
A-4-26 [(S)-2-(3-Benzo[1 ,3]dioxol-5-yl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1 ,2,3]triazol- 2-yl-phenyl)-methanone; LC-MS B: tR = 0.86 min; [M+H]+ = 445.11
A-4-27 {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.99 min; [M(35CI)+H]+ = 449.05
A-4-28 {(S)-2-[3-(2-Chloro-6-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.91 min; [M(35CI)+H]+ = 449.09
A-4-29 {(S)-2-[3-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone; LC-MS B: tR = 0.97 min; [M+H]+ = 429.16
A-4-30 {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.94 min; [M+H]+ = 433.10
A-4-31 {(S)-2-[3-(2-Chloro-3-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.94 min; [M(35CI)+H]+ = 449.02 A-4-32 {(S)-2-[3-(2-Chloro-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.78 min; [M(35CI)+H]+ = 436.14
A-4-33 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-phenyl)^
yl]-pyrrolidin-1-yl}-methanone; LC-MS B: tR = 0.96 min; [M+H]+ = 468.91
A-4-34 {(S)-2-[3-(3-Chloro-pyrazin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.84 min; [M(35CI)+H]+ = 436.93
A-4-35 {(S)-2-[3-(2-Hydroxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2- yl-phenyl)-methanone; LC-MS B: tR = 0.77 min; [M+H]+ = 416.94
A-4-36 {(S)-2-[3-(2-Methoxy-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.83 min; [M+H]+ = 431.97
A-4-37 {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.87 min; [M+H]+ = 467.01
A-4-38 {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.86 min; [M+H]+ = 449.77
A-4-39 {(S)-2-[3-(2-Fluoro-3-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.84 min; [M+H]+ = 449.77
A-4-40 {(S)-2-[3-(2-Chloro-4-methyl-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.78 min; [M(35CI)+H]+ = 449.69
A-4-41 {(S)-2-[3-(3,5-Dimethyl-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.62 min; [M+H]+ = 430.01
A-4-42 {(S)-2-[3-(2,3-Dihydro-benzo[1 ,4]dioxin-5-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl- 2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.88 min; [M+H]+ = 458.94
A-4-43 {(S)-2-[3-(1 H-lndol-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone; LC-MS B: tR = 0.82 min; [M+H]+ = 439.96
A-4-44 {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2- yl-phenyl)-methanone; LC-MS B: tR = 0.87 min; [M+H]+ = 445.02
A-4-45 {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.84 min; [M+H]+ = 446.00
A-4-46 {(S)-2-[3-(5-Methoxy-1 H-indol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.89 min; [M+H]+ = 469.99
A-4-47 {(S)-2-[3-(3-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.90 min; [M+H]+ = 466.95
A-4-48 {(S)-2-[3-(2-Methoxymethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.87 min; [M+H]+ = 445.0
A-4-49 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-propoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1-yl}-methanone LC-MS A: tR = 0.97 min; [M+H]+ = 458.97 A-4-50 {(S)-2-[3-(1 H-lndol-7-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone; LC-MS B: tR = 0.90 min; [M+H]+ = 439.97
A-4-51 {(S)-2-[3-(3,5-Dimethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.96 min; [M+H]+ = 461.11
A-4-52 {(S)-2-[3-(2-Cyclobutoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.92 min; [M+H]+ = 471.98
A-4-53 {(S)-2-[3-(2-Cyclopentyloxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.97 min; [M+H]+ = 485.99
A-4-54 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(1 H-pyrrolo[2,3-b]pyridin-3-yl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS B: tR = 0.70 min; [M+H]+ = 440.94
A-4-55 {(S)-2-[3-(1-Methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.78 min; [M+H]+ = 454.95
A-4-56 [(S)-2-(3-Benzo[1 ,3]dioxol-4-yl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-(5-methyl-2-[1 ,2,3]triazol- 2-yl-phenyl)-methanone; LC-MS A: tR = 0.90 min; [M+H]+ = 444.92
A-4-57 {(S)-2-[3-(2-Ethyl-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol- 2-yl-phenyl)-methanone; LC-MS B: tR = 0.65 min; [M+H]+ = 429.94
A-4-58 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methyl-3-trifluoromethyl-phenyl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS B: tR = 0.98 min; [M+H]+ = 482.98
A-4-59 {(S)-2-[3-(3-Ethoxy-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.80 min; [M+H]+ = 445.97
A-4-60 {(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.92 min; [M+H]+ = 462.99
A-4-61 {(S)-2-[3-(1-Methyl-1 H-indol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.94 min; [M+H]+ = 454.02
A-4-62 {(S)-2-[3-(4-Methyl-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.74 min; [M+H]+ = 416.36
A-4-63 {(S)-2-[3-(2,3-Dimethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.83 min; [M+H]+ = 461.03
A-4-64 {(S)-2-[3-(1-Methyl-1 H-pyrazol-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.79 min; [M+H]+ = 405.08
A-4-65 {(S)-2-[3-(5-Ethyl-4-methyl-pyridin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone;L LC-MS B: tR = 0.81 min; [M+H]+ = 443.99
A-4-66 {(S)-2-[3-(4,5-Dimethyl-pyridin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.76 min; [M+H]+ = 430.04
A-4-67 {(S)-2-[3-(5,6-Dimethyl-pyridin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.77 min; [M+H]+ = 430.01 A-4-68 {(S)-2-[3-(4-Hydroxy-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.63 min; [M+H]+ = 446.95
A-4-69 {(S)-2-[3-(2,6-Dimethyl-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.60 min; [M+H]+ = 430.00
A-4-70 {(S)-2-[3-(2-Methoxy-6-methyl-pyrid^
[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.89 min; [M+H]+ = 446.00
A-4-71 {(S)-2-[3-(6-lsobutyl-4-methyl-pyridin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.92 min; [M+H]+ = 472.06
A-4-72 {(S)-2-[3-(2-Methyl-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.59 min; [M+H]+ = 416.0
A-4-73 {(S)-2-[3-(2,6-Difluoro-3-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.84 min; [M+H]+ = 466.97
A-4-74 {(S)-2-[3-(2-Chloro-3-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.86 min; [M(35CI)+H]+ = 465.03
A-4-75 {(S)-2-[3-(2-lsopropoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.89 min; [M+H]+ = 460.03
A-4-76 {(S)-2-[3-(2-Fluoro-6-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.82 min; [M+H]+ = 448.92
A-4-77 {(S)-2-[3-(2-Chloro-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.83 min; [M(35CI)+H]+ = 435.92
A-4-78 {(S)-2-[3-(1-Methyl-1 H-indol-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.89 min; [M+H]+ = 454.04
A-4-79 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(1 H-pyrrolo[2,3-b]pyridin-4-yl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS B: tR = 0.72 min; [M+H]+ = 441.01
A-4-80 {(S)-2-[3-(2-Fluoro-6-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.87 min; [M+H]+ = 432.92
A-4-81 {(S)-2-[3-(1-Methyl-1 H-indol-7-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.89 min; [M+H]+ = 454.00
A-4-82 {(S)-2-[3-(2-Methyl-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.61 min; [M+H]+ = 415.99
A-4-83 {(S)-2-[3-(4-Methyl-1 H-indol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.90 min; [M+H]+ = 453.96
A-4-8 {(S)-2-[3-(3,4-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 429.12
A-4-1 1 {(S)-2-[3-(2,4-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 1.00 min; [M+H]+ = 429.11 82 A-4-85 {(S)-2-[3-(3,4-Dimethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.91 min; [M+H]+ = 461.12
83 A-4-18 {(S)-2-[3-(3-Methyl-pyridin-2-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.82 min; [M+H]+ = 416.11
84 A-4-20 {(S)-2-[3-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 429.09
Example 85: 1 -(3-{5-[(S)-1 -(5-Methyl-2-[1 ,2,3]triazol-2-yl-benzoyl)-pyrrolidin-2-yl]- [1 ,2,4]oxadiazol-3-yl}-indol-1 -yl)-ethanone
NaH 60% (3.3 mg, 0.07 mmol) was added to a rt solution of Example 15 (20 mg, 0.05 mmol) and TEA (19 uL, 0.14 mmol) in THF (1 mL) and the resulting suspension was stirred at rt for 1 h, then acetyl chloride (1 drop) was added and stirred at rt for another 1 h. The rxn mixture was concentrated and purified by prep. HPLC (method G) to give the title compound as a beige solid. LC-MS B: tR = 0.90 min; [M+H]+ = 481.69.
Example 86: {(S)-2-[3-(2-Difluoromethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
Step A: PyBOP (208 mg, 0.4 mmol) was added to a rt solution of carboxylic acid A-3-1 (100 mg, 0.33 mmol), hydroxyamidine-derivative A-4-83 (102 mg, 0.67 mmol) and DIPEA (0.17 mL, 1.0 mmol) in DCM (2 mL). After stirring at rt for 1 h, the rxn mixture was concentrated and dioxane (2 mL) was added. The resulting solution was heated to 80°C for 2 days. The crude was purified by prep. HPLC (method G) followed by a prep. TLC (DCM/ MeOH 9:19 yielding {(S)-2-[3-(2-hydroxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol- 2-yl-phenyl)-methanone as a yellow oil. LC-MS B: tR = 0.59 min; [M+H]+ = 417.68.
Step B: NaH 60% (4 mg, 0.1 mmol) was added to a rt solution of {(S)-2-[3-(2-hydroxy-pyridin-3- yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone (15 mg, 0.04 mmol) in MeCN (0.6 mL). The resulting suspension was stirred at rt for 10 min, then a solution of 2,2-difluoro-2-(fluorosulfonyl)acetic acid (6 uL, 0.06 mmol) in MeCN (63 uL) was added. The resulting rxn mixture was stirred at rt for 18h, then diluted with water and extracted with DCM (3x).The combined org. layers were concentrated, dried (MgS04), filtered and concentrated in vacuo. Purification by prep. TLC (DCM/MeOH 95:5) afforded the title compound as a colorless oil. LC-MS B: tR = 0.84 min; [M+H]+ = 467.91 .
Example 87: ((S)-2-{3-[2-(2-Hydroxy-ethyl)-phenyl]-[1 ,2,4]oxadiazol-5-yl}-pyrrolidin-1 -yl)- (5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
Step A: To a solution of 2-(2-hydroxyethyl)benzonitrile (200 mg, 1 .36 mmol) in THF (8 mL), 1 H- imidazole (102 mg, 1.49 mmol), followed by ferf-butylchlorodimethylsilane (209 mg, 1 .39 mmol) was added. The resulting yellow suspension was stirred at rt for 18h, then quenched with sat aq. NH4CI and extracted with EtOAc (2x). The combined org. layers were concentrated in vacuo to yield 2-(2-((fe/t-butyldimethylsilyl)oxy)ethyl)benzonitrile as a yellow oil that was used without further purification. LC-MS B: tR = 1.06 min; [M+H]+ = 262.09.
Step B: Hydroxylamine HCI (214 mg, 3.06 mmol) was added to a rt solution of 2-(2-((tert- butyldimethylsilyl)oxy)ethyl)benzonitrile (399 mg, 1 .53 mmol) and NaHC03 (257 mg, 3.06 mmol) in MeOH (5 mL) and the resulting suspension was stirred at 65°C for 2 days. The rxn mixture was concentrated to yield 2-(2-((fe/t-butyldimethylsilyl)oxy)ethyl)-/\/- hydroxybenzamidine that was used further without purification. LC-MS B: tR = 0.69 min; [M+H]+ = 295.1 1 .
Step C: PyBOP (129 mg, 0.25 mmol) was added to a rt solution of carboxylic acid A-3-1 (60 mg, 0.20 mmol) and DIPEA (103 uL, 0.60 mmol) in DCM (1 mL) and the rxn mixture was stirred for 5 min, before a solution of 2-(2-((ferf-butyldimethylsilyl)oxy)ethyl)-/\/-hydroxybenzamidine (126 mg, 0.21 mmol) in DCM (1 mL) was added and stirring was continued at rt for 18h. The rxn mixture was concentrated in vacuo, then dioxane (2 mL) was added and the resulting solution was heated to 80°C for 18h. The crude was concentrated and purified by prep. HPLC (method G) to yield (S)-(2-(3-(2-(2-((ferf-butyldimethylsilyl)oxy)ethyl)phenyl)-1 ,2,4-oxadiazol-5- yl)pyrrolidin-1 -yl)(5-methyl-2-(2/-/-1 ,2,3-triazol-2-yl)phenyl)methanone as a colorless oil. LC-MS B: tR = 1.16 min; [M+H]+ = 559.03.
Step D: Tetrabutylammonium fluoride (1 M in THF, 27 uL, 0.027 mmol) was added to a rt solution of (S)-(2-(3-(2-(2-((fert-butyldimethylsilyl)oxy)ethyl)phenyl)-1 ,2,4-oxadiazol-5- yl)pyrrolidin-1 -yl)(5-methyl-2-(2/-/-1 ,2,3-triazol-2-yl)phenyl)methanone (10 mg, 0.02 mmol) in THF (1 mL) and stirred at rt for 3h. The rxn mixture was concentrated and the residue was quenched with sat. aq. NaHC03. The org. layer was separated and the aq. layer was extracted with DCM (1 x). The combined org. layers were evaporated and purified by prep. HPLC (method G) to give the title compound as a beige solid. LC-MS B: tR = 0.77 min; [M+H]+ = 444.96.
General Method F for Amide Formation: TBTU/DIPEA DMF
TBTU (1.1 mmol) was added to a solution of the required carboxylic acid A-1 (1.0 mmol) and DIPEA (2.0 mmol) in DMF (2.0 mL). After stirring at rt for 10 min a solution of the required amine B-3 (1 .0 mmol) in DMF (1.0 mL) was added. The resulting rxn mixture was stirred at rt for up to 3 d before being purified directly by prep. HPLC (method G) to furnish the desired product.
General Method G for Amide Formation: HATU/DIPEA DMF/DCM
A solution of DIPEA (0.4 mmol, 4 eq.) in DCM/ DMF 1 :1 (200 uL) was added to a solution of carboxylic acid A-1 (0.1 mmol) in DCM/ DMF 1 :1 (200 uL) followed by a solution of the required amine B-3 (0.1 mmol) in DCM/ DMF 1 :1 (200 uL) and a solution of HATU (0.105 mmol) in DMF. After the rxn mixture was stirred overnight, the mixtures were diluted with DCIW DMF 1 : 1 (1 mL) and PL-HC03 (1 .87 mmol/g) (213 mg, 0.4 mmol) was added and stirred for 1 h. The resin was filtered off, washed with DCIW MeOH 1 : 1 and concentrated in vacuo. Purification by prep. HPLC (method G) furnished the desired product.
General Method H for Amide Formation: EDC/DMAP DMF
EDC HCI (0.15 mmol) was added to a rt solution of the required carboxylic acid A-1 (0.1 mmol) and DMAP (0.02 mmol) in DMF (0.5 mL). After stirring at rt for 10 min, a solution of the required amine B-3 (0.1 mmol) in DMF (0.5 mL) was added. The resulting rxn mixture was stirred at rt for hours up to days before being purified directly by prep. HPLC (method G) to furnish the desired product.
Listed in Table 25 below are example compounds, prepared according to the above mentioned method, from corresponding amine B-3 and carboxylic acid A-1 .
Table 25
Ex. SM SM GM Compound of Formula (I)
No. A-1 B-3
88 A-1 -35 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-methyl-biphenyl-2-yl)-methanone;
LC-MS A: tR = 1.08 min; [Mpci)+H]+ = 458.08
89 A-1 -28 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methyl-2-pyrazol-1-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 448.06
90 A-1 -38 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methyl-2-pyridin-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.91 min; [M(35CI)+H]+ = 459.09
91 A-1 -53 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(2-methyl-5-m-tolyl-oxazol-4-yl)-methanone;
LC-MS A: tR = 1.03 min; [Mpci)+H]+ = 463.08
92 A-1 -42 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-m-tolyl-oxazol-4-yl)-methanone;
LC-MS A: tR = 1.02 min; [Mpci)+H]+ = 448.97
93 A- 1 -4 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.93 min; [M(35CI)+H]+ = 434.82 94 A-1 -43 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[5-(3-chloro-phenyl)-thiazol-4-yl]-methanone;
LC-MS A: tR = 1.02 min; [Mpci)+H]+ = 484.99
95 A- 1 -6 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(4,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 1.01 min; [Mpci)+H]+ = 462.97
96 A- 1 -3 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.97 min; [M(35CI)+H]+ = 448.85
97 A-1 -21 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-[1 ,2,3]triazol-2-yl-5-trifluoromethyl-phenyl)-methanone;
LC-MS A: tR = 1.04 min; [M(35CI)+H]+ = 503.07
98 A-1 -18 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.01 min; [Mpci)+H]+ = 448.97
99 A-1 -23 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-[1 ,2,3]triazol-2-yl-5-trifluoromethoxy-phenyl)-methanone;
LC-MS A: tR = 1.04 min; [Mpci)+H]+ = 519.05
100 A-1 -10 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 1.00 min; [M(35CI)+H]+ = 464.97
101 A-1 -39 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(4-methoxy-biphenyl-2-yl)-methanone;
LC-MS B: tR = 1.08 min; [M+H]+ = 473.94
102 A-1 -47 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-phenyl-3H-imidazol-4-yl)-methanone;
LC-MS B: tR = 0.74 min; [Mpci)+H]+ = 433.65
103 A-1 -1 1 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.99 min; [Mpci)+H]+ = 478.93
104 A- 1 -7 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.95 min; [M(35CI)+H]+ = 452.95
105 A-1 -13 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-methoxy-4-methyl-2-pyrazol-1 -yl-phenyl)-methanone;
LC-MS B: tR = 0.98 min; [M(35CI)+H]+ = 477.98 106 A-1 -29 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methoxy-2-pyrazol-1-yl-phenyl)-methanone;
LC-MS B: tR = 0.92 min; [Mpci)+H]+ = 463.98
107 A-1 -51 B-3-1 F [2,2']Bipyridinyl-3-yl-{(S)-2-[3-(3-chloro-2-methyl-phenyl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.96 min; [Mpci)+H]+ = 445.98
108 A-1 -14 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(6-methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS B: tR = 0.89 min; [M(35CI)+H]+ = 449.68
109 A-1 -31 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(6-methyl-3-pyrazol-1-yl-pyridin-2-yl)-methanone;
LC-MS B: tR = 0.95 min; [M(35CI)+H]+ = 448.99
110 A-1 -24 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4,5-difluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.98 min; [Mpci)+H]+ = 470.91
111 A-1 -32 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-fluoro-2-pyrazol-1-yl-phenyl)-methanone;
LC-MS B: tR = 0.95 min; [Mpci)+H]+ = 451.92
112 A- 1 -8 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.96 min; [M(35CI)+H]+ = 452.92
113 A-1 -30 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(3-fluoro-2-pyrazol-1-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 451.93
114 A-1 -15 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(3-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.95 min; [Mpci)+H]+ = 452.91
115 A-1 -25 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4,5-dimethyl-2-pyrazol-1-yl-phenyl)-methanone;
LC-MS B: tR = 1.00 min; [Mpci)+H]+ = 461.92
116 A-1 -40 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-[5-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS B: tR = 0.88 min; [M(35CI)+H]+ = 451.89
117 A-1 -41 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS B: tR = 0.87 min; [M(35CI)+H]+ = 451.89 118 A-1-20 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(4-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [Mpci)+H]+ = 464.88
119 A-1-17 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(3,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.99 min; [Mpci)+H]+ = 462.95
120 A-1 -36 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-oxazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 434.86
121 A-1 -16 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(4-chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 1.01 min; [M(35CI)+H]+ = 468.90
122 A-1 -22 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-[1 ,2,3]triazol-2-yl-4-trifluoromethyl-phenyl)-methanone;
LC-MS A: tR = 1.03 min; [Mpci)+H]+ = 502.97
123 A-1-44 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[5-(3-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone;
LC-MS B: tR = 1.01 min; [Mpci)+H]+ = 483.01
124 A-1 -46 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[5-(2-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone;
LC-MS B: tR = 1.01 min; [M(35CI)+H]+ = 483.01
125 A-1-45 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[5-(4-fluoro-phenyl)-2-methyl-thiazol-4-yl]-methanone;
LC-MS B: tR = 1.01 min; [M(35CI)+H]+ = 482.99
126 A-1-54 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone;
LC-MS B: tR = 1.03 min; [Mpci)+H]+ = 480.17
127 A-1 -49 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[4-(3-chloro-phenyl)-2-methyl-pyrimidin-5-yl]-methanone;
LC-MS B: tR = 1.01 min; [Mpci)+H]+ = 494.03
128 A-1 -48 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[3-(3-methoxy-phenyl)-pyrazin-2-yl]-methanone;
LC-MS B: tR = 0.96 min; [M(35CI)+H]+ = 476.06
129 A-1-27 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(3,4-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.0 min; [M(35CI)+H]+ = 463.09 130 A-1 -26 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.99 min; [Mpci)+H]+ = 483.05
131 A-1 -37 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methyl-2-oxazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.98 min; [Mpci)+H]+ = 448.96
132 A-1 -33 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-fluoro-3-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 467.04
133 A-1 -12 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4,5-dimethoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 495.07
134 A-1 -50 B-3-2 G [2-(3-Methyl-[1 ,2,4]oxadiazol-5-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone,
LC-MS A: tR = 0.96 min; [M+H]+ = 486.09
135 A-1 -52 B-3-2 F Biphenyl-2-yl-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5- yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M+H]+ = 479.96
136 A-1 -35 B-3-2 G (4-Methyl-biphenyl-2-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.06 min; [M+H]+ = 494.12
137 A-1 -28 B-3-2 G (5-Methyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.98 min; [M+H]+ = 484.12
138 A-1 -38 B-3-2 F (5-Methyl-2-pyridin-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.92 min; [M+H]+ = 494.92
139 A-1 -53 B-3-2 G (2-Methyl-5-m-tolyl-oxazol-4-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1 :02 min; [M+H]+ = 499.10
140 A-1 -42 B-3-2 G (5-m-Tolyl-oxazol-4-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 485.09
141 A- 1 -4 B-3-2 F (2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 470.91 142 A-1 -43 B-3-2 G [5-(3-Chloro-phenyl)-thiazol-4-yl]-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [Mpci)+H]+ = 521.02
143 A- 1 -5 B-3-2 G (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [Mpci)+H]+ = 505.05
144 A- 1 -9 B-3-2 G (2-Fluoro-3-methoxy-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 519.11
145 A-1 -1 B-3-2 F (2-Fluoro-3-methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 502.89
146 A- 1 -6 B-3-2 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [M+H]+ = 498.97
147 A- 1 -3 B-3-2 F (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.98 min; [M+H]+ = 484.91
148 A-1 -21 B-3-2 G (2-[1 ,2,3]Triazol-2-yl-5-trifluoromethyl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.02 min; [M+H]+ = 539.07
149 A-1 -18 B-3-2 G (2-Methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 485.10
150 A-1 -23 B-3-2 G (2-[1 ,2,3]Triazol-2-yl-5-trifluoromethoxy-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.03 min; [M+H]+ = 555.06
151 A-1 -10 B-3-2 G (5-Methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 501.11
152 A-1 -39 B-3-2 F (4-Methoxy-biphenyl-2-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 1.00 min; [M+H]+ = 509.95
153 A-1 -47 B-3-2 F (5-Phenyl-3H-imidazol-4-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.87 min; [M+H]+ = 469.95 154 A-1 -1 1 B-3-2 F (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.01 min; [M+H]+ = 515.10
155 A- 1 -7 B-3-2 F (5-Fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.91 min; [M+H]+ = 488.96
156 A-1 -13 B-3-2 F (5-Methoxy-4-methyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS B: tR = 0.93 min; [M+H]+ = 513.76
157 A-1 -29 B-3-2 F (5-Methoxy-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.88 min; [M+H]+ = 499.97
158 A-1 -51 B-3-2 F [2,2']Bipyridinyl-3-yl-{(S)-2-[3-(2-trifluoromethoxy-phenyl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.83 min; [M+H]+ = 481.73
159 A-1 -14 B-3-2 F (6-Methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.93 min; [M+H]+ = 485.95
160 A-1 -31 B-3-2 F (6-Methyl-3-pyrazol-1-yl-pyridin-2-yl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.84 min; [M+H]+ = 484.96
161 A-1 -24 B-3-2 F (4,5-Difluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.94 min; [M+H]+ = 506.94
162 A-1 -32 B-3-2 F (4-Fluoro-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.91 min; [M+H]+ = 487.96
163 A- 1 -8 B-3-2 F (4-Fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.92 min; [M+H]+ = 488.93
164 A-1 -30 B-3-2 F (3-Fluoro-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 487.93
165 A-1 -15 B-3-2 F (3-Fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 488.92 166 A-1 -29 B-3-2 F (4,5-Dimethyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.96 min; [M+H]+ = 497.66
167 A-1 -40 B-3-2 F [5-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.84 min; [M+H]+ = 487.89
168 A-1 -41 B-3-2 F [3-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS B: tR = 0.84 min; [M+H]+ = 487.90
169 A-1 -20 B-3-2 F (4-Methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.95 min; [M+H]+ = 500.90
170 A-1 -17 B-3-2 F (3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.95 min; [M+H]+ = 498.95
171 A-1 -36 B-3-2 F (2-Oxazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 470.93
172 A-1 -16 B-3-2 F (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.97 min; [M(35CI)+H]+ = 504.91
173 A-1 -22 B-3-2 F (2-[1 ,2,3]Triazol-2-yl-4-trifluoromethyl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.01 min; [M+H]+ = 538.96
174 A-1 -26 B-3-2 F (4-Fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 519.04
175 A-1 -37 B-3-2 F (5-Methyl-2-oxazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 485.06
176 A-1 -33 B-3-2 F (5-Fluoro-3-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 503.08
177 A-1 -12 B-3-2 F (4,5-Dimethoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.94 min; [M+H]+ = 531.09 178 A- 1 -4 B-3-3 F (2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.85 min; [M+H]+ = 454.92
179 A- 1 -5 B-3-3 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.92 min; [Mpci)+H]+ = 488.90
180 A- 1 -3 B-3-3 F (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.90 min; [M+H]+ = 468.94
181 A- 1 -6 B-3-3 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.93 min; [M+H]+ = 482.95
182 A-1-1 1 B-3-3 F (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS B: tR = 0.92 min; [M+H]+ = 498.92
183 A-1-41 B-3-3 F [3-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.80 min; [M+H]+ = 471.92
184 A-1 -38 B-3-3 F (5-Methyl-2-pyridin-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.80 min; [M+H]+ = 478.97
185 A- 1 -4 B-3-4 F {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.83 min; [M+H]+ = 452.92
186 A- 1 -5 B-3-4 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-difluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.89 min; [Mpci)+H]+ = 486.89
187 A- 1 -3 B-3-4 F {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.87 min; [M+H]+ = 466.92
188 A- 1 -6 B-3-4 F {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.91 min; [M+H]+ = 480.95
189 A-1 -1 1 B-3-4 F {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.90 min; [M+H]+ = 496.88 190 A-1 -41 B-3-4 F {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS B: tR = 0.77 min; [M+H]+ = 469.93
191 A-1 -38 B-3-4 F {(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methyl-2-pyridin-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.77 min; [M+H]+ = 476.97
192 A-1 -17 B-3-5 F (3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.88 min; [M+H]+ = 462.99
193 A- 1 -4 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1 -yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.82 min; [M+H]+ = 434.90
194 A- 1 -5 B-3-5 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.90 min; [Mpci)+H]+ = 486.92
195 A- 1 -3 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1 -yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.87 min; [M+H]+ = 448.91
196 A- 1 -6 B-3-5 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.91 min; [M+H]+ = 462.99
197 A-1 -34 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1 -yl}-(3-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.84 min; [M+H]+ = 448.93
198 A-1 -14 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1-yl}-(6-methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS B: tR = 0.77 min; [M+H]+ = 449.69
199 A-1 -10 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1 -yl}-(5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.84 min; [M+H]+ = 464.91
200 A- 1 -7 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-
1-yl}-(5-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.84 min; [M+H]+ = 452.93
201 A-1 -1 1 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1-yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS B: tR = 0.90 min; [M+H]+ = 478.97 202 A-1 -41 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-
1-yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS B: tR = 0.77 min; [M+H]+ = 451.95
203 A-1 -38 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-
1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.76 min; [M+H]+ = 458.97
204 A-1 -16 B-3-5 F (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.90 min; [M(35CI)+H]+ = 468.92
205 A-1 -22 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1-yl}-(2-[1 ,2,3]triazol-2-yl-4-trifluoromethyl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 502.99
206 A-1 -26 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1-yl}-(4-fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.93 min; [M+H]+ = 483.05
207 A-1 -33 B-3-5 F {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1-yl}-(5-fluoro-3-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 467.09
208 A-1 -12 B-3-5 F (4,5-Dimethoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2- methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.88 min; [M+H]+ = 495.11
209 A-1 -17 B-3-6 F (3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3- yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.85 min; [M+H]+ = 460.02
210 A- 1 -5 B-3-6 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.87 min; [Mpci)+H]+ = 465.67
211 A- 1 -3 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.84 min; [M+H]+ = 445.98
212 A- 1 -6 B-3-6 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3- yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.88 min; [M+H]+ = 460.01
213 A-1 -14 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(6- methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS B: tR = 0.73 min; [M+H]+ = 447.00 214 A- 1 -7 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.81 min; [M+H]+ = 449.70
215 A-1 -13 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.87 min; [M+H]+ = 476.01
216 A-1 -41 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3- fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS B: tR = 0.73 min; [M+H]+ = 448.92
217 A-1 -38 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methyl-2-pyridin-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.72 min; [M+H]+ = 455.99
218 A- 1 -4 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.79 min; [M+H]+ = 431.97
219 A-1 -34 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(3- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.80 min; [M+H]+ = 455.98
220 A-1 -10 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.8 min; [M+H]+ = 461.98
221 A-1 -16 B-3-6 F (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.88 min; [M(35CI)+H]+ = 465.66
222 A-1 -22 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-4-trifluoromethyl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 500.02
223 A-1 -26 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4- fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.90 min; [M+H]+ = 480.09
224 A-1 -37 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methyl-2-oxazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 446.08
225 A-1 -33 B-3-6 F {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- fluoro-3-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.90 min; [M+H]+ = 464.10 226 A-1 -12 B-3-6 F (4,5-Dimethoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-
3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.85 min; [M+H]+ = 492.14
227 A- 1 -4 B-3-7 F {(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.85 min; [M+H]+ = 416.90
228 A- 1 -5 B-3-7 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.91 min; [M(35CI)+H]+ = 450.87
229 A- 1 -3 B-3-7 F {(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 430.95
230 A- 1 -6 B-3-7 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.91 min; [M+H]+ = 444.95
231 A-1 -1 1 B-3-7 F (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.91 min; [M+H]+ = 460.98
232 A-1 -10 B-3-7 F {(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 446.95
233 A- 1 -7 B-3-7 F (5-Fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.87 min; [M+H]+ = 434.89
234 A-1 -40 B-3-7 F [5-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.81 min; [M+H]+ = 433.68
235 A-1 -14 B-3-7 F {(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(6- methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS A: tR = 0.81 min; [M+H]+ = 431.93
236 A- 1 -5 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 454.85
237 A- 1 -3 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M(35CI)+H]+ = 434.86 238 A- 1 -6 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5- dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [Mpci)+H]+ = 448.89
239 A-1 -1 1 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [Mpci)+H]+ = 464.90
240 A-1-10 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.92 min; [M(35CI)+H]+ = 450.86
241 A- 1 -7 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 469.88
242 A-1-14 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(6- methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS A: tR = 0.87 min; [Mpci)+H]+ = 435.86
243 A- 1 -4 B-3-8 F {(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.90 min; [Mpci)+H]+ = 420.88
244 A- 1 -4 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 418.90
245 A- 1 -5 B-3-9 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.98 min; [M(35CI)+H]+ = 452.92
246 A- 1 -3 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 432.90
247 A- 1 -6 B-3-9 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 446.98
248 A-1 -1 1 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 462.98
249 A-1 -10 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 448.91 250 A- 1 -7 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 436.93
251 A-1 -34 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(3-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 432.91
252 A-1 -14 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(6-methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS A: tR = 0.90 min; [M+H]+ = 433.72
253 A-1 -41 B-3-9 F {(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 435.95
254 A-1 -41 B-3-10 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3- fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methanone;
LC-MS A: tR = 0.85 min; [M+H]+ = 447.95
255 A- 1 -5 B-3-10 F (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [Mpci)+H]+ = 464.92
256 A- 1 -3 B-3-10 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 444.98
257 A- 1 -6 B-3-10 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-phenyl)-
[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.96 min; [M+H]+ = 459.01
258 A-1 -1 1 B-3-10 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 475.01
259 A-1 -14 B-3-10 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(6- methyl-3-[1 ,2,3]triazol-2-yl-pyridin-2-yl)-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 445.98
260 A- 1 -4 B-3-10 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 430.96
261 A-1 -10 B-3-10 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.91 min; [M+H]+ = 460.99 262 A-1 -34 B-3-1 0 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-(3- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.90 min; [M+H]+ = 444.97
263 A- 1-7 B-3-1 0 F {(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-(5- fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.91 min; [M+H]+ = 448.91
264 A- 1 -5 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 1.06 min; [M(35CI)+H]+ = 468.98
265 A- 1 -9 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(2-fluoro-3-methoxy-6-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 483.08
266 A-1-1 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(2-fluoro-3-methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.99 min; [Mpci)+H]+ = 466.88
267 A-1-50 B-3-1 G {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-[2-(3-methyl-[1 ,2,4]oxadiazol-5-yl)-phenyl]-methanone;
LC-MS A: tR = 0.97 min; [Mpci)+H]+ = 449.84
268 A-1-52 B-3-1 G Biphenyl-2-yl-{(S)-2-[3-(3-chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1 -yl}-methanone;
LC-MS A: tR = 1.05 min; [M(35CI)+H]+ = 444.08
269 A-1-56 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 - yl}-(5-methoxy-4-methyl-2-pyrimidin-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 490.07
270 A- 1 -2 B-3-12 F (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-methanone;
LC-MS A: tR = 1.01 min; [M+H]+ = 485.10
271 A-1-27 B-3-2 F (3,4-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 499.1 1
272 A-1-27 B-3-5 F (3,4-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 463.09
273 A-1-27 B-3-6 F (3,4-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3- yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-methanone;
LC-MS A: tR = 0.91 min; [M+H]+ = 460.14 274 A-1 -55 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methyl-2-pyrimidin-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [Mpci)+H]+ = 460.08
275 A-1 -19 B-3-2 F 4-[1 ,2,3]Triazol-2-yl-3-{(S)-2-[3-(2-trifluoromethoxy-phenyl)- [1 ,2,4]oxadiazol-5-yl]-pyrrolidine-1-carbonyl}-benzonitrile;
LC-MS A: tR = 0.96 min; [M+H]+ = 496.08
276 A-1 -19 B-3-1 F 3-{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidine-
1-carbonyl}-4-[1 ,2,3]triazol-2-yl-benzonitrile;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 460.07
277 A-1 -19 B-3-9 F 3-{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidine-
1-carbonyl}-4-[1 ,2,3]triazol-2-yl-benzonitrile;
LC-MS A: tR = 0.95 min; [M+H]+ = 444.09
278 A-1 -19 B-3-5 F 3-{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidine-1-carbonyl}-4-[1 ,2,3]triazol-2-yl-benzonitrile;
LC-MS A: tR = 0.91 min; [M+H]+ = 460.99
279 A-1 -19 B-3-6 F 3-{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidine-1- carbonyl}-4-[1 ,2,3]triazol-2-yl-benzonitrile;
LC-MS A: tR = 0.88 min; [M+H]+ = 457.11
280 A-1 -59 B-3-1 F (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-chloro-2- methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 499.02
281 A-1 -59 B-3-2 F (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 535.03
282 A-1 -59 B-3-5 F (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2- methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 499.03
283 A-1 -59 B-3-1 1 F (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3- fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.0 min; [M(35CI)+H]+ = 512.98
284 A-1 -59 B-3-6 F (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy- pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.94 min; [M(35CI)+H]+ = 496.07
285 A-1 -56 B-3-2 H (5-Methoxy-4-methyl-2-pyrimidin-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.01 min; [M+H]+ = 526.09 286 A-1 -56 B-3-5 H {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin- 1-yl}-(5-methoxy-4-methyl-2-pyrimidin-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 490.10
287 A-1 -56 B-3-6 H {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-pyrimidin-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.92 min; [M+H]+ = 487.11
288 A- 1 -4 B-3-1 1 F {(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 448.99
289 A- 1 -3 B-3-1 1 F {(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 463.09
290 A- 1 -6 B-3-1 1 F (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3-fluoro- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 477.10
291 A-1 -1 1 B-3-1 1 F {(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 493.10
292 A-1 -26 B-3-1 1 F {(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(4-fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 496.98
293 A-1 -58 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(5-chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.05 min; [M(35CI)+H]+ = 483.00
294 A-1 -16 B-3-9 F (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 453.03
295 A-1 -59 B-3-9 F (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2- methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 483.05
296 A-1 -61 B-3-1 F {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-(3-chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.98 min; [M(35CI)+H]+ = 468.99
297 A-1 -61 B-3-5 F (3-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.91 min; [M(35CI)+H]+ = 469.02 298 A-1-61 B-3-2 F (3-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 505.01
299 A-1-58 B-3-2 F (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 1.04 min; [M(35CI)+H]+ = 519.03
300 A-1-58 B-3-1 1 F (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3- fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 497.09
301 A-1-58 B-3-6 F (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy- pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 480.09
General Method I for Amide Formation: PyBOP/DIPEA
Example 302: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-[1 ,2,4]oxadiazol-3-yl)- pyrrolidin-1 -yl]-methanone
Step A: PyBOP (124 mg, 0.24 mmol) was added to a 0°C solution of C-2-1 (50 mg, 0.16 mmol), benzoic acid (30 mg, 0.25 mmol) and DIPEA (82 uL, 0.48 mmol) in DCM (2.0 mL). The resulting mixture was stirred at rt for 3h, then water was added. The org. layer was separated and the aq. layer was extracted with DCM (2x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give (S)-/V-(benzoyloxy)-1 -(5-methyl-2-(2/-/- 1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carboximidamide C-4-1 that was used further without purification.
Step B: The crude C-4-1 was dissolved in dioxane (2.0 mL) and heated to reflux (90°C) for 18h to 4 days. The solvent was removed in vacuo and the residue was purified by prep. HPLC (method G) to give the title compound as an off-white solid. LC-MS B: tR = 0.86 min; [M+H]+ = 401.12.
General Method J for Amide Formation: TBTU/DIPEA
Example 303: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)- [1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1 -yl}-methanone
Step A: TBTU (567 mg, 1.76 mmol) was added to a rt solution of 2-(trifluoromethoxy)benzoic acid (250 mg, 1.18 mmol) and DIPEA (0.60 mL, 3.53 mmol) in DCM (6.0 mL). After stirring for 15 min, a solution of C-2-1 (509 mg, 1 .29 mmol) in DCM (1 .0 mL) and DMF (0.3 mL) was added. The resulting mixture was stirred at rt for 1 h, then diluted with DCM and water. The layers were separated and the aq. layer extracted with DCM (1x). The combined org. extracts were washed with brine, dried (MgS04), filtered and concentrated in vacuo to give (S)-1-(5- methyl-2-(2H-1 ,2,3-triazol-2-yl)benzoyl)-/V-((2-(triflu^
carboximidamide C-4-2 that was used further without purification.
Step B: The crude C-4-2 was dissolved in dioxane (7.0 ml.) and heated to reflux (90°C) for 18h to 4 days. The solvent was removed in vacuo and the residue was purified by FC (EtOAc/hept 3:2) to give the title compound as a colorless paste. LC-MS A: tR = 0.98 min; [M+H]+ = 484.96.
General Method K for Amide Formation: EDC/ HOBt
Example 304: (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1 -yl}-methanone
Step A: EDC (59 mg, 0.31 mmol) was added to a rt solution of indazole-3-carboxylic acid (40 mg, 0.25 mmol), HOBT (40 mg, 0.30 mmol) and DIPEA (63 uL, 0.37 mmol) in DCM (1.8 ml_). After stirring for 10 min, C-2-1 (86 mg, 0.259 mmol) was added. The resulting mixture was stirred at rt for 18h, then diluted with DCM and water. The layers were separated and the aq. layer extracted with DCM (1 x). The combined org. extracts were washed with brine, dried (MgS04), filtered and concentrated in vacuo to give (S)-1 -(4,5-dimethyl-2-(2H-1 ,2,3-triazol-2- yl)benzoyl)-/V-((2-(trifluoromethoxy)benzoyl)oxy)pyrrolidine-2-carboximidamide C-4-3 that was used further without purification.
Step B: The crude C-4-3 was dissolved in dioxane (3.5 ml.) and heated to reflux (90°C) for 2 days. The solvent was removed in vacuo and the residue was purified by prep. HPLC (method F) to give the title compound as a foam. LC-MS A: tR = 0.86 min; [M+H]+ = 441.08.
Listed in Table 26 below are compounds of structure of formula (I), prepared according to the above procedure.
Table 26
Ex. SM SM GM Compound of Formula (I)
No. C-2 C-3
305 C-2-1 O I (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-m-tolyl- [1 ,2,4]oxadiazol-3-yl)-pyrrolidin-1-yl]-methanone;
LC-MS B: tR = 0.92 min; [M+H]+ = 415.26
306 C-2-1 0 J {(S)-2-[5-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-
(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 444.96
307 C-2-1 J {(S)-2-[5-(2,3-Dihydro-benzofuran-7-yl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-(5-methyl-2-[1,2,3]triazol-2-yl-phenyl)-
Figure imgf000171_0001
methanone; LC-MS A: tR = 0.90 min; [M+H]+ = 442.93
Figure imgf000172_0001
General Method L for Amide Formation: TBTU/DIPEA DMF
Example 318: {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1 -yl}- (5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
TBTU (664 mg, 2.07 mmol) was added to a rt solution of carboxylic acid A-1 (350 mg, 1 .72 mmol) and DI PEA (1 .47 ml_, 8.61 mmol) in DMF (5 mL) and after stirring for 10 min, D-4-1 (743 mg, 1 .72 mmol) was added. The resulting mixture was stirred at rt for 2h, then the rxn mixture was concentrated, dissolved in DMF and purified by prep. HPLC (method G) to give the title compound as an off-white solid. LC-MS B: tR = 0.99 min; [M(35CI)+H]+ = 449.91 .
Listed in Table 27 below are compounds of structure of formula (I), prepared according to the above procedure (General Method L).
Table 27
Ex. SM SM Compound of Formula (I)
No. D-4 A-1
319 D-4-3 A-1 -2 {(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 463.12
320 D-4-1 A-1 -1 1 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 479.10
321 D-4-1 A-1 -6 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5- dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.03 min; [M(35CI)+H]+ = 463.10
322 D-4-1 A-1 -26 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 483.09
323 D-4-3 A-1 -1 1 {(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 493.14
324 D-4-3 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 477.16
325 D-4-3 A-1 -26 {(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-
5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 496.98 326 D-4-3 A-1 -10 {(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 479.12
327 D-4-3 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 483.08
328 D-4-3 A-1 -3 {(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 463.10
329 D-4-3 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 483.08
330 D-4-4 A-1 -2 {(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.92 min; [M+H]+ = 446.12
331 D-4-4 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.96 min; [M+H]+ = 460.16
332 D-4-4 A-1 -26 {(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-5- methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.92 min; [M+H]+ = 480.14
333 D-4-5 A-1 -55 {(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 419.02
334 D-4-6 A-1 -4 {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.90 min; [M+H]+ = 435.04
335 D-4-5 A-1 -4 {(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.98 min; [M+H]+ = 432.99
336 D-4-6 A-1 -2 {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 449.01
337 D-4-5 A-1 -2 {(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.98 min; [M+H]+ = 433.04 338 D-4-6 A-1 -3 {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 449.00
339 D-4-5 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]tnazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 447.10
340 D-4-6 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]tnazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 463.10
341 D-4-6 A-1 -1 1 {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 479.10
342 D-4-5 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 453.03
343 D-4-6 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 469.03
344 D-4-4 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [M(35CI)+H]+ =465.74
345 D-4-4 A-1 -3 {(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.92 min; [M(35CI)+H]+ =446.09
346 D-4-4 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 465.78
347 D-4-13 A-1 -59 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 515.00
348 D-4-13 A-1 -1 1 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.0 min; [M(35CI)+H]+ = 495.05
349 D-4-13 A-1 -16 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 484.98 350 D-4-12 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 495.05
351 D-4-13 A-1 -2 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 464.97
352 D-4-10 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 495.04
353 D-4-1 1 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 495.06
354 D-4-13 A-1 -3 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 465.00
355 D-4-14 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 495.05
356 D-4-14 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 459.10
357 D-4-13 A-1 -5 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.98 min; [M(35CI)+H]+ = 484.98
358 D-4-14 A-1 -1 1 {(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 475.12
359 D-4-14 A-1 -2 {(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 445.08
360 D-4-13 A-1 -6 {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5- dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 479.04
361 D-4-14 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 465.01 362 D-4-14 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 464.99
363 D-4-6 A-1 -61 (3-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.91 min; [M(35CI)+H]+ = 469.01
364 D-4-14 A-1 -3 {(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 445.08
365 D-4-2 A-1 -58 (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.03 min; [M(35CI)+H]+ = 519.03
366 D-4-3 A-1 -58 (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 497.08
367 D-4-1 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-chloro-2-methyl- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 499.03
368 D-4-6 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 499.04
369 D-4-3 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 512.96
370 D-4-4 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 496.06
371 D-4-1 A-1 -58 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.05 min; [[M(35CI)+H]+ = 483.01
372 D-4-5 A-1 -26 (4-Fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 467.05
373 D-4-6 A-1 -26 {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 483.06 374 D-4-2 A-1 -3 (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 485.06
375 D-4-2 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 535.02
376 D-4-2 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 505.01
377 D-4-2 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 505.01
378 D-4-6 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 469.02
379 D-4-5 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.0 min; [M(35CI)+H]+ = 453.02
380 D-4-4 A-1 -58 (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.98 min; [M(35CI)+H]+ = 480.09
381 D-4-12 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 465.00
382 D-4-10 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 459.11
383 D-4-1 1 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 459.11
384 D-4-12 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 459.10
385 D-4-10 A-1 -1 1 {(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 475.12 386 D-4-1 1 A-1 -1 1 {(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M+H]+ = 475.11
387 D-4-12 A-1 -1 1 {(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 475.11
388 D-4-7 A-1 -2 {(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: fo 1.00= min; [M+H]+ = 428.495
389 D-4-8 A-1 -2 {(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 429.07
390 D-4-9 A-1 -2 {(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 429.07
391 D-4-7 A-1 -3 {(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 1.00 min; [M+H]+ = 429.07
392 D-4-8 A-1 -3 {(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.99 min; [M+H]+ = 429.07
393 D-4-9 A-1 -3 {(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.98 min; [M+H]+ = 429.07
394 D-4-7 A-1 -3 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 449.06
395 D-4-8 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazol-3- yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 448.97
396 D-4-9 A-1 -3 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 448.97
397 D-4-7 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 449.03
398 D-4-8 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazol-3- yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 449.02
399 D-4-9 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 449.04
400 D-4-7 A-1 -6 {(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl- 2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 1.02 min; [M+H]+ = 443.09 401 D-4-8 A-1 -6 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M+H]+ = 443.11
402 D-4-9 A-1 -6 {(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl- 2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 1.01 min; [M+H]+ = 443.09
403 D-4-7 A-1 -1 1 {(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: = 1.01 min; [M+H]+ = 459.11
404 D-4-8 A-1 -1 1 {(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: = 1.01 min; [M+H]+ = 459.11
405 D-4-9 A-1 -1 1 {(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 459.10
406 D-4-7 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 479.06
407 D-4-8 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 479.07
408 D-4-9 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 479.05
409 D-4-10 A-1 -2 {(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 445.10
410 D-4-1 1 A-1 -2 {(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 445.09
411 D-4-12 A-1 -2 {(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 445.09
412 D-4-10 A-1 -3 {(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 445.08 413 D-4-1 1 A-1 -3 {(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.97 min; [M+H]+ = 445.09
414 D-4-12 A-1 -3 {(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 445.08
415 D-4-10 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 464.99
416 D-4-1 1 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 465.00
417 D-4-12 A-1 -5 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 465.03
418 D-4-10 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 465.00
419 D-4-1 1 A-1 -16 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-
[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 465.00
General Method M for Amide Formation: TBTU/DIPEA DMF
Example 420: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-phenyl-isoxazol-5-yl)- pyrrolidin-1 -yl]-methanone
TBTU (58 mg, 0.18 mmol) was added to a rt solution of carboxylic acid A-1 -2 (31 mg, 0.15 mmol) and DI PEA (77ul, 0.45 mmol) in DMF (0.5 mL), the rxn mixture was stirred at rt for 10 min, before E-4-1 (32 mg, 0.15 mmol) was added and stirring was continued for 18h. The rxn mixture was directly purified by prep. HPLC (method G) to give the title compound as an off- white foam. LC-MS B: tR = 0.85 min; [M+H]+ = 400.10.
Listed in Table 28 below are compounds of structure of formula (I), prepared according to the above procedure (General Method M). Table 28
Ex. SM SM Compound of Formula (I)
No. E-4 or A-1
E7
421 E-4-1 A-1 -57 [5-(3-Chloro-phenyl)-2-methyl-thiazol-4-yl]-[(S)-2-(3-phenyl-isoxazol-5-yl)- pyrrolidin-1 -yl]-methanone; LC-MS B: tR = 0.91 min; [M(35CI)+H]+ = 449.67
422 E-4-2 A-1 -2 {(S)-2-[3-(2,3-Dimethyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.92 min; [M+H]+ = 427.98
423 E-4-3 A-1 -2 {(S)-2-[3-(3,5-Dimethyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.95 min; [M+H]+ = 427.99
424 E-4-4 A-1 -2 {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.95 min; [M(35CI)+H]+ = 447.93
425 E-4-5 A-1 -2 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)- isoxazol-5-yl]-pyrrolidin-1-yl}-methanone;
LC-MS B: tR = 0.94 min; [M+H]+ = 483.98
426 E-4-7 A-1 -2 {(S)-2-[3-(2-Methoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.81 min; [M+H]+ = 430.91
427 E-4-6 A-1 -2 {(S)-2-[3-(2-lsopropoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.92 min; [M+H]+ = 458.97
428 E-4-8 A-1 -2 {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.87 min; [M+H]+ = 444.99
429 E-4-9 A-1 -2 {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-
2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.89 min; [M+H]+ = 447.97
430 E-8-1 A-1 -2 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-isoxazol-3-yl)-pyrrolidin- 1-yl]-methanone; LC-MS A: tR = 0.93 min; [M+H]+ = 400.09
431 E-8-2 A-1 -2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 448.10 432 E-8-1 A-1 -1 1 (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-isoxazol-3- yl)-pyrrolidin-1-yl]-methanone; LC-MS A: tR = 0.95 min; [M+H]+ = 430.11
433 E-8-2 A-1 -1 1 {(S)-2-[5-(3-Chloro-2-rnethyl-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-
4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 1.01 min; [M(35CI)+H]+ = 478.12
434 E-8-3 A-1 -2 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)- isoxazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00. min; [M+H]+ = 484.14
435 E-8-3 A-1 -3 (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)- isoxazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.00 min; [M+H]+ = 484.13
436 E-8-3 A-1 -1 1 (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M+H]+ = 513.99
437 E-8-3 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 534.03
General Method N for Amide Formation: TBTU/DIPEA DMF or PCM
Example 438: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-m-tolyl-[1 ,3,4]oxadiazol-2- yl)-pyrrolidin-1 -yl]-methanone
TBTU (56 mg, 0.174 mmol) was added to a rt solution of carboxylic acid A-1 -2 (29 mg, 0.15 mmol) and DI PEA (70 uL, 0.43 mmol) in DMF (1 mL) and the rxn mixture was stirred for 10 min, before F-4-2 (33 mg, 0.15 mmol) was added and stirring continued for 1 h. The rxn mixture was directly purified by prep. HPLC (method G) to give the title compound as a colorless oil. LC-MS B: tR = 0.82 min; [M+H]+ = 415.23.
Listed in Table 29 below are compounds of structure of formula (I), prepared according to the above procedure (General Method M).
Table 29
Ex. SM SM Compound of Formula (I)
No. F-4 A-1
439 F-4-1 A-1 -2 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-[1 ,3,4]oxadiazol-2-yl)- pyrrolidin-1-yl]-methanone; LC-MS B: tR = 0.77 min; [M+H]+ = 401.16 440 F-4-3 A- 1 -2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS B: tR = 0.93 min; [M(35CI)+H]+ = 448.98
441 F-4-4 A-1 -2- (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-o-tolyl-[1 ,3,4]oxadiazol-2-yl)- pyrrolidin-1-yl]-methanone; LC-MS A: tR = 0.88 min; [M+H]+ = 415.08
442 F-4-5 A-1 -2 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 485.06
443 F-4-5 A-1 -44 [5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 519.01
444 F-4-5 A-1 -46 [5-(2-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.94 min; [M+H]+ = 519.01
445 F-4-3 A-1 -1 1 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 479.06
446 F-4-3 A-1 -59 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-chloro-2-methyl- phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.97 min; [M(35CI)+H]+ = 498.97
447 F-4-3 A- 1 -6 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-(4,5- dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 463.07
Example 448: {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1 - yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
Step A: PyBOP (78 mg, 0.15 mmol) was added to a rt solution of 3-fluoro-2-methoxybenzoic acid (20 mg, 0.12 mmol) and DI PEA (60 uL, 0.35 mmol) in DCM. The rxn mixture was stirred for 10 min, then G-3-1 (36 mg, 0.12 mmol) was added and stirring continued overnight. The mixture was concentrated to yield crude (S)-/\/'-(3-fluoro-2-methoxybenzoyl)-1 -(5-methyl-2-(2/-/- 1 ,2,3-triazol-2-yl)benzoyl)pyrrolidine-2-carbohydrazide G-4-1 which was used further without purification. LC-MS A: tR = 0.80 min; [M+H]+ = 467.09.
Step B: Burgess' reagent (55 mg, 0.23 mmol) was added to a rt solution of crude G-4-1 in dioxane (2.0 mL) and the rxn mixture was irradiated in the microwave at 1 10°C for 30 min to 1 h, then the rxn mixture was concentrated, dissolved in DMF and directly purified by prep. HPLC (method G) to yield the title compound as a yellow solid. LC-MS A: tR = 0.87 min; [M = 449.00.
Listed in Table 30 below are compounds of structure of formula (I), prepared according to the above procedure (Example 448), using hydrazide G-3-1.
Table 30
Figure imgf000185_0001
Example 458: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)- [1 ,3,4]thiadiazol-2-yl]-pyrrolidin-1 -yl}-methanone
TBTU (80 mg, 0.25 mmol) was added to a rt solution of carboxylic acid A-1 -2 (39 mg, 0.19 mmol) and DIPEA (80 uL, 0.48 mmol) in DMF (0.7 ml_). After 15 min, H-2-1 (65 mg, 0.21 mmol) was added and the resulting mixture was stirred at rt for 2h. The rxn mixture was directly purified by prep. HPLC (method F) to give the title compound as white solid. LC-MS A: tR = 0.98 min; [M+H]+ = 501.08.
Example 459: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(4-phenyl-oxazol-2-yl)- pyrrolidin-1 -yl]-methanone
Boron trifluoride diethyl etherate (5 drops) was added to a rt solution of 1-2-1 (413 mg, 0.67 mmol) and acetamide (204 mg, 3.45 mmol) in diethylether (2.5 ml.) and o-xylene (1.5 ml_). The yellow solution was stirred at 120°C overnight and at 140°C for another 24h. The rxn mixture was diluted with EtOAc and washed with water (1x). The org. layer was concentrated in vacuo and the residue was purified by prep. HPLC (method E) to give the title compound as an off- white solid. LC-MS A: tR = 0.90 min; [M+H]+ = 400.13.
Example 460: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[4-(2-trifluoromethoxy-phenyl)- oxazol-2-yl]-pyrrolidin-1 -yl}-methanone
The title compound was prepared from I-2-2 in analogy to the procedure described for Example 459. LC-MS A: tR = 1 .00 min; [M+H]+ = 484.10.
Example 461 : (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-oxazol-2-yl)- pyrrolidin-1 -yl]-methanone
Polyphosphoric acid (4.08 g, 17 mmol) was added to J-2-1 (337 mg, 0.50 mmol) at rt and the solution was heated to 150°C for 1 h. The rxn mixture was poured into ice-water and basified with sat. aq. Na2C03. The aq. layer was extracted with EtOAc (2x) and the combined org. extracts were dried (MgS04), filtered and concentrated in vacuo. The residue was purified by prep. HPLC (method G) to yield the title compound as a yellow solid. LC-MS A: tR = 0.86 min; [M+H]+ = 400.14.
Example 462: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-o-tolyl-oxazol-2-yl)- pyrrolidin-1 -yl]-methanone
The title compound was prepared from J-2-2 in analogy to the procedure described for Example 461. LC-MS A: tR = 0.92 min; [M+H]+ = 413.48.
General Method O for Amide Formation: TBTU/DIPEA DMF or PCM
Example 463: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-4H-[1 ,2,4]triazol-3-yl)- pyrrolidin-1 -yl]-methanone
TBTU (56 mg, 0.17 mmol) was added to a rt solution of carboxylic acid A-1 -2 (29 mg, 0.15 mmol) and DIPEA (70 uL, 0.43 mmol) in DMF (1 mL). After stirring for 10 min, K-2-2 (33 mg, 0.15 mmol) was added and the resulting mixture was stirred at rt for 1 h, then the rxn mixture was directly purified by prep. HPLC (method G) to give the title compound as a colorless oil. LC-MS: tR = 0.80 min; [M+H]+ = 400.07.
General Method P for Amide Formation: EDC/HOBt DMF or PCM
Example 464: {(S)-2-[5-(2-Methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1 -yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
EDC-HCI (71 mg, 0.37 mmol) was added to a rt solution of A-1 -2 (30 mg, 0.148 mmol), HOBT (24 mg, 0.18 mmol) and DIPEA (50 uL, 0.30 mmol) in DMF (1 ml.) and the rxn mixture was stirred for 5 min before K-2-8 (40 mg, 0.16 mmol) was added and stirring continued for 1 h. The mixture was directly purified by prep. HPLC (method F) to give the title compound as an off- white solid. LC-MS A: tR = 0.80 min; [M+H]+ = 430.1 1 .
Listed in Table 31 below are compounds of structure of formula (I), prepared according to the above procedures (General Method O or P).
Table 31
Ex. SM SM GM Compound of Formula (I)
No. A-1 K-2
465 A-1 -2 K-2-1 O (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.82 min; [M+H]+ = 484.09
466 A- 1 -6 K-2-8 P (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)- 4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.83 min; [M+H]+ = 444.15
467 A-1 -59 K-2-8 P (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.84 min; [M(35CI)+H]+ = 480.12
468 A-1 -1 1 K-2-8 P (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.83 min; [M+H]+ = 460.17
469 A-1 -58 K-2-8 P (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.87 min; [M(35CI)+H]+ = 464.12
470 A-1 -16 K-2-8 P (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H- [1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.78 min; [M(35CI)+H]+ = 449.95 471 A- 1 -3 K-2-8 P {(S)-2-[5-(2-Methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.80 min; [M+H]+ = 430.13
472 A-1 -59 K-2-7 P (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2- rnethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.87 min; [M(35CI)+H]+ = 498.00
473 A-1 -1 1 K-2-7 P {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin- 1-yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-rnethanone; LC-MS A: tR = 0.87 min; [M+H]+ = 478.17
474 A- 1 -6 K-2-7 P (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.87 min; [M+H]+ = 462.17
475 A-1 -58 K-2-7 P (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2- methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.90 min; [M(35CI)+H]+ = 482.01
476 A-1 -16 K-2-7 P (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.86 min; [M(35CI)+H]+ = 468.10
477 A- 1 -3 K-2-7 P {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-
1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.84 min; [M+H]+ = 448.14
478 A-1 -59 K-2-6 P (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy- pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.86 min; [M(35CI)+H]+ = 495.13
479 A-1 -1 1 K-2-6 P {(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5- methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.85 min; [M+H]+ = 475.17
480 A- 1 -6 K-2-6 P (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3- yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 459.18
481 A-1 -16 K-2-6 P (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-
4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.85 min; [M(35CI)+H]+ = 465.03
482 A- 1 -3 K-2-6 P {(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.82 min; [M+H]+ = 445.15 483 A-1 -63 K-2-1 0 (5-Phenyl-thiazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-
[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 485.92
484 A-1 -64 K-2-1 0 (5-Phenyl-oxazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-
[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.84 min; [M+H]+ = 470.03
485 A-1 -65 K-2-1 0 (5-m-Tolyl-thiazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-
[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 500.00
486 A-1 -42 K-2-1 0 (5-m-Tolyl-oxazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-
[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.87 min; [M+H]+ = 484.00
487 A-1 -58 K-2-6 P (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy- pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.82 min; [M+H]+ = 479.14
488 A- 1 -2 K-2-9 P {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-
1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 464.11
489 A- 1 -3 K-2-9 P {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-
1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 464.12
490 A-1 -1 1 K-2-9 P {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin- 1-yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.83 min; [M+H]+ = 494.11
491 A-1 -59 K-2-9 P {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin- 1-yl}-(4-chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.85 min; [M+H]+ = 513.95
492 A- 1 -6 K-2-9 P {(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin- 1-yl}-(4,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.90 min; [M+H]+ = 478.15
493 A- 1 -2 K-2-3 0 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1- yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.89 min; [M(35CI)+H]+= 448.08
494 A- 1 -2 K-2-4 0 {(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1- yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 432.06 495 A- 1 -2 K-2-5 0 {(S)-2-[5-(2-Ethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.85 min; [M+H]+ = 444.19
496 A- 1 -2 K-2-6 0 {(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.82 min; [M+H]+ = 445.06
497 A- 1 -2 K-2-7 0 {(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin- 1 -yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.84 min; [M+H]+ = 448.08
498 A- 1 -6 K-2-1 0 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 497.68
499 A-1 -1 1 K-2-1 0 (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2- trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.93 min; [M+H]+ = 513.61
500 A-1 -58 K-2-1 0 (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2- trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 517.91
501 A- 1 -3 K-2-1 0 (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.9 min; [M+H]+ = 484.01
502 A-1 -16 K-2-1 0 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.92 min; [M(35CI)+H]+ = 503.89
503 A- 1 -4 K-2-1 0 (2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-
[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.86 min; [M+H]+ = 470.08
504 A- 1 -5 K-2-1 0 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone; LC-MS A: tR = 0.92 min; [M(35CI)+H]+ = 503.93
505 A-1 -53 K-2-1 0 (2-Methyl-5-m-tolyl-oxazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 497.78
506 A-1 -62 K-2-1 0 (2-Methyl-5-phenyl-thiazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 500.05 507 A-1 -54 K-2-1 0 (2-Methyl-5-m-tolyl-thiazol-4-yl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-
4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.91 min; [M+H]+ = 513.64
508 A-1 -52 K-2-1 0 Biphenyl-2-yl-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3- yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.95 min; [M+H]+ = 479.03
509 A-1 -59 K-2-1 0 (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2- trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}- methanone; LC-MS A: tR = 0.93 min; [M(35CI)+H]+ = 533.95
510 A-1 -18 K-2-1 0 (2-Methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ = 485.10
General Method Q for Triazole Formation:
Example 511 : {(S)-2-[5-(3,5-Dimethyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1 -yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
K2C03 (9 mg, 0.07 mmol) was added to a rt solution of F-1 -11 (20 mg, 0.12 mmol), C-1 (65 mg, 0.24 mmol) in n-BuOH (0.8 mL) and the resulting mixture was irradiated at 145°C for 30 min in the mW (with cooling function), followed by irradiation at 160°C for 1 h without cooling function). The mixture was concentrated in vacuo, DCM was added and acidified with 2N aq. HCI. The org. layer was separated and the inorg. layer was extracted with DCM (2x). The combined org. extracts were dried (MgS04), filtered and concentrated. The crude was purified by prep. HPLC (method F), followed by FC (EtOAc/hept 9: 1 ) to give the title compound as a white solid. LC-MS A: tR = 0.88 min; [M+H]+ = 428.12.
Listed in Table 32 below are compounds of structure of formula (I), prepared according to the above procedures (General Method Q).
Table 32
Ex. SM SM Compound of Formula (I)
No. C-1 F-1
512 C-1 F-1 -12 {(S)-2-[5-(2-Ethyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.87 min; [M+H]+ = 428.15
513 C-1 F-1 -13 {(S)-2-[5-(3-Methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.82 min; [M+H]+ = 430.51 514 C-1 F-1 -14 {(S)-2-[5-(4-Methoxy-phenyl) H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.80 min; [M+H]+ = 430.11
515 C-1 F-1 -15 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-propoxy-phenyl)-4H-
[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.89 min; [M+H]+ =458.18
General Method R for Amid Formation HATU/DIPEA:
Example 516: {(S)-2-[5-(2-Methoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1 -yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone
HATU (40 mg, 0.1 1 mmol) was added to a rt solution of A-1 -2 (20 mg, 0.1 mmol) and DI PEA (40 uL, 0.23 mmol) in DMF (0.5 mL) and the resulting mixture was stirred for 5 min before a solution of L-4-6 (30 mg, 0.10 mmol) and DI PEA (40 uL, 0.234 mmol) in DMF (0.5 mL) was added. The rxn mixture was stirred at rt for 48h, then directly purified by prep. HPLC (method E) to yield the title compound as a yellow oil. LC-MS A: tR = 0.72 min; [M+H]+ = 429.06.
Listed in Table 33 below are compounds of structure of formula (I), prepared according to the above procedures (General Method R).
Table 33
Ex. SM SM Compound of Formula (I)
No. A-1 L-4 or
M-5
517 A- 1 -3 L-4-5 (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-1 H- imidazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.75 min; [M+H]+ = 483.14
518 A- 1 -3 L-4-3 {(S)-2-[5-(2-Ethoxy-phenyl)-1H-imidazol-2-yl]-pyrrolidin-1-yl}-(4-methyl-2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.75 min; [M+H]+ = 443.17
519 A-1 -2 M-4-1 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(2-phenyl-3H-imidazol-4-yl)- pyrrolidin-1 -yl]-methanone; LC-MS A: tR = 0.67 min; [M+H]+ = 399.11
520 A- 1 -3 M-4-1 (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(2-phenyl-3H-imidazol-4-yl)- pyrrolidin-1 -yl]-methanone; LC-MS A: tR = 0.67 min; [M+H]+ = 399.11
521 A-1 -2 M-4-2 {(S)-2-[2-(3-Chloro-2-methyl-phenyl)-3H-imidazol-4-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.71 min; [M(35CI)+H]+ = 447.08 522 A- 1 -3 M-4-2 {(S)-2-[2-(3-Chloro-2-methyl-phenyl)-3H-imidazol-4-yl]-pyrrolidin-1-yl}-(4- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: to = 0.71 min; [M(35CI)+H]+ = 447.11
523 A- 1 -2 L-4-7 {(S)-2-[5-(3-Chloro-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.73 min; [M(35CI)+H]+ = 432.95
524 A- 1 -2 L-4-8 {(S)-2-[5-(3-Methoxy-phenyl)-1 H-imidaz^
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.71 min; [M+H]+ = 429.22
525 A- 1 -2 L-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(5- methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.73 min; [M+H]+ = 447.08
526 A- 1 -2 L-4-3 {(S)-2-[5-(2-Ethoxy-phenyl)-1H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone; LC-MS A: tR = 0.75min; [M+H]+ =443.03
527 A- 1 -2 L-4-1 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-1 H-imidazol-2-yl)- pyrrolidin-1 -yl]-methanone; LC-MS A: tR = 0.68 min; [M+H]+ = 399.09
528 A- 1 -2 L-4-4 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethyl-phenyl)-1 H- imidazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.73 min; [M+H]+ = 467.10
529 A- 1 -2 L-4-5 (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-1 H- imidazol-2-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.75 min; [M+H]+ = 483.10
General Method S for Amid Formation HATU/DIPEA:
Example 530: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-2H-pyrazol-3-yl)- pyrrolidin-1 -yl]-methanone
HATU (90 mg, 0.24 mmol) was added to a rt solution of A-1 -2 (40 mg, 0.20 mmol), N-3-1 (56 mg, 0.20 mmol) and DIPEA (168 uL, 0.98 mmol) in DMF (0.7 mL) and the resulting rxn mixture was stirred at rt overnight. The rxn mixture was directly purified by prep. HPLC (method G) to give the title compound as a yellow oil. LC-MS A: tR = 0.86 min; [M+H]+ = 399.1
Listed in Table 34 below are compounds of structure of formula (I), prepared according to the above procedures (General Method S). Table 34
Figure imgf000194_0001
Example 535: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(1 -phenyl-1 H-[1 ,2,4]triazol-3-yl)- pyrrolidin-1 -yl]-methanone
TBTU (62 mg, 0.19 mmol) was added to a rt solution of A-1 -2 (32 mg, 0.15 mmol) and DIPEA (64 uL, 0.37 mmol) in DMF (0.6 mL) and the resulting mixture was stirred for 20 min at rt before a solution of 0-4-1 (51 mg, 0.18 mmol) and DIPEA (41 uL, 0.18 mmol) in DMF (0.5 mL) was added and stirring was continued for 1.5h. The rxn mixture was purified by prep. HPLC (method F), followed by FC (EtOAc/hept 24/1 ) to give the title compound as a white solid. LC-MS A: tR = 0.78 min; [M+H]+ = 400.06.
Example 536: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(1 -phenyl-1 H-[1 ,2,3]triazol-4-yl)- pyrrolidin-1 -yl]-methanone
HATU (46 mg, 0.12 mmol) was added to a rt solution of A-1 -2 (20 mg, 0.1 mmol), P-3-1 (30 mg, 0.12 mmol) and DIPEA (86 uL, 0.5 mmol) in DMF (1.0 mL) and the rxn mixture was stirred at rt overnight. The rxn mixture was directly purified by prep. HPLC (method E), to give the title compound as an orange oil. LC-MS A: tR = 0.85 min; [M+H]+ = 400.05.
General Method T for Amid Formation TBTU/DIPEA in DMF
Example 537: [(S)-2-Methyl-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]-(2- [1 ,2,3]triazol-2-yl-phenyl)-methanone
TBTU (58 mg, 0.18 mmol) was added to a rt solution of A-1 -4 (28 mg, 0.15 mmol) and DIPEA (77 uL, 0.45 mmol) in DMF (0.5 mL) and the resulting mixture was stirred for 5 min at rt before Q-4 (34 mg, 0.15 mmol) was added and stirring was continued at rt overnight. The rxn mixture was purified by prep. HPLC (method G) to give the title compound as an off-white foam. LC-MS B: tR = 0.86 min; [M+H]+ = 401.02.
Listed in Table 35 below are compounds of structure of formula (I), prepared according to the above procedure (General Method T).
Table 35
Figure imgf000195_0001
Example 540: [(S)-2-Methyl-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]-(5-methyl-2- [1 ,2,3]triazol-2-yl-phenyl)-methanone
Step A: PyBOP (104 mg, 0.2 mmol) was added to a rt solution of Q-5 (52 mg, 0.17 mmol) and DIPEA (86 uL, 0.5 mmol) in DCM (3 mL) and after stirring for 10 min, commercially available benzamidoxime (23 mg, 0.17 mmol) was added and the resulting mixture was stirred at rt for 2h. The mixture was concentrated in vacuo to give the crude product Q-6 that was used further without purification.
Step B: The crude Q-6 was dissolved in dioxane (1 .3 mL) and pyridine (0.3 mL) and heated to reflux (90°C) for 2 days. The solvent was removed in vacuo and the residue was purified by FC (EtOAc/hex 5:3) to give the title compound as a yellowish foam. LC-MS A: tR = 0.96 min; [M+H]+ = 415.08.
Example 541 : {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-2-methyl- pyrrolidin-1 -yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone
The title compound 541 was prepared from Q-5 and A-4-27 in analogy to the above described method (see example 540). LC-MS A: tR = 1 .02. min; [M(35CI)+H]+ = 463.02.
General Method U for Amid Formation HATU/DIPEA in DMF
Example 542: (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2- trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1 -yl}-methanone
HATU (23 mg, 0.06 mmol) was added to a rt solution of A-1 -2 (10 mg, 0.05 mmol), R-4-1 (16 mg, 0.05 mmol) and DIPEA (26 uL, 0.15 mmol) in DMF (0.5 mL) and the resulting rxn mixture was stirred at rt overnight. To the rxn mixture was added NH4OH (250 uL) to eliminate a sideproduct, followed by the addition of formic acid (500 uL). The crude was purified by prep. HPLC (method E) to give the title compound as a yellow oil. LC-MS A: tR = 0.93 min; [M+H]+ = 498.14.
Listed in Table 36 below are compounds of structure of formula (I), prepared according to the above procedure (General Method U).
Table 36
Ex. SM SM Compound of Formula (I)
No. A-1 R-4
543 A- 1 -3 R-4-1 (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.93 min; [M+H]+ = 498.14
544 A-1 -16 R-4-1 (4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.94 min; [M(35CI)+H]+ = 518.18
545 A-1 -58 R-4-1 (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2- trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.98 min; [M(35CI)+H]+ =532.27
546 A- 1 -6 R-4-1 (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2- trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 0.96 min; [M+H]+ = 512.32
547 A- 1 -5 R-4-1 (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy- phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1 -yl}-methanone;
LC-MS A: tR = 0.94 min; [M(35CI)+H]+ = 518.26
548 A-1 -66 R-4-1 (5-Methyl-biphenyl-2-yl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H- [1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: to = 1.0 min; [M+H]+ = 507.32
549 A-1 -35 R-4-1 (4-Methyl-biphenyl-2-yl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H- [1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone;
LC-MS A: tR = 1.0 min; [M+H]+ = 507.34
550 A- 1 -2 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin- 1 -yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.91 min; [M(35CI)+H]+ = 462.27
551 A- 1 -3 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-
1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.91 min; [M(35CI)+H]+ = 462.26 552 A- 1 -58 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-
1-yl}-(5-chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.96 min; [M(35CI)+H]+ = 496.26
553 A- 1 -6 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-
1-yl}-(4,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.94 min; [M(35CI)+H]+ = 476.32
554 A- 1 -5 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin- 1 -yl}-(5-chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.92 min; [M(35CI)+H]+ = 482.12
555 A-1 -16 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin- 1 -yl}-(4-chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
LC-MS A: tR = 0.92 min; [M(35CI)+H]+ = 482.12
556 A- 1 -35 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-
1-yl}-(4-methyl-biphenyl-2-yl)-methanone;
LC-MS A: tR = 0.99 min; [M(35CI)+H]+ = 471.30
557 A- 1 -66 R-4-2 {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-
1-yl}-(5-methyl-biphenyl-2-yl)-methanone;
LC-MS A: tR = 0.98 min; [M(35CI)+H]+ = 471.29
Reference compounds
Figure imgf000197_0001
Ref. compound 1 Ref. compound 2 Ref. compound 3
Figure imgf000197_0002
Ref. compound 4 Ref. compound 5 Ref. compound 6
Figure imgf000198_0001
Figure imgf000198_0002
Ref. compound 10
Reference compound 1 : [(S)-2-(3-Phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]-thiophen- 2-yl-methanone
Step A: (S)-Methyl 1 -(thiophene-2-carbonyl)pyrrolidine-2-carboxylate: TBTU (3.96 g, 12.3 mmol) was added to a rt solution of 2-thiophenecarboxylic acid (1.32 g, 10.3 mmol) and DIPEA (5.3 mL, 30.8 mmol) in DCM (70 mL) and the resulting mixture was stirred at rt for 15 min, before S-proline methyl ester HCI (1.70 g, 10.3 mmol) was added. After stirring at rt overnight, the rxn mixture was diluted with water, the org. layer separated and the aq. layer extracted with DCM (2x). The combined extracts were dried (MgS04), filtered and concentrated in vacuo and purified by FC (Biotage SP1 : EtOAc/hex 1 :4 to 1 :2) to yield (S)-methyl 1 -(thiophene-2- carbonyl)pyrrolidine-2-carboxylate as a brownish oil. LC-MS B: tR = 0.54 min; [M+H]+ = 240.23. Step B: (S)-1 -(Thiophene-2-carbonyl)pyrrolidine-2-carboxylic acid: 1 M aq. NaOH (20 mL) was added to (S)-methyl 1-(thiophene-2-carbonyl)pyrrolidine-2-carboxylate (2.48 g, 10.3 mmol) in THF (50 mL) and the resulting mixture was stirred at rt overnight. The rxn mixture was cooled to 0°C, acidified with 1 M aq. HCI (20 mL) to reach pH 1 and extracted with DCM (3x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give (S)-1- (thiophene-2-carbonyl)pyrrolidine-2-carboxylic acid as a white solid that was used without further purification. LC-MS B: tR = 0.45 min; [M+H]+ = 226.21 .
Step C: (S)-A -((1 -(Thiophene-2-carbonyl)pyrrolidine-2-carbonyl)oxy)benzimidamide:
PyBOP (156 mg, 0.3 mmol) was added to a rt solution of (S)-1-(thiophene-2- carbonyl)pyrrolidine-2-carboxylic acid (45 mg, 0.2 mmol) and DIPEA (103 uL, 0.6 mmol) in DCM (1.0 mL) and the rxn mixture was stirred at rt for 20 min, before /V-hydroxy-benzamidine (27 mg, 0.2 mmol) was added and the resulting mixture was stirred at rt overnight. The rxn mixture was concentrated in vacuo and the residue was used as such for the next step.
Step D: (S)-/V-((1 -(thiophene-2-carbonyl)pyrrolidine-2-carbonyl)oxy)benzimidamide was dissolved in dioxane (2.0 ml.) and stirred at 90°C overnight. The rxn mixture was concentrated in vacuo and purified by prep. HPLC (method G) to give the title compound (Ref. 1) as an off- white solid. LC-MS B: tR = 0.79 min; [M+H]+ = 326.27.
Reference compound 2: {(S)-2-[3-(3-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}- thiophen-2-yl-methanone
The title compound was prepared from (S)-1-(thiophene-2-carbonyl)pyrrolidine-2-carboxylic acid and A-4-22 following the procedure described for Reference compound 1 (Step C and D). LC-MS B: tR = 0.88 min; [M(35CI)+H]+ = 360.23.
Reference compound 3: Thiophen-2-yl-[(S)-2-(3-o-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 - yl]-methanone
The title compound was prepared from (S)-1-(thiophene-2-carbonyl)pyrrolidine-2-carboxylic acid and A-4-19 following the procedure described for Reference compound 1 (Step C and D). LC-MS B: tR = 0.93 min; [M+H]+ = 339.98.
Reference compound 4: Furan-3-yl-[(S)-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]- methanone
Step A: (S)-Methyl 1 -(furan-3-carbonyl)pyrrolidine-2-carboxylate: TBTU (3.96 g, 12.3 mmol) was added to a rt solution of furan-3-carboxylic acid (1.17 g, 10.3 mmol) and DIPEA (5.3 mL, 30.8 mmol) in DCM (70 mL) and the resulting mixture was stirred at rt for 15 min, before S- proline methyl ester HCI (1.70 g, 10.3 mmol) was added. After stirring at rt overnight, the rxn mixture was diluted with water, the org. layer separated and the aq. layer extracted with DCM (2x). The combined extracts were dried (MgS04), filtered and concentrated in vacuo and purified by FC (Biotage SP1 : EtOAc/hex 1 :2) to yield (S)-methyl 1-(furan-3-carbonyl)pyrrolidine- 2-carboxylate as a white solid. LC-MS B: tR = 0.47 min; [M+H]+ = 224.22.
Step B: (S)-1 -(Furan-3-carbonyl)pyrrolidine-2-carboxylic acid: 1 M aq. NaOH (15 mL) was added to (S)-methyl 1 -(furan-3-carbonyl)pyrrolidine-2-carboxylate (1 .37 g, 6.14 mmol) in THF (50 mL) and the resulting mixture was stirred at rt for 3h. The rxn mixture was cooled to 0°C, acidified with 1 M aq. HCI (20 mL) to reach pH 1 and extracted with DCM (3x). The combined org. extracts were dried (MgS04), filtered and concentrated in vacuo to give (S)-1-(furan-3- carbonyl)pyrrolidine-2-carboxylic acid as a yellow oil that was used without further purification. LC-MS B: tR = 0.39 min; [M+H]+ = 210.24.
Step C: (S)-A -((1 -(Furan-3-carbonyl)pyrrolidine-2-carbonyl)oxy)benzimidamide: PyBOP (156 mg, 0.3 mmol) was added to a rt solution of (S)-1 -(thiophene-2-carbonyl)pyrrolidine-2- carboxylic acid (45 mg, 0.2 mmol) and DIPEA (103 uL, 0.6 mmol) in DCM (1.0 ml.) and the rxn mixture was stirred at rt for 20 min, before /V-hydroxy-benzamidine (27 mg, 0.2 mmol) was added and the resulting mixture was stirred at rt overnight. The rxn mixture was concentrated in vacuo and the residue was used as such for the next step.
Step D: (S)-/V-((1 -(furan-3-carbonyl)pyrrolidine-2-carbonyl)oxy)benzimidamide was dissolved in dioxane (2.0 ml.) and stirred at 90°C overnight. The rxn mixture was concentrated in vacuo and purified by prep. HPLC (method G) to give the title compound (Ref. 4) as a brownish solid. LC- MS B: tR = 0.74 min; [M+H]+ = 310.31 .
Reference compound 5: {(S)-2-[3-(3-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}- furan-3-yl-methanone
The title compound was prepared from (S)-1-(furan-3-carbonyl)pyrrolidine-2-carboxylic acid and A-4-22 following the procedure described for Reference compound 1 (Step C and D). LC-MS B: tR = 0.82 min; [M(35CI)+H]+ = 344.27.
Reference compound 6: Furan-3-yl-[(S)-2-(3-o-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]- methanone
The title compound was prepared from (S)-1-(furan-3-carbonyl)pyrrolidine-2-carboxylic acid and A-4-19 following the procedure described for Reference compound 4 (Step C and D). LC-MS B: tR = 0.79 min; [M+H]+ = 324.32.
Reference compound 7: {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1 -yl}-[3-(2-chloro-phenyl)-5-methyl-isoxazol-4-yl]-methanone
The title compound was prepared from A-1 -60 and B-3-1 following the procedure described in General Method F. LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 483.0.
Reference compound 8: {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1 -yl}-[3-(2-chloro-phenyl)-5-methyl-isoxazol-4-yl]-methanone
The title compound was prepared from A-1 -60 and D-4-1 following the procedure described in General Method F. LC-MS A: tR = 1.02 min; [M(35CI)+H]+ = 483.0.
Reference compound 9: {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]- pyrrolidin-1 -yl}-[3-(2-chloro-phenyl)-5-methyl-isoxazol-4-yl]-methanone
The title compound was prepared from A-1 -60 and F-4-3 following the procedure described in General Method F. LC-MS A: tR = 0.95 min; [M(35CI)+H]+ = 483.0.
Reference compound 10: [3-(2-Chloro-phenyl)-5-methyl-isoxazol-4-yl]-{(S)-2-[3-(2- trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl}-methanone
The title compound was prepared from A-1 -60 and B-3-2 following the procedure described in General Method F. LC-MS A: tR = 1.00 min; [M(35CI)+H]+ = 519.01 . II. Biological Assays
Antagonistic activities on both orexin receptors have been measured for each example compound using the following procedure:
In vitro assay: Intracellular calcium measurements:
Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/mL G418, 100 U/mL penicillin, 100 μg/mL streptomycin and 10% heat inactivated fetal calf serum (FCS). The cells are seeded at 20Ό00 cells / well into 384-well black clear bottom sterile plates (Greiner). The seeded plates are incubated overnight at 37°C in 5% C02.
Human orexin-A as an agonist is prepared as 1 mM stock solution in MeOH: water (1 :1 ), diluted in HBSS containing 0.1 % bovine serum albumin (BSA), NaHC03: 0.375g/L and 20 mM HEPES for use in the assay at a final concentration of 3 nM.
Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 384-well plates using DMSO followed by a transfer of the dilutions into in HBSS containing 0.1 % bovine serum albumin (BSA), NaHC03: 0.375g/L and 20 mM HEPES. On the day of the assay, 50 μΙ_ of staining buffer (HBSS containing 1 % FCS, 20 mM HEPES, NaHC03: 0.375g/L, 5 mM probenecid (Sigma) and 3 μΜ of the fluorescent calcium indicator fluo-4 AM (1 mM stock solution in DMSO, containing 10% pluronic) is added to each well. The 384-well cell-plates are incubated for 50 min at 37° C in 5% C02 followed by equilibration at rt for 30 min before measurement.
Within the Fluorescent Imaging Plate Reader (FLIPR Tetra, Molecular Devices), antagonists are added to the plate in a volume of 10 μυννβΙΙ, incubated for 120 min and finally 10 μΙ_Λ /βΙΙ of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 3 nM orexin-A with vehicle in place of antagonist. The IC50 value (the concentration of compound needed to inhibit 50% of the agonistic response) is determined and may be normalized using the obtained IC50 value of an on-plate reference compound. Optimized conditions were achieved by adjustment of pipetting speed and cell splitting regime. The calculated IC50 values may fluctuate depending on the daily cellular assay performance. Fluctuations of this kind are known to those skilled in the art. In the case where IC50 values have been determined several times for the same compound, the geometric mean has been given. Antagonistic activities of example compounds are shown in Table 37. Table 37:
Ex ICso ICso Ex ICso ICso Ex ICso ICso 0X1 0X2 0X1 0X2 0X1 0X2 No. No. No.
[nM] [nM] [nM] [nM] [nM] [nM]
1 373 40 37 >5640 1060 73 3480 1 160
2 253 41 38 23 12 74 254 6
3 182 34 39 658 92 75 1570 261
4 >5040 897 40 22 4 76 901 40
5 403 554 41 22 7 77 52 8
6 21 27 42 1 12 108 78 2290 29
7 64 37 43 284 23 79 2751 1068
8 156 74 44 1 10 14 80 252 16
9 853 242 45 1 12 125 81 309 19
10 1041 150 46 4 9 82 874 131
11 58 6 47 316 90 83 3470 302
12 796 816 48 45 58 84 63 8
13 70 13 49 89 233 85 28 23
14 392 295 50 131 75 86 103 40
15 21 8 51 15 1 1 87 439 70
16 128 16 52 182 25 88 49 1 1
17 8 5 53 315 97 89 97 14
18 91 32 54 216 46 90 137 25
19 1860 652 55 241 41 91 104 91
20 600 177 56 16 7 92 120 53
21 339 19 57 7 4 93 399 28
22 942 322 58 >5040 536 94 237 201
23 40 7 59 1216 47 95 13 3
24 472 104 60 >1420 419 96 109 12
25 19 1 1 61 1480 271 97 568 194
26 77 5 62 >1630 242 98 462 127
27 125 8 63 1420 361 99 895 614
28 261 1 33 64 198 52 100 92 8
29 249 39 65 758 375 101 9 6
30 3600 365 66 302 155 102 171 287
31 2910 259 67 1252 333 103 30 2
32 2290 955 68 6670 915 104 1030 38
33 62 9 69 1840 163 105 133 8
34 51 8 70 623 53 106 327 28
35 952 142 71 8 22 107 1040 79
36 >5640 379 72 901 57 108 554 68 Ex ICso ICso Ex ICso ICso Ex ICso ICso 0X1 0X2 0X1 0X2 0X1 0X2 No. No. No.
[nM] [nM] [nM] [nM] [nM] [nM]
109 976 199 147 31 15 185 523 75
110 1690 159 148 241 285 186 138 17
11 1 1 150 261 149 184 85 187 79 31
112 833 121 150 457 341 188 20 3
113 1200 146 151 27 27 189 47 5
114 1080 83 152 9 35 190 53 14
115 78 6 153 781 460 191 1 19 27
116 457 34 154 30 2 192 135 15
117 21 1 5 155 174 43 193 263 25
118 260 48 156 80 14 194 77 9
119 188 24 157 99 73 195 71 1 1
120 483 37 158 323 140 196 10 2
121 145 15 159 88 71 197 354 93
122 933 221 160 238 212 198 485 85
123 133 1 1 1 161 751 204 199 83 12
124 145 77 162 818 347 200 307 32
125 353 80 163 495 87 201 27 2
126 221 1 18 164 333 171 202 53 10
127 581 125 165 286 79 203 56 16
128 200 181 166 26 7 204 65 10
129 419 287 167 1 14 43 205 340 43
130 188 16 168 27 10 206 409 10
131 45 8 169 137 90 207 1810 565
132 831 250 170 55 35 208 225 20
133 522 36 171 104 30 209 56 21
134 274 219 172 56 18 210 49 10
135 60 17 173 132 1 16 211 81 37
136 12 9 174 174 70 212 6 3
137 33 23 175 14 12 213 169 46
138 49 30 176 258 151 214 360 75
139 124 62 177 126 140 215 18 3
140 100 45 178 549 132 216 76 27
141 59 29 179 371 189 217 40 14
142 123 80 180 183 126 218 331 99
143 47 34 181 86 37 219 228 170
144 26 83 182 276 29 220 53 16
145 19 15 183 190 91 221 152 44
146 5 5 184 31 1 133 222 351 121 Ex ICso ICso Ex ICso ICso Ex ICso ICso 0X1 0X2 0X1 0X2 0X1 0X2 No. No. No.
[nM] [nM] [nM] [nM] [nM] [nM]
223 253 17 261 26 9 299 25 19
224 19 6 262 1 1 10 145 300 14 10
225 964 600 263 505 105 301 19 6
226 160 148 264 165 14 302 258 207
227 852 425 265 1 12 76 303 13 4
228 272 134 266 1 15 14 304 4 3
229 163 240 267 501 177 305 164 74
230 23 15 268 233 31 306 36 2
231 66 15 269 177 12 307 130 3
232 134 78 270 282 32 308 22 4
233 1410 341 271 69 189 309 13 1
234 962 430 272 149 252 310 59 2
235 361 992 273 148 134 311 16 4
236 1850 150 274 171 29 312 204 89
237 844 186 275 210 161 313 661 76
238 104 16 276 762 243 314 249 314
239 378 24 277 1480 297 315 1050 2130
240 1330 147 278 1 1 10 199 316 54 19
241 31 10 804 279 296 135 317 2480 1620
242 4360 1440 280 54 4 318 42 7
243 2680 312 281 42 17 319 1 1 2
244 306 18 282 44 1 320 25 1
245 262 21 283 34 7 321 7 1
246 135 14 284 32 5 322 158 6
247 17 3 285 90 56 323 9 1
248 64 2 286 90 6 324 3 1
249 151 8 287 73 42 325 151 6
250 489 38 288 666 52 326 27 3
251 626 90 289 44 37 327 38 4
252 1210 143 290 9 5 328 16 4
253 174 5 291 21 5 329 16 4
254 69 20 292 348 52 330 5 2
255 36 8 293 32 10 331 1 0.5
256 43 20 294 155 17 332 99 4
257 4 1 295 78 3 333 644 17
258 27 4 296 582 272 334 320 12
259 352 99 297 690 478 335 65 4
260 392 63 298 531 517 336 45 3 Ex ICso ICso Ex ICso ICso Ex ICso ICso 0X1 0X2 0X1 0X2 0X1 0X2 No. No. No.
[nM] [nM] [nM] [nM] [nM] [nM]
337 1 12 14 375 67 6 413 163 30
338 27 4 376 23 1 1 414 331 35
339 15 2 377 68 15 415 193 49
340 3 0.4 378 30 2 416 152 20
341 13 1 379 52 5 417 271 21
342 152 13 380 3 1 418 85 25
343 46 3 381 136 28 419 207 16
344 26 10 382 10 4 420 1060 133
345 33 1 1 383 30 4 421 571 717
346 23 2 384 22 2 422 152 4
347 15 1 385 26 8 423 81 39
348 10 1 386 1 18 7 424 8 4
349 27 3 387 57 3 425 4 10
350 36 2 388 381 15 426 414 30
351 22 4 389 35 15 427 80 292
352 19 4 390 73 6 428 67 28
353 54 5 391 68 14 429 98 26
354 12 5 392 17 17 430 359 51
355 188 8 393 57 10 431 19 2
356 57 7 394 134 12 432 322 16
357 81 17 395 31 10 433 19 1
358 128 10 396 134 15 434 21 5
359 325 30 397 85 5 435 35 31
360 7 1 398 33 18 436 49 13
361 127 61 399 77 10 437 62 15
362 171 100 400 36 4 438 1490 359
363 155 1 1 1 401 7 3 439 1800 1410
364 265 157 402 164 2 440 141 21
365 13 6 403 25 2 441 946 105
366 5 3 404 23 3 442 184 1 18
367 20 2 405 33 1 443 68 45
368 1 1 1 406 22 2 444 83 60
369 15 2 407 15 3 445 157 9
370 9 1 408 31 2 446 82 6
371 18 7 409 45 12 447 30 5
372 377 29 410 140 14 448 762 236
373 212 5 411 99 9 449 280 236
374 18 1 1 412 109 80 450 182 95 Ex ICso ICso Ex ICso ICso Ex ICso ICso 0X1 0X2 0X1 0X2 0X1 0X2 No. No. No.
[nM] [nM] [nM] [nM] [nM] [nM]
451 535 326 489 62 10 527 389 109
452 249 21 1 490 120 2 528 493 1 17
453 398 80 491 33 1 529 10 2
454 1 140 375 492 27 3 530 386 222
455 835 1690 493 1 143 29 531 255 57
456 1740 536 494 847 27 532 286 146
457 17000 3436 495 39 38 533 258 81
458 176 1 12 496 57 50 534 410 53
459 129 295 497 49 46 535 47 363
460 10 16 498 9 2 536 3430 2140
461 1 15 465 499 29 3 537 3980 2880
462 1 17 184 500 8 2 538 941 2810
463 704 209 501 27 4 539 560 1780
464 49 124 502 17 3 540 21 1 581
465 76 10 503 156 27 541 104 1 14
466 26 69 504 104 5 542 33 28
467 63 10 505 1670 592 543 10 20
468 84 35 506 171 1 16 544 5 6
469 25 45 507 107 135 545 4 8
470 57 31 508 239 84 546 4 8
471 49 127 509 22 3 547 25 34
472 19 2 510 477 53 548 35 65
473 57 6 511 642 1 13 549 31 64
474 16 8 512 652 80 550 272 178
475 1 1 2 513 812 181 551 43 24
476 27 3 514 >6560 3490 552 9 7
477 55 15 515 400 646 553 14 6
478 27 1 1 516 18 18 554 120 34
479 21 17 517 6 2 555 27 1 1
480 8 9 518 2 1 556 870 857
481 26 21 519 1390 720 557 292 224
482 68 94 520 650 392
483 1620 1790 521 2510 681 Ref 1 >8500 >10000
484 5020 3000 522 21 10 367 Ref 2 4260 7230
485 1300 1230 523 428 103 Ref 3 6270 >10000
486 2360 3130 524 709 45 Ref 4 >8500 >10000
487 23 8 525 343 88 Ref 5 >8500 >10000
488 136 14 526 28 5 Ref 6 >8500 >10000 Ref 7 529 593 Ref 9 1 1 100 >21800
Ref 8 >26200 >21800 Ref 10 782 2190
Compounds of the present invention may be further characterized with regard to their general pharmacokinetic and pharmacological properties using conventional assays well known in the art; for example relating to their metabolism and their pharmacokinetic (PK) properties in different species (such as clearance by human liver microsomes; PK in rat or dog); or relating to their ability to cross the blood-brain barrier, using for example a human P-glycoprotein 1 (MDR 1 ) substrate assay, or an in vivo assay to determine drug concentrations in the brain, e.g. in rats after oral dosing; or relating to their functional behavior in different disease related animal models {for example: the sedative effect of the compound using Electroencephalography (EEG) and Electromyography (EMG) signal measurments [F. Jenck et al., Nature Medicine 2007, 13, 150-155]; the effect of the compound in the fear-potentiated startle paradigm [Fendt M et al., Neuroscience Biobehav Rev. 1999, 23, 743-760; WO2009/0047723]; the effect of the compound on stress-induced hyperthermia [Vinkers CH et al., European J Pharmacol. 2008, 585, 407-425]; the effect of the compound on morphine- induced locomotor sensitization [Vanderschuren LJMJ et al., in Self DW, Staley JK (eds.) "Behavioral Neuroscience of Drug Addiction", Current Topics in Behavioral Neurosciences 3 (2009), 179-195] }; or for their properties with regard to drug safety and/or toxicological properties using conventional assays well known in the art, for example relating to cytochrome P450 enzyme inhibition and time dependent inhibition, pregnane X receptor (PXR) activation, glutathione binding, or phototoxic behavior.
Measurement of brain and systemic concentration after oral administration:
In order to assess brain penetration, the concentration of the compound is measured in plasma
([P]), and brain ([B]), sampled 3 h (or at different time points) following oral administration (e.g.
100 mg/kg) to male wistar rats. The compounds are formulated e.g. in 100% PEG 400.
Samples are collected in the same animal at the same time point (+/- 5 min). Blood is sampled from the vena cava caudalis into containers with EDTA as anticoagulant and centrifuged to yield plasma. Brain is sampled after cardiac perfusion of 10 mL NaCI 0.9% and homogenized into one volume of cold phosphate buffer (pH 7.4). All samples are extracted with MeOH and analyzed by LC-MS/MS. Concentrations are determined with the help of calibration curves.
Results obtained for the compound of Example 95:
(3 h after oral administration (100 mg/kg), n = 3): [P] = 309 ng / ml; [B] = 483 ng / g.
Results obtained for the compound of Example 154:
(3 h after oral administration (100 mg/kg), n = 3): [P] = 2237 ng / ml; [B] = 3253 ng / g.
Results obtained for the compound of Example 308: (3 h after oral administration (100 mg/kg), n = 3): [P] = 1763 ng / ml; [B] = 1585 ng / g.
Results obtained for the compound of Example 502:
(3 h after oral administration (100 mg/kg), n = 3): [P] = 2773 ng / ml; [B] = 1639 ng / g.
Results obtained for the compound of Example 544:
(3 h after oral administration (100 mg/kg), n = 3): [P] = 1073 ng / ml; [B] = 1 123 ng / g.
Sleep effects: EEG, EMG and behavioural indices of alertness recorded by radiotelemetrv in vivo in Wistar rats.
Electroencephalography (EEG) and Electromyography (EMG) signals were measured by telemetry using TL1 1 M2-F20-EET miniature radiotelemetric implants (Data Science Int.) with two pairs of differential leads.
Surgical implantation was performed under general anesthesia with Ketamin/Xylazin, for cranial placement of one differential pair of EEG electrodes and one pair of EMG leads inserted in either side of the muscles of the neck. After surgery, rats recovered in a thermoregulated chamber and received analgesic treatment with subcutaneous buprenorphine twice a day for 2 d. They were then housed individually and allowed to recover for a minimum of 2 weeks. Thereafter, rats— in their home cage— were placed in a ventilated sound-attenuating box, on a 12-h light / 12-h dark cycle, for acclimatization before continuous EEG / EMG recordings started. The telemetric technology that we used in this study allows accurate and stress-free acquisition of biosignals in rats placed in their familiar home cage environment, with no recording leads restricting their movements. Variables analyzed included four different stages of vigilance and sleep, spontaneous activity in the home cage and body temperature. Sleep and wake stages were evaluated using a rodent scoring software (Somnologica Science) directly processing electrical biosignals on 10 s contiguous epochs. The scoring is based on frequency estimation for EEG and amplitude discrimination for EMG and locomotor activity. Using these measurements, the software determines the probability that all components within each epoch best represent active waking (AW), quiet waking (QW), non-REM-sleep (NREM) or REM-sleep (REM). The percentage of total time spent in AW, QW, NREM- and REM-sleep was calculated per 12 h light or dark period. The latency to the onset of the first significant NREM- and REM-sleep episodes and the number and duration of those episodes were also calculated. AW, QW, NREM- and REM-sleep, home cage activity and body temperature were measured at baseline for at least one total circadian cycle (12 h-night, 12 h-day) before a test compound was administered. If baseline measurements indicated that animals were stable, test compound or vehicle was given in the evening by oral gavage at the end of the baseline 12- h day period, immediately before the nocturnal rise in orexin and activity in rats. All variables were subsequently recorded for 12 h following administration of the orexin receptor antagonist. The compound of Example 95 has been tested in this assay (oral dosage: 100 mg/kg po; effects analyzed over 12 hours): Results are: -7.3 % on active wake, -20.3 % on home cage activity, +1 1.2 % on NREM sleep, +7.8% on REM sleep; when compared to vehicle controls.
The compound of Example 154 has been tested in this assay (oral dosage: 100 mg/kg po; effects analyzed over 12 hours): Results are: -13.9 % on active wake, -26.8 % on home cage activity, +7.3% on NREM sleep, +0.9 % on REM sleep; when compared to vehicle controls.
The compound of Example 308 has been tested in this assay (oral dosage: 100 mg/kg po; effects analyzed over 12 hours): Results are: -24.0 % on active wake, -41.4 % on home cage activity, +14.3 % on NREM sleep, +35.2 % on REM sleep; when compared to vehicle controls. The compound of Example 502 has been tested in this assay (oral dosage: 100 mg/kg po; effects analyzed over 12 hours): Results are: -19.4 % on active wake, -47.1 % on home cage activity, +24.2 % on NREM sleep, +47.0 % on REM sleep; when compared to vehicle controls.
The compound of Example 544 has been tested in this assay (oral dosage: 30 mg/kg po; effects analyzed over 12 hours): Results are: -9.6 % on active wake, -18.5 % on home cage activity, +19.4 % on NREM sleep, +5.6 % on REM sleep; when compared to vehicle controls.

Claims

Claims
1. A compound of formula (I)
Figure imgf000210_0001
Formula (I)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration; R represents hydrogen or methyl;
ring A3 represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms; wherein at least one of said heteroatoms is nitrogen, and the remaining is / are independently selected from oxygen, sulfur and nitrogen;
ring A2 represents aryl or 5- to 10-membered heteroaryl; wherein said aryl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, hydroxy-(Ci-3)alkyl, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-; or ring A2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro; and
ring A represents phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6- membered heteroaryl independently is mono-, di-, or tri-substituted; wherein
> one of said substituents is attached in orffro-position to the point of attachment of A to the rest of the molecule; wherein said substituent is phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6-membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, halogen, cyano, (C1-3)fluoroalkyl, and (C1-3)fluoroalkoxy;
> and the other of said substituents, if present, is/are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
• provided that ring A is not isoxazol-4-yl, substituted in position 5 with (Ci-4)alkyl, attached to the rest of the molecule at position 4, and carrying said further ortho- substitutent in position 3; with the exception of the compound (1 , 1 '-biphenyl)-2-yl-{(S)-2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5- yl]-1 -pyrrolidinyl}-methanone;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 ; wherein the ring A3 is a meta di-substituted 5-membered heteroarylene ring selected from the group consisting of oxadiazol-diyl, triazol-diyl, isoxazol- diyl, oxazol-diyl, thiazol-diyl, pyrazol-diyl, imidazol-diyl, isothiazol-diyl, and thiadiazol-diyl;
or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1 ; which is also a compound of the formula (IV):
Figure imgf000211_0001
Formula (IV)
wherein the carbon atom at position 2 of the pyrrolidine ring is in absolute (S)-configuration; wherein
R represents hydrogen or methyl;
the ring
Figure imgf000211_0002
represents a meta di-substituted 5-membered heteroarylene ring containing one, two or three heteroatoms at any of the positions X-i, X2, X3, and/or X4; wherein at least one of said heteroatoms is nitrogen, and the remaining, if present, is / are independently selected from oxygen, sulfur and nitrogen;
Ar2 represents phenyl or 5- to 10-membered heteroaryl; wherein said phenyl or 5- to 10- membered heteroaryl is independently unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, cyano, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, hydroxy-(Ci-3)alkyl, -CO-(Ci-4)alkyl, and (C3-6)cycloalkyl-oxy-; or
Ar2 represents a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group optionally di-substituted with fluoro; (Rx)m represents one or two optional substituents independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy; and
Ar4 represents phenyl or 5- or 6-membered heteroaryl; wherein said phenyl or 5- or 6- membered heteroaryl substituent is independently unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxyl;
with the exception of the compound (1 , 1 '-biphenyl)-2-yl-{(S)-2-[3-(3-pyridinyl)-1 H-1 ,2,4-triazol-5- yl]-1 -pyrrolidinyl}-methanone;
or a pharmaceutically acceptable salt thereof.
ccording to claim 3; wherein the ring
Figure imgf000212_0001
represents a group selected from the group consisting of [1 ,2,4]oxadiazol-3,5-diyl, [1 ,2,4]triazol- 3,5-diyl, [1 ,2,4]triazol-1 ,3-diyl, 1 H-pyrazol-3,5-diyl, imidazol-2,4-diyl, isoxazol-3,5-diyl, oxazol- 2,4-diyl, oxazol-2,5-diyl, thiazol-2,4-diyl, [1 ,3,4]thiadiazol-2,5-diyl, and [1 ,3,4]oxadiazol-2,5-diyl; or a pharmaceutically acceptable salt thereof.
5. A compound according to any one of claims 3 or 4; wherein
• Ar4 is selected from the group consisting of unsubstituted triazolyl; unsubstituted pyrazolyl; unsubstituted oxazolyl; oxadiazolyl mono-substituted with methyl; unsubstituted pyridyl; unsubstituted pyrimidinyl; and unsubstituted or mono-substituted phenyl wherein the substituent is selected from the group consisting of (C1-4)alkyl, (Ci-4)alkoxy, and halogen; and
• (Rx)m represents one or two optional substituents independently selected from (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
or a pharmaceutically acceptable salt thereof.
6. A compound according to any one of claims 3 or 4; wherein
• Ar4 is unsubstituted triazolyl; or unsubstituted pyrimidinyl; and
• (Rx)m represents one or two substituents independently selected from (Ci-4)alkyl, (Ci-4)alkoxy, halogen, cyano, (Ci-3)fluoroalkyl, and (Ci-3)fluoroalkoxy;
or a pharmaceutically acceptable salt thereof. ing to any one of claims 3 or 4; wherein the group
Figure imgf000213_0001
is a group independently selected from the following groups A) to D):
Figure imgf000213_0002
or a pharmaceutically acceptable salt thereof.
8. A compound according to any one of claims 1 to 7; wherein the ring A2, respectively Ar2, represents
• phenyl which is unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy; hydroxy, (Ci-4)alkoxy-(Ci-3)alkyl, and hydroxy-(Ci-3)alkyl; or
• a 2,3-dihydro-benzo[1 ,4]dioxinyl, a 2,3-dihydro-benzofuranyl, or a benzo[1 ,3]dioxolyl group which is optionally di-substituted with fluoro; or • 6-membered heteroaryl; wherein said heteroaryl is independently unsubstituted, or mono-, or di-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, (C3-6)cycloalkyl, halogen, (Ci-3)fluoroalkyl, (Ci-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy-; or
• 8- to 10-membered heteroaryl; wherein said heteroaryl is independently unsubstituted, or mono-substituted; wherein the substituent is independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, and -CO-(Ci-4)alkyl;
or a pharmaceutically acceptable salt thereof.
9. A compound according to any one of claims 1 to 7; wherein ring A2, respectively Ar2, represents
• phenyl which is unsubstituted, or mono-, di-, or tri-substituted; wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, (C3-6)cycloalkyl, halogen, (C1-3)fluoroalkyl, (C1-3)fluoroalkoxy; hydroxy, (C1-4)alkoxy-(C1-3)alkyl, and hydroxy-(C1-3)alkyl; or
• 2,3-dihydro-benzo[1 ,4]dioxin-5-yl, 2,3-dihydro-benzofuran-7-yl, benzo[1 ,3]dioxol-4-yl, benzo[1 ,3]dioxol-5-yl, or 2,2-difluoro-benzo[1 ,3]dioxol-5-yl; or
• 5- or 6-membered heteroaryl selected from pyridyl, pyrazolyl, and pyrazinyl; wherein said heteroaryl is independently mono-, or di-substituted; wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, (Ci-3)fluoroalkoxy, and (C3-6)cycloalkyl-oxy-; or
• 8- to 10-membered heteroaryl selected from indolyl, pyrrolopyridyl, imidazothiazolyl, and indazolyl; wherein said heteroaryl is independently unsubstituted, or mono-substituted; wherein the substituent is independently selected from the group consisting of (C1-4)alkyl, (C1-4)alkoxy, and -CO-(C1-4)alkyl;
or a pharmaceutically acceptable salt thereof.
10. A compound according to any one of claims 1 to 7; wherein the group A3-A2, respectively respectively the group
Figure imgf000214_0001
represents a group independently selected from the following groups A) to H): A): [1 ,2,4]oxadiazol-3,5-diyl groups selected from the groups:
Figure imgf000215_0001
214
Figure imgf000216_0001
Figure imgf000216_0002
Figure imgf000217_0001
C): oxazol-2,4-diyl groups selected from:
D): oxazol-2,5-diyl groups selected from:
Figure imgf000217_0003
E): isoxazol-3,5-diyl groups selected from the groups:
Figure imgf000217_0004
F): [1 ,2,4]triazol-3,5-diyl groups selected from the groups:
Figure imgf000217_0005
Figure imgf000218_0001
): imidazol-2,4-diyl groups selected from the groups:
Figure imgf000218_0002
H): 1 ,3-diyl groups selected from:
Figure imgf000218_0003
or a pharmaceutically acceptable salt thereof.
11. A compound according to claim 1 selected from the group consisting of:
{(S)-2-[3-(2-Cyclopropyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(1 H-lndol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-p^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
methanone;
{(S)-2-[3-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrol idin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2,3-Dihydro-benzo[1 ,4]dioxin-5-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2 {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(1 H-lndol-7-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(1 -Methyl-1 H-pyrrolo[2,3-b]pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(1 -Methyl-1 H-indol-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-lsopropoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
1 -(3-{5-[(S)-1 -(5-Methyl-2-[1 ,2,3]triazol-2-yl-benzoyl)-pyrTolidin-2-yl]-[1 ,2,4]oxadiazol-3-yl}-indol-1-yl)-ethanone; {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-biphenyl-2-yl)-methanone; {(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dimet
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methoxy-biphenyl-2-yl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-meth
phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-ox
methanone;
(4-Methyl-biphenyl-2-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; (5-Methyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
(5-Methyl-2-pyridin-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5^
methanone;
(2-Fluoro-3-methyl-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2^]
1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-tnfluoromethoxy-phenyl)-[1 ,2
methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[3-(2-trmuoromethoxy-phenyl)-[1 ,2,4]oxad
methanone;
(5-Methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phen
methanone;
(4- ethoxy-biphenyl-2-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; (5-Methoxy -methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoro
pyrrolidin-1-yl}-methanone;
(4,5-Dimethyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
[3-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol^
methanone;
(5-Methyl-2-oxazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2- methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-me
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-y^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
phenyl)-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2^thoxy-pyridin-3-yl)-[
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phe^
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-meth
phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)-methanone; {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-oxazol-2-yl-phenyl)-methan (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-[1 ,2,4]oxadiazol^
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}- methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrroli
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phe^
methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy -methyl-2-[1 ,2
methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,2,3]tria
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,2^]oxadi
methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-^
methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH5-methy^
(5-Methoxy -methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluorome
pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy -meth
methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-meth
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimeth
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2^
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[5-(2-ethoxy-3-fluorO-phenyl)-[
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,2,3]tri
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadi
methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-ylH4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadi
methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrol idin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-y^
methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxad
methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl^
phenyl)-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiaz
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; (5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-isoxazol-5-yl]-pyrrolidin
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[4-(2-trifluoromethoxy-phenyl)-oxazol-2-yl]-pyrrolidin-1-yl}-methanone
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[3-(2-trifluoromethoxy-ph
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-^
yl}-methanone;
{(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phe^
methanone;
{(S)-2-[3-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5
phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-chloro-2-methyl-phenyl)-[1 ,2,4]oxa
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1,2,4]o
yl}-methanone; {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-y^
phenyl)-methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxad
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadia^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-p^
methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tn
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methy^
methanone;
{(S)-2-[5-(2-Ethyl^henyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
{(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-ph
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-methanone; {(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-[1 ,2,^
methanone;
(4,5-Dimethyl-2-[1 ,2,3]tnazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyr^^
{(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-met^
phenyl)-methanone;
{(S)-2-[5-(2-Ethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-[
methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-met^
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-[1,2,4]ox
yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethyl-phenyl)-[1 ,2,4]oxadiazo
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-[1,2,4]oxad
yl}-methanone;
{(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2^
methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-[1,2,4]oxadiazo
yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl-phenyl)-[1,2,4]ox
yl}-methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1,2 yl}-methanone;
{(S)-2-[5-(3-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4- phenyl)-methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1 ^
methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]^ methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1 ,2,^
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-chloro-5-metho phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-meth phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy^henyl)-[1 ,2,4]oxadiazol-3-yl]^yrrolidin-1-yl}-(4-chloro-2-[1 ,2 methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[ pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3 methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl^henyl)-[1 ,2,4] pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,^ methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-[ phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]tnazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H- methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phe pyrrolidin-1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H 1-yl}-methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]W^ methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-tnfluoromethoxy-phenyl)-4H-[1 ,2,4]^ methanone; (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-^
pyrrolidin-1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]tr^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]- pyrrolidin-1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-4H-[1 ,2^
methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methoxy-phenyl)-4H-[1
Figure imgf000225_0001
pyrrolidin-1-yl}-methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-y^
yl}-methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl) H-[1,2,4]triazol-3-yl]-pyrrolidin-1-ylH
phenyl)-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[5-(2-ethoxy-pyridin-3-yl)
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-4H-[1 ,2,4]tnazol-3-yn
methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-4H-[1,2,4]
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-chloro-5-meth
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl) H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4,5-di
phenyl)-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,^
1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazo 1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy-pyridin-3-yl)-[1 ,2,4]oxadi^^
methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,^
1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazo 1-yl}-methanone; (5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-ethoxy-pyridin-3-yl)-[1 ,2,4]oxad
methanone;
{(S)-2-[5-(2-Methoxy-phenyl)-1H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1,2,3]triazol-2-yl-phen
{(S)-2-[5-(2-Ethoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl^
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-1H-imid
methanone;
(4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-1H-im
methanone;
{(S)-2-[5-(2-Ethoxy-phenyl)-1 H-imidazol-2-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-(5-inethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-methanon (4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}-methanon (5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}- methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-phenyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl^^
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-m-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin^
{(S)-2-[3-(3-Methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(2-Methoxy-phenyl)-[1 ,2,4]oxadiazol^
{(S)-2-[3-(3,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tn^^
methanone;
{(S)-2-[3-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tr^^^
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(3-o-tolyl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1-yl]-m
{(S)-2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2^
{(S)-2-[3-(2-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol^
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tra
methanone;
{(S)-2-[3-(2-Chloro-3-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-^
methanone;
{(S)-2-[3-(2-Chloro-pyndin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazo^
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-phenyl)-[1,2^]oxad^
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2
methanone; {(S)-2-[3-(3-Dffluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-m
methanone;
{(S)-2-[3-(2-Methoxymethyl^henyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-m
methanone;
[(S)-2-(3-Benzo[1 ,3]dioxol-4-yl-[1 ,2,4]oxadiazol-5-yl)-pyrrolidin-1 -yl]-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methyl-3-trifluoromethyl-phenyl)-[1 ,2,4]o
yl}-methanone;
{(S)-2-[3-(3-Ethoxy-pyridin-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2- methanone;
{(S)-2-[3-(2,3-Dimethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-met
methanone;
{(S)-2-[3-(1 -Methyl-1 H-indol-4-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Fluoro-6-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(1 -Methyl-1 H-indol-7-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 , 2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Methyl-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Dffluoromethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-y^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-fluoro-3-m
phenyl)-methanone;
Biphenyl-2-yl-{(S)-2-[3-(3-chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyrazol-1-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH2-[1 ,2,^
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1,2,3]tri
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone; {(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (5-fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (5-methoxy-4-methyl-2-pyrazol-1-yl- phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (5-methoxy-2-pyrazol-1-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (4,5-dimethyl-2-pyrazol-1-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- ;5-fluoro-2-(2H-pyrazol-3-yl)-phenyl]- methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- [3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]- methanone;
{(S)-2-[3-(3-Chloro-2 methyl ■phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (4-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (3,5-dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl) methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (2-oxazol-2-yl-phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (4-chloro-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2 methyl phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (4-fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
{(S)-2-[3-(3-Chloro-2 methyl ■phenyl) [1 ,2,4]oxadiazol 5-yl] -pyrrolidin-' -yl}- (4,5-dimethoxy-2-[1 ,2,3]triazol-2-yl- phenyl)-methanone;
Biphenyl-2-yl-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone;
(5-m-Tolyl-oxazol-4-yl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-methanone; (2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrrolidm
(5-Fluoro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxad
methanone;
(5-Methoxy-4-methyl-2-pyrazol-1-yl-phenyl)-{(S)-2-[3-(2-trifluorornethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1- yl}-methanone;
[5-Fluoro-2-(2H-pyrazol-3-yl)-phenyl]-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-pyrro methanone;
(3,5-Dimethyl-2-[1 ,2,3]tnazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-pheny^
methanone;
(2-Oxazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluorom
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1,2,4]oxadiazol-5-y^
methanone; (4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-ph
methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethyl-p
1-yl}-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-difluoromethoxy-phenyl)^
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl^
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2^
methanone;
{(S)-2-[3-(2-Difluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)- methanone;
(3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3 luoro-2-methoxy-phenyl)-[1 ,2,4]oxa
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]tria^
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadia^^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,2^ methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5 luoro-2-^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyr^^ methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyridin-2-yl-phenyl)- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadia^^
methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triazol-2-yl^ phenyl)-methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4 luoro-5-met
phenyl)-methanone;
(4,5-Dimethoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methoxy-phenyl)-[1 ,2,4]oxa
yl}-methanone;
(3,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-ethoxy^yridin-3-yl)-[1,2,4^
methanone; {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(6-m
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phen methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2^thoxy-pyridin-3-yl)-[1 ,2
methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-fluoro-5-methoxy-2-[1 ,2,3]t phenyl)-methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-methoxy-phenyl)-[1 ,^
methanone;
{(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4,5-dimethyl-2-[1 ,2,3]triazol-2- methanone;
{(S)-2-[3-(2-Chloro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-[1 ,^
methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(2-[1,2,3]triazol-2-yl-p
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl-phenyl)-[1 ,2
methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]tn
methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-m
phenyl)-methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-2-[1 ,2,3^
methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2^]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-fluoro-2-[1,2
methanone;
{(S)-2-[3-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluorO-2-(2H-pyrazol-3-yl)-phenyl]- methanone;
{(S)-2-[3-(2-Ethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-[3-fluoro-2-(2H-pyrazol-3-yl)-phenyl]-methan {(S)-2-[3-(3,4-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(2,4-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone; {(S)-2-[3-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-rnethyl-2-pyrirnidin-2-yl- phenyl)-methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-trifluoromethoxy-phenyl)-[1 ^
methanone;
{(S)-2-[3-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-pyrirnidin-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,3-Dihydro-benzofuran-7-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[
methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-metho
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-5-metho
phenyl)-methanone;
{(S)-2-[5-(2-Ethoxy-3-fluoro-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-5-methoxy-2-[1 ,2
phenyl)-methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-fluoro-5-methoxy-2-[1 ,2,3]
phenyl)-methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(2-[1,2,3]triazol-2-y^
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(2-[1 ,2,3]triaz^
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-[1 ,2^]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,^
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1 ,24]oxadiazol^
methanone;
{(S)-2-[3-(2,3-Dimethyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(3,5-Dimethyl-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(2-Methoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-methanone; {(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-isoxazol-5-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1,2,3]tri
methanone;
[5-(3-Fluoro-phenyl)-2-methyl-thiazol-4-yl]-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-yl}- methanone; {(S)-2-[5-(3-Chloro-2-methyl-phenyl)-[1 ,3,4]oxadiazol-2-yl]-pyrrolidin-1-ylH5-m
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-chloro-2-methyl-phen
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-chloro-2-methyl-phen
pyrrolidin-1-yl}-methanone;
{(S)-2-[3-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-pyrimidin-2-yl- phenyl)-methanone;
{(S)-2-[3-(2-Ethoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-pyrimidin-2-yl-phenyl)- methanone;
(4-Fluoro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1,2,4]ox
1-yl}-methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-[1 ,2,^
phenyl)-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]- pyrrolidin-1-yl}-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-[1,2^]oxadiazol- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-fluoro-2-methyl-phenyl)-[1 ,2
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3-fluoro-2-methyl-phenyl)-[1 ,2
methanone;
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[5-(2-trmuoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrol idin-1 -yl)-(5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(3-Fluoro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tn
methanone;
{(S)-2-[5-(2-Ethoxy-pyridin-3-yl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tri
methanone;
{(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrFolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrFolidin-1-ylH5-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone;
{(S)-2-[5-(2,3-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)- methanone; {(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[^
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl^henyl)-[1,2,4]oxad
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,3-dimethyl-phenyl)-[1,2,4]
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2,5-dimethyl-phenyl)-[1,2,4]oxadiazol-3-y^
methanone;
{(S)-2-[5-(2,5-Dimethyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl^
methanone;
{(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1^
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-5-methyl-phenyl)-[1 ,2,4]oxadia^
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[5-(5-methoxy-2-methyl-phenyl)-^
methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrol idin-1 -yl)- methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-pheny
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S^
methanone;
(4-ChlorO-2-[1 ,2,3]triazol-2-yl-phenyl)^(S)-2-[5-(2-methoxy-5-methyl-phenyl)-[1 ,2,4]oxadiaz
methanone;
{(S)-2-[5-(5-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}- phenyl)-methanone;
{(S)-2-[5-(2-Methoxy-5-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-methyl-2-[1 ,2 phenyl)-methanone; (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(3 luoro-2-methyl-ph
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(5-methoxy-2-methyl^h
pyrrolidin-1-yl}-methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(3-methoxy-2-methyl^h
pyrrolidin-1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl^henyl)-{(S)-2-[5-(3-methoxy-2-methyl-phenyl)-[
yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-chloro-2-[1 ^
methanone;
{(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy
phenyl)-methanone;
{(S)-2-[5-(3-Methoxy-2-methyl-phenyl)-[1,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-^
methanone;
(2-[1 ,2,3]Triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-methanone; (5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]tr^
methanone;
(4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-p methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,^
methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-y^
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-met^
phenyl)-methanone;
{(S)-2-[5-(3-Fluoro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-methyl^
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl^
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-methyl^
methanone;
{(S)-2-[5-(3-Chloro-2-methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methoxy-4-m
yl-phenyl)-methanone;
{(S)-2-[5-(4-Chloro-6-methoxy-pyridin-2-yl)-[1 ,2,4]oxadiazol-3-yl]-pyrrolidin-1-yl}-(5-me
phenyl)-methanone;
{(S)-2-[5-(3-Methoxy-phenyl)-1H-imidazol-2-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1,2,3]tria
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-isoxazol-3-yl)-pyrrolidin-1-yl]-methanone;
(5-Methoxy-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(5-phenyl-isoxazol-3-yl)-pyrrolidin-1-yl]-methanone; (4-Chloro-5-methoxy-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-trifluoromethoxy-phenyl)-isoxazol-3-yl]-pyrrolidin-1-yl}- methanone;
{(S)-2-[3-(2-Cyclobutoxy-pyridin-3-yl)-[1 ,2,4]oxadiazol-5-yl]-pyrrolidin-1-yl)-(5-m
methanone;
(2-Fluoro-3-methoxy-6-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[3-(2-trifluoromethoxy-phenyl)-[1 ,2,4]oxadiazol-5-yl]- pyrrolidin-1-yl}-methanone;
{(S)-2-[5-(2-Methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(5-methyl-2-[1 ,2,3]tnazol^
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-[5-(2-methoxy-phenyl)-4H-[1 ,2,4]tria^^
methanone;
{(S)-2-[5-(2-Methoxy-phenyl)-4H-[1 ,2,4]triazol-3-yl]-pyrrolidin-1-yl}-(4-methyl-2-[1 ,2,3]tn
and
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-[(S)-2-(1-phenyl-1 H-[1 ,2,4]triazol-3-yl)-pyrrolidin-1^
or a pharmaceutically acceptable salt thereof.
12. A compound according to claim 1 selected from the group consisting of:
(5-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl ^
1-yl}-methanone;
4-Methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2^
1-yl}-methanone;
(4-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2^
1-yl}-methanone;
(5-Chloro-4-methyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H
pyrrolidin-1-yl}-methanone;
(4,5-Dimethyl-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-pheny
pyrrolidin-1-yl}-methanone;
(5-Chloro-2-[1 ,2,3]triazol-2-yl-phenyl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenyl)-4H-[1 ,2,4]tri
1-yl}-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-1-y^
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-1-y^
[1 ,2,3]triazol-2-yl-phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-1-yl}-(4,5-dim
phenyl)-methanone; and
{(S)-2-[5-(3-Chloro-2-methyl-phenyl)-4H-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidin-1-y^
phenyl)-methanone;
{(S)-2-[5-(3-Chloro-2-methyl-phenylHH-[1 ,2,4]triazol-3-yl]-2-methyl-pyrrolidi
phenyl)-methanone; (5-Methyl-biphenyl-2-yl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-pheny
methanone; and
(4-Methyl-biphenyl-2-yl)-{(S)-2-methyl-2-[5-(2-trifluoromethoxy-phenylH
methanone;
or a pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising, as active principle, one or more compounds according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.
14. A pharmaceutical composition according to claim 13 for use in the prevention or treatment of mental health diseases or disorders relating to orexinergic dysfunctions.
15. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use as a medicament.
16. A compound according to any one of claims 1 to 1 1 , or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of diseases selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.
17. A compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, and appetite disorders.
18. A method of treatment of sleep disorders, anxiety disorders, addiction disorders, cognitive dysfunctions, mood disorders, or appetite disorders; comprising administering to a patient a compound as defined in any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof.
PCT/IB2013/059233 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives WO2014057435A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
KR1020157012089A KR102151288B1 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
JP2015536264A JP6244365B2 (en) 2012-10-10 2013-10-09 [Orthobi- (hetero-) aryl]-[2- (methabi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone derivatives orexin receptor antagonists
EA201500399A EA201500399A1 (en) 2012-10-10 2013-10-09 OREXIN RECEPTOR ANTAGONISTS, WHICH ARE REPRESENTING DERIVATIVES OF [ORTO-BI- (HETERO) ARYL] - [2- (META-BI- (HETERO) ARYL) PYRROLIDIN-1-IL] METHANON
CA2885180A CA2885180C (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
SG11201502493XA SG11201502493XA (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
BR112015007516A BR112015007516A2 (en) 2012-10-10 2013-10-09 orexin receptor antagonists that are derived from [ortho-bi- (hetero-) aryl] - [2- (meta-bi- (hetero-) aryl) -pyrrolidin-1-yl] -methanone
MA38075A MA38075A1 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists, which are [ortho bi (hetero) aryl] - [2- (meta-bi (hetero) aryl) -pyrrolidin-1-yl] -methanone derivatives
AU2013328301A AU2013328301A1 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
US14/434,997 US9493446B2 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN201380051391.3A CN104703980B (en) 2012-10-10 2013-10-09 Belong to the orexin receptor antagonists of [adjacent double (miscellaneous) aryl] [base of 2 (double (miscellaneous) aryl) pyrrolidines 1] ketone derivatives
MX2015004638A MX2015004638A (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives.
EP13805561.1A EP2906553B1 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero)aryl)-pyrrolidin-1-yl]-methanone derivatives
PH12015500627A PH12015500627A1 (en) 2012-10-10 2015-03-20 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
IL238052A IL238052A0 (en) 2012-10-10 2015-03-31 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP12188019 2012-10-10
EP12188019.9 2012-10-10
EP13157809 2013-03-05
EP13157809.8 2013-03-05

Publications (1)

Publication Number Publication Date
WO2014057435A1 true WO2014057435A1 (en) 2014-04-17

Family

ID=49765598

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/059233 WO2014057435A1 (en) 2012-10-10 2013-10-09 Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives

Country Status (16)

Country Link
US (1) US9493446B2 (en)
EP (1) EP2906553B1 (en)
JP (1) JP6244365B2 (en)
KR (1) KR102151288B1 (en)
CN (1) CN104703980B (en)
AR (1) AR092955A1 (en)
AU (1) AU2013328301A1 (en)
BR (1) BR112015007516A2 (en)
CA (1) CA2885180C (en)
EA (1) EA201500399A1 (en)
IL (1) IL238052A0 (en)
MX (1) MX2015004638A (en)
PH (1) PH12015500627A1 (en)
SG (1) SG11201502493XA (en)
TW (1) TW201414727A (en)
WO (1) WO2014057435A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015087993A1 (en) * 2013-12-13 2015-06-18 大正製薬株式会社 Oxazolidine and oxazinane derivatives
WO2016100157A3 (en) * 2014-12-19 2016-08-18 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2018202689A1 (en) 2017-05-03 2018-11-08 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
US10329287B2 (en) 2012-06-04 2019-06-25 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (en) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
TWI664177B (en) 2013-12-03 2019-07-01 瑞士商愛杜西亞製藥有限公司 Crystalline forms
CN106349228B (en) 2015-07-17 2019-07-09 广东东阳光药业有限公司 Substituted quianzolinones and its preparation method and application
JP6936224B2 (en) 2015-11-23 2021-09-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Octahydropyrro [3,4-c] pyrrole derivatives and their use
CN106986859B (en) * 2016-01-20 2020-02-11 广东东阳光药业有限公司 Indole derivatives and uses thereof
WO2018081167A1 (en) 2016-10-24 2018-05-03 Yumanity Therapeutics Compounds and uses thereof
EP3594202B1 (en) * 2017-03-08 2021-08-11 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
CN108794454B (en) * 2017-04-27 2023-08-15 广东东阳光药业股份有限公司 Preparation method of imidazole ring compound
WO2019018795A1 (en) * 2017-07-20 2019-01-24 Yumanity Therapeutics Compounds and uses thereof
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. Compounds and uses thereof
US10653682B2 (en) 2017-10-26 2020-05-19 Southern Research Institute Oxadiazoles and thiadiazoles as TGF-β inhibitors
JP2021522253A (en) 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド Compounds and their use
PE20211700A1 (en) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co HETEROCICLIC COMPOUND AND ITS USE
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11897850B1 (en) 2023-10-11 2024-02-13 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound

Citations (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
WO2002044172A1 (en) 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2002090355A1 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amines
WO2003002561A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2003002559A2 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. Piperidine compounds for use as orexin receptor antagonist
WO2003032991A1 (en) 2001-10-11 2003-04-24 Smithkline Beecham Plc N-aroyl piperazine derivatives as orexin receptor antagonists
WO2003041711A1 (en) 2001-11-10 2003-05-22 Smithkline Beecham P.L.C. Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
WO2003051873A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham Plc Piperazine compounds and their phamaceutical use
WO2003051368A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
US6660759B1 (en) 1999-08-30 2003-12-09 Fujisawa Pharmaceutical Co. Ltd. 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
WO2004024725A1 (en) * 2002-08-30 2004-03-25 Grünenthal GmbH 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
WO2004041807A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited Novel compounds
WO2004041816A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited Azacyclic compounds as orexin receptor antagonist
WO2004041791A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
WO2005044797A1 (en) 2003-11-06 2005-05-19 Addex Pharmaceuticals Sa Allosteric modulators of metabotropic glutamate receptors
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2005121131A1 (en) 2004-06-08 2005-12-22 Santhera Pharmaceuticals (Schweiz) Ag Dpp-iv inhibitors
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006012349A1 (en) 2004-06-25 2006-02-02 Hewlett-Packard Development Company, L.P. Discrete universal denoising with reliability information
WO2006123249A2 (en) 2005-05-18 2006-11-23 Addex Pharma Sa Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2007039781A2 (en) 2005-10-05 2007-04-12 Richter Gedeon Vegyészeti Gyár Rt. New compounds
WO2007105177A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008020405A2 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008069997A1 (en) 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
WO2008081399A2 (en) 2006-12-28 2008-07-10 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
WO2008117241A2 (en) 2007-03-26 2008-10-02 Actelion Pharmaceuticals Ltd Thiazolidine derivatives as orexin receptor antagonists
WO2008139416A1 (en) 2007-05-14 2008-11-20 Actelion Pharmaceuticals Ltd 2-cyclopropyl-thiazole derivatives
WO2008144380A1 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US20080300279A1 (en) 2007-06-01 2008-12-04 Mirjana Andjelkovic Piperidine-amide derivatives
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
WO2009003997A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
WO2009003993A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2009004772A1 (en) 2007-07-05 2009-01-08 Panasonic Corporation Robot arm control device and control method, robot and control program
WO2009004584A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
WO2009016560A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2009016564A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
WO2009047723A2 (en) 2007-10-10 2009-04-16 Actelion Pharmaceuticals Ltd Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
WO2009104155A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009124956A1 (en) 2008-04-10 2009-10-15 Glaxo Group Limited Pyridine derivatives used to treat orexin related disorders
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010048012A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010060472A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010063663A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
WO2010063662A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
WO2010072722A1 (en) 2008-12-23 2010-07-01 Glaxo Group Limited Piperidine derivatives useful as orexin antagonists
WO2010114978A1 (en) 2009-04-03 2010-10-07 Merck Sharp & Dohme Corp. Renin inhibitors
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050198A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2012039717A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001247569A (en) 1999-08-12 2001-09-11 Japan Tobacco Inc Pyrrolidine derivative or piperidine derivative and its medicinal use
PE20050226A1 (en) 2003-06-04 2005-05-18 Aventis Pharma Sa ARIL-HETEROAROMATIC PRODUCTS AND COMPOSITIONS CONTAINING THEM
WO2005113522A1 (en) 2004-05-07 2005-12-01 Janssen Pharmaceutica, N.V. Azole carboxamide inhibitors of bacterial type iii protein secretion systems
JP2009544625A (en) * 2006-07-20 2009-12-17 メーメット・カーラマン Benzothiophene inhibitors of RHO kinase
EP2051977A2 (en) * 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLbeta-HSD-1
ATE496043T1 (en) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS
WO2008147697A1 (en) 2007-05-22 2008-12-04 Boehringer Ingelheim International Gmbh Benzimidazolone chymase inhibitors
AR067665A1 (en) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd DERIVATIVES OF TRANS-3- AZA-BICYCLE (3.1.0) HEXANO
BRPI0821115A8 (en) 2007-12-18 2017-12-26 Actelion Pharmaceuticals Ltd AMINOTRIAZOLE DERIVATIVE COMPOUND, DRUG, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND
EP2334643A1 (en) 2008-10-14 2011-06-22 Actelion Pharmaceuticals Ltd. Phenethylamide derivatives and their heterocyclic analogues
KR101444559B1 (en) 2009-06-09 2014-09-26 액테리온 파마슈티칼 리미티드 Fluorinated aminotriazole derivatives
EA029899B1 (en) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Benzimidazole-proline derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists

Patent Citations (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660759B1 (en) 1999-08-30 2003-12-09 Fujisawa Pharmaceutical Co. Ltd. 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
WO2001096302A1 (en) 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
WO2002044172A1 (en) 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2002090355A1 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amines
WO2003002561A1 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2003002559A2 (en) 2001-06-28 2003-01-09 Smithkline Beecham P.L.C. Piperidine compounds for use as orexin receptor antagonist
WO2003032991A1 (en) 2001-10-11 2003-04-24 Smithkline Beecham Plc N-aroyl piperazine derivatives as orexin receptor antagonists
WO2003041711A1 (en) 2001-11-10 2003-05-22 Smithkline Beecham P.L.C. Piperazine bis-amide derivatives and their use as antagonists of the orexin receptor
WO2003051873A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham Plc Piperazine compounds and their phamaceutical use
WO2003051368A1 (en) 2001-12-19 2003-06-26 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2004024725A1 (en) * 2002-08-30 2004-03-25 Grünenthal GmbH 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
US7105538B2 (en) 2002-08-30 2006-09-12 Gruenenthal Gmbh 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
WO2004041807A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited Novel compounds
WO2004041816A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited Azacyclic compounds as orexin receptor antagonist
WO2004041791A1 (en) 2002-11-06 2004-05-21 Glaxo Group Limited N-aryl acetyl cyclic amine derivatives as orexin antagonists
WO2005044797A1 (en) 2003-11-06 2005-05-19 Addex Pharmaceuticals Sa Allosteric modulators of metabotropic glutamate receptors
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
WO2005121131A1 (en) 2004-06-08 2005-12-22 Santhera Pharmaceuticals (Schweiz) Ag Dpp-iv inhibitors
WO2006012349A1 (en) 2004-06-25 2006-02-02 Hewlett-Packard Development Company, L.P. Discrete universal denoising with reliability information
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006123249A2 (en) 2005-05-18 2006-11-23 Addex Pharma Sa Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
WO2007039781A2 (en) 2005-10-05 2007-04-12 Richter Gedeon Vegyészeti Gyár Rt. New compounds
WO2007105177A1 (en) 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
WO2008008517A2 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008020405A2 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds as orexin receptor antagonists
WO2008038251A2 (en) 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008069997A1 (en) 2006-12-01 2008-06-12 Merck & Co., Inc. Substituted diazepan compounds as orexin receptor antagonists
WO2008081399A2 (en) 2006-12-28 2008-07-10 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
WO2008117241A2 (en) 2007-03-26 2008-10-02 Actelion Pharmaceuticals Ltd Thiazolidine derivatives as orexin receptor antagonists
WO2008139416A1 (en) 2007-05-14 2008-11-20 Actelion Pharmaceuticals Ltd 2-cyclopropyl-thiazole derivatives
WO2008144380A1 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
US20080300279A1 (en) 2007-06-01 2008-12-04 Mirjana Andjelkovic Piperidine-amide derivatives
WO2009003997A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Imidazo [1, 2-c] pyrimidin-2-ylmethylpiperidines as orexin receptor antagonists
WO2009003993A1 (en) 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2009004584A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
WO2009004772A1 (en) 2007-07-05 2009-01-08 Panasonic Corporation Robot arm control device and control method, robot and control program
WO2009016560A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2009016564A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
WO2009047723A2 (en) 2007-10-10 2009-04-16 Actelion Pharmaceuticals Ltd Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
WO2009104155A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009124956A1 (en) 2008-04-10 2009-10-15 Glaxo Group Limited Pyridine derivatives used to treat orexin related disorders
WO2010004507A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010048012A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
WO2010060472A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010063663A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
WO2010063662A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
WO2010072722A1 (en) 2008-12-23 2010-07-01 Glaxo Group Limited Piperidine derivatives useful as orexin antagonists
WO2010114978A1 (en) 2009-04-03 2010-10-07 Merck Sharp & Dohme Corp. Renin inhibitors
WO2010122151A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited 3 -azabicyclo [4.1.0] heptanes used as orexin antagonists
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
WO2011050198A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2012039717A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors

Non-Patent Citations (54)

* Cited by examiner, † Cited by third party
Title
"Salt selection for basic drugs", INT. J. PHARM., vol. 33, 1986, pages 201 - 217
ADAM, TC ET AL., PHYSIOL BEHAV, vol. 91, no. 4, 2007, pages 449 - 458
ASTON-JONES G ET AL., BRAIN RES, vol. 1314, 2010, pages 74 - 90
BERRIDGE CW ET AL., BRAIN RES, vol. 1314, 2009, pages 91 - 102
BORGLAND SL ET AL., NEURON, vol. 49, no. 4, 2006, pages 589 - 601
BOUTREL B ET AL.: "Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior", PROC NATL ACAD SCI, vol. 102, no. 52, 2005, pages 19168 - 19173
BOUTREL, B ET AL., PROC NATL ACAD SCI, vol. 102, no. 52, 2005, pages 19168 - 19173
BRISBARE ET AL., NATURE MEDICINE, vol. 13, 2007, pages 150 - 155
C BOSS; C BRISBARE-ROCH; F JENCK, JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, 2009, pages 891 - 903
CARTER ME ET AL.: "The brain hypocretins and their receptors: mediators of allostatic arousal", CURR OP PHARMACOL., vol. 9, 2009, pages 39 - 45, XP025916388, DOI: doi:10.1016/j.coph.2008.12.018
CARTER ME; BORG JS; DELECEA L., CURR OP PHARMACOL., vol. 9, 2009, pages 39 - 45
CHEMELLI R.M. ET AL., CELL, vol. 98, 1999, pages 437 - 451
CHROUSOS, GP ET AL., JAMA, vol. 267, no. 9, 1992, pages 1244 - 1252
F. JENCK ET AL., NATURE MEDICINE, vol. 13, 2007, pages 150 - 155
FENDT M ET AL., NEUROSCIENCE BIOBEHAV REV., vol. 23, 1999, pages 743 - 760
FENG P ET AL., J PSYCHOPHARMACOL, vol. 22, no. 7, 2008, pages 784 - 791
FURLONG T M ET AL., EUR J NEUROSCI, vol. 30, no. 8, 2009, pages 1603 - 1614
GOZZI A ET AL., PLOS ONE, vol. 6, no. 1, 2011, pages E16406
H DIETRICH; F JENCK, PSYCHOPHARMACOLOGY, vol. 212, 2010, pages 145 - 154
HOLLANDER JA ET AL., PROC NATL ACAD SCI, vol. 105, no. 49, 2008, pages 19480 - 19485
HUTCHESON DM ET AL., BEHAV PHARMACOL, vol. 22, no. 2, 2011, pages 173 - 181
J. ORG. CHEM, 2007, pages 9786 - 9
JE KANG ET AL.: "Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle", SCIENCE, vol. 326, no. 5955, 2009, pages 1005 - 1007
KOOB, GF ET AL., CURR OPIN INVESTIG DRUGS, vol. 11, no. 1, 2010, pages 63 - 71
LANGMEAD, BRIT. J. PHARMACOL., vol. 141, 2004, pages 340 - 346
LAWRENCE AJ ET AL., BR J PHARMACOL, vol. 148, no. 6, 2006, pages 752 - 759
LESAGE MG ET AL., PSYCHOPHARMACOLOGY, vol. 209, no. 2, 2010, pages 203 - 212
LIU X ET AL., SLEEP, vol. 30, no. 1, 2007, pages 83 - 90
LUCCA ET AL., J. MED. CHEM., 1998, pages 2411 - 2423
MAJZOUB, JA ET AL., EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 155, no. 1, 2006, pages S71 - S76
MJ PRUD'HOMME ET AL., NEUROSCIENCE, vol. 162, no. 4, 2009, pages 1287 - 1298
NOLLET ET AL., NEUROPHARM, vol. 61, no. 1-2, 2011, pages 336 - 46
QUARTA D ET AL.: "The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization", NEUROCHEM INT, vol. 56, no. 1, 2010, pages 11 - 15, XP026906710, DOI: doi:10.1016/j.neuint.2009.08.012
R. STICKGOLD ET AL.: "Sleep-dependent memory consolidation", NATURE, vol. 437, 2005, pages 1272 - 1278
REMINGTON: "The Science and Practice of Pharmacy", 2005, LIPPINCOTT WILLIAMS & WILKINS, article "Pharmaceutical Manufacturing"
SAKURAI T. ET AL., CELL, vol. 92, 1998, pages 573 - 585
SALOMON RM ET AL., BIOL PSYCHIATRY, vol. 54, no. 2, 2003, pages 96 - 104
SHARF R ET AL., BRAIN RES, vol. 1314, 2010, pages 130 - 138
SMITH RJ ET AL.: "Orexin/hypocretin is necessary for context-driven cocaine-seeking", NEUROPHARMACOLOGY, vol. 58, no. 1, 2010, pages 179 - 184, XP026736770, DOI: doi:10.1016/j.neuropharm.2009.06.042
SMITH RJ ET AL.: "Orexin/hypocretin signaling at the orexin 1 receptor regulates cue- elicited cocaine-seeking", EUR J NEUROSCI, vol. 30, no. 3, 2009, pages 493 - 503
SPEALMAN ET AL., PHARMACOL. BIOCHEM. BEHAV., vol. 64, 1999, pages 327 - 336
SUTCLIFFE, JG ET AL., NAT REV NEUROSCI, vol. 3, no. 5, 2002, pages 339 - 349
T.S. SHIPPENBERG; G.F. KOOB: "Neuropsychopharmacology: The fifth generation of progress", 2002, article "Recent advances in animal models of drug addiction", pages: 1381 - 1397
T.W. GREENE; P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY-INTERSCIENCE
TETRAHEDRON LETTERS, 2009, pages 1267 - 1269
TSUJINO N; SAKURAI T., PHARMACOL REV., vol. 61, 2009, pages 162 - 176
TSUJINO N; SAKURAI T: "Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward systems", PHARMACOL REV., vol. 61, 2009, pages 162 - 176, XP055180000, DOI: doi:10.1124/pr.109.001321
TSUJINO, N; SAKURAI, T, PHARMACOL REV, vol. 61, no. 2, 2009, pages 162 - 176
VANDERSCHUREN LJMJ ET AL.: "Current Topics in Behavioral Neurosciences", vol. 3, 2009, article "Behavioral Neuroscience of Drug Addiction", pages: 179 - 195
VINKERS CH ET AL., EUROPEAN J PHARMACOL., vol. 585, 2008, pages 407 - 425
W. FOULDS MATHES ET AL., APPETITE, vol. 52, 2009, pages 545 - 553
WINROW ET AL., NEUROPHARMACOLOGY, vol. 58, no. 1, 2009, pages 185 - 94
Y. KAYABA ET AL., AM. J. PHYSIOL. REGUL. INTEGR. COMP. PHYSIOL., vol. 285, 2003, pages R581 - 593
ZHANG W ET AL.: "Multiple components of the defense response depend on orexin: evidence from orexin knockout mice and orexin neuron-ablated mice", AUTON NEUROSCI, 2006, pages 126 - 127,139-145

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329287B2 (en) 2012-06-04 2019-06-25 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US11040966B2 (en) 2012-06-04 2021-06-22 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2015087993A1 (en) * 2013-12-13 2015-06-18 大正製薬株式会社 Oxazolidine and oxazinane derivatives
WO2016100157A3 (en) * 2014-12-19 2016-08-18 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
US9938276B2 (en) 2014-12-19 2018-04-10 Merck Sharp & Dohme Corp. 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
WO2018202689A1 (en) 2017-05-03 2018-11-08 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
US11124488B2 (en) 2017-05-03 2021-09-21 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
IL270274B (en) * 2017-05-03 2022-08-01 Idorsia Pharmaceuticals Ltd Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Also Published As

Publication number Publication date
TW201414727A (en) 2014-04-16
US9493446B2 (en) 2016-11-15
CA2885180A1 (en) 2014-04-17
US20150252032A1 (en) 2015-09-10
CN104703980A (en) 2015-06-10
AU2013328301A1 (en) 2015-05-28
EP2906553A1 (en) 2015-08-19
CN104703980B (en) 2017-09-22
PH12015500627A1 (en) 2015-05-11
JP2015533157A (en) 2015-11-19
SG11201502493XA (en) 2015-04-29
EA201500399A1 (en) 2015-09-30
KR102151288B1 (en) 2020-09-03
EP2906553B1 (en) 2019-06-26
AU2013328301A8 (en) 2015-06-11
AR092955A1 (en) 2015-05-06
BR112015007516A2 (en) 2017-07-04
JP6244365B2 (en) 2017-12-06
CA2885180C (en) 2021-03-02
IL238052A0 (en) 2015-05-31
KR20150064753A (en) 2015-06-11
MX2015004638A (en) 2015-07-14

Similar Documents

Publication Publication Date Title
EP2906553B1 (en) Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero)aryl)-pyrrolidin-1-yl]-methanone derivatives
US11040966B2 (en) Benzimidazole-proline derivatives
US9403813B2 (en) Azetidine amide derivatives as orexin receptor antagonists
WO2013068935A1 (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
IL285246B1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
WO2013050938A1 (en) 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AU2005268023A1 (en) Pyrazole derivative
CA2991404A1 (en) Imide derivatives and use thereof as medicine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13805561

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2013805561

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2885180

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12015500627

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2015000889

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2015536264

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14434997

Country of ref document: US

Ref document number: MX/A/2015/004638

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015007516

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 38075

Country of ref document: MA

ENP Entry into the national phase

Ref document number: 20157012089

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201504362

Country of ref document: UA

Ref document number: 201500399

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2013328301

Country of ref document: AU

Date of ref document: 20131009

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015007516

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150402